Inflammatory markers as novel predictors of cardiovascular disease by Welsh, Paul I
 INFLAMMATORY MARKERS AS NOVEL 
PREDICTORS OF CARDIOVASCULAR 
DISEASE 
 
 
 
 
 
 
 
Paul Welsh BSc (Hons) 
Faculty of Medicine 
Division of Cardiovascular and Medical Sciences 
 
 
 
 
 
 
 
Thesis submitted for the degree of PhD to the University of 
Glasgow 
January 2008 
 
 
 
 
 
 
 
 
© Paul Welsh 30/01/2008 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The folly of mistaking a paradox for a discovery, a metaphor for a proof, a torrent of 
verbiage for a spring of capital truths, and oneself for an oracle, is inborn in us.” 
Introduction to the Method of Leonardo da Vinci (1895) 
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seulement essayé d’inventer.” 
Unsourced 
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SUMMARY 
 
 
Inflammation is widely considered to be an important contributing factor in atherogenesis 
and the risk of atherothrombotic complications. Baseline measurements of some 
inflammatory markers are known to be predictive risk factors for future cardiovascular 
disease (CVD) events in prospective epidemiological studies. Inflammatory markers 
dominant in the literature are acute phase response (APR)-associated and include 
fibrinogen, C-reactive protein (CRP) and, more recently, interleukin- (IL-) 6. This thesis 
reviews the literature and suggests the need for further research into novel inflammatory 
markers of CVD risk. The broad aim was to expand on limited existing data and ascertain 
if circulating levels of four novel inflammatory markers (tumour necrosis factor 
α [TNFα], IL-18, soluble CD40 ligand [sCD40L], and matrix metalloproteinase-9 
[MMP-9]) are associated with classical cardiovascular risk factors, and with future CVD 
events in several epidemiological studies.  
 
In studies of pre-analytical variables, all four markers had commercially available assays 
acceptable for epidemiological use, but only IL-18 and TNFα displayed assay stability 
and the ability to be measured in plasma or serum.  
 
Due to limited serum samples, MMP-9 and sCD40L were less extensively measured. 
Results suggest a moderate positive association of MMP-9 with coronary heart disease 
(CHD) risk (although confounded by smoking and markers of general inflammation), 
while serum sCD40L may be moderately inversely related to CHD risk. More data is 
required for these markers. 
 
IL-18 and TNFα displayed similar degrees of short-term biological variability and 
regression dilution as CRP. Population distributions of both cytokines were consistent 
with limited previous reports. Both displayed associations with conventional vascular risk 
factors (such as age, gender, HDL cholesterol, and smoking), although interestingly, 
associations with epidemiological measures of obesity were poor. Both cytokines 
demonstrated moderate associations with vascular disease in a retrospective CHD study. 
In 3 prospective CHD or CVD studies, IL-18 demonstrated consistent but moderate 
  xv
associations with risk of vascular events in age- and sex-adjusted models (Odds ratio 
[OR]~1.6 in the top versus bottom third of the population). The association became 
borderline significant after adjustment for conventional risk markers. Associations of 
TNFα with risk of CHD in these studies were inconsistent, and more data are needed.  
 
In 3 prospective stroke studies, TNFα demonstrated some moderate associations with 
acute stroke outcome and recurrent stroke risk, but not with incident stroke in the elderly 
with vascular disease. IL-18 demonstrated no association with risk or outcome in any 
stroke study.  
 
Meta-analysis in 4 suitable prospective studies showed (in full adjustment models) that 
IL-18 (OR 1.18 [95% CI 0.95-1.48] comparing extreme thirds) and TNFα (OR 1.05 
[0.67-1.64]) have at best weak independent associations with CVD risk. Therefore these 
markers are unlikely to add significantly to clinical vascular risk prediction models, 
although these cytokines may still be of biological significance and potential therapeutic 
targets. More data is required for these markers. 
 
In conclusion IL-18, TNFα, MMP-9 and sCD40L may show weak associations with 
CVD. However, despite animal and tissue models indicating that they may play pivotal 
roles in atherogenesis, circulating concentrations of these inflammatory markers have 
limited independent vascular risk associations. Elevated circulating levels of APR-
associated markers may sensitively reflect exposure to a wide range of adverse pro-
inflammatory stimuli including lifestyle exposures, whereas some other inflammatory 
markers may not.  
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CHAPTER 1 
 
LITERATURE REVIEW OF CARDIOVASCULAR DISEASE, INFLAMMATION 
AND EPIDEMIOLOGY  
 
1.1 CARDIOVASCULAR DISEASE INTRODUCTION 
 
1.1.1 The Global Cardiovascular Disease Epidemic                                                
 
Cardiovascular disease (CVD) is the primary cause of mortality and morbidity 
worldwide, and is projected to remain so indefinitely (1Murray and Lopez, 1997). In 
terms of global burden of disease, in 1999 the World Health Organization (WHO) placed 
Coronary heart disease (CHD) in sixth place and stroke in seventh place, but by 2020 
they will have moved to first and fourth place, respectively (www.who.int/cardiovascular 
diseases/). CHD is the end result of accumulation of atheromatous plaques within the 
walls of the arteries that supply the myocardium. Recent estimates suggest that half of 
currently healthy 40-year-old males will develop CHD in the future, and one in three 
healthy 40-year-old women (AHA, 2007). 
 
The WHO estimates that cardiovascular disease killed 14.7 million people in 1990, rising 
to 17 million in 1999 and with a projected further increase to 24.8 million in 2020 
(1Murray and Lopez, 1997; Poulter et al, 2003; www.who.int/cardiovascular_diseases/). 
CVD is acknowledged to be causally linked to the lifestyle of the individual (including 
behaviours such as smoking, a sedentary lifestyle, a poor diet) a fact popularised by the 
media. In the developed world increasing urbanization of inner cities has caused a major 
change in behaviour patterns at all levels of the social spectrum. Widely available motor 
transportation and mechanisation of traditionally manual labour jobs has meant an 
increase in the proportion of people leading sedentary lifestyles. In addition, urbanisation 
promotes tobacco-smoking, and an unhealthy diet (high saturated fat and salt, low fruit 
and vegetables). Physical (in)activity and poor diet are likely to be the two most 
significant factors in the pandemic of obesity in the developed world. Indeed the WHO 
estimates that 60% of the world’s population is insufficiently physically active, and in 
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1999 61% of US adults were considered overweight or obese (body mass index [BMI] 
25+ kg/m2) (Bonow et al, 2002), rising to 64.5% in 2004 (Health, United States, 2003. 
Atlanta, Georgia Centres for Disease Control and Prevention, National Centre on Vital 
Statistics), a trend increasingly prevalent in the Westernised world. 
 
Cardiovascular disease is also a major problem in the developing world (2Murray and 
Lopez, 1997). This may largely be a consequence of improving medical treatment and 
increasing affluence (with the exception of sub-Saharan Africa), meaning the population 
is subjected less to malnutrition and communicable disease and is hence more likely to 
die of chronic degenerative diseases associated with older age (Yusuf et al, 2001). China 
is a particularly apt model of this “Epidemiological shift” (Yusuf et al, 2001) in 
developing countries, where increasingly Westernised lifestyles, jobs, smoking and 
unhealthy diets has brought about the emergence of cardiovascular disease as the major 
cause of morbidity and mortality after a lag period of one or two decades (Tsung 1998, 
Novak, 1998). 
 
It is clear then that cardiovascular disease prevention is an important social and clinical 
issue, but it is also an economic one. It is thought that CVD costs the UK economy £26bn 
per year, (£474 per capita, and 57% of which are in direct healthcare costs) (British Heart 
Foundation Database. Coronary heart disease statistics, 2007 Edition). For this reason 
much recent research has focused on identifying individuals most at risk of a primary 
cardiovascular event, and administering effective prophylaxis, such as aspirin, beta-
blockers and statins, as well as advice on lifestyle choices. Although this approach has 
had some success, more research is required to understand the molecular mechanisms 
through which cardiovascular disease progresses, to aid informed development of novel 
preventative approaches. 
 
1.1.2 The Development of Atherosclerosis in Cardiovascular Disease 
 
The presence of atherosclerotic lesions within the vasculature is virtually a pre-requisite 
for acute ischaemic events. Advanced lesions within the coronary arteries can cause 
luminal occlusion leading to stable and unstable angina pectoris. Erosion or rupture of 
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vulnerable lesions can lead to the atherothrombotic complications of myocardial 
infarction (MI), stroke, renal failure, heart failure, sudden death and peripheral vascular 
disease (Cohn, 2004; Hansson et al, 2005) (Figures 1.1-1.5). Indeed, although vascular 
pathology is usually discussed and managed on an organ by organ basis, atherosclerosis 
and atherothrombosis are generalised processes. Patients may only clinically present with 
arterial pathology in a specific area, but the disease is almost invariably ubiquitous, and is 
the root cause of the associated morbidity and mortality. For example, one study of 1500 
patients with leg artery atherosclerosis (intermittent claudication) found that in a 4-10 
year follow-up, 60% of deaths were cardiac, 17% were cerebrovascular, and 8% were due 
to other vascular causes such as ruptured aortic aneurysm (Laing et al, 1991). In addition 
a recent study has demonstrated that the ankle brachial blood pressure index (ABI) (a 
marker of peripheral atherosclerosis and subclinical stenosis) is associated with the site 
and number of arterial beds affected by atherosclerosis in vascular patients and to a lesser 
extent with the patient risk factor profile (Fowkes et al, 2006). These studies show that 
the atherosclerosis underlying the claudication pathology is also by far the main cause of 
mortality in this patient group. Considering the ubiquitous nature of atherosclerosis in the 
Westernised population, and its diffuse nature in the vasculature, it is therefore desirable 
to fully understand the cellular and molecular interplay involved in the development of 
atherosclerosis so that individuals at risk of progressing to an event may be identified, 
and possible pathways of therapeutic intervention may be examined. 
 
Until the mid-1970s atherosclerosis was considered a bland lipid storage disease where 
lesion swelling and stenosis were thought to be the primary cause of luminal occlusion 
leading to ischaemic heart disease and stroke (Ross and Harker, 1976). Indeed, much 
historical and current evidence supports the role of plasma lipids (cholesterol and 
triglycerides) and lipoproteins (low-density lipoprotein [LDL] and very low density 
lipoprotein [VLDL]) in atherogenesis (Kannel et al, 1979; Martin et al, 1986; Lloyd-
Jones et al, 2001). To suggest that lipid storage alone is the cause of atherogenesis is 
however a vast over-simplification. If atherosclerosis was purely a lipid storage disease it 
would be a reasonable assumption that the main driving force would be hyperlipidaemia, 
with the extent of atherosclerosis being proportional to sustained blood lipid 
concentration in most cases. Although hyperlipidaemia is a major risk factor for future 
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cardiovascular death, almost half of all coronary events occur in individuals without 
clinical hyperlipidaemia (Braunwald, 1997), and other risk factors such as smoking and 
blood pressure are of similar importance. Furthermore, hyperlipidaemia is only weakly 
related to ischaemic stroke (Shahar et al, 2003). 
 
The development of atherosclerosis in vivo is currently thought to be a more complex 
process, requiring persistent lipid presence, endothelial dysfunction and inflammation 
(Libby, 2002, Willerson and Ridker, 2004, Szmitko, 2003, Hansson, 2005) (Figures 1.1-
1.5).  This model gives inflammatory cells and cytokines a pivotal role in the 
development of the lesion.  
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Figure 1.1 Low density-lipoprotein (LDL) infiltrates the arterial wall and is modified by 
oxidation processes. It is then phagocytosed by macrophages which become active 
inflammatory lipid-laden foam cells characteristic of early atherosclerotic fatty streaks. 
Figures 1.1-1.5 adapted from Hansson, 2005. 
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Figure 1.2 Activated local endothelium starts to produce P- and E- selectins and integrins 
such as vascular cell adhesion molecule-1 (VCAM-1). Monocytes and activated 
lymphocytes from the periphery roll, adhere and extravasate into the tissue. Macrophages 
activated via toll like receptors (TLRs) produce inflammatory cytokines, chemokines, 
proteases, and free radicals which perpetuate inflammation and damage tissue. 
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Figure 1.3 A Th1 type adaptive response (see text 1.2.5) becomes established and 
interferon- (IFN-) γ is produced. This stimulates further activation of macrophages and 
proliferation of smooth muscle cells (SMCs). A stable fatty lesion develops with the 
collagenous cap manufactured by the SMCs. 
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Figure 1.4 Production of IL-6 and other cytokines (interleukin-1, TNFα) leads to 
stimulation of the hepatic acute phase response (APR) releasing acute phase reactants 
such as fibrinogen, serum amyloid A, and C-reactive protein (CRP). 
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Figure 1.5 (A) A cross-section of a coronary artery depicting a massive thrombus 
occluding the coronary artery after rupture(stained with Trichrome, rendering luminal 
thrombus and haemorrhage red and collagen blue). The area in between arrows shows the 
ruptured fibrous cap. (B) Following rupture, lipids can be seen seeping into the lumen 
(high powered micrograph). (C) Cellular involvement in atherothrombosis. 
Immunological cells as well as endothelial and smooth muscle cells within the plaque 
may play an important role in promotion and stabilisation of the thrombus. 
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1.1.3 Endothelial Dysfunction 
 
Endothelial dysfunction is usually defined as a diminished ability of the endothelium to 
produce the vasorelaxing compound nitric oxide (NO), or a profound imbalance in the 
relative amounts of other vasoactive compounds such as angiotensin II and oxidants 
(Verma and Anderson, 2002). Using this definition, endothelial dysfunction is confined 
to describing inappropriate vasomotor constriction of the vasculature, hence aggravating 
luminal occlusion caused by established atherosclerotic lesions. In the current model of 
atherosclerotic development however, diminished NO production by the endothelium is 
an intricate player in the development of pathophysiological inflammatory and molecular 
processes in the vasculature. (Szmitko et al, 2003).  In addition to vasodilatory effects, 
NO also generates an anti-thrombotic environment by limiting platelet aggregation at the 
endothelium (de Graaf et al, 1992), prevents leukocyte adhesion to the endothelium by 
suppressing expression of adhesion molecules (Gauthier et al, 1995), and it maintains 
vascular smooth muscle in a non-proliferative state (Cornwell et al, 1994). This is a 
delicate balance, and local changes in vascular environments (such as LDLcholesterol, 
free radicals, infectious microorganisms, low shear stress, and angiotensin II-induced 
hypertension) can cause endothelial activation, in part by reducing the intracellular 
concentration of NO (1Ross, 1999). 
 
1.1.4 Initiation of the Atherosclerotic Lesion; Where Inflammation and Endothelial 
Dysfunction Meet 
 
Atherosclerosis is initiated and exacerbated in the presence of systemic risk factors such 
as elevated LDL, hypertension, high blood sugar, and by-products of tobacco smoking. 
Although the entire vascular endothelium is exposed to these stimuli, atherosclerotic 
lesions develop preferentially at bifurcations, branch points, and inner curvatures of 
arteries, suggesting that local factors contribute to disease susceptibility. It is widely 
accepted that the complex patterns of blood flow in these regions expose the endothelium 
to "disturbed" haemodynamic forces (low shear stress; Lowe, 2003), which may in turn 
cause physical disruption of the endothelium and concomitant inflammation (Gimbrone 
et al, 1997; Garcia-Cardena et al, 2001). 
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In chronically hyperlipaemic plasma the vasculature is exposed to LDL cholesterol, 
which penetrates the endothelial cell layer around areas of low shear stress and moves 
into the intima, and then under oxidising conditions forms oxidised LDL (oxLDL) 
(Alderman et al, 2002) (Figure 1.1). This modified lipoprotein can bind to the 
endothelium and causes an increase in superoxide production, at the expense of lowering 
vascular concentration of NO, resulting in endothelial activation (Cominaciniet al, 2001). 
Activation of the endothelium begins the process of localised inflammation, allowing 
leukocyte extravasation through selectin and integrin production. Rapid externalisation of 
Weibel-Palade bodies results in P-selectin and E-selectin expression on the endothelial 
surface (Dong et al, 2000). The selectins weakly bind Lewis X-antigens on the surface of 
leukocytes, allowing loose “rolling” along the surface of the endothelial barrier. 
Endothelial expression of integrins such as VCAM-1 (vascular cellular adhesion 
molecule) allows arresting adhesion of Mac-1 (CD18/CD11b) expressing monocytes, 
which can then extravasate into the tunica intima underlying the endothelium (Piqueras et 
al, 2000) (Figure 1.2). Interestingly, VCAM-1 is expressed in large quantities by 
endothelial cells in animal models of atherosclerosis as part of the initial vascular 
response to cholesterol accumulation (Cybulsky and Gimbrone, 1991). This expression is 
not uniform and is patchy in appearance, and subsequent fatty streaks develop at the site 
of VCAM-1 expression only, and so too have a patchy appearance (Nakashima et al, 
1998). This probably reflects areas of low shear stress and flow turbulence, hence 
disturbing the integrity of the endothelium sufficiently for lipids to migrate through to the 
intima. Accordingly, the same haemodynamic stress may ultimately cause the rupture of 
more complex plaques. 
 
Maturing monocytes underlying the tunica intima express cytokines such as TNFα which 
help initiate and perpetuate the immune response and endothelial activation. Chemokines 
such as interleukin (IL)-8 and monocyte chemoattractant protein (MCP)-1 allow 
recruitment of monocytes to areas of concentrated inflammation (Wang et al, 1996.) 
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1.1.5 Early Development and Progression of the Lesion 
 
Maturing monocytes become tissue macrophages and express scavenger receptors, such 
as SR-A, CD36 and importantly oxLDL receptor-1 (LOX-1) (Bobryshev, 2006). LOX-1 
is particularly important as it allows phagocytosis of modified LDL, and providing that 
blood lipid levels remain high, the macrophages gorge themselves and become lipid 
laden “foam cells.” (Jovinge et al, 1996; Sano et al, 2004). The fatty streaks develop as 
more monocytes arrive and mature in the pro-inflammatory cytokine network (Figure 
1.3). 
 
Angiotensin II, produced by the activated endothelium, is a vasoconstrictor that opposes 
NO action. NO normally regulates angiotensin II production, although this feedback is 
disturbed during endothelial dysfunction.  This molecule may be important in the initial 
development of a pro-inflammatory local cytokine network through its action on smooth 
muscle cells (SMCs) which produce interleukin-6 (IL-6) and hence help initiate the 
systemic acute phase response (APR) through hepatocyte activation (Funakoshi et al, 
1999).  
 
IL-6 also acts in an autocrine manner to further activate the local SMCs (Klouche M et al, 
1999) which then proliferate (Schonbeck and Libby, 2001; Porreca et al, 1997).  SMCs 
control the maintenance of the extracellular matrix (ECM) through collagen production 
(Ford et al 1999) which is normally offset by matrix turnover and is mediated by matrix 
metalloproteinases (MMPs) (Galis et al, 1999). The MMPs are a family of zinc atom-
containing endopeptidases, consisting of collagenases, gelatinases and stromyelysins. 
Degradative turnover of the ECM is controlled both by collagen production and tissue 
inhibtors of MMPs (TIMPs) both of which are produced by SMCs (Squire et al, 2004). 
Disturbance of matrix homeostasis is a major cause of vascular pathology. 
 
In this way the plaque becomes more lipid-laden and cellular, but in the early stages of 
formation matrix deposition by proliferating SMCs provides mechanical support for the 
increasingly complex structure of the lesion (also contributing to luminal occlusion). 
Plaque development has long been believed to be an absolute and irresistible progressive 
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state, although some evidence suggests that this may not be the case. Coronary 
angiographic studies in a cohort of patients at different time points, suggests that plaque 
development may progress in a punctuated non-continuous fashion (Yokoya et al, 1999). 
The reasons for this are not clear, but several mechanisms have been proposed. One 
hypothesis is that neoangiogenesis in the plaque can result in fragile new 
microvasculature, which is prone to rupturing. The resulting thrombosis leads to 
thrombin generation, causing SMC proliferation and migration through a platelet derived 
transforming growth factor (TGF)-β dependant mechanism (Libby, 2002). This increase 
in SMC population would tip the balance in favour of collagen deposition, and 
progression of the lesion to a more bulky fibrous stenosis (Figure 1.6). 
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Figure 1.6 A representation of inflammatory factors contributing to progression of plaque 
development and atherothrombosis through collagen disruption and de-stabilisation of the 
lesion. The role of MMPs is pivotal in this process. Adapted from Van den Steen et al, 
2001. 
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1.1.6 Activation of the Adaptive Response in the Developing Lesion 
 
The presence of T-cells in plaque was first noted in 1985 by Hansson’s group (Jonasson 
et al, 1985). Most T-cells found in lesions are CD4+, although some are CD8+, effector 
or memory cells (i.e. not immunologically naive) (Stemme et al, 1992) and the proportion 
of activated cells increases with disease severity (Hosono et al, 2003).  
 
How and why these T-cells become activated is a more problematic issue. Recent 
findings suggest that, as in most infections, dendritic cells (DCs) activated in the lesion 
migrate to draining lymph nodes, and there activate naive T-cells (Galkina et al, 2006). 
DCs resembling Langerhans cells of the skin are found within the lesion, and are likely to 
capture antigen, such as modified LDL, through continuous macropinocytosis (Bobrysev, 
2005; Alderman et al, 2002). “Danger signals” such as cytokines, stimulation of Toll-like 
receptors (TLRs) (perhaps by modified LDLs; 1Miller et al, 2005), and apoptotic bodies 
cause the DCs to become activated, and they move to the draining lymph node. Here they 
theoretically have access to a naive T-cell repertoire that may be largely immunologically 
ignorant of “altered-self” antigens such as oxidised and modified LDL antigens. The T-
cell repertoire are probably only ever exposed to these antigens except under pro-
inflammatory stimulus from DCs matured in the lesion (Alderman et al, 2002), and in 
theory this may cause cognate T-cells to clonally expand and initiate the adaptive 
response.   
 
Despite the logical role of oxLDL antigens in stimulating T-cell responses, molecular 
genetic studies have shown that T-cells found in lesions are highly heterogeneous in 
terms of T-cell receptor (TCR) specificity (Stemme et al, 1991) and only 10% of clones 
derived from T-cell plaques respond to oxidised LDL in an MHC class II-dependant 
manner (Stemme et al, 1995). In theory these T-cells could be activated by some 
superantigen or inflammatory stimulus more proximal to the lesion. Alternatively, there 
may be a great number of “altered-self” antigens within the developing lesion. Indeed 
heat shock proteins and pathogen-derived antigens among others have been suggested as 
other sources of foreign or “altered-self” antigen (Robertson and Hansson 2006). 
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Naïve CD4+ T-cells have the potential to become activated in one of two categorised 
functional manners; T helper (Th)-1 type or Th2 type. Briefly, Th1 cells are primarily 
noted for their interferon (IFN)γ producing capability and consequential stimulation of a 
largely macrophage mediated cellular response. Th2 cells are noted for the production of 
IL-4 and IL-13, which are required to drive B-cell clonal expansion and an antibody 
mediated response. In the prevalent response T-cell activation tends to skew towards a 
general “consensus” i.e. generally Th1 and Th2 have an inverse relationship. This 
happens by (poorly understood) multi-factorial mechanisms, perhaps including DC 
maturation signals, molecular interactions in the immunological synapse, epigenetic 
limitations, and through a positive feedback response in the cytokine milieu (e.g. IL-12 
from macrophages promotes differentiation of Th1 cells, which in turn produce IFNγ) 
(Figure 1.3). Th1 versus Th2 skewing is excellently reviewed elsewhere (Crane and 
Forrester, 2005). In atherogenesis, IFNγ is produced by the vast majority of T-cells in the 
lesion (Hanson et al, 1989; Stemme et al, 1995) and the majority of evidence suggests 
that inflammatory components of atherogenesis are Th1 driven. 
 
In spite of this B-cells are also activated in the atherogenic immune response and several 
types of potentially self-reactive “altered-self” specific antibodies have been described, 
particularly antibodies to various forms of altered LDL. However, studies of mice 
aberrant in B-cell responses suggest that B-cells are atheroprotective, in contrast to 
macrophages and T-cells (Stoll et al, 2006). This may reflect a pro-atherothrombotic role 
for athero-antibodies, but an overall protective role for Th2 responses, probably primarily 
through the consequent limitation of classical Th1 cytokines. 
 
1.1.7 The Vulnerable Lesion and Atherothrombosis: 
 
Regardless of the mechanisms of adaptive response activation, activated T-cells are 
present in developing lesions and IFNγ is produced locally by almost all of them 
(Stemme et al, 1995). This Th1 cytokine is known to possess several proatherogenic and 
prothrombotic effects, including increasing matrix turnover both through direct action on 
SMCs and activation of MMP producing macrophages (Mallat et al, 1995; Libby, 2002; 
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Robertson and Hansson, 2006.) Certainly IFNγ absence or impairment in various mouse 
models results in reduced vascular pathology (Robertson and Hansson, 2006). 
 
Concomitantly, oxLDL accumulates in the lesion and causes apoptosis of SMCs (and 
macrophages i.e. necrotic core formation) (Kataoka et al, 2001). SMCs are a major 
source of TIMPs, and in their relative absence MMPs become more physiologically 
active. Despite the presence of large populations of scavenger cells, overwhelming debris 
means many of the apoptotic cells will progress to secondary necrosis, leading to further 
inflammation. This all leads to a microenvironment of matrix degradation prevalence, a 
change from the early balance where collagen deposition allowed development of a stable 
bulky stenosis (Figure 1.6). 
 
Over time the plaque becomes destabilised as the fibrous cap thins, and the mechanical 
structure holding the lesion containing the necrotic core and inflammatory cells is 
compromised. One study has suggested that coronary artery lesions with high densities of 
foam cells and thin fibrous plaques account for only 10-20% of the overall plaque 
population, and yet cause 80-90% of clinical events due to propensity to rupture (Brown 
et al, 1993). It is now recognised that plaque stability, rather than absolute size has the 
determining role in the potential to rupture (Mallat et al, 1999). Since the plaques 
accumulate in regions of non-laminar flow, haemodynamic factors put mechanical stress 
on the plaque, hence providing a mechanism for erosion of the endothelial layer and 
propensity to rupture, exposing procoagulant stimuli underneath the endothelial layer 
(such as tissue factor) to the blood stream. Therapeutic prevention of (or limitation of the 
likelihood to experience) plaque rupture therefore is the primary goal of vascular 
medicine. Elucidation of modifiable causal risk factors in atherogenesis and subsequent 
atherothrombotic events is the first step towards this goal. 
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1.2 EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE 
 
1.2.1 The Concept of “Risk Factors” 
 
The concept of risk factors is derived from epidemiological studies trying to ascertain the 
factor(s) responsible for chronic diseases historically associated with infection and 
nutritional deficiency. As public health has improved and chronic diseases associated 
with aging (such as cardiovascular disease and cancer) have become more common, the 
focus of this type of research has subsequently adapted.  Hence epidemiological methods 
have been long been used to assess which factors are statistically linked to a variety of 
disease states. For CVD, the concept of “risk factors” was popularised initially in the 
Framingham Heart Study (Kannel, 1961). Under the initial definition the risk factor 
(from the latin verb “facere” meaning “to make”) must be causal in the development of 
disease progression. Technically, where a factor has been associated with risk of a 
disease but has not yet been proven causal, the term “risk marker” should be employed, 
although the names are often used interchangeably. 
 
In some diseases there is a clear-cut cause, e.g. infections where a single common 
pathogen gives rise to the clinically observed symptoms and disease state (e.g. HIV virus 
infection giving rise to the acquired immunodeficiency syndrome, AIDS.) CVD however, 
is not so clear-cut. The complex molecular and cellular interplay involved in the 
development of atherosclerosis, and the further complications determining likelihood, 
position and size of a damaging thrombus mean that there are many factors that 
contribute before clinical presentation of an end-point event. Determining which of these 
factors has most influence over progression of disease is a key issue, either for use as a 
predictive marker or therapeutic target. 
. 
1.2.2 Current Cardiovascular Risk Factors 
 
Current major cardiovascular risk factors are summarised in Table 1.1. Seminal 
epidemiological work, such as the Framingham Study (Kannel, 1961) helped identify the 
classical or conventional risk factors for CVD that all health care professionals, and most 
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lay people are aware of. In general these are: male sex, increasing age, family history, 
smoking habit, presence of diabetes, obesity (especially high levels of visceral adiposity), 
hypertension, hyperlipidaemia and a sedentary lifestyle. Most of these risk factors inter-
relate in some way either directly or indirectly. Age, sex and family history are obviously 
non-modifiable, so the five main risk factors usually considered clinically are smoking, 
diabetes, hyperlipidaemia, adiposity, and blood pressure. These major risk factors are 
currently combined in scores or charts which predict risk of CVD, e.g. the Joint British 
Societies chart (Figure 1.7). This current chart utilises the total:HDL cholesterol ratio as a 
measure of atherogenic blood lipids and hence takes into account the fact that not all 
cholesterol is equal in terms of CHD risk. VLDL and LDL cholesterol play direct roles in 
atherogenesis, but HDL cholesterol, in contrast, plays a role in reverse lipid transport 
(and other anti-atherogenic processes) and hence reduces risk of coronary heart disease 
(Barter, 2004). So although in general hyperlipidaemeia is a risk factor for CHD, this can 
be tempered if a high part of the total circulating cholesterol is HDL. 
 
Importantly there is scientific evidence that each of the risk factors shown in Figure 1.7 is 
known to be causally involved in increasing the risk of CHD, either through increasing 
lipids available to generate plaques, or altering vascular biology to make the vasculature 
more susceptible to plaques, or increasing the likelihood of rupture and thrombosis (or 
some combination). Use of specific therapeutic intervention has shown that lowering 
each of these factors (e.g. by stopping smoking, lowering blood pressure, lowering of 
blood cholesterol by statins [hydroxymethylglutaryl-CoA reductase inhibitors] or control 
of obesity and diabetes) results in diminished risk in the general healthy population, as 
well as those with established vascular disease (Gotto et al, 2005; Lawes et al, 2002; 
Rodgers et al, 2006). These established risk factors are believed to account for 
somewhere in the region of 70-90% of incident CHD cases (Beaglehole and Magnus, 
2002; Emberson et al 2003 & 2004).  
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Table 1.2 Emerging potential risk markers for CVD 
Classification of Factor Examples of Risk 
Non-modifiable Sex (♂>♀), age, diabetes, social class (historical) 
Metabolic/ Dietary markers 
Markers of endothelial 
dysfunction/ oxidative stress 
Triglycerides, impaired glucose tolerance, metabolic syndrome, 
leptin, adiponectin 
oxLDL, sICAM-1, NO, brachial artery reactivity, glutathione 
Non-invasive imaging 
biomarkers 
Ankle brachial pressure index (ABI), MRI angiography, US 
carotid IMT, CT coronary calcification 
Novel lipids LP(a), apoA, apoB 
Inflammatory markers 
Intravascular US, coronary angiography Invasive imaging 
biomarkers 
Thrombotic markers t-PA, PAI-1, D-dimer, vWF, homocysteine 
Fibrinogen, PV, WCC, hsCRP, IL-6, TNFα, IL-18, sCD40L, 
MMPs, αoxLDL Abs 
Table 1.1 Major conventional risk factors for CVD 
BMI, body mass index; MRI, magnetic resonance imaging; US, ultra sound; IMT, 
intima-media thickness; CT, computerised tomography; s, soluble; LP(a), 
lipoprotein(a);  apoA/B, apolipoprotein A/B; hsCRP, high sensitivity C-reactive 
protein; IL, interleukin; αoxLDL Abs, anti oxLDL antibodies; PV, plasma viscosity; t-
PA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor-1; vWF, von 
Willebrand factor. 
Classification of Factor Examples of Risk 
Modifiable 
Smoking, blood pressure, sedentary lifestyle, adiposity (BMI or 
waist circumference), cholesterol (total or total:HDL) 
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Figure 1.7 Clinical Joint British Societies risk assessment chart for CHD (example shown 
is in diabetics). 
(From: Joint British recommendations on prevention of coronary heart disease in clinical 
practice: summary. BMJ .2000; 320: 705-708) 
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1.2.3 Emerging CVD Risk Markers 
 
Emerging CVD risk factors are summarized in Table 1.2 and fall into numerous 
overlapping categories. Considerable interest has been shown in novel metabolic and 
dietary markers in recent times. The metabolic syndrome (The WHO criteria, 1999; 
defined as presence of diabetes mellitus, impaired glucose tolerance, impaired fasting 
glucose or insulin resistance, plus any two of hypertension, dylipidaemia, obesity, and 
microalbuminuria – although there are several proposed clinical definitions) has attracted 
considerable attention as a predictor of type 2 diabetes as well as cardiovascular disease. 
Recent meta-analysis shows it is a predictor of CVD (Odds ratio [OR] 1.74 95% 
confidence intervals [CI] 1.29 – 2.35) (Galassi et al, 2006) although the clinical utility in 
diagnosing the syndrome as a CHD risk marker over and above the Framingham risk 
assessment is extremely dubious despite enthusiasm for its use particularly in the USA 
(1Wannamethee et al, 2005; 1Sattar, 2006).  In other examples of individual dietary 
hormones and lipids, triglycerides have recently been confirmed to be moderately 
associated with incident CHD during meta-analysis (Sarwar et al, 2006) as have 
lipoprotein(a) (LP(a)) (1Danesh et al, 2000) and apolipoprotein B:A ratios (Thompson et 
al, 2006). In contrast the hormone adiponectin is often reported to be inversely associated 
with CHD, but any association was recently shown to be weak on meta-analysis (2Sattar 
et al, 2006). 
 
Some haemostatic markers have also shown association with incident CVD, perhaps due 
to their roles in thrombus formation, longevity and degradation. These include fibrin D-
dimer fragment (1Danesh et al, 2001), von Willebrand factor (vWF; Whincup et al, 
2002), and tissue plasminogen activator (t-PA; 1Lowe et al, 2004). 
 
In addition to these, measurements of subclinical plaque progression and stenosis have 
also been shown to have associations with incident CVD. The simplest measure of 
peripheral arterial resistance is the ABI which shows a low sensitivity, but high 
specificity association with CVD and CHD risk (Doobay et al, 2005; Fowkes et al, 2006). 
More recent computer imaging shows both non-invasive, and (the less clinically 
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attractive) invasive procedures can predict CHD risk (Rigatelli and Rigatelli, 2005; 
Simon et al, 2006). 
 
Typically all of these markers have risk associations with CVD and CHD that can be 
described as moderate, but are clearly not as useful as the Framingham-based tests in 
clinical practice.  
 
1.2.4 Inflammatory Risk Markers 
 
As the aforementioned role of inflammation in atherogenesis would suggest, a great deal 
of work has been done looking for inflammatory markers that are risk factors for CHD 
(Libby et al, 2002). The most extensively examined markers are fibrinogen, C-reactive 
protein (CRP), white cell count (WCC), and IL-6. All of these markers are acute phase 
response associated, and hence circulating levels reflect the current inflammatory state of 
the individual, WCC and CRP being the routine clinical measures of inflammation. They 
have been used in epidemiological studies to examine the hypothesis “elevated baseline 
inflammation predicts risk of CVD.” 
 
Meta-analysis of prospective studies in generally healthy populations has shown that 
WCC (Wheeler et al, 2004), CRP (Danesh et al, 2004), and fibrinogen (Fibrinogen 
Studies Collaboration, 2005) are risk predictors for CHD. Based on 6944 first non-fatal 
MI events, a 1g/L increase in circulating fibrinogen is associated with an OR of 2.42 
(95% CI 2.24 – 2.60), which once adjusted for most conventional risk factors is 
attenuated to OR 1.80 per 1g/L increase (Fibrinogen Studies Collaboration, 2005). CRP 
has been promoted as a risk marker in cardiovascular disease, and much publication 
space has been devoted to this, particularly from the USA (1Verma et al, 2005). Recent 
meta-analysis (Danesh et al, 2004) has shown however that after adjustment for the 
baseline values of established risk factors, the OR for CHD was 1.45 (95% CI 1.25 - 
1.68) in a comparison of participants in the top third of the group with respect to baseline 
CRP values with those in the bottom third. There is however evidence of publication bias 
in early smaller studies that overestimated relative risk (Danesh et al, 2004). Regression 
to the mean over subsequent studies has seen the OR approach a lower value. Publication 
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bias is an important confounding factor in the epidemiological study of newer risk 
markers. 
 
CRP level measurements have been suggested to add to established risk factors for 
individual risk prediction for cardiovascular prevention in the USA (Pearson et al, 2003) 
but not in Europe. The conference that debated this decision in the USA assessed several 
potential inflammatory markers to be added to Framingham risk assessments. The criteria 
for marker consideration included: (1) the ability to standardize the assay and to control 
the variability of the measurement; (2) independence from established risk factors; (3) 
association with CVD clinical end points in observational studies and clinical trials; (4) 
the presence of population norms to guide interpretation of results; (5) ability to improve 
the overall prediction beyond that of traditional risk factors; (6) generalization of results 
to various population groups; and (7) acceptable cost of the assays. (Pearson et al, 2003). 
Several other markers were considered possible candidates as inflammatory risk markers 
in this debate (including WCC, fibrinogen and IL-6), but it was decided that CRP best-
fitted the above criteria, and was generally the most comprehensively studied of the 
markers. (Pearson et al, 2003). 
 
1.2.5 Are CRP and Fibrinogen Useful as Clinical Prognostic Markers? 
 
Some authors question the validity of adding inflammatory markers to clinical risk 
assessment protocols (Lowe, 2005; Lowe and Pepys, 2006; Lloyd-Jones et al, 2006). 
Generally in epidemiological studies of these markers they have univariable (unadjusted) 
ORs for CHD of 1.5 - 3.0 in the top third of the population versus bottom third of the 
population distribution, and then the risk association attenuates to around 1.0-1.5 upon 
adjustment for classical risk factors. Although a 50% increase in risk above conventional 
risk factors sounds impressive, a recent study (Pepe et al, 2004) suggests that when a 
marker is considered concomitantly with classical risk factors, it needs a multivariable 
OR of 3.0 in order to improve the C-statistic (area under the receiver-operator curve) by 
an additional 5% or more, which appreciably increases the risk assessment capability. 
Indeed, as considered by Lloyd-Jones et al (Lloyd-Jones et al, 2006) assuming that the 
correlation between CRP levels and the existing Framingham risk score is r = 0.3 (Albert 
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et al, 2003) a multivariable OR of 3.4 in top versus bottom quartiles of CRP distribution 
would be required to improve the C-statistic from 0.80 to 0.85. Neither CRP, fibrinogen, 
nor any other novel risk factor has been reported to attain that independent level of risk 
association.  
 
In fact, when considering recent publications, CRP seems to add very little to 
Framingham risk assessments. The Atherosclerosis Risk in Communities study (ARIC) 
examined incident CHD in 15792 people followed for 20 years and examined 19 novel as 
well as all conventional risk factors (Folsom et al, 2005). A basic risk factor model (age, 
race, sex, total and HDL cholesterol, systolic BP, antihypertensive medication, smoking 
and diabetes) gave a C-statistic of 0.8 (that is 80% of CHD events were detectable). 
Including CRP only added 0.003 to this figure, and other novel markers did not add 
greater than 0.011 (Folsom et al, 2005). This makes sense considering the close 
association of CRP with conventional risk markers. One study has shown in 15341 
people that high levels of CRP (>3mg/L) were attributable to conventional CHD risk 
factors in 78% of men and 67% of women (2Miller et al, 2005). These results were 
confirmed in the Framingham study, showing that traditional risk factors had a C-statistic 
of 0.78 for CVD events, a value unchanged by the addition of CRP (1Wilson et al, 2005). 
Subsequently Ridker’s group published data on the Women’s Heath Study (WHS) (Cook 
et al, 2006) arguing that CRP adds accuracy to classifying women by stratification of risk 
(i.e. 5%-10%, or 10-20% risk over 10 years) by reassigning ~20% of women to more 
accurate categories. However, the model used only incorporated age, BP and smoking as 
conventional risk factors, and examining the women in “categories” of risk loses 
statistical information, even if the model reflects clinical assessment. 
 
There is further debate as to whether CRP or fibrinogen could be used as “tie-breakers” 
in order to categorise patients at the threshold of being classified as at high or moderate 
risk, a theory currently being tested by the Jupiter (The Justification for the Use of Statins 
in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin) Trial (1Ridker, 
2003; Gotto, 2007). In the WHS Cook et al (2006) point out that when using the 
improvement in C-statistic as the criteria for use as a clinical prognostic marker, 
cholesterol measurements (total, LDL or HDL) actually add similarly little value to the 
  26
Framingham assessment as CRP (although it is worth noting only in their 
age/BP/smoking/unisex model). So then why include measurements of cholesterol and 
not CRP? The logical answer is that cholesterol is known to be directly causal in risk of 
CHD (through atherogenesis) whereas evidence of inflammatory markers playing causal 
roles in atherogenesis/thrombosis is less compelling. Using statins to lower cholesterol 
level will reduce the risk of CHD even if other risk factors are absent. Hence cholesterol 
is not only causal, but modifiable (either through lifestyle or therapeutic interventions), 
and so inclusion in risk assessment is rational. 
 
1.2.6 Problems in Implicating Causality for Risk Factors 
 
The argument for measurement of inflammatory markers such as fibrinogen and CRP in 
CVD risk assessment now begs the question “are they causally involved in chronic 
atherogenesis and/or acute atherothrombotic events, and hence the risk of CHD?”  
 
One of the problems associated with epidemiological studies is that observations of 
association in themselves cannot be used to infer causality (Lowe et al, 2005). 
Hypothetical illustrations of problems encountered in epidemiologically implicating a 
factor as causal are shown in Figure 1.8.  
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Figure 1.8 An illustration of the distinctions between 3 types of risk factors. Arrows 
denote causation. Bidirectional arrows, which may exist in real life, are not included, and 
this example does not include all possible relationships. (From Brotman et al, 2005). 
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From Figure 1.8, it is evident that directly causal factors are invariably associated with a 
biological outcome (A), presuming they can be accurately measured. However, in 
complex biological systems these causal factors can often have their own causal factors 
in turn, which may also be associated with the biological outcome, so they can be said to 
be indirectly causal (B). In addition both direct and indirect causal factors may promote 
distal noncausal factors, which may then also be associated with outcome, but only by co-
incidence (C). Adding further complexity (and not illustrated in the figure) there are often 
interactions between these types of factors and also reverse interactions, which result in 
confounding. In many studies of populations with prevalent disease the biological 
outcome itself may result in altered levels of risk factors (reverse causation bias), and 
since in most studies of CVD there is at least subclinical atherosclerosis even in healthy 
populations, reverse causation bias cannot be ruled out. Complex biological systems 
mean that empirical observations in epidemiology cannot, in isolation, infer causality, 
and there is therefore a need for evidence-based approaches as well. 
 
There are 3 main ways to study causality of a hypothetical risk factor 
1. “Experimental” animal and pathology studies of molecular and cellular interactions. 
2. Genetic epidemiological studies coupled with molecular epidemiology observations - 
“Mendelian randomisation studies.” 
3. Randomised, double-blinded, placebo-controlled trials using specific therapeutic 
inhibitors. 
 
Experimental animal studies are useful in that they are scientifically cleaner because of 
the potential to remove confounding factors in elegant experiments. However, whilst they 
attempt to model disease, they are unlikely to replicate it. Tissue studies are usually done 
in vitro or in situ and hence are limited, and since animals are physiologically and 
biologically distinct from humans they often experience disease, especially disease 
brought about through genetic aberrations or experimental stimulation in a different way 
to humans.  
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Mendelian randomisation studies are an epidemiologically based method of inferring 
causality, and take advantage of the randomized inheritance of genes, which are not 
confounded by external biological or sociological factors (1Davey Smith and Ebrahim , 
2005). In these studies inheritance of functional polymorphisms of genes of interest (such 
as promoter polymorphisms of CRP or fibrinogen) are studied in relation to the risk of 
CVD or CHD. As such these polymorphisms provide a background for a “natural” 
randomized, controlled trial of exposure, assuming the polymorphism has a known and 
quantifiable biological effect on the action or circulating level of the gene product, and 
that circulating levels of that gene product are associated with CHD outcome. If then the 
genotype is shown to have influence on CHD incidence in prospective studies, then there 
is triangulation, and strong implication of causality (see Figure 1.9) (Davey Smith and 
Ebrahim, 2004, 1Davey Smith and Ebrahim 2005).  
 
The gold standard to infer a factor as being causal is a randomised double-blinded 
placebo controlled trial of a drug which specifically targets the marker in question e.g. 
studies suggest stains lower cholesterol levels and risk of CHD in any population. This 
level of causal proof has not yet been achieved with any inflammatory marker in CHD 
risk 
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Figure 1.9 Random inheritance of alleles is independent from reverse causation bias, or 
external confounders seen in other areas of epidemiology. Complete triangulation in 
molecular (B) and genetic (A) risk association observations provides strong evidence of 
causality, whilst no association between genotype and CHD incidence (C) would 
implicate confounders and reverse causation underlying observation B. Adapted from 
1Davey Smith et al, 2005. 
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1.2.7 Are CRP and Fibrinogen Causal in CHD? 
 
CRP is highly evolutionarily conserved with homologous proteins in all vertebrates, 
indicating an important physiological role. Human CRP binds with high affinity to 
phosphorylcholine residues and other constituents of micro-organisms, but intrinsically it 
also binds to modified lipoproteins (oxLDL) (Pepys et al, 1985; Chang et al, 2002), and 
various particles related to necrotic and apoptotic cells (Pepys et al, 2003, and 2005; 
Chang et al, 2002). It is thought to opsonise all these particles through activation of the 
classical complement pathway (Mold et al, 1999) and hence mediate innate defense and 
help prevent autoimmunity. It therefore may play a role in promoting the development of 
foam cells through the opsonization of modified LDLs in the endothelial wall. CRP is 
also reported to be a procoagulant (Lagrand et al, 1997; Singh et al, 2005), to mediate 
endothelial dysfunction (Yaron et al, 2006), and to behave in a cytokine-like manner. 
This seems inherently unlikely, as no other cytokine is thought to be so variable in 
expression (up 10,000-fold circulating increases) and indeed would be dangerous in the 
uncontrolled inflammation they would elict if they were (Pepys et al, 2003).  
 
Animal models of CRP action have thus far proven problematic. Serum amyloid P 
component (SAP) is the major acute phase reactant in mice, and in rats native CRP does 
not activate complement, and although transgenic or extrinsic human CRP can be used to 
activate complement in rats, studies using these animals are heavily artificial (de Beer et 
al, 1982; Pepys et al, 2003). Earlier studies suggested that addition of extrinsic CRP to 
rodent models exacerbated atherosclerosis, but more recent models have shown that 
moderately elevated CRP levels in ApoE*3-Leiden transgenic mice do not have any 
effect on early atherogenesis (Trion et al, 2005) and furthermore, injection of even 
enormous doses of purified human CRP into mice and rats neither elicits inflammation 
nor produces any clinical ill effects (Clapp et al, 2005). Indeed, it is now believed that 
earlier inferences that CRP in vitro directly induced endothelial activation and other pro-
inflammatory properties were due to azide and LPS contamination in commercial 
products (Taylor et al, 2005; Pepys et al, 2005). Nevertheless, Pepys et al (2006) have 
shown that a small human CRP antagonist reduced the area of myocardial infarcts in an 
animal model of MI. The relevance of this to rodent and human atherosclerosis remains 
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to be determined further studies, although the potential epidemiological implications of 
being able to use this CRP antagonist in human double blinded placebo-controlled trials 
are obvious (Pepys et al, 2006). 
 
Evidence of a causal link for fibrinogen in atherosclerosis is mixed. Intuitively, 
fibrinogen may have a role in the development of atherothrombosis in established 
atherosclerosis since it is a haemostatic factor as well as an inflammatory marker as an 
APR protein. Fibrinogen may directly increase CHD risk because of its role in platelet 
aggregation, increasing plasma viscosity, and fibrin formation (Kannel, 2005) and hence 
may partially mediate the thrombogenic effect of other environmental risk factors. For 
example, epidemiological studies show that fibrinogen levels correlate with the number 
of cigarettes smoked and fall after smoking cessation (2Wannamethee et al, 2005), and 
fibrinogen decline may be a mechanism for CHD risk reduction following smoking 
cessation (McCallum, 2005).  
 
In molecular and animal studies, fibrinogen and its degradation products may promote 
expression of proinflammatory cytokines such as IL-6 and IL-1β (Lee et al, 1999; Perez 
et al, 1999). Despite this, mouse models show that transgenic hyperfibrinogenaemia has 
no effect on diet induced atherogenesis in C57/B6 or ApoE KO mice (Gulledge et al, 
2003; Rezaee et al, 2002). Further analysis of these mice show that they do have 
augmented fibrin formation and degradation, altered coagulation cascade function, and 
altered vascular response to injury (Kerlin et al, 2004) hence perhaps alluding to a role 
for fibrinogen in thrombosis rather than atherogenesis.  
 
Meta-analyses of Mendelian randomized trials have so far failed to implicate either CRP 
(2Davey Smith et al, 2005; Timpson et al, 2005; Casas et al, 2006) or fibrinogen 
(Keavney et al, 2006) as being causal agents in increasing the risk of CHD. This must be 
considered in light of known limitations of these new studies, which include that the 
study must be sufficiently powered to pick up small hypothetical increases in OR often 
associated with small increases in levels of markers from polymorphisms in promoters, 
and that the genetic biology of the markers (including potential linkage disequilibrium 
confounders) should be well recognised (Davey Smith and Ebrahim, 2004; Davey Smith 
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et al, 2003). Canalisation of gene carriers is also a potential confounder. Although sound 
in principle, these studies have yet to prove consistently useful tools in epidemiology. 
 
Much has recently been published about the pleiotropic effects of statins, particularly 
their seeming ability to dampen inflammation (Schonbeck et al, 2004). Some authors 
have ascribed this alternative function to being a “CRP lowering” function, and speculate 
that this CRP lowering provides some evidence of a causal role of CRP in CHD risk 
(2Ridker, 2003). While it is true that statins lower CRP levels concomitantly with 
cholesterol (Jain and Ridker, 2005), this is largely due to inhibition of activation of 
nuclear transcription factor kappa b (NFκB), and activator protein-1 (AP-1) which are 
responsible for aiding transcription of many pro-inflammatory cytokines including CRP 
(Blanco-Colio et al, 2003; Jain and Ridker, 2005). Since this protective effect is both 
immunosuppressive and immunomodulatory in a multi-factorial manner however, lower 
incidences of acute CHD cannot be attributed to CRP level reduction. Hence attempts to 
disentangle influences of statins on CRP and CHD outcomes in the PROVE-IT 
(PRavastatin Or atorVastatin Evaluation and Infection Therapy) trial (Ridker et al, 2005) 
are essentially impossible. 
 
Incidental evidence of a non-causal role for fibrinogen and CRP in CHD also exist; there 
is a lack of specificity linking them with human CHD in observational studies. As 
markers they also predict risk of all-cause and non-vascular mortality, and with an OR 
almost identical to observed vascular risks (Fibrinogen Studies Collaboration, 2005; 
Lowe, 2005; Mendall et al, 2000; 1Lee et al, 2006). Inflammatory markers such as CRP 
and IL-6 have also recently been shown to correlate with a decline in cognitive function 
in the elderly in the Edinburgh Artery Study, although this could arguably be 
mechanistically linked to vascular disease through stenosis and silent ischaemic events 
(Rafnsson et al, 2007). Lack of CVD risk specificity argues against a causal role, since 
elevated circulating levels of markers may be attributable to lifetime exposure to adverse 
risk factors for diseases that may or may not be cardiovascular related (Lowe, 2005)  
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1.2.8 IL-6 and CHD Risk Prediction 
 
The literature therefore appears to confirm that both CRP and fibrinogen are markers of 
CHD risk, but has not as yet convincingly causally implicated either marker. Since both 
of these inflammatory markers are proteins of the acute phase response, it stands to 
empirical reason that stimulators of the acute phase response may also be risk markers (at 
the very least due to indirect associations with acute phase reactants). In this regard the 
pro-inflammatory cytokine IL-6 has recently been extensively examined in the literature. 
In the interest of putting other inflammatory markers measured in this thesis into context, 
a brief overview of IL-6 and its associations with CVD are included here. 
 
IL-6 is a 26 kDa pleiotropic cytokine mainly produced by endothelial cells, macrophages, 
adipocytes and lymphocytes (Le et al, 1989; Kerr et al, 2001). As mentioned previously, 
IL-6 is implicated as a pivotal APR-inducing cytokine in IL-6 KO mice, although there is 
evidence it is not exclusively responsible for this (Fattori et al, 1994; Kopf et al, 1994). In 
addition to its role in the APR it is thought to stimulate haemostasis and influence T- and 
B-cell differentiation (Kerr et al, 2001) as well as stimulating endothelial cells to produce 
chemokines (in complex with soluble IL-6 receptor [sIL-6R]) (Romano et al, 1997) and 
plays a role in the transition between acute and chronic inflammatory responses (Gabay, 
2006).  
 
Mouse models indicate that exogenous addition of IL-6 exacerbates atherogenesis, 
indicating a role for IL-6 (Huber et al, 1999) through the mechanisms described above. 
Despite this IL-6 KO models indicate that basal physiological levels of IL-6 may be 
required to maintain plaque integrity (Schieffer et al, 2004; Song et al, 2004). This 
observation may be consistent with some of the condition-specific pro- versus anti- 
inflammatory actions of IL-6 (Kerr et al, 2001; Gabay, 2006). 
 
In epidemiology, major correlates of IL-6 are age, smoking and acute phase response 
markers (Woodward et al, 1999). A recent meta-analysis of 10 available prospective 
studies (Harris et al, 1999; 1and2Ridker et al, 2000; Volpato et al, 2001; Jenny et al, 2002; 
Pradhan et al, 2002; Luc et al, 2003; 2Lowe et al, 2004; Pai et al, 2004), including 2089 
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cases of non-fatal MI or CHD death, demonstrated that men in the top third of the 
population for IL-6 expression had an OR 1.67 (95% confidence intervals [CI] 1.35 – 
2.05) independent of conventional risk markers (Mann et al, submitted). This does not 
include more recent data, such as that from the Edinburgh Artery Study (Tzoulaki et al, 
2007), although the data is again in broad agreement with the meta-analysis; OR 1.85 
(1.33 to 2.58) in the top versus bottom tertile in a fully adjusted model. 
 
In the same study (Mann et al, submitted), a meta-analysis of the well studied IL-6 
promoter polymorphism -174 G/C was performed, since this allele is generally thought to 
be associated with elevated circulating concentrations of IL-6. In this analysis, and in 
contrast with some published literature, no association between the SNP and circulating 
levels of IL-6 was observed (in 9 studies with 5871 participants) and unsurprisingly nor 
was there any association with CHD risk. Hence IL-6, like fibrinogen and CRP, is 
associated with atherogenesis in some molecular and animal models, and is associated 
with CHD risk in epidemiological studies to a similar extent. 
 
1.2.9 Rationale for the Study of Novel Risk Markers: 
 
Having examined the evidence currently available for the role of inflammation in 
vascular disease and event risk prediction, several points can be made. Low-grade 
inflammation is thought to have a role in the development of atherosclerosis, and is likely 
to be causal on some level in atherogenesis and subsequent propensity to plaque rupture. 
Further weight is given to this argument by the observation that people with high-grade 
systemic Th1 autoimmune responses (such as systemic lupus erythematosus [SLE], 
insulin dependant diabetes mellitus, and rheumatoid arthritis [RA]) experience 
accelerated atherosclerosis and propensity to cardiovascular events compared with 
healthy controls with similar risk factors (Sattar and McInnes, 2005; Sherer et al, 2006). 
Indeed, the risk of myocardial infarction in women with RA was twice that of women 
without RA in the Nurses' Health Study (Solomon et al, 2003). Circulating markers of the 
acute phase response predict risk of vascular disease and consequent vascular events, but 
have not been shown to be mechanistically causal in a convincing way. In the absence of 
pharmaceutical therapies to specifically lower individual acute phase reactants, this 
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debate cannot currently be resolved by double-blinded placebo controlled trials. In 
addition these markers may lack the predictive capabilities required to add information by 
simultaneous determination with the Framingham assessment (conventional risk 
markers).  
 
There is a rationale then to examine novel markers of inflammation as risk factors for 
cardiovascular events, provided there is existing pathological/animal data indicating they 
have roles early on in the development of an inflammatory response and are thought to 
have a strong causal mechanism in the development of atherosclerosis and/or propensity 
of established plaques to rupture. Ideally, these markers should not be involved in the 
APR as a “primary” function; all inflammatory markers are of course in some way linked 
to the APR, but information is required regarding markers further upstream of the APR. I 
hypothesized that, in particular, inflammatory markers implicated in the classical Th1-
type response characteristic of an atherogenic environment, and highly expressed in 
diseases such as RA, would be associated with risk of incident CVD. Since the thesis 
aims to add information to the debate on causality of inflammation in CVD any markers 
it considers would, ideally, be potential future therapeutic targets. 
 
From these criteria I constructed a short-list of possible markers for examination: 
 
- Interferon γ (IFNγ) 
- Tumour necrosis factor α 
- Interleukin (IL)-1β 
- IL-12 
- IL-18 
- IL-8 
- Matrix metalloproteinase (MMP)-9 
- Soluble CD40 ligand (sCD40L / sCD154) 
 
IFNγ is a cytokine, produced by activated Th1 cells, which is a powerful stimulus for 
macrophage activation, resulting in IL-12 production to form a positive feedback loop,. 
Both these processes are important in atherosclerotic development (Gupta et al, 1997; 
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Lee et al, 1999). Neither cytokine, however, is easily detectable in the circulation of 
normal healthy people, and hence are unsuitable for population-based stuides. Similarly, 
IL-1β is a potent pro-inflammatory cytokine expressed early in an inflammatory 
response, and IL-8 is an important macrophage chemokine, but neither of which are 
detectable in the majority of healthy people.  
 
Of the other four markers, all have a generally strong putative role in risk of CVD events, 
but the literature is inconclusive. IL-18 shares structural homology with IL-1β and 
functional homology with IL-12 and plays an important role in RA, and so was 
considered an interesting possible marker. TNFα is an early pro-inflammatory cytokine 
and like IL-1β, is also important in RA and perhaps the metabolic syndrome, and recent 
development of a high sensitivity assay allows detection of circulating concentrations in 
normal people (<1pg/ml). MMP-9 may play a role in plaque rupture, and sCD40L has an 
enigmatic role in the circulation, but appears to be associated with atherogenesis. 
 
In light of this, and the data reviewed below, I set out to examine TNFα, IL-18, MMP-9, 
and sCD40L as markers of CVD risk. Brief literature reviews of each marker are 
included in which a general overview of the expression, regulation and biological 
function of the marker is given before considering the potential causal roles of the 
markers in atherogenesis, and existing epidemiological data on each. The aims of the 
thesis are discussed at the end of this chapter. 
 
 
1.3 TNFα LITERATURE REVIEW 
 
1.3.1 Introduction: 
 
TNFα has a long scientific history associated with CVD. For more than 2.5 millennia it 
has been recognised that patients with end-stage chronic heart failure (CHF) share 
clinical features with individuals with neoplasia or inflammatory disorders (Katz, 1962). 
Clinical wasting of these patients was a puzzling phenomenon, which was thought to be 
symptomatic of the body consuming itself, worsening the condition. In the mid-1800s 
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Bruns reported regression of tumours in humans following some bacterial infections 
(Bruns et al, 1868). It was demonstrated that these effects were caused by an inducible 
serum factor mediator, concomitantly named tumour-necrotizing factor (O’Malley et al, 
1962) which was later re-named tumour necrosis factor (TNF) (Carswell et al, 1975). 
Following this discovery, the issue of cardiac cachexia syndrome was eventually resolved 
(Levine et al, 1990) when it was shown that TNFα was responsible for mediating the 
symptoms in the different conditions. 
 
TNFα is now recognised as being a pluripotent cytokine, and the mechanisms of many of 
its biological activities are still not clearly understood. It seems to be capable of inducing 
diverse, and at times, contradictory physiological effects depending on the experimental 
setting. It is known that TNFα can cause apoptosis, septic shock, inflammation and 
cachexia systemically (Beutler et al, 1988). Yet, in contrast, it can induce growth through 
mitosis, it immunologically protects the host, and may also help induce obesity by 
metabolic mechanisms (Ferrari et al, 1999). 
 
1.3.2 TNFα Expression, Synthesis, and Regulation 
 
The TNFα and TNFβ genes are single copy genes located on the short arm of human 
chromosome 6 near the MHC region. TNFα is produced by neutrophils, activated T and 
B cells, NK cells, macrophages, astrocytes, SMCs, endothelial cells, adipose tissue, and 
some transformed cells whereas TNFβ is restricted to production by lymphocytes 
(Ruddle, 1992) 
 
Human TNFα is a polypeptide of 157 amino acid (Ruddle, 1992) and the biologically 
active form of TNFα has a homotrimeric structure that is the hallmark of the TNF 
superfamily (Jones, 1989). TNFα, unlike TNFβ, has no signal peptide sequence but is 
initially manufactured as a larger peptide with an N-terminal sequence containing 
hydrophilic and hydrophobic domains. It is hence expressed in a membrane bound form 
initially (Luettig et al, 1989) and is biologically active in this form, physiologically acting 
in a lytic manner (Perez et al, 1990). It is currently thought that membrane bound and the 
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soluble proteolytically cleaved (possibly via TNFα converting enzyme protease– TACE) 
TNFα have distinct in vivo roles (Idress et al, 2000). 
 
Most inflammatory settings result in an early local upregulation of TNFα production, 
which helps establish an innate immune response. In the acute stages of inflammation 
TNFα is known to largely regulate itself in an autocrine fashion (Hensel et al, 1987 and 
Xaus et al, 2000) although it also induces specific negative regulatory elements to 
maintain tight control of its own production (Carballo et al, 1998). TNFα also initiates 
the production of many other macrophage and DC derived cytokines, particularly IL-1β 
and IL-8 (1Papadakis et al, 2000). 
 
In most classical hypothetical immune responses it is the presence of the highly 
conserved pathogen associated molecular patterns (PAMPs) that initiates the immune 
response through stimulation of TLRs, and results in the production of early TNFα and 
IL-1β (Akira et al, 2003). This begs the question of what the early stimulus is for the 
production of cytokines at a developing fatty streak in the arteries. Jovinge (Jovinge et al, 
1996) originally demonstrated that human monocytes and macrophages become activated 
and release TNFα in response to oxLDL, probably through LOX-1 and SR-A mediated 
uptake. An interesting twist in these results came from results showing that early 
modified LDLs (not fully oxidized mmLDLs) are recognised by TLR4 and induce 
signalling and responses superficially similar to LPS, including TNFα production 
(1Miller et al, 2005). Theoretically, the TLR4 signalling would provide a potent stimulus 
for the initial and sustained TNFα expression whilst local levels of mmLDLs and 
oxLDLs are elevated in the vessel tunica intima underlying the disrupted endothelium. 
 
1.3.3 TNFα Receptors and Signalling 
 
TNFα has two functional receptors, the p55 TNFR1 and the p75 TNFR2. These receptors 
display limited extracellular homology and almost no intracellular homology, alluding to 
distinct signalling mechanisms and consequences (Idriss et al, 2000). TNFR1 is almost 
ubiquitously expressed, whereas TNFR2 has more restricted expression on cells with 
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haematopoetic origin (MacEwan et al, 2002). TNFα homotrimer binding to p55 or p75 
results in clustering and cross-linking of the TNFRs on the cell surface (Idriss et al, 
2000). TNFα signalling is excellently reviewed elsewhere (MacEwan et al, 2002 and 
Aggarwal, 2003) and is too complex and controversial an issue to describe in depth here. 
 
Membrane bound TNFα can also act as a receptor as well as a ligand for soluble p55 (and 
perhaps p75) and this “reverse-signalling” has physiological consequences (Eissner et al, 
2000 and Waetzig et al, 2005). The level of complexity implicated by two functional 
TNFRs (soluble and membrane bound), two functional ligands (also, soluble and 
membrane bound), a range of in vitro versus in vivo phenomena, as well as a staggering 
array of complex and partially understood signalling and reverse signaling has meant 
slow development in this field, and generally it is probably appropriate to focus on the 
larger physiological picture of TNFα than the molecular detail. 
 
1.3.4 General Biological Effects of TNFα 
 
The many and varied biological effects of TNFα are likely to be caused by a variety of 
restrictive signalling factors such as TNFα concentration, whether the TNFα ligand is 
soluble or membrane bound, other interacting cytokines in the microenvironment milieu, 
target cell expression of TNF receptor(s), target tissue specific expression of adaptor 
molecules and kinases, and target tissue specific epigenetic configuration of promoter 
regions (Goeddel, 1999). 
 
Systemically, TNFα effects can be categorized in two manners that reflect the general 
inflammatory response; the acute and chronic phases. A high grade acute response with 
excessive TNFα levels can lead to systemic vasodilation and a consequential drop in 
blood pressure leading to clinical shock and multiple organ failure as well as (at slightly 
lower concentrations) fever, disseminated intravascular coagulation, gastrointestinal and 
acute renal tubular necrosis, vascular leakage syndrome, adrenal haemorrhage and 
catabolic hormone release (Tracey et al, 1994). Low-grade chronic exposure can lead to 
weight loss (change in metabolic rates), protein catabolism, hepatosplenomegaly, 
subendocardial inflammation, insulin resistance, enhanced tumour metastasis, endothelial 
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activation and acute-phase protein production by hepatocytes (Tracey et al, 1994). As one 
would expect from the hypothesis of plasma TNFα as an underlying causal agent in 
atherogenesis, some of these symptoms may be consistent with the systemic development 
of atherosclerosis. In support of this acute versus chronic TNFα categorization, an 
interesting study has suggested that mouse cardiac tissue can produce different isoforms 
of the NF−κB transcription factor with divergent effects dependant on the exposure time 
to TNFα (Haudek et al, 2001). 
 
TNFα is regarded as a pivotal pro-inflammatory cytokine in “normal” physiological 
function. In mouse knock-out models it has been shown that p55-null mice are 
moderately resistant to LPS induced shock but succumb quickly to L.Monocytogenes 
infection (Pfeffer et al, 1993) whilst p75-null are also resistant to TNFα induced shock 
(Erickson et al, 1994). These examples demonstrate the potential importance of the 
cytokine in fighting infection, but also demonstrate the other side of the coin where 
inappropriate and excessive expression of the cytokine can be directly linked 
pathophysiology in the host. In line with the latter, TNFα has been implicated as pivotal 
in many human Th1 type autoimmune responses such as rheumatoid arthritis (Maini and 
Taylor, 2000) diabetes (Rabanovitch, 1998) and IBD (Crohns disease) (2Papadakis et al, 
2000). It is interesting that these autoimmune conditions (notably RA) have overlapping 
risk factor clustering with cardiovascular disease. TNFα has been cited as a potential 
common causative immunopathogenic factor across these disease states. 
 
1.3.5 Pathological and Animal Studies of TNFα in CVD 
 
There is a wealth of literature on the role of TNFα in CHF. The myocardium itself has 
the potential, under mechanical stress and volume overload, to produce large quantities of 
TNFα and TNFRs p55 and p75, whilst there is no biosynthesis in the non-failing heart 
(Torre-amione et al, 1999). Mice with targeted over-expression of TNFα develop left 
ventricular (LV) dilation (Kubota et al, 1997), characterized by disproportionate thinning 
of the left ventricle due to myocardial necrosis, adversely affecting cardiac diastolic 
function in the long-term. This phenomenon of LV dilation that is thought to involve 
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time-dependant changes in the MMP/TIMP regulation of extra cellular matrix (1Li et al, 
2000). In addition to this, TNFα induces negative inotropic effects on cardiac cells. 
Cardiocyte shortening is substantially depressed when exposed to TNFα at graded Ca2+ 
concentrations through a mechanism that is thought to involve elevated intracellular 
Ca2+ concentrations, hence impairing flux (Yokoyama et al, 1993). This impaired 
contractility would be devastating in an already failing heart. Furthermore, TNFα has 
been implicated in the production of pathological concentrations of NO, as well as 
directly causing apoptosis in myocytes and endothelial cells (Panas et al, 1998; Finkel et 
al, 1992), both contributing to impaired cardiac and vascular function. Clearly, these 
conditions may overlap with atherogenesis in terms of prevalent pathologies in many 
patients with chronic vascular disease. 
 
There is strong molecular evidence for a role of TNFα in the development of 
atherothrombosis. Circulating TNFα is present in the vasculature at baseline in all 
individuals, although it does increase with age (Paolisso et al, 1998) and blood vessels 
themselves from older mice produce increased levels of TNFα in response to stimulation 
(Belmin et al, 1995). TNFα can also be detected in many human atheromas (Barath et al, 
1990). It is produced in murine and in human atherosclerotic lesions, primarily by 
macrophages/foam cells, activated T-cells, smooth muscle cells, and endothelial cells 
(Barath et al, 1990; Kaartinen et al, 1996; Reckless et al, 1999). On a local level within 
the lesion per se, TNFα has the potential to promote cellular infiltration to the plaque via 
endothelial activation (Berk et al, 2001) and may induce endothelial dysfunction (Picchi 
et al, 2006). It also promotes the production of other cytokines as well as chemokine 
expression (Zhao et al, 2003), the expression of matrix metalloproteinase-9 (Saren et al, 
1996) (hence increasing plaque instability) and it can promote angiogenesis (Leibovich et 
al, 1987). The main potential proatherogenic effects are summarized in Table 1.3. 
 
Despite this strong putative molecular role for TNFα in atherogenesis and CVD, in vivo 
mouse models report evidence both for (Elhage et al, 1998; Niemann-Jonsson et al, 2000; 
1Li et al, 2000; Branen et al, 2004; Canault et al, 2004) and against (Schreyer et al, 1996; 
Reckelss et al, 1999; Hansen et al, 2001; Schreyer et al, 2002) a causal role. Schreyer et 
al (1996) originally reported that C57Bl/6J mice lacking the p55 TNFR had exacerbated 
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lesions in the aortic sinus, 2.3 times larger than wild types. This counter-intuitive result 
was accompanied by excessive SR-A expression by macrophages, thought to be 
symptomatic of the fact that TNFα modulates scavenger expression. The same group 
later published results suggesting that lymphotoxin, but not TNFα, was required for 
‘normal’ wild-type lesion development in a KO model (Schreyer et al, 2002). These 
results have been refuted in similar models by different groups. Indeed, the model used 
was recently re-assessed (Canault et al, 2004) and it was found that soluble TNFα was 
required for normal lesion development in the aortic sinus. In agreement with a vital role 
for TNFα in atherosclerosis, Branen et al (2004) demonstrated in ApoE KO mice that 
whether they restricted TNFα action by TNFR1 pellet administration, by conditional 
TNFα KO, or by total TNFα KO, mice exhibited diminished lesion development relative 
to a WT ApoE mouse (50-83% reduction in lesion size, range dependant on model). 
These discrepancies illustrate the caution that must be employed when considering 
knock-out models. Differences are probably partly to do with varying models, and partly 
due to the complex nature of TNFα biology. It has recently been confirmed in the ApoE 
KO model (more widely studied than the Schreyer et al model), that it is p75 that is 
required for normal atherogenesis (Chandrasekharan et al, 2007). Overall, the animal and 
tissue evidence seems to point towards an important role for TNFα in atherogenesis. 
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Table 1.3 Illustrative table of potential direct and indirect proatherogenic stimulators and 
processes induced by TNFα expression in experimental settings 
Inflammatory 
stimuli produced 
Molecule Major biological property 
and cellular source 
Reference 
Cytokine 
IL-1β 
IFNγ 
IL-6 
Chemokine 
Selectins/ 
integrins 
MCP-1 
IL-8 
RANTES 
ICAM-1 
Inhibition of SMC production of 
collagen/TIMPS. 
Produced by Th1 cells/macrophage 
Neutrophil/T-cell recruitment via 
CXCR1/2. Produced by activated 
macrophages 
T-cell/monocyte recruitment via 
CCR1/3/5. Produced by endothelial 
cells and monocytes 
Induction of APR. T-cell 
differentiation. 
Produced by macrophage and T-cells 
Activation of all major inflammatory 
cells/endothelium. Pyrogen. 
Produced by innate cells 
Recruitment of monocytes/ T-cells 
via CCR2. Produced by endothelial 
cells 
Endothelial arresting adhesion of 
LFA-1/Mac-1 expressing PBMCs. 
Expressed on activated endothelium 
Marucha et al, 1991 
Ng et al, 1994 
 Raab et al, 2003 
E-Selectin 
Endothelial rolling adhesion of 
Lewisx Ag expressing PBMCs. 
Expressed on activated endothelium 
 
Raab et al, 2003 
Metabolism Triglycerides 
Increased circulating triglyceride-
rich lipoproteins in blood. Produced 
by hepatocytes. 
Feingold et al, 1989 
Decreased 
Lipoprotein lipase 
Kawakami and 
Cerami, 1981 
Coagulation PAI-1 
Decrease turnover of spontaneous 
clots by plasminogen. Produced by 
endothelium 
Schleef, 1988 
Tissue factor 
Increased thrombotic potential after 
erosion or rupture in plaque. 
Produced by endothelium. 
Esmon, 2004 
Hiranoet al, 2003 
Increased free circulating fatty acids 
and hence increased triglycerides 
produced by liver 
1Papadakis et al, 2000 
Mytar et al, 1995 
Murao et al, 2000 
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Table 1.3 Continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other 
Decreased 
Thrombomodulin 
Limits protein C activation and 
promotes thrombus. Acts on 
endothelium 
Conway and 
Rosenberg, 1988 
MMPs Collagen turnover and destabilisation 
of venerable plaques. Produced by 
foam cells 
Rajavashisth et 
al, 1999 
Heparin –binding 
Epidermal growth factor-
like growth factor 
Increased mitogenic potential of 
SMCs in vasculature produced by 
macrophages 
Yoshizumi et al, 
1992 
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1.3.6 TNFα and CVD in Genetic Epidemiology Studies 
 
In terms of genetic epidemiology, TNFα is a very well studied marker. There are eight 
known TNFα promoter functional SNPs, and these have been investigated in a variety of 
diseases, including RA, ankylosing spondylitis, multiple sclerosis, asthma, and CVD 
(Bayley et al, 2004). Associations with disease and risk factors have so far been variable. 
For instance, the fairly common -308G/A polymorphism may be associated with 
increased transcription of the TNFα gene in vitro (Wilson et al, 1997). The 
polymorphism has been suggested to associate with metabolic markers, such as body fat 
and the hormone leptin levels (Fernandez-Real et al, 1997; Herrmann et al, 1998).  
 
The less frequent polymorphism -238G/A is in complete linkage disequilibrium with -
308, and was shown to be associated with insulin resistance (Day et al, 1998), and 
associated with the risk of MI in a retrospective study of 1213 cases (Bennet et al, 2006) 
(although the-308 polymorphism was not itself significantly associated with any factor in 
either of these studies). Another study failed to find either polymorphism associated with 
metabolic factors (Koch et al, 2000). In a further study of 641 Caucasians there was no 
association of the -308 SNP with the number of significantly diseased vessels (>50% 
occlusion), or angiographically demonstrable coronary disease (Wang and Oosterhof, 
2000). A very recent meta-analysis has examined the association of the -308 
polymorphism with ischaemic heart disease and ischaemic stroke, using >17,000 subjects 
from 23 studies (Pereira et al, 2007). Overall, no association was found; Odds ratio [OR], 
1.07; 95% confidencde intervals [CI] 0.94-1.21 and OR, 0.99; 95% CI, 0.70-1.41 for IHD 
and stroke respectively. 
 
Although this fails to implicate TNFα as a causal marker, it is important to re-emphasise 
the limitations of Mendelian randomized studies. Even if a hypothetical polymorphism 
results in a hypothetically un-confounded increase in the circulating levels of the gene 
transcript by as much as 10% (potentially a very large influence for an individual SNP) in 
the general population, this increase probably does not account for much increase in risk. 
The statistical power required to pick up the increase in risk with small confidence 
intervals is staggering. For instance, as previously described a 1g/L increase in circulating 
  47
fibrinogen results in an independent increase in OR of CHD of 1.8. In the general 
population however, a 10% increase in fibrinogen is only ~0.25g/L, which translates to 
an OR of just 1.2, and the confidence intervals of the above study of >17000 people 
(Pereira et al, 2007) would only just be sufficient to detect this in theory. This 
conservative example illustrates the problems associated with genetic epidemiological 
studies. 
 
1.3.7 TNFα and CVD in Molecular Epidemiology Studies 
 
There has been a strong suggestion in the literature that TNFα is associated with 
metabolic disorders. Adipose tissue is often considered a major producer of TNFα (Kern 
et al, 2001; Hotamisligil et al, 1993 and 1995). Indeed it appears that weight reduction in 
obese subjects without (Ziccardi et al, 2002) and with other CVD risk factors 
(Samuelsson et al, 2003) results in lowered circulating TNFα levels. Furthermore, 
systemic TNFα is a candidate mediator of insulin resistance (Borst et al, 2004) as well as 
having potential roles in influencing dylipidaemia and glucose metabolism (Feingold et 
al, 1989 and 1992; Jovinge et al, 1998). TNFα may hence be involved in both the local 
processes of atherogenesis and atherothrombosis as well as the more global metabolic 
syndrome, which as been linked with CHD risk.  
 
In two population studies TNFα levels correlated well with lipid parameters in the 
expected directions (Jovinge et al, 1998 and Skoog et al, 2002) and non-fasting glucose 
and pro-insulin correlate positively with TNFα (Jovinge et al, 1998). These results 
generally reaffirm the idea that TNFα is a candidate mediator of obesity-related insulin 
resistance and metabolic syndrome (Borst et al, 2004). A recent study suggests TNFα 
may play at least some role related to cholesterol levels and metabolism, from 
observations that a high fat meal results in depressed endothelial function and elevated 
circulating TNFα, a difference more exaggerated in those with pre-existing metabolic 
syndrome (Esposito et al, 2007). Whether TNFα is causally involved in these processes is 
currently unclear.  
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Another study contradicts all this, finding that in young healthy families (170 families), 
that TNFα levels are only associated with total cholesterol (in females) and, interestingly, 
had strong associations with IL-6 (another adipokine), but not CRP or soluble adhesion 
molecules (Haddy et al, 2003).  
 
Aside from metabolic markers of disease, TNFα does not correlate (either at all or only 
very weakly) with ultrasonic measurements of carotid intima media thickness (IMT) or 
maximal carotid plaque thickness (MCPT) in healthy people, nor with degree of 
angiographically determined coronary artery disease (CAD) and nor does it correlate with 
ABI (Skoog et al, 2002; Elkind et al, 2002 and 2005; Sukhija et al, 2007). Strong 
associations between ABI and extent of atherosclerosis have been reported (Fowkes et al, 
2006) so these results are perhaps not surprising. In addition, one recent study showed 
that TNFα did not associate with 24 hour ambulatory blood pressure in healthy 
normotensive people (Abramson et al, 2006). These results showing a lack of correlation 
of TNFα with prevalent “vascular condition” do not support, but neither do they 
preclude, a role for TNFα in CVD. 
 
There are a large number of studies which have suggested that circulating levels of 
TNFα are elevated in patients with prevalent CVD such as angina pectoris (Blabay et al, 
2001; Mizia-Stec K et al, 2002; Waehre et al, 2002; 1Cesari et al, 2003; Mizia-Stec K et 
al, 2003; Wang et al, 2004; Pasqui et al, 2006). In addition, a retrospective study (Jovinge 
et al, 1998) noted a very significant difference in TNFα levels (4.1 pg/ml ± 1.6 vs 2.5 
pg/ml ± 0.4, p<0.0001) between young male 4-6 month post-infarct patients (n= 92 and 
60) and matched healthy controls (n=63). In these retrospective studies, although acute 
inflammation may have reduced, the elevated inflammation is likely to be partially a 
consequence of reverse causation and partially due to post-infarct pathologies (such as 
CHF). 
 
In terms of TNFα being a prospective risk marker for CVD events, there are only very 
limited data in the literature and the available data appears quite disparate. This data is 
summarised in Table 1.4. Studies published after commencement of this thesis (October 
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2004) are not discussed in this section, since these were not available in considering 
assessing TNFα as a risk marker.  
 
The two earliest studies in Table 1.4 (Koukkunen et al, 2001 and the CARE trial) 
examine patients with prevalent CHD, and who have (or are likely to have; Koukkunen et 
al study) experienced ischaemic events. Inflammation caused by reverse causation in 
these patients may confound associations of baseline inflammation with risk, although 
inflammatory markers may still be useful prognostic tools in these patients. This is a 
general limitation to consider in nested case-control prospective studies comprising 
participants with prevalent CHD. Interestingly, the CARE trial, which studies recurrent 
MI, found TNFα to be a poor prognostic indicator (the paper is essentially negative since 
the 95th percentile represents only 27 people; Table 4.1). Koukkunen et al however found 
TNFα to be a reasonable prognostic marker in a similar patient group to the CARE study. 
Unfortunately it is difficult to assess the study fully because of the limited details 
divulged in the publication abstract (full paper not available). 
 
The ABC study (Table 1.4) was the only prospective study of TNFα and CVD in healthy 
people at commencement of this thesis (2Cesari et al, 2003). In this study the 180 CHD 
cases had elevated levels of TNFα, and the top tertile of TNFα expression were at 
significantly increased risk even after adjustment for classical risk factors: OR 1.6 (95% 
CI 1.23-2.26). In contrast, TNFα had no association with the risk of stroke, although both 
prospective observations were hampered by a very small number of cases. This finding 
therefore requires verification in larger studies. 
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Table 1.4 Publications of TNFα as a prospective risk marker of CVD; methods for systematic review of the literature detailed 
in chapter 2. 
* Point in population distribution at which publication reports a statistically determined increased risk (either p<0.05 or OR 
lower 95% CI > 1.00) 
† Odds ratio of event at the point of significance stated in the table after adjustment for conventional risk factors (variables are 
paper specific) unless otherwise indicated 
‡ OR of combined top 3 quartiles 
ns: Not significant
Publication Study Population Follow-
up 
End-point n cases Proportion of 
population at 
increased risk* 
OR at sig † 
(95% CI) 
Linear 
increase in 
OR? 
3Ridker et al, 
2000 
CARE Previous MI 
8.9 
months 
CHD death or 
MI 
272 > 95th percentile 2.5 (1.3–5.1) 
No (yes 
after 90%) 
Koukkunen et 
al, 2001 
- 
Unstable 
angina 
17 
months 
CHD mortality 
? 
Events from 
263 entry 
patients 
3rd tertile 3.5 (??-??) Yes 
2Cesari et al, 
2003 
ABC 
Healthy 70-
79 years old 
7 years 
CHD category 
 
Stroke category 
180 
 
60 
3rd tertile 
 
ns 
1.6 (1.23-2.26) 
 
- 
Yes 
 
- 
Tuomisto et 
al, 2006 
FINRISK 
General 
population 
9 years 
CHD event 
CVD event 
All cause death 
151 
205 
183 
2nd quartile 
2nd quartile 
4th quartile 
2.11 (1.18-4.14)‡ 
2.05 (1.15-3.36) 
2.15 (1.23-3.76) 
No 
No 
No 
Sukhija et al, 
2007 
- 
Chest pain 
and 
coronary 
angiography 
6 
months 
MI, 
coronary re-
vasularisation, 
CHD death 
55 ns (unadjusted) 1.14 (0.61-2.14) - 
50 
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1.3.8 Clinical Trials of Anti-TNFα Therapies and use in CVD 
 
Specific intervention of TNFα in human trials is possible thanks to the development of 
anti-TNFα therapies, such as etanercept, infliximab and adalimumab. TNFα is the only 
marker examined in this thesis with such existing antagonists that are approved for use in 
humans. The drugs were originally developed for use in RA, but interest is growing in 
using them in a variety of disease states, including CVD.  
 
Infliximab is a human-murine (25% murine) chimeric monoclonal antibody with high 
affinity and specificity for TNFα (Knight et al, 1993). Etanercept is a dimeric fusion 
protein, and consists of the extracellular portion of TNFR p55 linked to Fc IgG1, and 
forms less strong bonds with monomeric and membrane bound TNFα than the infliximab 
antibody (Scallon et al, 2002). Adalimumab is a recombinant human monoclonal IgG1 
antibody that is more humanized than the others (Keystone, 2004). 
 
Most clinical trials of anti-TNFα in CVD were performed on patients with CHF, due to 
the well documented association of the condition with elevated TNFα (1.3.5). On the 
basis of pre-clinical studies showing that etanercept was sufficient to reverse deleterious 
negative inotropic effects of TNFα in vitro (Kapadia et al, 1995) phase I clinical trials 
began. Small short-term studies were promising (Deswal et al, 1999). After a longer term 
world-wide study however, the RENEWAL trial (Randomized Etanercept Worldwide 
evaluation; n=1500) suggested that there was no benefit to patients, on the basis of all-
cause mortality and hospitalization for heart-failure (Mann et al, 2004). Infliximab was 
evaluated in a phase II randomised double-blind placebo-controlled pilot study where 
there was a dose dependant increase in death and CHF hospitalizations with infliximab 
compared to placebo at 14 (21%) and 28 (26%) weeks (Packer et al, 2002). It is 
interesting to speculate that in CHF patients treated with infliximab, that the ability of the 
drug to bind membrane bound TNFα in stressed cardiac tissue may mediate apoptosis, 
and worsen the ability of the heart to cope (Scallon et al, 1995 and Lugering et al, 2001) 
 
In light of these disappointing results, prescription of anti-TNFα therapies to patients 
with moderate to advanced heart failure (measured on the New York Heart Association 
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[NYHA] chronic heart failure scale as Grades III and IV) has been restricted. This 
coupled with some of the more ubiquitous side-effects of anti-TNFα therapy, such as 
hypersensitivity reactions, autoimmune reactions, acytopoenia, and some neurologic 
effects (Suryaprasad et al, 2003) as well as immunosupression, with a very high 
occurrence of respiratory infection and tuberculosis reactivation among patients (Gardam 
et al, 2003) is clearly a problem. 
 
In more recent times, a cautious optimism has crept back in to the study of the potential 
uses of these drugs in CVD. In a small cohort (n=46, controls =13) of RA patients given 
adalimumab there was a significant rise in HDL cholesterol level, and a fall in CRP and 
IL-6 levels (Popa et al, 2005). Also very recently, the new onercept therapy in 127 
psoriatic arthritis patients induced significant reductions in the levels of CRP, Lp(a), and 
homocysteine, although levels of Apo B and triglycerides were also increased (Sattar et 
al, 2007). Indeed another recent study has found that TNFα blockade may reduce carotid 
IMT in patients with RA (Porto et al, 2007). That anti-TNFα therapies can bring about a 
positive change in known cardiovascular risk markers is encouraging. However, this 
study was done on high risk, high inflammatory RA patients, and this may have some 
bearing on mechanisms by which these results are achieved, since it is not clear how 
high-grade inflammation compares to low-grade inflammation in terms of CVD 
progression (Sattar and McInnes, 2005). 
 
Prescription of TNFα blockers to patients with high-grade inflammatory disease and low 
quality of life is ethically acceptable (most are non-responders to conventional RA 
therapy); however prescription to patients that are overtly healthy individuals, or 
individuals with subclinical disease who will probably not ever experience a CVD event 
is another proposition entirely. These ethical issues mean that use of anti-TNFα therapy 
in CVD is a field that may have to wait for a new generation of drugs. 
 
1.3.9 Conclusions: 
 
Although there is strong molecular evidence for the involvement of TNFα in the 
development of the metabolic syndrome, atherosclerosis, and progression to incident 
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CVD, there is little in the way of molecular epidemiological studies to confirm these 
observations, especially in healthy populations. The existing epidemiological data 
regarding TNFα is generally hampered by small numbers, and genetic epidemiological 
studies are so disparate that no real conclusions can be drawn from the literature. 
Important roles for TNFα in RA have further led to speculation that it may be a possible 
further major CVD risk factor in patients with active high-grade inflammatory disease, 
and there is some evidence to corroborate this in studies of TNFα blockers in these 
patients. Further studies are required to elucidate the true association between TNFα and 
other CVD risk factors in the general population, as well as its association with incident 
cardiovascular events. 
 
 
1.4 IL-18 LITERATURE REVIEW 
 
1.4.1 Introduction 
Interleukin-18 (IL-18) is now recognised to be a key cytokine in the regulation of innate 
and acquired immune responses. It is expressed in tissue microenvironments central to 
pathologies in infectious disease, autoimmune disorders, at least some cancers, as well as 
at sites of chronic inflammation including atherosclerosis (Gracie et al, 2003). Being a 
relatively recently discovered cytokine there are still many enigmas regarding its in vivo 
function, although these are rapidly being elucidated and expanded on.  
 
IL-18 is a member of the IL-1β superfamily of cytokines, with a similar β-pleated sheet 
secondary structure (Bezan et al, 1996) to its homologue, although it is functionally 
related to IL-12, being synergistic in the production of IFNγ from Th1 cells (Okamura et 
al 1998). Indeed, IL-18 was originally named and identified as an IFNγ-inducing factor 
before the systematic name of IL-18 was given. The role of IL-18 in the production of 
IFNγ is particularly pertinent to atherosclerosis, since IFNγ has been shown to be 
important in progression of stable plaques to lesions with an unstable phenotype (Gupta 
et al, 1997). 
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1.4.2 IL-18 Expression, Synthesis, and Regulation 
 
IL-18 mRNA is constitutively expressed in a wide variety of cells including macrophages 
(foam cells), Kuppfer cells, T and B cells, osteoblasts, keratinocytes, dendritic cells, 
microglia and astrocytes (Akira, 2000). IL-18 has also, more recently, been observed to 
be produced by adipocytes in relatively low levels in vitro (Skurk et al, 2005). 
Constitutive expression of mRNA has speculatively been attributed to absence of 
AUUUA destabilization sequences (Puren et al, 1999) although little is known of 
regulation of transcription or translation of IL-18, or for the biological stimuli for IL-18 
expression (Gracie et al, 2003). 
 
The 24kDa precursor protein pro-IL-18 requires processing to become the biologically 
active mature 18kDa protein. Intracellular interleukin-1β converting enzyme (ICE or 
caspase-1) may mediate this cleavage (Gu et al, 1997) and capase-1 deficient mice are 
resistant to ischaemic acute renal failure (Melnikov et al, 2001). Secreted pro-IL-18 may 
be cleaved to maturity extracellularly by proteinase-3 (Sugawara et al, 2001) although the 
full relevance of this pathway is not clear in vivo. Mature IL-18 may be degraded in the 
circulation by active caspase-3, and this represents a major regulatory pathway of IL-18 
activity (Akita et al, 1997). 
 
Mature IL-18 is also regulated through the production of an IL-18 binding protein (IL-
18bp). When given to mice IL-18bp abrogates induction of IFNγ by IL-18 or LPS 
administration (Novick et al, 1999). IL-18bp belongs to the immunoglobulin superfamily 
and has limited homology to the type II IL-1 receptor (and hence binds IL-18 in a 1:1 
ratio), but lacks a transmembrane signalling domain (Akira, 2000). The discovery of IL-
1H, which has homology to IL-1 receptor antagonist, and binds the IL-18 receptor (via 
IL-1Rrp) but not the IL-1 receptor, has sparked speculation of another level of regulation 
(Pan et al, 2001). Heavy and multi-factorial regulation of IL-18 alludes to a potent 
physiological function for the cytokine. Circumstantial evidence for the immunological 
potency of IL-18 comes from the IL-18bp-like p13 protein encoded by the ectromelia 
poxvirus which inhibits IL-18 activity in vitro (Xiang et al, 1999), viral inhibition of Th1 
responses being a major virulence factor. 
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1.4.3 IL-18 Receptor and Signalling: 
 
The IL-1 and IL-18 receptors are very similar. Like IL-1β, the IL-18 functional receptor 
has a low-affinity α chain (IL-1Rrp) and a signal transducing β chain (AcPL) (Torigoe et 
al, 1997 and Born et al, 1998). Consistent with this receptor similarity, they share 
remarkable signalling similarity with each other, and the evolutionarily more ancient 
Toll-like receptors (TLRs) (Takeda et al, 2003). Upon ligand binding in these receptors, 
exposure of intracellular TIR domains (Toll/IL-1 receptor) results in recruitment of the 
adaptor proteins. The subsequent signalling process is reviewed elsewhere (Gracie et al, 
2003). In light of the fact that TIR-mediated IL-18R signalling is evolutionarily 
conserved, spatially and temporally restricted expression of the IL-18R is clearly 
important to avoid dangerously exacerbated immune responses. Among the cells shown 
to express the IL-18R are NK cells, SMCs, macrophages, vascular endothelial cells, and 
T-cells (Leung et al, 2001, Gerdes et al, 2002) 
 
1.4.4 General Biological Function of IL-18 
 
As discussed previously, the Th1/Th2 paradigm may be important in atherosclerosis. 
Although Th1 cells are thought to be the major in vivo source of IFNγ, IL-18, and IL-12 
act synergistically to increase IFNγ  production from murine macrophages (Munder et al 
1998), a potential pathway for autocrine macrophage regulation in chronic responses 
which has recently been confirmed elsewhere (Bastos et al, 2007). This mirrors several 
studies in T-cells where the combination of both cytokines was far more potent than 
either alone (Barbulescu et al, 1998). 
 
The importance of IL-18 in the production of IFNγ is evident in IL-18 deficient mice. 
These mice have circulating levels of IL-12 similar to WT controls. However, 
preconditioning of the mice with P Acnes bacterium for 7 days followed by LPS injection 
shows IL-18-deficient mice attain circulating IFNγ levels one fifth that of WT mice 
(Takeda et al, 1998). These are similar to findings in mice treated with anti-IL-18 
antibodies (Okamura et al, 1995) or caspase-1 null mice (Gahyur et al, 1997). 
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IL-18 is clearly important in the production of IFNγ. It is unsurprising then that IL-18 has 
a central role in the Th1/Th2 paradigm in the literature. IL-12 induces the expression of 
IL-18 receptors on the surface of naïve T-cells (Yoshimoto et al, 1998). Once established 
in this cytokine milieu Th2 associated IL-4 receptors are downregulated on the T-cells, 
and hence the IL-18R α chain is often used as a functional marker of Th1 cells in murine 
systems (Xu et al, 1998). In contrast, TCR ligation in the presence of IL-4 results in 
downregulation of the IL-18R α chain (Smeltz et al, 2001). It was originally thought that 
IL-18 could not contribute to Th2 responses. Gel-shift assays suggested that IL-18 did not 
induce translocation of NF-κB in Th2 cells but did in Th1 (Robinson et al, 1997). 
Whether this is an experimental artefact or if IL-18 induces other signalling pathways in 
Th2 cells is unclear, but evidence suggests that IL-13 (a Th2 cytokine) can be induced by 
IL-18 and IL-2 in synergy in the absence of IFNγ (Hosino et al, 1999). It hence seems 
possible that IL-18 can help drive a Th2 response in the absence of a Th1 cytokine 
milieu.  
 
Interestingly, it has been shown that IFNγ can be produced in atherosclerosis models in 
the absence of T-cells (SCID mice) by macrophages and smooth muscle cells although 
IL-18 and IL-12 are still required to induce production (Gerdes et al, 2002, Tenger et al, 
2005). It has also been shown that T-cells without cross-linked antigen receptors can be 
stimulated by IL-18 and IL-12 to become potent IFNγ producing cells without becoming 
antigen stimulated memory cells (Yoshimoto et al, 1998). These novel pathways in the 
production of IFNγ may have important ramifications for the process of atherogenesis 
and the development of unstable lesions. 
 
1.4.5 Pathological and Animal Studies of IL-18 in CVD: 
 
Mallat et al were the first group to show that IL-18 is expressed in human carotid plaques 
(1Mallat et al, 2001). They went on to demonstrate that transfection of ApoE -/- mice 
with intramuscular IL-18bp cDNA inhibited de novo lesion formations and slowed 
progression of more developed plaques (2Mallat et al, 2001). This work was of seminal 
importance in identifying IL-18 as a central player in atherogenesis, and was followed up 
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by Whitman (et al, 2002). They showed in the ApoE -/- model that exogenous addition of 
IL-18 increased lesion size two fold in the aortic arch and ascending aorta, but that this 
effect was almost totally abrogated in ApoE IFNγ double -/-. This directly implicates 
IFNγ as the major proatherogenic factor induced by IL-18. Yet this group also reported 
that IFNγ−deficiency had no effect on lesion size in female mice and the effect was 
restricted to male mice in a surprising gender-specific mechanism. Interestingly no 
studies have been published on IL-18 deficient female mice regarding atherosclerotic 
lesion development. Indeed, Elhage (et al, 2003) went on to show that ApoE IL-18 KO 
had reduced atherosclerosis compared to the ApoE counterparts, although the study, 
again, only used male mice. Whether this gender-specific IFNγ (and possibly IL-18) role 
is exclusive to the ApoE mouse strain, or if it is species specific, or indeed a trans-species 
phenomenon remains to be seen. The latter possibility would obviously have implications 
in the use of anti-IL-18 therapies and use of IL-18 as a marker for end-point 
cardiovascular events. However, despite this speculation a recent study has shown that 
exogenous IL-18 can mediate proatherogenic effects independently of T-cells (in SCID 
mice) (Tenger et al, 2005). This importantly suggests that IL-18 has some control of both 
innate and adaptive responses in the atherogenic setting, and hence represents a good 
potential therapeutic target. Mechanisms of potential ways IL-18 orchestrates 
proatherogeneic responses are illustrated in Figure 1.10 and in Table 1.5 
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Figure 1.10 Schematic diagram of the potential cells through which IL-18 can mediate 
proatherogenic effects (from Caligiuri et al, 2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MØ, macro-phages; DC, dendritic cells; NOS, NO synthase; COX2, cyclooxygenase 2; 
MMP3, stromelysin; TIR, Toll/IL-1R domain; IL-18BP, IL-18 binding protein; IRAK, 
IL-1 receptor–associated kinase; TRAF6, TNF receptor–associated factor 6; IL-18R , ß, 
and ß chains of IL-18 receptor. 
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Table 1.5 Illustrative table of potential direct and indirect proatherogenic stimulators and 
processes induced by IL-18 expression in experimental settings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecule 
type 
Molecule Major biological property 
and cellular source 
Reference 
Cytokine 
IL-1β 
TNFα 
IFNγ 
IL-6 
Chemokine 
Other 
MIP 1α 
IL-8 
MCP-1 
ICAM-1 
GM-CSF 
Inhibition of SMC production of 
collagen/TIMPS. 
Produced by Th1 cells/macrophage 
Neutrophil/T-cell recruitment via 
CXCR1 
Produced by activated macrophages 
T-cell/monocyte recruitment via 
CCR2 
Produced by endothelial cells 
Induction of APR. T-cell 
differentiation. 
Produced by macrophage and T-cells 
Local inflammation and endothelial 
activation. 
Produced by macrophage and T-cells 
Activation of all major inflammatory 
cells/endothelium. Pyrogen. 
Produced by macrophages 
Recruitment of all major 
inflammatory cells via CCR1/5 
Produced by PBMCs 
Endothelial adhesion of LFA-1/Mac-
1 expressing PBMCs 
Expressed on activated endothelium 
Recruitment and growth of 
endothelial cells and SMCs and DCs 
Produced by macrophages and T-
cells 
Kirii et al, 2003 
Boisvert et al, 2000 
Song et al, 2004 
Whitman et al, 2002 
Bruunsgaard, 2000 
Harrington, 2000 
Sheikine, 2004 
Kondo, 2005 
Werner, 2002 
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1.4.6 IL-18 in Genetic Epidemiology Studies: 
 
There has only been one report of IL-18 polymorphisms and their association with CVD 
risk. The Atherogene investigators report (Tiret et al, 2005) demonstrated in 1288 
patients that IL-18 haplotypes account for a small amount of heterogeneity in inter-
individual IL-18 expression (around 2%) and that these haplotypes were also associated 
with cardiovascular disease (CVD) mortality (P=0.006). Haplotypes GCAGT and 
GCCAT were associated with opposite effects on risk (OR=0.57, 95% CI 0.36 to 0.92, 
versus OR=3.01, 95% CI 1.27 to 7.13, respectively).  That IL-18 gene polymorphisms are 
associated with both circulating IL-18 levels and incident CVD (the haplotype 
association with incident CVD was abrogated when corrected for IL-18 expression) adds 
further evidence of a possible causal role to existing animal and tissue studies. These 
findings require corroboration, especially in light of sizeable confidence intervals, despite 
the reasonable study size. 
 
Very recently several IL-18 polymorphisms have been investigated in relation to obesity 
and the need for coronary bypass artery grafting, and the study found some promoter 
polymorphisms to be associated with these clinical conditions (Thompson et al, 2007). 
The associations were not particularly strong, and more studies are required. 
 
1.4.7 IL-18 in Molecular Epidemiology Studies: 
 
Like TNFα, IL-18 may be associated with the metabolic syndrome and adipose tissue 
mass. In a study of 120 pre-menopausal women, 60 women who improved their diet over 
2 years consequently lowered their BMI and a concomitant drop in circulating levels of 
cytokines, including IL-18 was observed (Esposito et al, 2003). In another study, serum 
IL-18 concentration measured in 955 subjects correlated with metabolic syndrome traits 
including body mass index (BMI), waist circumference, triglyceride, high-density 
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lipoprotein (inversely), and fasting glucose and insulin levels (Hung et al, 2005). In this 
study, after adjusting for age, gender, BMI, and insulin levels, increasing IL-18 levels in 
the top tertile were associated with an OR for metabolic syndrome of 2.28, strongly 
suggesting that elevated circulating IL-18 is either a cause or consequence of metabolic 
syndrome (Hung et al, 2005). These findings are contradicted in a later study of 261 
healthy people, where IL-18 did not correlate with BMI, and only weakly with waist to 
hip ratio, although it did correlate with hypertension (Vilarrasa et al, 2006), and are also 
contradicted in the MONICA/KORA study, where IL-18 levels correlated with insulin 
sensitivity, predicted risk of type II diabetes, but did not associate with BMI or fat-free 
mass (Thorland et al, 2005; Herder et al, 2006). IL-18 is only produced in low levels by 
adipocytes in vitro (Skurk et al, 2005), and while this may be sufficient for 
adipocyte/leucocytes cross-talk, it is not yet consistently clear if this has any bearing on 
circulating levels of IL-18. 
 
Several studies have reported that in patients with prevalent CVD disease, IL-18 levels 
are correlated with the extent of CAD, as measured by degree of stenosis, number of 
affected vessels, or to a lesser extent coronary plaque area (Yamashita et al, 2003; 
Yamaoko et al, 2003; Suchanek et al, 2005) as well as diabetes and smoking (Suchanek 
et al et al, 2005). A study of 366 patients who had carotid IMT measured at 12 sites 
showed that serum IL-18 was associated with mean IMT (r = 0.36; p<0.001) (Yamagami 
et al, 2005) even after adjustment for traditional risk factors and CRP (r = 0.20; p<0.001). 
However, a larger study (n=1111) recently suggested that only the univariate association 
was significant (Chapman et al, 2006). In addition, a recent study (Espinola-Klein et al, 
2007) found in 720 patients that IL-18 levels were not different in patients with no 
significant CAD, those with CAD, or those with clinically relevant multi-vessel disease. 
Although these studies are not entirely consistent, overall there is evidence to suggest that 
in human populations that circulating IL-18 may be associated with some markers of the 
metabolic syndrome and degree of atherosclerosis. 
 
Several small studies (Seta et al, 2000; Mallat et al, 2002; Rosso et al, 2005) have shown 
that circulating levels of IL-18 are elevated in patients with prevalent CHD, and that IL-
18 levels correlate with the extent of myocardial necrosis (Seta et al, 2000) and with left 
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ventricle ejection fraction (LVEF) (Mallat et al, 2002). Recently, univariate comparisons 
between retrospective MI cases and controls have shown IL-18 levels to be elevated 
among cases (309.6 pg/ml ± 138.6 vs 285.4 pg/ml ± 115.7 p<0.01) (Hulthe et al, 2006). 
Another small study (Nairns et al, 2004) has shown that in patients requiring 
percutaneous coronary intervention, a cohort that recently experienced MI had elevated 
plasma levels of IL-18 compared to those who had not. The significance of this result 
improved when instead of using circulating IL-18, IL-18/IL-18bp ratio was used (p<0.05 
vs p<0.02). This suggests that IL-18 may be active in post-MI dysfunction as opposed to 
acting as a passive marker of subsequent systemic inflammation.  
 
There are limited prospective data available linking IL-18 to CVD risk. These are 
summarised in Table 1.6. Studies published after commencement of this thesis (October 
2004) are not discussed in this section, since these were not available in considering 
assessing IL-18 as a risk marker. As can be seen in Table 1.6 before this thesis was 
undertaken, the published literature prospectively examining IL-18 was dominated by 
one group, who showed that IL-18 was predictive of risk of incident CVD in both healthy 
middle-aged men, and in a population with existing CAD (Blankenberg et al, 2002 
[Atherogene]; Blankenberg et al, 2003 [PRIME]). Strikingly, IL-18 had fairly similar 
predictive properties in both cohorts (although the Atherogene cohort was divided in 
quartiles and not thirds). In the PRIME cohort IL-18 was suggested to be a better 
predictor of risk than total cholesterol/HDL cholesterol ratio or CRP when 
simultaneously introduced in a model additionally adjusted for BMI, smoking status, 
diabetes, and hypertension. The adjusted ORs (per tertile) were 1.65 (95% CI 1.19 to 
2.29) for the lipid ratio, 1.63 (95% CI 1.17 to 2.27) for CRP, and 1.82 (95% CI 1.30 to 
2.55) for IL-18, respectively (top versus bottom tertile). These reported associations are 
quite strong. In the Atherogene study, after adjustment for most potential confounders 
including ejection fraction and inflammatory variables, patients within the highest 
quartile of IL-18 had a 3.3-fold (95% CI, 1.3 to 8.4; P=0.01) increase in risk. Similarly in 
PRIME there was an OR~2 in the top tertile of IL-18 for combined endpoints in fully 
adjusted models. In both cases IL-18 was a better predictor than CRP. These interesting 
results clearly required further investigation. 
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Table 1.6 Publications of IL-18 as a prospective risk marker of CVD; methods for systematic review of the literature detailed 
in Chapter 2. 
* Point in population distribution at which publication reports a statistically determined increased risk (either p<0.05 or OR 
lower 95% CI > 1.00) 
† Odds ratio of event at the point of significance stated in the table after adjustment for conventional risk factors (variables are 
paper specific) unless otherwise indicated 
‡ Increase in OR per quartile/tertile 
§ Same study, different follow-up 
ns: Not significant
Publication Study Population Follow
-up 
End-point n 
cases 
Proportion of 
population at 
increased risk* 
OR at sig  
(95% CI)† 
Linear 
increase in 
OR? 
Blankenberg 
et al, 2002§ 
Atherogene 
Stable/ 
unstable 
angina 
3.9 
years 
CVD death 95 2nd quartile 1.44 (1.17-1.78)‡ Yes 
1Blankenberg 
et al, 2003 
PRIME 
Healthy men 
50-59 yrs 
5 
years 
CHD death or 
MI or angina 
onset 
335 2nd tertile 1.42 (1.13-1.79)‡ Yes 
Kip et al, 
2005 
WISE 
Women with 
suspected MI 
4.7 
years 
MI, stroke, 
CHF, CHD 
death 
136 ? ? ? 
Tiret et al, 
2005§ 
Atherogene CAD 
5.9 
years 
Death from 
CVD 
142 4th quartile 2.31 (1.42-3.73) Yes 
Blankenberg 
et al, 2006 
HOPE 
CAD, stroke, 
PVD, diabetes 
4.5 
years 
MI, stroke, 
CHD death 
501 3rd tertile 1.29 (1.03-1.62) Yes 
Koenig et al, 
2006 
MONICA 
Augsberg 
Healthy men 
and women 
11 
years 
Incident CHD 382 ns 1.21 (0.8-1.69) n/a 
Espinola-
Klein et al, 
2007 
Atherogene 
Coronary 
angiography 
6.5 
years 
Cardiovascular 
Death 
75 Above median 2.8 (1.6–4.9) n/a 
63 
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1.4.8 Clinical trials of Anti-IL-18 Therapies and use in CVD: 
 
Original interest in the inhibition of IL-18 came from rheumatic disease research, much 
as did anti-TNFα therapies. There are currently no IL-18 inhibitors approved for use in 
humans, although there are several drugs in phase one and two clinical trials. These drugs 
act at several levels of inhibition, including anti-IL-18 mAbs, recombinant / homologous 
IL-18bp, recombinant / homologous IL-1H, and ICE inhibitors. ICE inhibitors obviously 
have a direct effect on IL-1β production as well as IL-18. There have been several 
attempts at clinical trials of these drugs (such as Pralnacasan) although these have so far 
been unsuccessful due to excessive toxicity (Randle et al, 2001). 
 
1.4.9 Conclusions: 
 
Similarly to TNFα, there is pathological and limited genetic and epidemiological 
evidence that IL-18 may be important in atherogenesis, the metabolic syndrome, and in 
association with risk of subsequent cardiovascular events. As with TNFα, IL-18 plays a 
major role in the Th1 RA-associated chronic inflammatory response, and is a possible 
molecular link between RA and elevated CVD risk. At the outset of this thesis there was 
currently only one study that prospectively examines the association of IL-18 with risk in 
generally healthy populations. There is a requirement for more prospective data of IL-18 
as a marker, produced by other laboratories, in order to confirm the current literature and 
to expand on it. 
 
 
1.5 MMP-9 LITERATURE REVIEW 
 
1.5.1 Introduction: 
 
The matrix metalloproteinases (MMPs) are a family of zinc-containing endoproteinases 
that have similar structural domains, but differ in terms of substrate specificity, cellular 
source, expression, and regulation. Recent advances have seen the list of known MMPs 
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extend to in excess of twenty members identified in mammals (Woessner, 2002). These 
enzymes can be classified into a family based on several observations pertinent to the 
function of them all (Klein et al, 2004): 
 
• Their enzymatic function centrally involves degradation of extracellular matrix 
components (ECM), although the family as a whole has a spectrum of specificity. 
• They are zymogens and require to be enzymatically activated to become proteolytic. 
• The active domain has an unusual, but functionally important Zn2+ atom. 
• They are inhibited by a family of specific tissue inhibitors (TIMPS). 
• Ca2+ is required for stability 
• They function at neutral pH 
 
Based on major substrate specificity, the MMPs were historically categorised into four 
subgroups (Creemers et al, 2001): 
• Collagenases such as MMP-1 (interstitial collagenase). These can cleave fibrillar 
collagens (types I, II and III) which are dense and highly cross-linked. 
• Stromelysins such as MMP-3. These are broad specificity proteinases for proteoglycans, 
lamanins, fibronectin, vitronectin and some collagens. 
• Gelatinases, including MMP-9 and MMP-2 (gelatinase B and A respectively). These are 
well known for the ability to degrade gelatins (i.e. denatured collagen fragments).  
• The last group are membrane-type MMPs (MT-MMPs) which degrade some ECM 
components and are able to activate soluble MMPs. 
 
1.5.2 MMP-9 Expression, Synthesis, and Regulation: 
 
MMP-9 (also known as gelatinase B and 92kDa type IV collagenase) was originally 
discovered as a neutrophil product (Sopata et al, 1974) where it is expressed in large 
quantities in tertiary granules (Cowland et al, 2000). It is also found in monocyte 
supernatents (Mainardi et al, 1984). Neutrophils and macrophages are still regarded as the 
major in vivo cellular sources of MMP-9, although lymphocytes, dendritic cells, 
connective tissue cells and epithelial cells can also be induced to express under 
inflammatory conditions (1Opdenakker et al, 2001). It noteworthy that whilst most 
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immunological cells express gelatinase A constitutively, gelatinase B requires adequate 
inflammatory triggering, and neutrophils produce the only biologically pre-stored MMP-
9 in tertiary granules (1Opdenakker et al, 1991). 
 
MMP-9 is regulated at the transcriptional level, with several cis elements in the promoter 
region playing a major role (Huhtala et al, 1991 and Gum et al, 1996). Chief stimulators 
of MMP-9 include IL-1β , platelet-derived growth factor, TNFα and EGF (Huhtala et al, 
1991; Fabunmi et al, 1996; Kondapaka et al, 1997). In addition, a cell surface protein that 
induces general MMP expression has been identified in both normal and diseased human 
tissue and has been termed extracellular MMP inducer (EMMPRIN) (Spinale et al, 2000).  
 
The MMP-9 molecule is initially expressed in a latent state and requires proteolytic 
cleavage to become activated. Extracellular cleavage can be mediated by a number of 
proteinases, although plasmin is thought to be the most potent activator of most MMPs in 
vivo (Murphy et al, 1994), via cleavage of a cysteine sulfhydryl switch. It is thought that 
plasmin cleaves the latent MMP, which induces a conformational change and renders the 
activation site ready to be cleaved by a second protease, usually another MMP (see 
Figure 1.11), although the first cleavage is probably the rate-limiting step for activation 
(Nagase H, 1997). In addition to this, in neutrophils, intra-granular hypochlorous acid can 
directly activate pro-MMP-9 (Peppin et al, 1986). 
 
Once secreted, MMP-9 can still be regulated by degredation or by inhibition. α2- 
macroglobulin is a universal protease inhibitor present in human serum and inhibits 
MMP-9 directly (Birkedal-Hansen et al, 1993). More specifically, there are a group of 
tissue inhibitors of matrix metalloproteinases (TIMPs) comprising TIMP-1,-2,-3 and -4 
which bind to MMPs non-covalently in a 1:1 ratio (Gomez et al 1997). These TIMPs 
demonstrate limited specificity for MMPs, with TIMP-1 being the major inhibitor of 
MMP-9, but TIMP-2 and -3 also are (Gomez et al, 1997). TIMP-1 is similar to MMP-9 in 
that it requires to be induced, whilst TIMP-2, which has stronger specificity for gelatinase 
A, is produced constitutively (Gomez et al, 1997). Interestingly, TIMP-1 and -3 can bind 
pro-MMP-9 (Olson et al, 1997). 
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MMP-9 produced by macrophages is directly released in a pro-MMP-9/TIMP-1 complex 
(2Opdenakker et al, 1991) whilst neutrophils do not make TIMP-1 at all (Masure et al, 
1991). It is interesting to speculate that this reflects different roles of each cell 
respectively in terms of inflammation and ECM turnover. Neutrophils represent a more 
acute response requiring ECM turnover as a pre-requisite for repair and angiogenesis, 
whilst monocytes require an inflammatory microenvironment to bring about ECM 
degredation, representing a more chronic response type. 
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Figure 1.11 The known activation network of MMPs. Arrows indicate the active form of 
one enzyme may participate in the activation of the other enzyme from its latent state. 
Note that MMP-9 is an end-product of the pathway, which may signify biochemical 
importance. From Van Den Steen et al, 2002 
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1.5.3 General biological function of MMP-9: 
 
Gelatinases are identified on the basis of their ability to cleave the ¾ and ¼ collagen 
fragments yielded from the actions of interstitial collagenases on collagen. The substrate 
based division of MMPs was useful in the past, but increasingly it has become clear that 
functional profiles of these enzymes are gradually graded rather than absolute (and are 
not restricted to proteolysis of ECM components). MMP-9 is a good example of this 
since it can also degrade interstitial collagens (Okada et al, 1995) and type IV collagen in 
the basement membrane (Pauly et al, 1994) as well as proteoglycan core protein and 
elastin (Birkedal-Hansen, et al 1993), which are resistant to degradation by some other 
MMPs. Indeed, although MMP-9 is primarily regarded to functionally be a gelatinase, 
this function remains to be directly proven in vivo. However, broad specificity clearly 
may make MMP-9 a key player in ECM turnover. 
 
The normal turnover of ECM is an important physiological process. The ubiquitous ECM 
provides biomechanical support to structures on all scales from individual cells to 
complex organs, and ECM turnover permits growth, repair and replacement of cellular 
tissue (Birkedal-Hansen, et al 1993) whilst controlling transformed cell growth though 
steric limitations. Interestingly, MMP-9 has been implicated in tumour cell invasion and 
metastasis largely due to its ability to degrade ECM, and in particular type IV collagen in 
the basement membrane (Himelstein et al, 1994). 
 
Unsurprisingly for a molecule with such stark association with immune cells, the MMP-9 
molecule also seems to possess some pro-inflammatory properties. It is postulated that 
MMP-9 plays a major role in leukocytosis and inflammation for several reasons. Firstly, 
it may be functionally important in allowing peripheral stem-cell mobilization (Pruijt et 
al, 1999) and extravasation of circulating leukocytes (Opdenakker et al, 1998) through 
targeted degradation of the basement membrane. This allows a localized cellular immune 
response to take place. Secondly, there is a positive feedback loop seen between IL-8 and 
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MMP-9. Active MMP-9 potentiates IL-8 tenfold by aminoterminal processing through 
cleavage to IL-8(7-77), and this more potent IL-8 is a stronger chemoattractant for more 
neutrophils, which degranulate locally and release MMP-9 (Van den Steen et al, 2000) 
(see Figure 1.12). The same study showed that some other chemokines such as CTAP-III, 
PF-4 and GRO-α were degraded by MMP-9, alluding to the fact that MMP-9 does not 
only amplify a cellular response through IL-8, but fine-tunes it (Van den Steen et al, 
2000). Thirdly, further upstream in the immune response, MMP-9 can take the place of 
interleukin-1β converting enzyme (ICE) and cleave the pro-form of the cytokine, not to 
potentiate, but to activate (Schonbeck et al, 1998) although the physiological relevance of 
this in “normal” in vivo processes is not clear. 
 
On a larger scale MMP-9 has a role in many important physiological processes and 
disease states (see Table 1.7). Many of the disease states MMP-9 has been implicated in 
are classical Th1 type inflammatory driven diseases, and it has been observed that Th1 
cytokines enhance MMP-9 expression, whilst Th2 cytokines (such as IL-4, IL-10 and 
TGF-β) suppress expression of MMP-9 and/or enhance expression of TIMP-1 (Van den 
Steen et al, 2001). 
 
Interestingly MMP-9 null mice themselves show very little if any signs of having 
immunological deficiencies (Van Den Steen et al, 2002) in pathogen free, or conventional 
animal house conditions (Dubois et al, 1999) a fact that has stepped up efforts in research 
for pharmacological inhibition of MMP-9.  
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Figure 1.12 Simplified diagram of the positive feedback inter-relationship between IL-8 
and MMP-9. Adapted from 2Opdenakker et al, 2001 
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Table 1.7 Illustrative table of some of the physiological and pathological non-CVD 
functions of MMP-9. Adapted from Van den Steen et al, 2002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathological Function 
 
References KO mouse phenotype References Physiological Function 
Reproduction –  
Female menstrual cycle 
Blastocyte implanation 
Van Den Steen et al, 
2002; Librach et al, 
1991 
Impaired reproductive 
abilities 
Dubois et al, 2000 
Growth and development Everts et al, 1992 Delayed ossification of 
long bones, reduced 
angiogenesis 
Vu et al, 1998 
Bergers et al, 2000 
Inflammation and 
leukocyte mobilization 
Kobyashi et al, 
1999; Van Den 
Steen et al 2002; 
Opendakker et al, 
2001 
Impaired stem/progenitor 
cell recruitment, impaired 
neutrophil/ langerhans 
cell chemotaxis, 
prolonged delayed 
hypersensitivity 
Hessig et al, 2002; 
D’Hase et al, 2000; 
Wang et al, 1999 
References KO mouse phenotype References 
Tumour growth and 
progression 
Himelstein et al, 
1994 
Impaired pro-angiogeneic 
function and metastasis 
of transformed cells 
Bergers et al, 2000; 
Itoh et al, 1999 
Autoimmune diseases e.g 
Rheumatoid arthritis  and 
SLE (inititation by 
immunodominant antigen 
processing?) 
Van Den Steen et al, 
2002;  Koolwijk et al, 
1995; Ram et al, 2006 
Resistant to experimental 
autoimmune 
encephalomyelitis 
Dubois et al, 1999 
Chronic wounds Wysoki et al, 1993 Resistance to necrotizing 
tail lesions 
Dubois et al, 1999 
Bacterial sepsis Paemen et al, 1997 Resistance to LPS shock Dubois et al, 2002 
Altzheimer’s disease Backstrom et al, 
1996 
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1.5.4 Pathological and animal studies of MMP-9 in CVD: 
 
In chronic inflammation associated with build up of atherosclerotic plaques, neutrophils 
are usually present only in very low numbers in the vasculature (Hiuchi et al, 2002), 
hence any MMP-9 present is likely to be (largely) produced by macrophages and foam 
cells. Indeed macrophages have been shown to produce MMP-9 in both experimental 
(Galis et al, 1995) and human (Galis et al, 1994; Brown et al, 1995) atherosclerotic 
plaques. 
 
A wealth of literature associates increased expression of MMP-9 with compensatory 
vascular remodelling during atherosclerotic lesion growth. It is currently believed that 
vascular expansion compensates for luminal occlusion caused by lesion swelling, but that 
this process may be (partially) causal in rendering the plaque prone to rupture in the 
longer term (Nishioka et al, 1997). Expansion of the vasculature requires the action of 
MMPs, as suggested by Pasterkamp et al (Pasterkamp et al, 2000) who reported that 
although constrictive and expanded coronary arteries contain similar macrophage loads in 
the plaque, both MMP-9 and MMP-2 are expressed in greater quantities in the expanding 
arteries. This role for MMP-9 is supported by experiments in MMP-9/ApoE double 
knock-out mice. It was shown that ApoE KO mice had increased artery size by 3.1 fold 
14 days following induction of flow cessation (area measured encompassed external 
elastic lamina) whilst there was only a 1.6 fold increase in the double KOs (Lessner et al, 
2004). The presence of MMP-9 in pathological vascular expansion (aneurisms) 
(Freestone et al, 1995) also supports MMP-9 playing a role in vascular remodelling. 
Another study has shown that MMP-9 KO mice on the 129/SvEv background have 
impaired SMC migration in an intimal lesion model (Galis et al, 2002). Although this 
observation may have limited relevance to humans (since the human intima already has 
SMCs), SMCs from the KO mice had impaired capability to contract collagen, suggesting 
a role not only in degradation, but also in reorganisation of collagenous matrix.  This was 
supported by the observation that these KO mice had decreased intimal thickening as 
well as impaired geometric remodelling. 
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In the face of this evidence then, it is perhaps not surprising that MMP-9 has been 
associated with de-stabilisation of atherosclerotic lesions. Although the mechanisms of 
this process are not fully elucidated, especially in humans, it may be implied that as the 
plaque grows in an inflammatory environment MMP-9 compensates by opening up the 
lamina through geometrical remodelling. Although this temporarily relives potential 
occlusion, the plaque and the necrotic lipid core becomes bulkier, and further matrix 
turnover in the face of decreased collagen deposition due to SMC necrosis compromises 
the supportive collagenous matrix, rendering the lesion prone to stress-induced or 
spontaneous rupture. These potential mechanistic roles of MMPs in the development of 
ACS have been summarized previously in Figure 1.6. 
 
This model is supported by several studies. Libby’s group (Galis et al 1994) originally 
demonstrated that atherosclerotic plaques displayed locally increased concentrations of 
MMP-9 in the shoulders and regions of high-density foam cell accumulation. 
Furthermore, they showed via in situ zymography that this MMP-9 was active as opposed 
to the latent form found in normal arteries. In addition, the production of MMP-9 has 
been shown to be higher in unstable carotid plaques (Loftus et al, 2000). It was also 
shown in vitro that human monocyte-derived macrophages (HMDMs) can directly 
degrade fibrous caps from aortic of carotid plaques, and that this process could be limited 
by the addition of TIMP-1 (Prediman et al, 1995).  
 
As well as playing a role in the build up to MI (and perhaps other ACS) MMP-9 had been 
implicated in playing a pathophysiological role in post-MI changes in myocardial tissue. 
The processes involved in these changes are not fully understood, but include left 
ventricular dilation, potentially leading to CHF or, in extreme cases, LV rupture 
(Thompson et al, 2002). Following the acute insult of ischaemia/reperfusion injury to the 
myocardial tissue, neutrophils rush to the area of insult and degranulate (Lindsey et al, 
2001), releasing MMP-9 and resulting in further inflammation and tissue injury (Van den 
Steen et al, 2000; Frangogiannis et al, 2002). Romanic et al (Romanic et al, 2001) 
demonstrated that MMP-9 was upregulated within 24hrs of MI and that this was 
simultaneous with a decrease in TIMP-1, and MMP-9 knock-outs have smaller infarcts 
than controls (Romanic et al, 2002). Similarly, MMP-9 is also thought to play a role in 
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disruption of the blood brain barrier following focal cerebral ischemia (Fujimura et al, 
1999) and so is important in pathologies following ischaemic events in both stroke and 
ACS. 
 
Similarly to the acute inflammatory model of ischaemia/reperfusion, MMP-9 is also 
suggested to be involved in restenosis following percutaneous coronary intervention 
injury. MMPs in general are considered important contributers to intimal hyperplasia that 
follows either stent implantation or balloon angioplasty by allowing cellular infiltrates to 
extravasate following injury (Bendeck et al, 1996) and MMP-9 may be particularly 
important in these processes (Feldman et al, 2001). 
 
1.5.5 MMP-9 and Plasma or Serum Measurement: 
 
Manufacturer’s instructions for the performance of MMP-9 ELISA (R&D Systems) 
indicate that citrated and EDTA plasmas are unsuitable for use in determination of 
circulating MMP-9 (see Chapter 2). Measurement of MMP-9 in serum has recently been 
called into question in the literature by one report, which suggests that serum samples are 
not suitable for use in measurement of MMP-9 due to “artificially high levels” in serum 
compared with plasma and EDTA (n=8 for each) (Gerlach et al, 2007). Although there is 
probably some basis for this argument, the authors make several assumptions:  
 
1. That zymography and ELISA measurements are equivalent in measuring circulating 
MMP-9 (since they used zymography, but not ELISA techniques; something unlikely to 
be done in mass screening of a biomarker). 
2. That because serum levels of MMP-9 are high and citrated or heparin samples are low, 
that these low levels reflect “true” circulating biological levels. This is not necessarily 
true, since it may reflect assay interference e.g. through chelation.  
3. Tying in with the previous point, levels of plasma MMP-9 are very often below the 
level of detection in healthy populations (e.g. Sundstrom et al, 2004; ~20% of a healthy 
population had detectable circulating MMP-9) and therefore measurements are 
statistically weak for use in multivariate models of disease risk. 
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More research is required in this area, although this may have to wait for newer ELISA or 
other related detection technologies for MMP-9. 
 
1.5.6 MMP-9 in Genetic Epidemiology Studies: 
 
As mentioned previously in this report, MMP-9 expression is primarily regulated at the 
transcriptional level, and accordingly there has been some interesting epidemiological 
work done on a functional MMP-9 promoter polymorphism.  
 
Zhang (Zhang et al, 1999) reported a novel –1562 C to T polymorphism in the MMP-9 
promoter, and that this polymorphism showed increased expression functionality in 
transfection models. Studying this promoter, a sample of 584 male patients with MI and 
645 controls from the ECTIM study (Etude Cas-Temoins de I’Infarctus du Myocarde) 
were genotyped, and although allele frequencies between cases and controls did not vary, 
26% of those carrying 1 or 2 copies of the T allele had >50% stenosis in 3 coronary 
arteries, as opposed to only 15% of C/C homozygotes (p<0.02 after adjustment for age 
and referral centers) (Zhang et al, 1999). This suggests that although the polymorphism 
may not be associated with actual MI incidence, it is associated with angiographically 
determined symptoms of advanced atherogenesis, although in epidemiological terms the 
statistical association is fairly weak. A later study confirmed this finding in an autopsy 
study of 276 men (Pollanen et al, 2001) and showed MMP-9 genotype was associated 
with complex lesion area after adjustment for age, BMI, hypertension, diabetes and 
smoking (p=0.012). Another more recent study in 215 untreated hypertensive men 
showed that the T allele was associated with higher serum MMP-9, higher BP (r=0.25) 
and pulse wave velocity (r=0.48) (Zhou et al, 2007). Other studies have found the 1562C-
T polymorphism not be associated with aneurysmal CAD (Lamblin et al, 2002), risk of 
MI (1Blankenberg et al, 2003), spontaneous cervical artery dissection (Wagner et al, 
2004,) haemorrhagic transformation or parenchymal haematoma following recombinant 
tissue plasminogen activator (rt-PA) administration in stroke treatment (Montaner et al, 
2003), nor differential levels of detectable MMP-9 activity in the plasma of healthy 
subjects at all (Demacq et al, 2006). 
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A different promoter polymorphism in the MMP-9 promoter, encompassing a (CA)n 
repeat element, has been implicated in intra-cranial aneurysm through action in the circle 
of Willis (Peters et al, 1999), although small study numbers (n=76) makes this study less 
robust. Another study suggests the number of repeats may be linked to plaques with thin 
fibrous cap and echolucent core (OR, 13.1; 95% CI, 1.6 to 100), although again this was 
only in 110 patients, and the confidence intervals are very wide (Fiotti et al, 2006). 
 
1.5.7 MMP-9 in Molecular Epidemiological Studies: 
 
Data regarding correlations of MMP-9 with other risk markers, particularly those 
associated with atherosclerosis, are sparse in the literature. One report in the Anglo-
Scandinavian Cardiac Outcome Trial (ASCOT) showed that in 96 hypertensive patients, 
a clinical “package of care” treatment to reduce BP resulted in lowered MMP-9 levels 
(110 vs 80 ng/ml median; p= 0.035) as well as BP over 3 years (1Tayebjee et al, 2004). In 
line with some of the genetic studies above, molecular studies also suggest an association 
of MMP-9 with hypertension and arterial elasticity (2Tayebjee et al, 2004; Yasmin et al, 
2005). A cross-section of the Framingham cohort was used to examine circulating MMP-
9 plasma levels and correlations with CVD-specific echocardiographic left ventricular 
measurements (Sundstrom et al, 2004). Unfortunately, since the study used plasma 
(presumably citrated) only 20% (detectable n=138) of the cohort had detectable MMP-9.  
They did show that detectable plasma MMP-9 was significantly correlated with heart rate 
and antihypertensive medication. It also showed associations with increased LV internal 
dimensions, LV mass, and LV wall thickness in men but not in women, although these 
observations are hampered by small numbers of observations.  
 
Circulating MMP-9 has been shown to be elevated in the blood of patients with acute 
coronary syndromes, including unstable (but not stable) angina (Kai et al, 1998; Inukubo 
et al, 2001; Fukuda et al, 2006). Interestingly, this could mean that MMP-9 is elevated in 
people who experience ischaemic events (silent or clinical) but not in those with only 
diffuse atherosclerosis, which may preclude use of MMP-9 as a marker of long-term risk. 
These are only small studies however, and more data is required. The FINRISK 
retrospective study has reported (cases n=120) that MMP-9 levels are significantly raised 
  78
in men with a history of MI compared with healthy controls (Renko et al, 2004). This is 
consistent with the hypothesis for a role for MMP-9 in post-ischaemic pathologies. 
Interestingly, there is a peak in MMP-9 expression immediately following MI in both 
coronary arteries and venous blood (Funayama et al, 2004; Squire et al, 2004), and 
MMP-9 levels correlate with echocardiographic and neurohormonal (N-terminal B-type 
natriuretic peptide) measures of LV dysfunction, and may be prognostic of post-MI CHF 
(Squire et al, 2004).   
 
There are limited prospective data available for MMP-9, especially in healthy 
populations. These are summarized in Table 1.8. Studies published after commencement 
of this thesis (Oct 2004) are not discussed in this section, since these were not available 
in considering assessing MMP-9 as a risk marker. As can be seen, there was only one 
prospective study of MMP-9 at the outset of this thesis. The Atherogene study 
(2Blankenberg et al, 2003) examined 97 incidents of MI or fatal CVD in CAD patients, 
and found that MMP-9 was a moderate predictor of CHD; OR 1.4 (95% CI 1.2 to 1.8; 
p<0.0001), which attenuated to 1.3 after adjustment for confounders (95% CI 1.1 to 1.6; 
p=0.005). MMP-9 was not significantly associated with non-fatal MI, perhaps due to 
small numbers (n=41), although the unadjusted combined (fatal and non-fatal) OR was 
1.3 (95% CI 1.11 to 1.52; p<0.002). The authors also show that (in this study) MMP-9 
does not correlate strongly with acute-phase reactants, or associated, markers, and adds 
complementary information by simultaneous determination with IL-18. This isolated 
study suggests that MMP-9, generally similarly to other inflammatory markers, is a 
moderate marker of risk of MI in a population with prevalent CVD. More data is required 
to confirm and expand on this. 
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Table 1.8 Publications of MMP-9 as a prospective risk marker of CVD; methods for systematic review of the literature detailed 
in chapter 2. 
* Point in population distribution at which publication reports a statistically determined increased risk (either p<0.05 or OR 
lower 95% CI > 1.00) 
† Odds ratio of event at the point of significance stated in the table after adjustment for conventional risk factors (variables are 
paper specific) unless otherwise indicated 
‡ OR of increasing quartiles (univariable) 
§  Univariate OR 
ns: Not significant
Publication Study Population Follow-
up 
End-point n cases Proportion of 
population at 
increased risk* 
OR at sig  
(95% CI)† 
Linear 
increase 
in OR? 
2Blankenberg 
et al, 2003 
Atherogene CAD 
4.1 
years 
CVD death 
or non-fatal 
MI 
137 2nd quartile 
1.30 (1.11–
1.52)‡ 
Yes 
Wu et al, 
2005 
- Stable angina 
17.7 
Months 
CVD event 48 ns - - 
Cavusoglu et 
al, 2006 
 - 
Patients 
undergoing 
angiography 
2 years 
All cause 
mortality 
51 ns 
0.78 (0.58-
1.04)§ 
- 
Eldrup et al, 
2006 
- 
CAD 
patients 
4.4 
years 
Stroke or 
CVD death 
53 Above median 1.9 (1.1-3.5) n/a 
79 
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1.5.8 Clinical Trials of Anti-MMP-9 Therapies and use in CVD: 
 
Due to the wide range of diseases that MMPs in general play a role in there has been 
much interest in pharmacological inhibition, although this has not as yet proven 
successful in terms of acceptable toxicity of inhibitors. 
 
Use of TIMPs as therapeutic inhibitors of MMPs is attractive, although non specific 
actions would precludes them from use in controlled trials to study specific MMP-9 
inhibition. In any case, short TIMP half-life currently precludes therapeutic use (Curran 
et al, 2000).  
 
Other ways inhibition may be achieved include at the transcriptional level, or directly on 
the enzyme itself. Known low molecular weight transcriptional inhibitors include 
xanthine derivatives, non-steroidal anti-inflammatories, and statins (2Wilson et al, 2005; 
Bellosta et al, 1998; McMillan et al 1996; Van den Steen et al, 2001). Hydroxamates, D-
penicillamine, and tetracyclines have been described to inhibit MMP-9 activity directly 
(Cuzner et al, 1999). Although interesting these drugs have limited use in experimental 
models or in the clinic in terms of specific inhibition of MMP-9 or indeed MMPs in 
general. Many of these synthetic inhibitors were designed to be zinc-chelators, and 
reacted with other MMPs and proteases (Pavlaki et al, 2003). Lack of specificity may 
bring about additional unwanted side-effects in clinical trials of these drugs, e.g. in cancer 
therapies (Pavlaki et al, 2001; Hidalgo et al, 2001), whilst it renders them unsuitable in 
experimental models due to confounding effects. The most promising current compound 
is the covalent-binding mechanism based SB-3CT, which has specificity for gelatinases 
(although, again, not specifically MMP-9) and has shown some promise in the area of 
cancer research (Kruger et al, 2005). This research has also been extended to a potential 
use in acute stroke, since mice with focal cerebral ischaemia can be rescued from MMP-
9-mediated laminin fragment induced neuronal apoptosis (Gu et al, 2005). 
 
Interestingly, a novel approach to MMP inhibition in coronary intervention has seen an 
attempt to incorporate an MMP inhibitor (GM6001) into the fabric of the stent used, and 
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represents a novel pathway for localised anti-inflammatory treatment (Caldwell et al, 
2003).  
 
1.5.9 Conclusions: 
 
Although MMP-9 is a molecule that has rightly received a lot of attentive research in the 
last decade, and its biology is becoming clearer, much of the research has been focused 
on cancer metastasis, and there are still glaring gaps in data, particularly in the 
cardiovascular area. Despite this there is a putative role for MMP-9 in bringing about 
mechanical instability in established plaques, and it may also play an auxiliary role in the 
inflammatory process. Consistent with this, the only study at the outset of this thesis 
which has prospectively examined MMP-9 as a marker of risk in CVD found it to be a 
moderate risk marker in a population with documented CAD. More epidemiological data 
in larger studies, and in healthy populations, are required to confirm expand on these 
findings. 
 
 
1.6 sCD40L: BIOLOGY, AND EXPERIMENTAL AND EPIDEMIOLOGICAL 
ASSOCIATIONS WITH CVD 
 
1.6.1 Introduction: 
 
CD40 ligand (CD40L, CD154, gp39, TRAP, TBAM) is a member of the TNF 
superfamily, and interacts with CD40 (a TNF receptor superfamily member) in the 
trimeric manner typical of the family (Peitsch et al, 1993; Matsuura et al, 2001). 
Discovered in 1992 and originally thought to be largely restricted to expression on T-
cells (Armitage et al, 1992; Graf et al, 1992), research into the functionality of CD40L 
has been dominated by adaptive immunology.  
 
A growing appreciation of a wider cellular expression of the CD40/CD40L dyad, and the 
important role the dyad plays in inflammation and pathophysiological processes in 
general, mean the molecules are increasingly seen as central inflammatory players, rather 
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than an exclusive facet of lymphocyte biology. This review will focus on the role of 
membrane-bound CD40L (mCD40L) and its soluble form (sCD40L) in inflammation, 
how it interacts with its receptors, and in the role of the molecule more specifically in 
cardiovascular disease. 
 
1.6.2 CD40L Expression, Synthesis, and Regulation: 
 
Mapped to chromosome X q26.3 – q27.1 (Graf et al, 1992), the CD40L gene yields a 261 
amino acid polypeptide with a small transmembrane domain. Much like its family 
relative TNFα, the molecule is externalised at the cell surface bound as a pre-formed 
trimer (Chan et al, 2000). Although perhaps not restricted to expression on T-cells 
(described below), most of our knowledge of the expression of CD40L is derived from 
studies employing activated mature CD4+ T-cells, which express high quantities of the 
protein.  
 
Memory T-cells express CD40L on the cells surface as soon as 5 mins after activation, 
indicating expression of pre-formed CD40L (Casamayor-Palleja et al, 1995). De novo 
production of CD40L in naive T-cells is a more controversial issue, with T-cell receptor 
(TCR) stimulation and T-cell:antigen presenting cell co-stimulation playing an important 
role, but exactly which co-stimulation depends on the experimental setting (Jaiswal et al, 
1996; Nusslein et al, 1996). 
 
Other cells that have been shown to express CD40L include monocytes/macrophages, 
platelets, B-cells, basophils, eosinophils, mast cells, dendritic cells, endothelial cells, 
SMCs and epithelial cells (Gauchat et al, 1993; Gauchat et al, 1995; Grammer et al, 1995; 
Mach et al, 1997; Pinchuk et al, 1996; Henn et al, 1998; Gaweco et al, 1999). Induction 
of expression of CD40L in these cells is a poorly defined process and probably varies for 
different cell types; soluble factors such as IL-1β, TNFα, and IL-4 are thought to be 
important (Mach et al, 1997; Gauchat et al, 1994). Some of the cell types mentioned 
above are more classically known for expressing CD40 (typically being antigen 
presenting cells in an immunological context), but in some cases cross-linking of basal 
levels of CD40 on the cell surface with either CD40L or a CD40L-IgFc fusion protein 
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may result in expression of CD40L on the surface (Pinchuk et al, 1996). It should be 
noted that a more recent study specific to atheromas has re-examined the evidence that 
these “novel cell types” express CD40L using new labelling antibodies, and could not 
corroborate this claim phenotypically or in terms of mRNA production (Buchner et al, 
2003). They found only CD4+ T-cells and platelets to express CD40L in the 
atheromatous lesions. 
 
Soluble forms of CD40L have been described, and are currently very topical in the 
literature. The existence of these soluble forms was first noted, again in T-cells, in 1995 
(Graf et al, 1995). The lighter soluble molecules have several isotypes although the 
molecular and functional differences between these are not clear (Graf et al, 1995; 
Ludewig et al, 1996; Wykes et al, 1998) 
 
In terms of inhibition of CD40L, no cell-bound or soluble factor has been described as 
directly binding and inhibiting or cleaving either cell-bound or sCD40L. Indeed the only 
described physiological inhibition of expression of CD40L is at the transcriptional level, 
where transforming growth factor-β and IFNγ have been reported to inhibit mRNA 
expression in T-cells (Gauchat et al, 1994; Roy et al, 1993) 
 
1.6.3 mCD40L, sCD40L, Platelets, and General Biological Functions: 
 
Activated Th1 cells express CD40L and interact with CD40 to bring about cell mediated 
immunity (Grewal and Flavell, 1998). It has also been proposed that CD40 ligation on 
dendritic cells stimulates IL-12 production and helps skew a Th1-type response typical of 
an atherosclerotic environment (Van Kooten and Banchereau, 2000). Also well studied is 
the interaction between CD40L on Th2 cells and CD40 on B-cells to bring about humoral 
immunity. Ligation of CD40 on B-cells via recombinant CD40L or anti-CD40 Abs 
results in activation of B-cells as evidenced by surface marker expression (such as CD23, 
CD80, CD86) and soluble cytokines (such as IL-10, IL-6, TGF-β) (Schonbeck and Libby, 
2001). 
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These specific functions of CD40L were for many years were the focal point of research, 
and it was widely considered that expression of CD40/CD40L must be largely restricted 
to immunological cells in order to prevent disseminated adaptive immunological 
activation. To some extent this may be true; controlled expression of the dyad is 
important as evidenced by the regression of many experimental autoimmune diseases in 
models where a disruptive antibody to the CD40/CD40L dyad is added (Howard and 
Miller 2004). As discussed above however, there may be scope for controlled expression 
of the dyad in other cell types. 
 
 
Platelets warrant specific attention when talking about CD40L. The role platelets play in 
the development of atherosclerosis is now widely acknowledged, if poorly understood, 
and the concept that they play a role in development of plaques as well as thrombotic 
complications stretches back to Ross’s first proposal of platelet interaction with injured 
epithelium in 1976 (Ross and Glomset, 1976). Although this hypothesis went out of 
favour, it was recently shown that introduction of activated platelets to ApoE -/- mice 
exacerbates atherosclerosis (Huo et al, 2003), suggesting some role in disease 
progression. 
 
Henn et al first demonstrated that platelets store pre-formed CD40L (Henn et al, 1998). It 
is now believed that platelets contain around 95% of the circulating pre-formed CD40L 
(although it should be noted this view is not universal) and this is quickly expressed on 
the platelet surface following stimulation with various agonists such as thrombin (Henn et 
al, 1998) although it is distinct in kinetics from other markers of activation such as P-
selectin (Hermann et al, 1998). Emphasising this, one recent model shows patients 
undergoing allogenic stem cell transplants and suffering subsequent graft versus host 
disease had elevated sCD40L, and this correlated very poorly with circulating sIL-2 
receptor (a T-cell activation marker) levels, but correlates well with platelet number 
(Nagasawa et al, 2005). This may suggest that platelets are a major source of sCD40L. 
 
mCD40L on platelets allows interaction with other platelets via CD40 (Henn et al, 2001) 
as well as the platelet integrin GPIIb/IIIa, and this interaction can stabilise arterial 
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thrombi via high-shear platelet aggregation, and hence conferring thrombogenic 
proclivity (Andre et al, 2002). CD40L may also bind to the promiscuous integrin Mac-1, 
mediating endothelial cell activation and facilitating extravasation of inflammatory cells 
(Zirlik et al, 2007).  
 
It appears that platelet-platelet interaction is vital in the unknown hydrolysis process that 
sequesters mCD40L to sCD40L. It has been demonstrated that interrupting either CD40-
CD40L or CD40L-GPIIb/IIIa interactions via blocking monoclonal antibodies prevents 
production of sCD40L, suggesting the need for a surface-bound proteinase (Henn et al, 
2001; Furman et al, 2004). An MMP (Furman et al, 2004) or TACE (Schonbeck and 
Libby, 2001) have been suggested as a possible candidates for this proteolytic process.  
 
Interestingly, the biological properties of sCD40L are largely unknown. While it is 
undisputed that mCD40L is proinflammatory, and acts as such in the atherosclerotic 
environment (discussed below), if studying CD40L as a biomarker, then it is the soluble 
form that is measured in plasma or serum, and yet its function remains enigmatic. Many 
investigators site evidence that recombinant sCD40L upregulates endothelial expression 
of adhesive proteins (Hollenbaugh et al, 1995), promotes chemokine production from 
PBMCs (Kiener et al, 1995), and induces pulmonary inflammation (Wiley et al, 1997). 
Yet Henn et al, who crucially discovered platelet production and release of sCD40L, also 
demonstrated in their work that under their experimental setting, natural sCD40L failed 
to induce an inflammatory response either in isolation or in combination with sub-optimal 
TNFα in human endothelial cells (Henn et al, 2001). Hence, the sequestering event may 
bring about some change in the function of the CD40L molecule. Indeed, even a study 
showing that sCD40L inhibits re-endothelialization of injured blood vessels used an in 
vitro technique and recombinant sCD40L (Urbich et al, 2002). T-cells appear to have 
different signalling mechanisms in the regulations of mCD40L and sCD40L (Matthies et 
al, 2006). Some work suggests that membrane polarised CD40 receptor/ligand clustering 
is required to bring about a highly concentrated, localised cellular activation site, and 
hence full signalling (Grassme et al, 2002). Sequestered CD40L (in a natural state) may 
be unable to accomplish this polarised clustering. It is also interesting that sCD40 has 
been implicated in disrupting signalling in T-cell interactions by acting as an antagonist 
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(Nemoto et al, 2002) although no experimental evidence yet describes such a role for 
sCD40L. Taken together this evidence clearly suggests that mCD40L and sCD40L may 
be physiologically different. 
 
1.6.4 Pathological and Animal Studies of CD40L in CVD: 
 
Three frequently discussed pro-atherothrombotic functions of sCD40L are illustrated in 
Figure 1.13. The most relevant of these with reference to the marker’s potential to 
promote sub-clinical atherosclerosis and act as an active biomarker is its supposed pro-
inflammatory activity. 
 
Most of the reported studies in CVD to date have used models pertinent to mCD40L and 
not specifically sCD40L (reported in section 1.6.3). mCD40L and sCD40L are both 
found in human atheromas (Mach et al, 1997; Buchner et al, 2003) irrespective of which 
type of cell may be expressing them. This CD40L has the hypothetical potential to 
interact with CD40 (or other receptor) expressing cells in the vicinity and bring about a 
range of pro-atherogenic functions (listed in Table 1.9).  
 
In animal models the evidence that the CD40 dyad is implicated in the development of 
atherosclerotic lesions is compelling. It was initially shown by Libby’s group that LDL 
receptor-deficient mice fed a high cholesterol diet and given anti-CD40L antibodies had 
limited formation of initial lesions as compared with controls (Mach et al, 1998). Lutgens 
et al confirmed this finding, showing that ApoE-/- mice crossed onto a CD40L -/- 
background had drastically smaller plaque area as well as altered plaque composition (in 
this case, 77% fewer T cells in early plaques) (Lutgens et al, 1999). It was Libby’s group 
again however which reported the most compelling finding in a later study (Schonbeck et 
al, 2000). They fed 8-10 week old LDL receptor-deficient mice a high-cholesterol diet for 
13 weeks, before a group were sacrificed as a baseline control (n=8), and 22 continued on 
the diet in conjunction with either saline (n=8), rat IgG (n=8) or anti-CD40L treatment 
(n=6). This allowed them to study if the interruption of the CD40 dyad could limit 
evolution or cause regression of established lesions. They showed that although the 
CD40L antibody could not cause regression of lesions, it did moderately limit evolution. 
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More impressive however, was the fact that the mice given the CD40L antibody had the 
cellular composition of the lesions altered, and contained more SMCs and fewer 
macrophages as well as less lipid; a far more stable phenotype in terms of rupture. 
Interestingly, a very recent study has shown in CD40 LDLR double KO mice, that 
inhibition of atherosclerosis progression is not mediated by CD40 (atherogenesis being 
essentially normal in these mice) but perhaps by CD40L interactions with other cognate 
receptors, potentially including the Mac-1 integrin (Zirlik et al, 2007). 
 
In contradiction to these reported animal models, one study shows that CD40L KO mice 
that receive cardiac allografts can become allospecific immunotolerant, but develop 
significant graft arteriosclerosis 8-12 weeks post-transplant (Shimizu et al, 2000). 
Although an exceptional experimental circumstance, this demonstrates that under 
extreme conditions CD40L may not necessarily be absolutely required for atherogenesis, 
although notably the authors here do not report phenotypic observations as to plaque 
morphology. It seems possible that the atherosclerosis progression in this report may be 
“trauma-propagated.” 
 
Generally these findings may have important implications for potential therapies of 
atherosclerosis and atherothrombotic complications, since they generally implicate 
CD40L as pivotal to the prevalent general inflammatory environment. It is currently 
impossible to untangle the influences of mCD40L and sCD40L or even relative 
importance of cognate receptors in these models. Such a model would require a selective 
antibody, or animals with a genetic alteration to the CD40L gene rendering the molecule 
non-sequestering. Since little is known of the mechanism of the sequestering process, this 
has not yet been achieved. Currently more experimental work in animal and tissue 
models work is required using human natural sCD40L. 
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Figure 1.13 Three putative functions of sCD40L released from platelets during 
thrombosis. sCD40L is released from platelet-rich thrombi and contributes to various 
steps in atherosclerotic lesion progression: (1) Inflammation; sCD40L induces the 
production and release of proinflammatory cytokines from vascular cells and matrix 
metalloproteinases from resident cells in the atheroma. (2) Thrombosis; sCD40L 
stabilizes platelet-rich thrombi. (3) Restenosis; sCD40L inhibits the reendothelialization 
of the injured vessel. Adapted from Andre et al, 2002 
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Table 1.9 Inflammatory processes initiated by the ligation of CD40 on various cell types. 
Note that hypothetically almost all aspects of atherothrombosis are potentially affected by 
CD40-CD40L interactions, i.e. initiation, perpetuation, necrotic core formation, 
destabilisation, and thrombus promotion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mechanism of 
proatherogenic/ 
atherothrombotic 
function 
Primary responsible 
cell type(s) expressing 
cognate receptor 
Resultant processes/ 
factors produced 
through CD40 ligation 
References 
Increased extravasation 
of lymphocytes 
(vascular permeability) 
 
Endothelial cells Endothelial activation 
Production of adhesion 
molecules (VCAM-1, 
ICAM-1, E-selectin) 
 
Karmann et al, 1995 
Kotowicz et al, 2000. 
Zirlik et al, 2007 
Inflammatory cell 
chemotaxis to site of 
plaque 
Macrophage Chemokine production 
(RANTES, IL-8, MIP-
1α) 
 
Kiener et al, 1995; 
Kornbluth et al, 1995 
Localised inflammatory 
cytokine production 
 
Endothelial cells, 
smooth muscle cells, 
macrophages, T-cells, 
NK-cells etc 
 
ΤΝFα, IL-1, IL-6, (IL-
12, IFNγ − Th1) 
Mach et al, 1997; 
Kiener et al, 1995; 
1Schonbeck et al, 2001 
Destabilisation of 
established plaque 
Macrophages 
 
MMP expression 
(including MMP-9) 
 
Schonbeck et al, 1999,  
2Schonbeck et al 2001; 
Mach et al, 1999 
Thrombogenic 
proclivity 
Endothelial cells, 
platelets, 
Expression of tissue 
factor and promotion of 
platelet aggregation. 
Miller et al, 1998 
Zhou et al, 1998 
Andre et al, 2002 
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1.6.5 Plasma or Serum in the Measurement of sCD40L: 
 
The use of serum or plasma samples in the measurement of sCD40L is currently a 
controversial issue, and it has been addressed in a number recent studies. Ahn (et al, 
2004) examined serum clotted on ice (serum-I) or at room temperature (serum-RT) as 
well as platelet poor plasma (PPP) in patients with thrombocytopenia (n=10), patients 
with thrombocytosis (n=12), and healthy controls (n=8). They found that serum-I appears 
to reduce much “ex vivo” release of sCD40L compared with serum-RT. In fact they 
report that serum-I levels are closer in magnitude to PPP, except in thrombocytosis 
patients, and the authors note this may be an artefact of more platelets releasing more 
sCD40L in the short time before cooling and separation compared to the other groups. Of 
note, although not reported, the data appears to show little difference in plasma levels 
between the different study groups (a median < 0.5ng/ml for all). This may allude to 
measurements being at the limit of sensitivity for the assay. 
 
Interestingly, the authors (Ahn et al, 2004) go on to use a 0.1µM filter to demonstrate that 
a large proportion of “sCD40L” found in all sample types is in fact microparticle-bound. 
Therefore sCD40L is actually the sum of “true” sCD40L and microparticle-bound 
CD40L (mpCD40L). The proportion of mpCD40L is higher in serum-RT although the 
reason for this is not clear. The biological function of mpCD40L and its biochemical 
differences with sCD40L are also currently unknown. 
 
In another recent report (Mason et al, 2005) PPP levels, and platelet surface expression of 
CD40L in patients with stable (n=40) and unstable (n=40) angina was examined. They 
found that PPP sCD40L did not differ between the groups, however, serum levels were 
lower (1.4 ± 1.3 vs 5.2 ± 3.7ng/ml, p< 0.001) and platelet membrane expression was 
higher (1.4 ± 0.7% vs 0.9 ± 0.6%, p<0.03) in unstable compare with stable angina. 
Speculatively, this may be a reflection of in vivo platelet activation. In patients with 
elevated baseline inflammation, platelets are activated and express surface mCD40L and 
sCD40L, and consequently there are fewer platelet granules to release upon serum 
activation. Hence, platelets in patients with prevalent CHD, platelets may appear 
exhausted ex vivo. This hypothesis has been partially corroborated in other work using 
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serum, where those with prevalent CVD have lower serum levels of sCD40L (Aukrust et 
al, 1999; Tanne et al, 2006) and at least non-significant trends have been observed in 
other work (Weber et al, 2007; Kiani et al, 2007). This is in contrast to many of the other 
biomarkers of CVD risk where higher circulating levels predict greater risk (the notable 
exception being high-density lipoprotein HDL; although this does not mean that sCD40L 
is acting in an atheroprotective protective manner.) 
 
Other studies (Varo et al, 2006; Weber et al, 2006) broadly agree with these data, finding 
not only serum and anticoagulants to be important factors, but also centrifugation e.g. 
processing time, and sample condition (haemolysis, bilirubin etc) to be important factors 
in measuring sCD40L. Mason et al, (Mason et al, 2005) meanwhile reported that they 
used two different commercially available sCD40L ELISA kits to measure the same 
samples, and got very different results. Halldorsdottir (et al, 2005) report that a new 
Bender Medsystems high-sensitivity ELISA may preferable for the measurement of 
plasma sCD40L, and a new developmental electrochemiluminescence immunoassay 
(Elecsys®; Roche Diagnostics) also shows some promise (Weber et al, 2006). This 
means that while multi-centre trials are ongoing, the researchers must make every effort 
possible to keep conditions constant within a study, and results should be interpreted with 
caution until the full extent of these pre-analytical variables are determined. Review of 
the data is not helped by reports that do not fully explain methodologies used, or indeed 
contradict themselves in terms of anticoagulants used in the study (Yan et al, 2004). 
 
Platelet degranulation is undoubtedly a problematic issue in serum measurements, 
however, EDTA anticoagulant also has undesirable and to some extent “non-specific” 
effects on the morphology and biochemistry of platelet function (Golanski et al, 1996), 
and all of the above study authors noted a trend towards higher sCD40L levels in EDTA 
anticoagulated compared with citrated plasma. This is almost certainly an in vitro artifact. 
While I would concede that circulating sCD40L levels are perhaps more accurately 
represented in citrated plasma, sodium citrate also has some platelet activating functions 
(Golanski et al, 1996). Indeed, very recent findings suggest that plasma levels of sCD40L 
are very much an in vitro artifact and are unrelated to prevalent disease in the individual 
(Ivandic et al, 2007). In addition, circulating levels of sCD40L in normal healthy patients 
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is often at, or below, the limit of detection in citrated samples (e.g. Malarstig et al, 2006; 
and chapter 3) in ELISAs that are not high-sensitivity (~100pg/ml). While it may be true 
that rigorous standardized conditions are required throughout studies for the measurement 
of sCD40L, this is certainly just as true for plasma samples as it is for serum. 
 
In light of evidence that much sCD40L in circulation may be microparticle-bound in a 
poorly defined manner, that the effect of chronic inflammation on sCD40L expression is 
poorly understood, that the anticoagulant effect on sCD40L released is poorly 
(objectively) described, and that ELISAs by different manufacturers give very disparate 
results, it seems we are only beginning to learn of the complex underlying biology of the 
CD40L molecule. . 
 
1.6.6 sCD40L in Genetic Epidemiology Studies: 
 
Only one study has examined haplotypes of CD40L and risk of CVD events to date 
(Malarstig et al, 2006).  In this study 2359 patients with non-ST elevation ACS had 
citrated blood taken although the number of MI cases obtained in follow-up is not stated 
by the authors and 7% of patients had undetectable sCD40L. The authors report the -3459 
A-G polymorphism was associated with sCD40L levels. Patients hemi or homozygous 
for the G allele (23.6%) had ~10% increased levels of sCD40L. In the placebo group, 
patients above the median of sCD40L were at increased risk of MI; OR 2.5 (95% CI 1.6 – 
3.9). Despite this, the G allele was not associated with risk of MI, although as previously 
discussed it is quite possible that the study was insufficiently powered to detect the 
corresponding increased risk due to a 10% increase in sCD40L levels.  
 
1.6.7 sCD40L in Molecular Epidemiological Studies: 
 
Due to the aforementioned issue regarding sCD40L levels in different sample types there 
is limited comparability between existing reports and limited conclusions can be drawn. 
 
Data in larger population have so far demonstrated few associations of sCD40L with 
other inflammatory and classical risk markers. The largest such study to date was the 
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Dallas Heart Study performed by Libby’s group (de Lemos et al, 2005), although the 
study used EDTA anticoagulated samples. sCD40L levels were measured in 2811 
patients. Quartiles of sCD40L in the population showed no association with age, sex, 
race, BMI, diabetes, smoking, creatinine clearance, LDL cholesterol, HDL cholesterol, or 
CRP, nor was it associated with coronary artery calcium or aortic plaque mass. There was 
a weak association with total cholesterol and triglycerides. Lack of association with 
plaque mass is perhaps not surprising when it is considered (as discussed previously) 
sCD40L had a greater effect on plaque composition than on plaque mass in animal 
studies (Schonbeck et al, 2000). This report is supported by other MRI work in citrated 
plasma showing sCD40L levels correlate with degree of carotid artery lipid pool, but not 
actual stenosis size (Blake et al, 2003) and not with plaque size nor coronary calcification 
in a group of SLE patients (Kiana et al, 2007).  
 
Lack of sCD40L correlation with conventional risk factors was seen in a study of 400 
men with no history of CVD who had sCD40L levels measured in plasma (anticoagulant 
not stated) (2Verma et al, 2005). The study ascertained that circulating levels again did 
not correlate, or correlated very weakly with other risk markers, and also did not correlate 
with the subject’s perceived Framingham Risk Score in univariate analysis (r=0.074, 
p=0.14).  
 
In contrast to these findings, one report found that 36 patients with and 32 without overt 
CVD benefited from a multi-factorial cardiovascular risk clinical intervention “package 
of care” (Lim et al, 2004). Both groups had a drop in plasma sCD40L after 1 year 
(median of 47% and 60% of pre-intervention levels respectively) whereas IL-6 levels 
were not significantly changed in either group. The study is however small, and as with 
all such “package of care” studies it is impossible to directly implicate the cause of 
individually lowered biomarkers. 
 
In serum samples, weak correlations with aspects of the metabolic syndrome have been 
demonstrated in 313 patients with CAD (2Lee et al, 2006). In agreement with this 
observation serum sCD40L levels may be elevated in children with 
hypercholesterolaemia (although numbers were very small; 16 children total) (Martino et 
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al, 2007). Significantly, the only very strong correlation reported with sCD40L levels is 
that of numbers of circulating platelet/monocyte aggregates and the levels of the platelet 
activation marker p-selectin in serum (Heeschen et al, 2003; Yan et al, 2004). The 
tendency of platelets to form aggregates can be seen as the “thrombotic proclivity” of the 
circulating blood, and hence may be a risk factor for ischaemic events. As discussed 
previously mCD40L has clear potential to play a role in this aggregation, but the 
physiological relationship to sCD40L is unclear. 
 
Increased levels of sCD40L have been found in a range of cardiovascular diseases, such 
as diabetes, peripheral arterial disease (PAD), pulmonary hypertension, acute/chronic 
heart failure, and stable/unstable angina (UA) (Aukrust et al, 1999; Marx et al, 2003; 
Blann et al, 2005; 1Varo et al, 2003; Damas et al, 2004; Ueland et al, 2005; Novo et al, 
2005). The majority of these were performed on plasma samples, although the first such 
report was performed in serum and demonstrated elevated levels of circulating sCD40L 
in patients with stable and unstable angina, although it was quite a small study (total 
n=74) (Aukrust et al, 1999). The study also reported that platelets taken from patients 
suffering angina had decreased intra-granule stores of sCD40L, and that stimulation of 
these platelets from patients with a thrombin receptor agonist resulted in reduced release 
of sCD40L ex vivo. This is consistent with the preceeding “platelet exhaustion” 
hypothesis in patients with prevalent CVD. Despite this, another very small study has 
found that serum levels of sCD40L are raised in patients with prevalent CHD (Tsuzuki et 
al, 2005). 
 
There were limited prospective data available for sCD40L, especially in healthy 
populations before commencement of this thesis. These are summarized in Table 1.10. 
Studies published after commencement of this thesis (October 2004) are not discussed in 
this section, since these were not available in considering assessing sCD40L as a risk 
marker. Libby’s group were the first to show that sCD40L was predictive of CHD in 
patients after a primary acute event (2Varo et al, 2003). The study was a nested case 
(n=195) – control (n=195) study using citrated plasma and with end points of death, MI 
or CHF. After adjustment for conventional risk markers, CRP and cardiac troponin 
(cTnI), sCD40L was a risk marker for MI, and death/MI composite in the upper half of 
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the population (OR 1.9, p<0.001 for both).  sCD40L was also an independent predictor of 
death (RR 1.9 p<0.05). In contrast, the MIRACL (Myocardial Ischemia Reduction with 
Aggressive Cholesterol Lowering) study found sCD40L to only be a univariate predictor 
of incident CHD in a cohort with prevalent CHD, and then only in the 90th percentile 
(~30 cases) (Kinlay et al, 2004). Another paper has suggested that sCD40L levels in 
patients with previous ACS are associated with CHD events (Yan et al, 2004), however 
the study is not included in the table due to it being inadequate in meeting systematic 
review criteria (poorly reported results and contradictory methodology). 
 
There has been only one prospective study that has examined sCD40L as a risk marker in 
healthy people. Libby and Ridker’s groups (3Schonbeck et al, 2001) used a nested case-
control study of healthy women (Women’s Health Study using EDTA plasma samples) 
where 130 women subsequently developed MI, stroke or CVD death in a four year follow 
up. These cases were age and smoking status-matched with 130 women who remained 
disease free. Cases had higher baseline sCD40L levels than did controls (2.86 ± 
0.35ng/ml vs 2.09 ± 0.19ng/ml, p<0.02). However, the OR of experiencing an event did 
not become significantly higher until sCD40L levels were in the 95th percentile 
(univariate RR 3.29, 95% CI 1.26 – 6.59, p<0.02). With only 11 cases above the 95th 
percentile of distribution to define the statistically significant RR, the result is unreliable, 
and the authors concede it is “limited data.”
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Table 1.10 Publications of sCD40L as a prospective risk marker of CVD; methods for systematic review of the literature 
detailed in chapter 2. 
Key as Table 1.4, 1.6 and 1.8 
Publication Study Population Follow-
up 
End-point n cases Sample 
type 
Proportion of 
population at 
increased risk* 
OR at sig  
(95% CI)† 
Linear OR 
increase? 
3Schonbeck 
et al, 2001 
Womens 
Health Study 
Healthy middle 
aged women 
4 year 
MI, Stroke, 
Fatal CVD 
event 
130 EDTA 95th percentile ‡ 3.29 (1.26–6.59) Yes 
2Varo et al, 
2003 
OPUS-TIMI16 
Recent CVD 
event 
10 
months 
New MI, CHF 
or death 
195 Citrate Above median ‡ 1.8 (1.1 - 2.5) § n/a 
Kinlay et al, 
2004 
MIRACL 
Patients with 
symptomatic 
CHD 
4 
months 
MI, cardiac 
arrest, 
worsening 
angina, death 
256 EDTA 90th percentile ‡ 1.86 (1.25 – 2.77) Yes 
Heeschen et 
al, 2005 
CAPTURE 
Patients with 
acute chest pain 
and CAD 
6 
months 
Incident CHD 
or mortality 
193 
Plasma 
(? Anti-
coag) 
>5.0 ug/L 2.45 (1.39- 4.32) ? 
Malarstig et 
al, 2006 
FRISC-II 
(Patients with 
ACS 
symptoms) 
Placebo group 
6 
months 
MI 
?  
1233 
patients 
  
Citrate 
 
Above median 
 
 
2.5 (1.6 - 3.9) 
 
? 
Low mol 
weight heparin 
group 
6 
months 
 
MI 
?  
1225  
patients 
Citrate ns 1.1 (0.7 - 1.6) n/a 
Tanne et al, 
2006 
BIP Chronic CHD 
7.9 
years 
Incident CVD 
or sudden 
death 
233 Serum ns 
0.70 (0.34–1.41) at 
90th percentile 
Linear 
inverse 
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1.6.8 Clinical trials of Anti-sCD40L Therapies and use in CVD: 
 
It is already acknowledged in the literature that safe, direct, non-toxic inhibition of the 
CD40-CD40L dyad may be prove to be impossible in the long-term without serious 
complications resultant from immunocompromisation of the patient. It may therefore be 
more desirable to direct therapies towards downstream signalling events caused by 
CD40L in the atheroma setting (Lutgens et al, 2007). 
 
The non-specific effect of cardiovascular drugs on sCD40L levels and consequent risk of 
events has been investigated by some authors. In the CAPTURE trial (c7E3 Fab Anti-
platelet Therapy in Unstable Refractory Angina) (Table 1.10) 1088 patients with ACS 
had been randomized into groups comparing the glycoprotein IIb/IIIa inhibitor abciximab 
with placebo controls (Heeschen et al, 2005). These patients had sCD40L measured at 
baseline (plasma; anticoagulant not stated). The authors found that patients with elevated 
sCD40L (>5.0ug/ml) were at increased risk of death or MI (OR 2.71, 95% CI 1.51-5.35, 
p=0.001). In the study patients with sCD40L levels in the top two quintiles benefited 
from abciximab treatment, with a reduction in risk from an OR of 1.12 in the third 
quintile to an OR of 0.35 in the fourth. Among troponin T-negative patients, high levels 
of sCD40L identified a subgroup whose risk was reduced by treatment with the drug 
(5.5% vs 13.6% for those receiving placebo; p=0.03). This extremely interesting study is 
hampered by the fact that, because the gp IIb/IIIa receptor can bind other ligands such as 
von Willebrand factor (vWF) and fibrinogen, effects cannot be only attributed to sCD40L 
based on these observation. The only way to eliminate this possibility is in a placebo 
controlled drugs trial involving a specific mAb against sCD40L, and this is not yet 
available. 
 
In the MIRACL cohort (Kinlay et al, 2004) (Table 1.10) EDTA plasma levels of sCD40L 
were measured in 2908 subjects on admission within 24 and 96 hours of onset of unstable 
angina, or MI, with a further measurement at 16 weeks following high-dose atorvastatin 
(80mg/day) or placebo treatment. The study did not convincingly find that the drug alters 
circulating sCD40L after 16 weeks (all patients p=0.08). This may suggest that the 
protective effects of the drug on patients with high sCD40L levels are completely 
independent of any effects on the marker. This study may be consistent with previous 
findings in patients with stable coronary syndromes or familial history of CVD in which 
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the authors found that serum levels of sCD40L took 2 years to be lowered by statin 
treatment (Semb et al, 2003).  
 
1.6.9 Conclusions: 
 
Published literature in animal models clearly suggests that CD40L interactions with 
CD40 (and perhaps other novel receptors) play a role in the development of 
atherothrombosis. The potentially separate roles of sCD40L and mCD40L in this process 
have yet to be elucidated. Current epidemiological studies have failed to consistently 
show any association of plasma or serum sCD40L levels with conventional vascular risk 
factors, prevalent vascular disease, or risk of CHD events. This may be partially 
attributed to small studies and inadequate observations of standardized protocols for 
collection of blood samples in some studies. More data in larger and high quality studies 
is therefore required. 
 
 
1.7 INFLAMMATORY MARKER ASSOCIATIONS WITH STROKE 
 
“STROKE is one of the oldest recognized diseases, but remains one of the least 
understood. A description of one of the most classic stroke syndromes, the left middle 
cerebral artery embolism, may have been described in the Bible: ‘If I forget you, O 
Jerusalem, let my right hand wither! Let my tongue cleave to the roof of my mouth, if I 
do not remember you, if I do not set Jerusalem above my highest joy!’ (Psalm 137).” 
(from Elkind, 2003) 
 
1.7.1 Introduction 
 
Having examined the associations of CRP, fibrinogen and the four novel potential risk 
markers and their associations with atherosclerosis, vascular risk markers and (primarily) 
CHD, it is important to consider the associations of these markers also with stroke in a 
separate section. The aetiological differences between CHD and stroke have long been 
considered a puzzling phenomena, and inflammation may be at least a partial key in 
explaining these observations. This section of the literature review will briefly discuss the 
current data. 
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1.7.2 Atherosclerosis: Differences in Relationship with Stroke and CHD 
 
The early introduction of this thesis discussed the diffuse nature of atherosclerosis and 
the consequential plethora of CVD-related morbidities this may cause as the 
atherosclerosis progresses and become clinically apparent. This is clearly because 
atherosclerosis plays causal roles in these pathologies, and the incidence of stroke 
(cerebrovascular accident) may be included in these pathologies. Despite this relationship 
it is important to differentiate stroke in its broadest definition from other CVDs, including 
CHD, due to the range of underlying aetiologies. 
 
Stroke may either be haemorrahagic or ischaemic in origin. Haemorrhagic stroke more 
often has associations with micro-aneuyrsms than with atherosclerosis and as such can be 
considered as a separate vascular disease. However, even within ischaemic stroke there 
are several broad categories. While nearly all CHD is linked to coronary atheroma, only 
half of stroke is due to large vessel atheroma (Di Napoli et al, 2002). Other causes can be 
heart valve diseases, or cardiac arrhythmias (e.g. atrial fibrillation) leading to emboli in 
larger vessels, or lacunar stroke where occlusion occurs within the small vessels of the 
brain. A system for categorization of subtypes of ischemic stroke has been developed in 
the Trial of Org 10172 in Acute Stroke Treatment (TOAST) (Adams et al, 1993). It can 
generally be said however that the most severe ischaemic stroke cases usually occur as a 
result of thrombosis originating from larger vessels such as the common carotid artery or 
aortic arch. 
 
1.7.3 Stroke, Cholesterol, and Statins 
 
A major reason necessitating the differentiation of stroke and CHD is the different roles 
conventional risk factors seemingly play in the respective diseases. For instance, blood 
pressure is the single most important modifiable risk factor for primary and secondary 
stroke prevention (Cosentino et al, 2005). However, cholesterol measurements only 
weakly predict ischaemic stroke (Shahar et al, 2003). It could be argued this observed 
effect is due to composite pooling of strokes of different origin in investigating studies, 
although cholesterol is still only weakly related to isolated thrombotic stroke in slightly 
less powerful analyses (Oliver et al, 2000).  
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In accordance with these observations, fibrate drugs to lower circulating serum 
cholesterol failed to show efficacy in lowering risk of stroke on meta-analysis (Herbert et 
al, 1995). Also one study demonstrated that partial ileal bypass surgery reduced 
circulating LDL-cholesterol in patients with hypercholesterolaemia and previous MI, and 
it lowered risk of MI by 35%, but did not lower risk of stroke (Buchwald et al, 1990). In 
contrast with this lack of association with cholesterol, most major trials have reported that 
taking statins reduces the risk of incident stroke irrespective of the study population. In 
the 4S trial (Scandinavian Simavastatin Survival Study) of secondary prevention, the 
active therapy group had a 51% decreased risk of ischaemic stroke and 35% decreased 
risk of TIA (SSSS Study group, 1994). Similar results were found in the CARE trial 
(Plehn et al, 1999). In primary prevention trials the reduction in risk seems smaller if at 
all beneficial, as seen in the WOSCOPS study, although this observation was limited in 
strength by small numbers of incident stroke (46 vs 51 p=0.61) (WOSCOPS Study group, 
1996) and the length of follow-up (since more recent data suggest that reduction of stroke 
risk in primary studies may take 3 years therapy to observe; Byington et al, 2001; 
Pedersen et al, 1998). Observations that taking statins reduce stroke risk are confirmed on 
meta-analysis (2Ross et al, 1999; Di Napoli et al, 2002). The reduction in risk of stroke 
from taking statins is also relatively independent of reduction in cholesterol level when 
comparisons are made with CHD. (Warshafsky et al, 1999) (Di Napoli et al, 2005). 
Indeed, in the Womens Health Study (n=15 632) a prospective cohort of initially healthy 
women, direct comparisons were made between CHD and stroke, and lipid levels were 
significant risk determinants for ischemic stroke but with a magnitude of effect much 
smaller than that observed for CHD (Everett et al, 2006). Recently, the meat-analysis of 
all statin tirals showed that statins reduce stroke risk (Cholesterol Trialist’s Collaboration, 
2005). 
 
Clearly inflammation has a role in the subsequent degenerative neuronal damage in the 
acute phase following ischaemic stroke, and as such may be an attractive concomitant 
therapeutic target for use with recombinant tissue plasminogen activator (rt-PA) 
thrombolytic therapies (Lapchak and Araujo, 2007). However, progression from sub-
clinical to the acute phase is a confounder of incident associations (del Zoppo and 
Hallenbeck, 2000). Prospective studies are required to establish the relationship between 
inflammatory markers and incident stroke. 
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1.7.4 CRP and Fibrinogen and the Prediction of Stroke 
 
In a pattern of argument already discussed, many of the general points proponents of 
measuring CRP as a risk marker for CHD have used have also been applied to the clinical 
setting of stroke risk prediction (Pearson et al, 2003).  
 
CRP has recently been shown to correlate with IMT of the carotid artery in 2 separate 
studies, and to differentially predict increased thickening of IMT over a number of years 
in 700 and 392 adults respectively (Schmidt et al, 2006, Lee et al, 2007) although the 
association with IMT was modest in both studies, and IL-6 appeared a superior marker 
compared to CRP in one study after adjustment for traditional confounders (p<0.001 vs 
p<0.05; Lee et al, 2007). Interestingly upon MRI scanning, the associations between 
severity and progression of small vessel disease-related brain abnormalities and CRP 
were nonsignificant (Schmidt et al, 2006) suggesting non-uniform associations of CRP 
with carotid atherosclerosis and lacunar pathology. Indeed, a separate study found that 
cholesterol and LDL were better markers of small vessel disease, whilst inflammatory 
markers were associated with extracranial large vessel disease (Suwanwela et al, 2006), 
underscoring potentially different aetiological roles of inflammation within subsets of 
ischaemic stroke.  
 
A qualitative meta-analysis of the link between elevated circulating CRP and primary 
stroke is shown in Figure 1.14 (Di Napoli et al, 2005). As can be seen, those in the top 
population quartile of CRP expression have an elevated risk of stroke (~OR 1.5) 
comparable to that seen on meta-analysis for risk of CHD (Danesh et al, 2004), although 
no statistical data is presented in this report. More data has added to this debate recently. 
The Rotterdam Study showed prospectively in 498 primary strokes that CRP was very 
modestly associated with risk of all strokes (age- and sex-adjusted OR per SD, 1.14; 95% 
CI 1.04 - 1.24) and risk of ischemic stroke (age- and sex-adjusted OR per SD, 1.17; 95% 
CI 1.04 - 1.32) (Bos et al, 2006). The primary conclusion of this paper was that taking 
CRP levels into account did not improve the individual stroke risk prediction compared 
with Framingham assessment. Very recently these observations were confirmed in the 
prospective PROSPER study of elderly patients, where combined hard end points of 
stroke/TIA (n=120) or CHD events (n=638) were associated with elevated CRP, but CRP 
measurement themselves did not contribute extra information to Framingham (63.0% to 
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63.7% for all CVD), and nor were CRP levels associated with benefit in potential risk 
reduction from pravastatin administration (1Sattar et al, 2007). CRP was independently 
associated with stroke/TIA in PROSPER; OR 1.32 (1.03 - 1.79). 
 
The Women’s Health Study authors (Everett et al, 2006) assert that CRP is associated 
more closely with ischaemic stroke than with CHD (stroke upper tertile OR 2.76 (95% 
CI, 1.51 - 5.05) and 1.66 (95% CI 1.17 - 2.34). Despite this conclusion, the confidence 
intervals are large and overlap, so overall there is little strong epidemiological evidence 
that currently suggests that CRP is more strongly related to stroke than to CHD. 
Reviewing the above evidence, the associations of CRP to stroke and CHD seem 
remarkably similar. 
 
These broad data patterns in similarities in inflammatory risk markers for CHD and 
stroke are also seen for studies for fibrinogen. The Fibrinogen Studies Collaboration 
(2005) have published data on the association between fibrinogen and incident stroke, 
and again found broadly similar associations to those seen in CHD: for all types of stroke 
(n=2775) the age and sex-adjusted OR was 2.06 (95% CI, 1.83-2.33), ischemic stroke 
2.08 (95% CI, 1.74-2.48), hemorrhagic stroke 1.44 (95% CI, 1.05-1.96), and stroke 
attributed to unclassified causes 2.36 (95% CI, 1.94-2.86) per 1g/L increase in fibrinogen. 
These results are comparable to data for combined OR for all vascular deaths and events; 
2.35 (95% CI, 2.21-2.49) and was also similar to that for all nonvascular mortality 2.03 
(95% CI, 1.90 – 2.08). Hence fibrinogen’s association with stroke risk is similar to that 
seen in CHD risk and risk of non-vascular disease mortality, and although this does not 
preclude a causal role for fibrinogen it means there are potentially residual confounding 
biases in the data. 
 
Pro-inflammatory cytokines in general are increased in production, both within the brain 
and in the periphery, following ischaemic stroke (Ferrarese et al, 1999; Vila et al, 2000). 
Following acute stroke, a range of studies have studies have examined the association 
between CRP levels and stroke outcome, and found some association. The largest of 
these studies involved 716 patients with cerebrovascular accidents, drew blood within 
24hrs of the incident, and followed up for 12 months (Christensen and Boysen, 2004). 
This study found that CRP levels are higher in the first 24 hrs in severe (compared with 
moderate) stroke and correlates with disability (measured with the Modified Rankin 
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Score) and mortality for all causes 3 and 12 months after stroke. A smaller study suggests 
that CRP is not predictive of recurrent stroke after an index event, but it is predictive of 
death (adjusted OR 2.11; 95% CI 1.18-3.75) (Elkind et al, 2006), although this study 
failed to separate major stroke into subtypes due to its smaller size. These recent studies 
are consistent with general trends for relationships between CRP levels and acute stroke 
outcome in older smaller smaller studies (reviewed; Di Napoli et al, 2005). Similar 
associations with acute stroke outcome are seen for fibrinogen. One large recent study 
showing that among 900 unselected stroke patients that increased fibrinogen levels 
(>3.5g/L) are associated with one year mortality OR: 1.69 (95% CI 1.12-2.55) (Turaj et 
al, 2006).  
 
These results, collectively, suggest that although inflammation may be important as a 
causal factor for stroke, as evidenced by the non-cholesterol benefits of statins, acute 
phase reactants such as CRP and fibrinogen may not fully explain the risk association of 
stroke with inflammation. Novel inflammatory markers in stroke risk therefore warrant 
further study. 
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Figure 1.14: Prospective studies relating baseline plasma C-reactive protein (CRP) levels 
to the risk of first cerebrovascular event (up to 2003). Relative risk compares top and 
bottom quartile of baseline measurements. Black squares indicate the relative risk in each 
study, with the size of square proportional to number of cases. All studies were adjusted 
for standard vascular risk factors. Adapted from Di Napoli et al, 2005. 
 
IS, ischemic stroke; SR-S, self-reported stroke; TIA, transient ischemic attack; FS fatal 
stroke; PHS, Physicians’ Health Study; NHANES III, 3rd National Health and Nutrition 
Examination Survey; Framingham, Framingham Heart Study; HHS, Honolulu Heart 
Study; WHS, Women’s Health Study; Leiden-85P, Leiden Heart Study; and CHS, 
Cardiovascular Health Study.  
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1.7.5 IL-18 and TNFα and their Associations with Stroke: 
 
Due to lack of availability of suitable samples in studies, sCD40L and MMP-9 are not 
examined in relation to stroke in this thesis and hence are not reviewed here. 
 
IL-18 is expressed within human carotid plaques (1Mallat et al, 2001). A study of 366 
patients who had carotid IMT measured at 12 sites showed that serum IL-18 was 
associated with mean IMT (r = 0.36; p<0.001) (Yamagami et al, 2005) even after 
adjustment for traditional risk factors and CRP (r = 0.20; p<0.001). However, a larger 
study (n=1111) recently suggested that only the univariate association of IL-18 with IMT 
was significant (Chapman et al, 2006). Clearly, if there is an independent association of 
IL-18 with carotid IMT, it is unlikely to be statistically strong. Likewise the direct 
association between circulating TNFα and measures of carotid thickening and 
atherosclerosis are consistently fairly weak (adjusted r < 0.25; Skoog et al, 2002; Elkind 
et al, 2005). These weak associations do not rule out a causal role for these markers in 
atherogenesis per se.  
 
There is little published data on associations of TNFα or IL-18 with incident or prevalent 
stroke. For both IL-18 and TNFα there are data that report associations with composite 
“MI plus stroke risk” or “all CVD risk,” (e.g. 2Cesari et al, 2003, Wise et al, 2005, 
Blankenberg et al, 2006; see Tables 1.4 and 1.6) and although this is a perfectly 
reasonable methodology in terms of clinical risk assessment, it is not helpful in 
delineating associations with stroke risk specifically. This is especially true since CHD is 
far more common than stroke in prospective studies, particularly in non-elderly 
populations, hence resultant risk associations are naturally skewed to more strongly 
reflect associations with the more common end-point in these composite studies. 
 
One small study of 23 patients with ischaemic stoke (Zaremba and Losy, 2003) showed 
that, compared with controls, patients had elevated circulating IL-18 levels within 24 hrs 
of stroke and that these levels correlated with early hypodense CT areas (r=0.82 
P<0.0001). IL-18 levels also strongly correlated inversely with Scandinavian Stroke 
Scores (SSS) within 24 hrs (r=-0.76; p<0.0001) and with SSS scores at 2 weeks (r=-0.77; 
p<0.0001). Despite this a study of mice has shown that focal reversible occlusion of the 
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cerebral artery does not lead to IL-18 expression, and deletion of the IL-18 gene does not 
affect infarct volume (Wheeler et al, 2003). This finding may be an artifact of experiment 
however, since it is essentially a model of lacunar stroke in the absence of atheroscleosis 
or thrombosis, and was transient in occlusion time (15 to 30 mins). There are no 
published studies examining IL-18 and risk of incident stroke. 
 
Similarly to IL-18, TNFα has been found to show an early and prolonged increase after 
stroke in 40 patients, but elevation was unrelated to lesion size, neurological impairment, 
or vascular risk factors, and the authors conclude it is elevated as part of the general acute 
phase response (Intiso et al, 2004). Clearly these types of small study tell us little on the 
association between these IL-18 and TNFα and stroke outcome, and the area requires 
clarification. The only published data examining stroke risk specifically and TNFα is 
from the ABC study (2Cesari et al, 2003) and contained only 60 incident strokes (see 
Table 1.4). In this study, TNFa was not associated with stroke risk, although there is 
clearly a need for larger studies. 
 
1.7.6 Stroke Summary: 
 
Ischaemic stroke has common risk factors with CHD, and this is as one would expect 
considering that they are general consequences of vascular disease brought about by 
atherosclerosis. While CHD events are almost always a consequence of rupture of 
plaques in the coronary arteries, lacunar and non-lacunar stroke may have distinct 
aetiologies, with reciprocal relative associations with inflammation and cholesterol. This 
may be why, while overall ischaemic stroke has poor associations with circulating 
cholesterol, risk of stroke is significantly reduced by statins; statins lower both 
generalised inflammation and cholesterol, and hence treatment is of benefit to both non-
lacunar and lacunar stroke aetiologies. 
 
It appears from general review of previous studies that “generalised inflammation” (as 
measured by CRP or fibrinogen) is not more strongly associated with stroke than CHD. If 
Th1 type inflammation plays a pro-atherosclerotic role and this is a greater aetiological 
risk factor for stroke than CHD, it may be that Th1 cytokines, such as IL-18 and TNFα, 
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are more important in stroke than CHD; this conjecture requires epidemiological 
investigation due to a current lack of data. 
 
 
1.8 AIMS OF THESIS 
 
1.8.1 General Aims 
 
This thesis shall broadly aim to study the epidemiology of TNFα and IL-18, and to a 
lesser extent MMP-9 and sCD40L (due to a lack or serum), and their relationships with 
cardiovascular disease i.e. their technical and biochemical properties as markers (pre-
analytical variables), their population distributions, their associations with other markers 
of CVD risk, and associations with risk of prevalent and incident CHD and stroke. 
 
To achieve these goals, the following aims were drawn up: 
 
1. To study assay-specific characteristics and the effects of pre-analytical variables on the 
markers: 
- Anticoagulant suitability  
- Intra/inter assay variation 
- Long-term storage of samples 
- Freeze-thaw cycles 
- Short-term biological variation (20 weeks)* 
- Long-term biological variation (4 years) i.e. regression dilution coefficient (British 
Regional Heart Study samples 16 vs 20 yrs) 
 
2. To establish the population distribution of markers, as well as associations with 
conventional CVD risk markers in a cross-sectional study: 
- MONItoring trends and determinants of CArdiovascular disease (4th Glasgow MONICA 
survey)* 
 
3. To establish marker associations with prevalent CHD and stroke: 
- GLAsgow Myocardial Infarction Study (GLAMIS)* 
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- Stroke In Progress (SIP) (Acute stroke)* 
 
4. To establish marker associations with incident vascular events: 
CHD  
- British Regional Heart Study baseline samples (middle-aged men) 
- Fletcher Challenge Study (New Zealand men and women)* 
CVD 
MONICA-4 (cross-sectional study) 
Stroke  
- PROSPER study (incident stroke in the elderly)* 
- PROGRESS study (recurrent stroke)* 
 
* Indicates that only plasma samples are available for this study, and so only IL-18 and 
TNFα can be measured. 
 
1.8.2 General Hypothesis: 
 
H0: Null hypothesis 
Circulating levels of the inflammatory markers TNFα, IL-18, sCD40L and MMP-9 are 
not related to risk of CVD independently of conventional risk markers. 
H1: Working Hypothesis 
Circulating levels of the inflammatory markers TNFα, IL-18, sCD40L and MMP-9 (at 
least some of) are associated with CVD risk, the association is strong and reproducable, 
and relatively free from confounding by conventional risk factors. These result(s) would 
reflect the putative roles of TNFα and IL-18 in the Th1 response (and inflammatory 
atherogenesis), MMP-9’s role in plaque rupture, and sCD40L’s role in thrombosis and 
general inflammation. Differential abilities between these markers and markers of the 
acute phase response to predict risk of CVD independently of conventional risk factors 
might reflect underlying roles of these inflammatory markers in atherogenesis and 
atherothrombosis. There would hence be rationale for further experiments, and 
considering these and other inflammatory markers as candidates for clinical risk 
prediction and as specific therapeutic targets in secondary treatment and perhaps the 
prophylaxis of CVD. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 REVIEW OF THE LITERATURE 
 
2.1.1 Search Strategies 
 
It is essential in modern literature reviews that systematic and thorough search strategies 
are employed in order that all studies pertinent to the area of interest are found. In order 
that a high level of coverage was obtained the following search strategies were used to 
obtain publications of interest. Searches were performed in Medline combining text 
words and MESH headings (using IL-18 as an example): 
 
Text Words 
 (((Coronary Heart Disease) OR (Ischaemic heart disease) OR (Ischemic heart disease) 
OR (Cardiovascular Disease) OR (Cardiovascular mortality) OR (Myocardial 
infarction)).tw) AND ((Interleukin-18) or (IL-18).tw) 
 
MESH Headings 
(((Coronary Disease/) OR (Cardiovascular Diseases/) OR (Myocardial Infarction/) OR 
(Myocardial Ischemia/)) AND (Interleukin-18/)) 
 
Hits were restricted to English language and when searching for only epidemiological 
data, were restricted to human subjects as well. When searching for literature on TNFα or 
MMP-9 or sCD40L the words  
 
((Tumour necrosis factor-alpha) OR (tumour necrosis factor α) OR (TNFα)) 
Or 
((Matrix metalloproteinase-9) OR (MMP-9) OR (gelatinase-b)) 
Or 
((Soluble CD40 ligand) OR (soluble CD40L) OR (sCD40L) OR (soluble CD154) OR 
(sCD154)) 
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were substituted in place of  interleukin-18. Searches were carried out at regular intervals 
to keep up to date with the literature. 
 
2.2 SUBJECTS AND SAMPLES 
 
2.2.1 Subject Recruitment 
 
Since each study in this thesis is comprised of a different cohort of patients the study 
recruitment procedure, venupuncture procedure, sample handling, and cohort follow-up 
are described in detail in each relevant chapter. 
 
2.2.2 Sample Handling and Storage 
 
The careful collection, sample handling, and storage of blood samples is an essential 
component of any epidemiological study in order that potential confounding inter-sample 
differences are minimised. The accuracy of results attained from empirical population-
based observations is ultimately a reflection of care taken with these procedures. For this 
reason this thesis will only consider studies where there is high quality and known history 
of the blood samples in question. In effect, whether samples were initially handled within 
our own laboratory (Chapter 3), locally (Chapters 4 and 5), or in multi-centre 
collaborations (other chapters) bloods were drawn by trained nurses or other health care 
professionals, and samples were handled in a standardised manner appropriate for 
epidemiological study. Individual study details are described in the relevant chapters. 
 
2.3 AUTOMATED LABORATORY METHODS 
 
2.3.1 Clottable Fibrinogen Assay (Clauss) 
 
When discussing observations for the markers of inflammation in this thesis, fibrinogen 
results may also be included for reasons of comparison. For all markers measurements 
were made in our laboratory either by myself, or a colleague with appropriate technical 
experience.  
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Fibrinogen was measured by the Clauss method (von Clauss, 1957) using an automated 
coagulometer (MDA 180, Biomerieux, Basingstoke, UK) (Figure 2.1). When thrombin is 
added to diluted plasma, fibrinogen is enzymatically converted to fibrin, which in turn 
undergoes polymerisation to form a fibrin mesh. Factor XIII is activated by thrombin, 
and catalyses cross-linking to form a stable clot. The clot is detected by its interception of 
light. The elapsed time from addition of thrombin to clot formation is inversely 
proportional to the fibrinogen concentration in the sample. Fibrinogen concentration is 
inferred from a standard curve. Fibrinogen reagents were provided by the manufacturer, 
and the calibrant used was the 9th British Standard for blood coagulation factors from the 
National Institute for Biological Standards and Control (NIBSC, Potters Bar, Herts) 
which is calibrated against the WHO international standard. In our laboratory the intra- 
and inter-assay coefficient of variation (CV) of fibrinogen measurements were 3.0% and 
3.7% respectively (Poorhang, MSc thesis, 2005). 
 
2.3.2 High Sensitivity-CRP Assay 
 
The hs-CRP assay was performed by the immunonephelometric method using a BN 
ProSpec nephelometer (Dade Behring, Milton Keynes, UK) (Figure 2.2). Latex particles 
coated with monoclonal antibodies to human CRP are mixed with plasma samples. This 
results in an aggregate of latex and protein complexes in solution. The degree of 
aggregation determines solution turbidity, and is proportional to the concentration of CRP 
present. Plane-polarised light passed through the solution is scattered in a manner 
proportional to the concentration of CRP. CRP concentration is inferred from a standard 
curve. All reagents and calibrators were obtained directly from the manufacturer. In our 
laboratory the intra- and inter-assay CV of CRP measurements were 5.2% and 8.3% 
(Poorhang, MSc thesis, 2005).  
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Figure 2.1 The MDA 180 Coagulometer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 The BN ProSpec Nephelometer 
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2.4 ENZYME LINKED IMMUNOSORBENT ASSAY METHODS 
 
2.4.1 Enzyme Linked Immunosorbent Assay Principle 
 
Enzyme linked immunosorbent assays (ELISAs) employ the sandwich antibody 
principle. Plasma (or other appropriate medium) samples containing the antigen of 
interest and standards of known concentration are added to a plate of microtest wells  
which are coated with a primary antibody to the antigen. After incubation sufficient to 
allow >95% of the antigen to bind the primary “capture” antibody the wells are washed to 
remove any unbound material. Excess enzyme-linked secondary antibody, specific for a 
different epitope of the antigen is added to each well. The genetically engineered 
secondary antibody can be linked to a one of a range of enzymes (e.g. alkaline 
phosphatase in the IL-6 assay). Suitable incubation time allows end-point binding of the 
secondary antibody to the captured antigen, and the plate is washed to remove excess 
unbound conjugate antibody. A substrate for the specific enzyme on the secondary 
antibody is then added (e.g. Reduced Nicotinamide adenine dinucleotide phosphate 
[NADPH] for IL-6) bringing about a colourimetric reaction. The rate at which the 
coloured product develops is directly proportional to the rate limiting step in the ELISA: 
the amount of antigen present. An acid solution is added to stop the reaction at a point 
where the standard curve added is detectable and linear. The colour change in each well 
is measured photometrically using an appropriate wavelength on a plate reader (Multi 
Scan EX, Thermo Electron Corporation, UK). The plate reader is programmed to draw a 
standard curve and infer the concentrations of the plasma samples from this curve using 
each relevant optical density (OD). Examples of ELISA plates are shown in Figure 2.3 
and 2.4. An example of a standard curve obtained for an ELISA is shown in Figure 2.5. 
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Figure 2.3 Part of an ELISA Procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: A Completed ELISA Plate 
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Figure 2.5 An abbreviated example of a standard curve readout for a IL-6 HS assay 
 
Name OD Conc. 
   
Cal_1 0.247  
 0.252  
 0.25 0.312 
   
Cal_2 0.353  
 0.341  
 0.347 0.624 
   
Cal_3 0.544  
 0.563  
 0.554 1.248 
   
Cal_4 0.943  
 0.937  
 0.94 2.496 
   
Cal_5 1.641  
 1.621  
 1.631 4.992 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Conc. Meas. CalcConc. Residual 
Cal_1 0.312 0.25 0.258 0.054 
Cal_2 0.624 0.347 0.589 0.035 
Cal_3 1.248 0.554 1.288 -0.04 
Cal_4 2.496 0.94 2.598 -0.102 
Cal_5 4.992 1.631 4.939 0.053 
   
Fit type:  Linear regression (SVD): y = a+b*x 
Meas. transformation: Linear   
Conc. transformation: Linear   
Parameters: a b  
  0.173 0.295  
Corr. coeff. R2: 0.997   
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2.4.2 High Sensitivity IL-6: 
 
High sensitivity IL-6 (IL-6 HS) was measured with a commercially available ELISA kit 
(R&D systems, Abingdon, UK). The manufacturers claim the assay is sensitive to < 
0.1pg/ml and the reported CV is 7.2% (sample level dependant). The only deviation from 
manufacturer’s instructions was to make the curve more sensitive at the bottom end of the 
range (since this is where circulating levels in healthy people generally are) and hence 
use a standard curve of 5.00, 2.50, 1.25, 0.625, 0.31, and 0 pg/ml. All R&D systems 
standard operating procedures can be procured from links on the website: 
http://www.rndsystems.com/product_detail_objectname_elisa_assay_product.aspx 
 
2.4.3 High Sensitivity TNFα: 
 
TNFα HS was measured with a commercially available ELISA kit (R&D systems, 
Abingdon, UK). The manufacturers claim the assay is sensitive to ~0.1pg/ml and the 
reported (sample level dependant) inter-assay CV is ~ 12.6%. The only deviation from 
manufacturer’s instructions was to make the curve more sensitive at the bottom end of the 
range (since this is where circulating levels in healthy people generally are) and hence 
use a standard curve of 4.00, 2.00, 1.00, 0.50, and 0 pg/ml.  
 
2.4.4 IL-18: 
 
IL-18 was measured with a commercially available ELISA kit (R&D systems, Abingdon, 
UK). The manufacturers claim the assay is sensitive to 12.5 pg/ml and the reported 
(sample value dependant) inter-assay CV is <10%. The only deviation from 
manufacturer’s instructions was to make the curve more sensitive at the end of the range 
for using 1:5 diluted serum or plasma samples (manufacturers suggested dilution) and 
hence use a standard curve of 200, 100, 50, 25, and 0 pg/ml. 
 
2.4.5 MMP-9: 
 
MMP-9 was measured with a commercially available ELISA kit (R&D systems, 
Abingdon, UK). The manufacturers claim the assay is sensitive to < 0.15 pg/ml and the 
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reported (sample value dependant) inter-assay CV is ~ 7.8%. The only deviation from the 
manufacturers instructions was to make the curve more sensitive at the end of the range 
for using 1:100 diluted serum samples (manufacturers suggested dilution) and hence use 
a standard curve of 20.0, 10.0, 5.0, 2.5, and 0 ng/ml. 
 
2.4.6 sCD40L: 
 
sCD40L was measured with a commercially available ELISA kit (R&D systems, 
Abingdon, UK). The manufacturers claim the assay is sensitive to 4.2 pg/ml and the 
reported (sample value dependant) inter-assay CV is ~ 6.0%. The only deviation from the 
manufacturers instructions was to make the curve more sensitive at the end of the range 
for using 1:5 diluted serum samples (manufacturers suggested dilution) and hence use a 
standard curve of 1000, 500, 250, 125, and 0 pg/ml. 
 
2.5 QUALITY CONTROL 
 
2.5.1 Internal QC: 
 
An in-house pooled plasma (or serum for MMP-9 and sCD40L) was used to monitor 
inter-assay QC in all assays. 20 healthy volunteers over a range (25 – 60 years) of ages 
donated blood which was drawn into either citrated (4.5ml blood into 0.5ml 0.109M 
trisodium citrate) or prepared for serum (5ml Z serum sep. clot activator; left to clot for 
30 mins at room temperature) vacutainers (Becton, Dickinson and Company, Oxford). 
Immediately after drawing (and clotting for serum) blood was centrifuged at 1500g for 10 
mins. The plasma or serum supernatant was then removed and pooled into a common 
container for all samples from the 20 volunteers, and then mixed for a maximum of 15 
minutes at room temperature. Samples were then aliquoted, and snap-frozen at -800C 
until required for assay. On automated analysers, a QC assay was performed at for least 
every 80 samples run through the machine. For ELISAs 2 separate QC samples were 
applied at the beginning and the end of each microplate (in order to monitor cross-plate 
stability).  
 
The mean concentration, standard deviation (SD), and 95% confidence intervals (2SDs) 
of this QC were determined over 20 separate runs for each assay. A Levey-Jennings plot 
  118
(Levey and Jennings, 1950) was generated for each assay, and results for every assay 
were plotted over time. The principle of the plot is that the values of the QC should 
fluctuate randomly on either side of the assigned mean value over time, such that 95% of 
results obtained should sit within 2 standard deviations from the mean (Levey and 
Jennings, 1950). Assays that did not comply with these stipulations, or were outside 3SDs 
from the mean (i.e. 99% confidence intervals) were re-performed. An example of a 
Levey-Jennings plot for MMP-9 is shown in Figure 2.7. 
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Figure 2.6 A Levey-Jennings plot of MMP-9 internal QC results. Note that, in general, 
values tend to stay within two standard deviations, and fluctuate either side of the mean 
determined concentration. In this example there was one assay which was an outlier, and 
was subsequently repeated. 
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2.6 STATISTICAL ANALYSIS 
 
2.6.1 General Statistical Overview 
 
Detailed statistical methods are discussed in each relevant chapter for the individual 
study. For the smaller hospital based studies in Chapter 3 (pre-analytical variables) I 
performed all statistical analysis including analysis of the short-term biological variation 
(Fleiss et al, 1986; See chapter 3) with the exception of the statistical “Random Effects 
Model” (3.6.2) and the work was checked for accuracy by co-supervisor statistician Prof 
Mark Woodward. I performed basic statistics on the regression dilution studies, whilst 
more complex statistical analysis (for comparison with Emberson et al, 2004) was 
performed by a statistical team at the BRH Study main centre, supervised by our 
collaborators (Prof Peter Whincup and Dr Goya Wannamethee), in consultation with 
myself. 
 
In larger more complex studies requiring large central databases, complex statistical 
models, and multivariate regression analysis (Chapters 4-9), statistical work was 
performed in collaberation of the co-ordinating group statistician, Prof Gordon Lowe, and 
I. Collaborating statisticians were either my co-supervisor (Prof Mark Woodward), our 
collaborators in the BRH Study (Prof Peter Whincup and Dr Goya Wannamethee), our 
collaborators in the Prosper study (Prof David Stott), or our collaborators in the SIP study 
(Prof Stott and Dr Mark Barber).  In practice, all statistical analysis was performed using 
SAS, SPSS, Minitab, or Excel software packages. 
 
2.6.2 Data Presentation, Skewedness, Medians and Means 
 
Most data of central importance to this thesis, the measurement of cytokines in general 
populations or in selected cohorts, is on an interval scale and is non-normally distributed. 
This can present some problems in accurately representing the point of central tendancy 
in the data, and a number of techniques were employed to do this.  
 
Skewedness and Kurtosis statistics were used to assess the data for non-parametric 
distribution. Limits of normal distributions were defined as at 2 standard errors of 
Skewdness and Kurtosis, where standard errors of Skewedness were approximated as 
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, and Kurtosis as √        (Tabachnick and Fidell, 1996). Where an indication of the 
spread of data was required, skewed data was generally presented as untransformed 
medians with interquartile ranges (IQRs). Alternatively, data was log- or power-
transformed to approximate normality, and medians and standard deviations were 
calculated on the transformed data, and were ultimately expressed as backtransformed 
data. The exception to this was the British Regional Heart Study (Chapter 6), where in 
order to compare with previously published data, data central tendancies were expressed 
as geometric means, defined as n results being multiplied (as opposed to being added in 
calculation of the arithmetic mean) and then the nth root of the resulting product being 
taken (as opposed to being dividing in the arithmetic mean). 
 
2.6.3 Testing for Statistical Differences in Groups 
 
Almost all tests in this thesis were comparisons of two unpaired samples with large 
amounts of data interval in each group. The two-tailed t-test is theortetically the best way 
to compare these groups in order to test the null hypothesis. The unpaired t-test requires 
that data is parametric for its use. Effort was made to normalise non-parametric data 
either by log- or power-transforming data as required to perform a t-test. Where this 
technique failed to induce normality, a Mann Whitney U test was employed to compare 
data sets (data not transformed). In univariate comparison of categorical variables, the 
chi-squared test was used to test the null hypothesis. Where there were comparisions of 
binary variables, and the numbers present were small (e.g. presence of baseline CVD in 
generally health populations), comparisons of groups were made by Fisher’s exact test. 
 
When testing two methods of comparing the same subjects (e.g. in Chapter 3), a general 
mistake is often made in the literature; comparisons are drawn using a test of correlation 
(a linear association) and perhaps a paired t-test (or Mann Whitney U). The problem with 
these is that it assumes that the effect of the different methods has uniform effects on the 
dependant variable, regardless of the value of the variable (i.e. the relationship is linear). 
This assumption may not be accurate (Woodward, 2005). In Chapter 3, the Bland-Altman 
test is employed to test the assumption of uniform effects of methodology on transformed 
data of paired samples (Bland and Altman, 1986; Woodward, 2005). Assuming the effect 
N
24 
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is uniform, the correlation test and paired t-test become a valid methodology of 
comparion and test for differences on the data groups. 
 
2.6.4 Correlation and Regression 
 
The correlation coefficient indicates the strength and direction of a linear relationship 
between two variables. Where data was normally distributed, or transformed to normal 
distributions, a Pearson product-moment correlation coefficient (r) was used to determine 
the relationship between variables. This statistic can be found by dividing the normalised 
covariance between the two variables by the product of their standard deviations. The 
product r2 is the proportion of change in variable X that can be attributed to change in 
variable Y (not necessarily causal). Where data was not parametric even after 
transformation, or the relationship of the variables was not linear, tests for correlation 
were performed uing Spearman’s correlation coefficient. This ranking test of correlation 
does not require the assumption that the relationship between the variables is linear, nor 
does it require normally distributed data, although the test is less sensitive. Again, a 
correlation coefficient (r) was obtained. As previously, data from the British Regional 
Heart study was modelled in a different way to other studies in order to compare with 
previous data, and trends across thirds of the population distribution (by cytokine thirds) 
were fitted using a sum of least squares method. 
 
In univariable analysis of the odds ratio of a CVD event in a population for a given 
cytokine, simple logistic regression analysis was used, coding for presence of a CVD 
event (1) or no CVD event (0) as a binary variable. The fitted line can be expressed as y= 
a + bX + error. Based on this relationship, the odds ratio of an event (p/q, where p is the 
probability of an event, and q is the probability of no event) can be implied from logit 
models; logit (p) = log (p/q) = a + bx             p/q=ea + bX (i.e the odds ratio can be 
computed by raising e to the power of the logistic coefficient, and X could be defined as 
being by thirds or standard deviations of the variable in the population as required). 
 
In a similar manner, multivariable logistic regression was used to assess the odds ratio of 
a CVD event for a cytokine in a population (by thirds or standard deviations) while 
mathematically holding constant a number of potential confounders such as classical 
CVD risk factors. This method adjusts for the effects of these potential confounders so 
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that, in theory, only the relationship of the cytokine with CVD event odds is investigated. 
In reality there are probably residual confounding factors. 
 
Finally, in some models, forward setepwise regression analysis was used (Chapter 9). 
This analysis is performed in order to model the explanatory variables most strongly 
related to adverse outcome (death or dependency). In this case all conventional clinical 
markers of poor stroke outcome were included in a multivariable model from the outset. 
Those not significantly independently associated with outcome (p>0.10) were removed 
from the model stepwise until all clinical markers were significantly associated with 
outcome. Novel markers of risk of poor outcome were included in the model stepwise, 
and retained if significant (p<0.05), while removing markers which became non-
significantly associated with outcome in the process (p>0.10). 
 
2.6.2 Power Calculations 
 
The studies used within this thesis were not specifically designed for the analysis of the 
novel inflammatory risk markers central to this thesis. The size of the studies, their 
offshoots, and the principal results are discussed in each individual chapter. Any power 
calculations performed on these studies would be retrospective. 
 
Power calculations are a useful tool in the design of a proposed epidemiological study. 
However, it is my (and others; Hoenig and Heisey, 2001; Lenth et al, 2007) opinion that 
retrospective power calculations are limited in utility. If a study finds no association 
between a variable and an outcome the study was underpowered, or there was no 
relationship at all. The power calculation adds nothing to the odds ratio and 95% 
confidence intervals found in the results. The researcher is required to then ascertain if 
another prospective study is required, and hence could use a prospective power 
calculation to design another study, based on variences observed in the present study. If 
there was a significant association, ofcourse the study was adequately powered to detect 
it. In order to comply with University recommendations, power calculations for each 
study are included in the discussion (Chapter 12). Power calculations were performed 
by……. 
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CHAPTER 3 
 
THE EFFECTS OF PRE-ANALYTICAL VARIABLES ON MEASUREMENTS 
OF IL-18, TNFα, MMP-9 AND sCD40L 
 
3.1 INTRODUCTION 
 
3.1.1 The Measurement of Pre-Analytical Variables: 
When blood tests are carried out, either in the clinic or for epidemiological studies, there 
are several variables which will affect the results obtained before the sample is analysed. 
These include season, time of day, diet, stress, and physical activity of the patient, as well 
as technical aspects such as venipuncture technique, anticoagulation of the blood, 
processing speed and technique, freezing, storage, and assay-specific variables (such as 
assay variability) (Thomson, 1992). 
 
The number of published studies examining biological variables that are potential risk 
markers for cardiovascular disease has increased at a logarithmic rate in the last 15 years 
(See Figure 3.1; publications in Medline citing ((coronary heart disease(s) OR 
cardiovascular disease(s)) AND (risk factor(s) OR risk marker(s))) as keywords). Of the 
cumulative total of 33, 979 publications over the last 15 years illustrated in Figure 3.1, 
only 193 of them (~0.5%) also include ((pre-analytical variables) OR (anticoagulants) 
OR (blood specimen collection) OR (specimen handling)) as a key word. Despite this 
illustration of seeming relative disinterest in this subject area, the examination of pre-
analytical variables is important prior to any epidemiological study, particularly with 
reference to the study of novel risk markers. The maintenance of high sample quality and 
observation of necessary specimen handling is ultimately reflected in the results obtained. 
Therefore, prior knowledge of the steps that must be taken to ensure minimisation of 
experimental error is essential. In addition to laboratory error, it is essential that 
biological variation is also accounted for when examining a risk marker.  
 
It is not possible when performing the studies described in this chapter to 
comprehensively examine all potential confounding pre-analytical variables for the four 
novel inflammatory markers. However, the results presented in this chapter were 
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generally sufficient to validate the use of the samples from epidemiological studies 
included in other chapters.  
 
The overall aim in this section was to validate IL-18, TNFα, MMP-9 and sCD40L for use 
in epidemiological studies (and to elucidate the requirements of these studies for accurate 
measurements of risk associations), and to assess potential use of these markers in meta-
analysis. 
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Figure 3.1 Illustrative graph of the logarithmic increase in the number of published 
studies examining risk markers in cardiovascular disease in each year since 1970. The 
search was performed in Medline searching for publications citing ((coronary heart 
disease(s) OR cardiovascular disease(s)) AND (risk factor(s) OR risk marker(s))) as 
keywords. * Due to the semi-log scale, breaks in the graph indicate a y-value of 0 
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3.2 PLASMA, ANTICOAGULANTS AND SERUM SAMPLES 
 
3.2.1 Introduction 
 
In most epidemiological studies, either serum (generally used in the measurement of lipid 
variables) or plasma (used to measure other biochemical or haemostatic variables) 
samples may be available. Due to ubiquity in the measurement of lipid variables these 
aliquots tend to be exhausted first, and there tends to be an excess of plasma samples 
available for analytical purposes in most studies. It was necessary to ascertain which of 
the inflammatory markers assessed in this thesis could be assayed in serum or plasma. 
 
In the literature, use of serum or plasma for the measurement of sCD40L and MMP-9 is 
controversial, and has been reviewed in Chapter 1 (1.5.5 & 1.6.5). As stated previously 
for MMP-9, “EDTA and citrate are not recommended anticoagulants for use in this assay 
due to their chelating properties.” (R&D Systems kit insert Ref DMP900). I, therefore, 
used serum with the R&D Systems ELISA in this thesis because of lack of availability of 
heparinised plasma. 
 
At the outset of this thesis there was no high-sensitivity sCD40L ELISA assay available 
for plasma sCD40L analysis, although one was recently released by Bender MedSystems 
(Vienna, Austria). This may prove more sensitive than the R&D ELISA for the 
measurement of sCD40L in plasma (Halldorsdottir et al, 2005) although this has not yet 
been investigated in peer-reviewed studies. I, therefore, used the R&D Systems ELISA in 
serum samples throughout this thesis. 
 
The manufacturers state that the R&D Systems hs-TNFα assay can be performed from 
samples “using serum…[or]…..plasma using EDTA, heparin or citrate as an 
anticoagulant” (R&D Systems kit insert ref HSTA00D) and this has been confirmed 
elsewhere (Flower et al, 2000). There have been no such studies for IL-18, although the 
manufacturers (MBL) state that “serum and EDTA plasma can be used” (R&D Systems 
[suppliers] kit ref 7620). 
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I, therefore, devised a small study, aiming to ascertain which (if any) anti-coagulated 
plasmas were acceptable to use in epidemiological studies of IL-18, TNFα and sCD40L, 
basing our decision both on manufacturer recommendations, as well as our own results.  
 
3.2.2 Subjects and Methods 
 
20 healthy laboratory volunteers (age range 23-57 years) donated venous blood which 
was collected by venipuncture in citrated vacutainers (0.11M; 9:1 v:v) and standard K3 
EDTA vacutainers (BD Vacutainers, Oxford) (1 citrate and 1 EDTA sample per subject). 
Blood samples were left on ice for a maximum of 30 minutes before centrifugation at 
2000g for 10 mins, and then were separated into aliquots, which were snap-frozen at -
80oC. Samples were assayed on the same ELISA assay (for each marker) within 1 week 
of blood letting. 
 
The hs-TNFα assay has been reported to be compatible with citrate, EDTA, heparin and 
serum (R&D Systems), and therefore only residual EDTA samples were assayed in this 
study to compare to manufacturer’s reported results and to establish reference levels in 
healthy young people. IL-18 has been validated for EDTA and serum by the 
manufacturers, and therefore experimental comparisons were made between EDTA and 
citrate in order to validate citrated plasma. sCD40L was initially assayed in both EDTA 
and citrated samples (not recommended for use by the manufacturer), and compared to 
manufacturer’s findings. Due to the reported chelation problems involving MMP-9 and 
plasma samples, MMP-9 was only run on serum samples throughout this study, and 
hence no results are reported here. 
 
For IL-18 and sCD40L, EDTA and citrate data was analysed by comparing equality of 
means using a Bland-Altman plot (Bland and Altman, 1986) on log-transformed data 
(Woodward, 2005). Comparisons of the anti-coagulants on the log-transformed 
(normalised) data were made using paired t-tests and Spearman correlation coefficients. 
For TNFα, due to there only being summary statistics available from the manufacturers, 
EDTA plasma levels were compared only qualitatively with findings from our own 
samples. The objective was to ascertain whether or not it was acceptable to run large 
epidemiological studies using anti-coagulated plasma samples, and to ascertain if the 
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study findings of circulating levels of antigens were similar to the manufacturer’s 
findings. 
 
3.2.3 Results 
 
Comparisons of EDTA and citrate measurements of IL-18 are shown in Table 3.1 and in 
Figure 3.2. Table 3.1 suggests that median levels of IL-18 in EDTA plasma are 14.4% 
higher than in citrate. This is confirmed in Figure 3.2, where the Bland-Altman plot 
shows that IL-18 levels are more often lower in citrated plasma (paired t-test p<0.0004. A 
random scatter of points suggests that the effects of taking EDTA or citrate has a uniform 
effect on levels, independent of the mean level of detectable of IL-18. Commensurate 
with this, citrate and EDTA values were highly correlated for IL-18 (r = 0.88).  Both anti-
coagulants were comparable to the manufacturers results in serum (means 126 pg/ml vs 
186 and 215 pg/ml for citrate and EDTA respectively), which seemed reasonable given 
the different study populations (manufacturers age range not stated). 
 
Results for TNFα in EDTA samples are shown in Table 3.2. This was performed only to 
ensure our results were comparable to the manufacturers, and hence results are 
qualitatively compared (given the different populations used and insufficient data from 
manufacturers for statistical tests). The results obtained by the manufacturers study and 
the current study were different (means 1.98 vs 0.41 pg/ml). This difference is clearly 
considerable (although only summary statistics were available for the manufacturer’s 
findings so no statistical test was possible). It is worth noting that the assay is reportedly 
sensitive to ~0.2 pg/ml, which when compared with this small cohort of people, would 
appear to be a low value even within a young and healthy population. 
 
sCD40L was shown to have far lower measurements in plasma when compared with the 
manufacturer’s estimates for levels present in normal serum (Table 3.3) (~50-fold lower 
in citrate). Generally, measurements in citrate in particular were “flat” with little inter-
individual variation, and although levels in EDTA were higher (60% comparing medians 
of citrate and EDTA), the mean detectable value of ~200 pg/ml in EDTA corresponds to 
an optical density (OD) readout of <0.15 on the standard curve of the assay (standard 
curve OD ranges from ~0.07 [Blank value] to ~1.60 [10,000 pg/ml]). The average 
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sCD40L value of plasma in healthy people is hence at the very limit of detection on the 
assay. As seen on the Bland-Altman plot, comparisons show that the noted trend for 
higher levels of sCD40L in EDTA than in citrate were significant (p<0.0003), and (unlike 
IL-18) Spearman correlations were relatively poor (r = 0.50), although the effects of the 
different anti-coagulants were uniform across sCD40L levels (random data scatter). This 
suggests that the differences caused by taking citrate or EDTA are unpredictable. 
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Table 3.1 Range, means and SDs for EDTA in trial study of IL-18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Bland-Altman analysis plotted on a log scale comparing IL-18 levels in citrate 
and EDTA plasma  
 
 
 
Serum 
n=46 
Citrate 
n=20 
EDTA 
n=20 
Minimum (pg/ml) 
Maximum (pg/ml) 
Mean (pg/ml) 
St Deviation 
36 
258 
126 
44 
52 
399 
186 
93 
47 
109 
215 
428 
Manufacturer’s 
Study 
Plasma 
Validation 
Study 
ND – Not detectible. N/A- Not determined 
 
Median (pg/ml) N/A 180 206 
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Mean difference (transformed) = -0.126 
Median EDTA levels 14.4% higher than citrate (untransformed) 
t-test p<0.0004 
Spearman correlation r = 0.88 
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Table 3.2 Range, means and SDs for anti-coagulants in trial study of TNFα. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 Range, means and SDs for anti-coagulants in trial study of sCD40L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ND – Not detectible. N/A- Not determined 
EDTA 
n=20 
EDTA 
n=35 
Minimum (pg/ml) 
Maximum (pg/ml) 
Mean (pg/ml) 
St Deviation 
ND 
4.22 
1.98 
N/A 
0.11 
1.34 
0.41 
0.29 
Manufacturer’s 
Study 
Plasma 
Validation 
Study 
ND – Not detectible. N/A- Not determined 
Median (pg/ml) N/A 0.31 
Serum 
n=58 
Citrate 
n=20 
EDTA 
n=20 
Minimum (pg/ml) 
Maximum (pg/ml) 
Mean (pg/ml) 
St Deviation 
ND 
11451 
5461 
N/A 
51 
241 
115 
42 
89 
130 
203 
565 
Manufacturer’s 
Study 
Plasma 
Validation 
Study 
Median (pg/ml) N/A 103 165 
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Figure 3.3 Bland-Altman analysis plotted on a log scale comparing sCD40L levels in 
citrate and EDTA  
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Mean difference (transformed) = -0.478 
Median EDTA levels 60% higher than citrate (untransformed) 
t-test p<0.0003 
Spearman correlation r = 0.50 
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3.2.4 Discussion 
 
IL-18 was successfully validated for determination in both EDTA and citrated plasma. 
The manufacturers tested serum samples from 46 healthy volunteers, and these are 
comparable with EDTA and citrate plasma results reported here. The mean and standard 
deviation (SD) were slightly higher in plasma compared to the manufacturer’s separate 
study in serum. In the current study, despite differences in absolute levels of IL-18 
detected in citrate and EDTA, the correlation between anticoagulants was r = 0.88, 
suggesting results between the two are highly associated. On the basis of these findings 
the conclusion was that IL-18 could be measured in EDTA or citrated plasma as well as 
serum. 
 
In the trial of TNFα with EDTA samples, the values obtained in this study were rather 
lower than the manufacturers range. It is possible that this was due to differences in the 
study populations used, although the observed differences were large. Since both our and 
the manufacturer’s trials were used on relatively fresh EDTA anti-coagulated plasma the 
reason for this difference could not be verified. Despite this, the kit was sensitive enough 
to measure the lower levels we detected in our study, and a decision was made to press 
ahead with further small studies to further verify the suitability of the assay for 
epidemiological use. The results of the manufacturer suggest that, like IL-18, TNFα can 
be measured in plasma or serum, and this is confirmed elsewhere (Flower et al, 2000). 
 
As stated previously, MMP-9 was not validated in this study due to chelation reactions in 
plasma, and use must be restricted to serum samples. 
 
sCD40L was shown to have far lower measurements in plasma when compared with the 
manufacturer’s estimates for levels present in normal serum. Measurements of citrate in 
particular looked “flat”, and results were clustered below the bottom standard and at the 
limit of detection for the assay. This suggests that this particular assay, although widely 
used in the literature up until 2005, was not developed to be sensitive enough to 
accurately detect sCD40L levels this low, as shown by the much higher (~50 fold) serum 
levels. EDTA had significantly higher sCD40L levels than citrate, perhaps due to the 
ability of the anti-coagulant to preserve as well as activate platelets (Golanski et al, 
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1996), but correlation with citrated samples was relatively weak (r = 0.50). Hence despite 
previous suggestions that sCD40L is not suitable for measurement in serum (Ahn et al, 
2004, Mason et al, 2005; Varo et al, 2006; Weber et al, 2006) there are severe 
contraindictions to the use of plasma in the ELISA technique. Indeed, even in platelet 
poor citrated plasma, carryover of very small platelet numbers may be sufficient to 
induce some ex-vivo sCD40L release, which may be sufficient to skew results (already at 
the limit of detection) to a meaningless artefact. Based on other results presented here 
(section 3.5), there is also the possibility that storage and freeze/thaw cycles may further 
reduce detectable levels of sCD40L, making older plasma samples hard to use. 
 
In light of these results, I concluded that while IL-18 and TNFα may be used in studies 
with citrated or EDTA plasma as well as serum samples in epidemiological studies, 
sCD40L and MMP-9 can only be used in serum samples. While serum may not be ideal 
for measurement of sCD40L, the alternative of using plasma in technologies available at 
the outset of this thesis seemed even less useful. 
 
3.3 INTRA- AND INTER-ASSAY VARIATION 
 
3.3.1 Introduction 
 
Laboratory error in the measurement of markers will be a contributing factor towards any 
underestimation of the association between the marker and its sequelae, such as 
cardiovascular disease. In addition, it is important to ascertain how sensitive an assay is. 
Since the inflammatory markers assessed in this thesis were measured by one operator 
using ELISA techniques, it may be assumed that operator error will be similar for each 
assay. Laboratory error is reported as the intra-assay (within assay) and inter-assay 
(between assay) variation. While the manufacturers report intra- and inter-assay variation 
values in the kit instructions, these require verification for the current operator. In this 
study I aimed to assess the level of intra- and inter-assay variation for each assay. 
 
3.3.2 Methods 
Inter-assay variation was determined by statistical analysis of the first 20 values obtained 
on different days (i.e. different assays over a period of up to 5 months) for the in-house 
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QC plasma (lot 777712; described in chapter 2) for each of the 4 cytokines. Intra-assay 
variation was determined by assaying a pooled QC plasma (not necessarily the in-house 
QC, but a pooled sample obtained by similar means; see 2.5.1) a number of times 
(number of times assay dependant; see results) on the same assay for each of the 4 
cytokines. Where possible, the intra-assay CV was calculated using two different 
standards of different mean values in order to ascertain the effect of different antigen 
concentrations on the observed CV. Mean value, standard deviation (SD) and coefficient 
of variation (CV) were then calculated.  
 
3.3.3 Results 
 
Intra-assay variation is summarized in Table 3.4, and inter-assay variation in Table 3.5. 
IL-18 and TNFα, MMP-9 and sCD40L assays generally show levels of intra-assay 
variation comparable to other inflammatory markers measured by ELISA, such as IL-6 
(CV 7.5%; data from Poorhang, MSc thesis, 2005). This is as expected, since the assays 
operate on the same immunodetection principle. Levels of variation rise sharply as the 
assays reach their limits of detection; this is especially applicable to TNFα, which at a 
level of 0.33 pg/ml has a CV of 36%, although it should be noted this level is particularly 
low. The second sCD40L sample used (n=5) did not have a substantially different level 
of sCD40L.  In general, all markers had decreasing CV with increasing levels of antigen 
in the sample. 
 
As expected, inter-assay variation (Table 3.5) is higher than intra-assay variation since it 
includes additional sources of variation. Direct comparisons of intra- and inter-assay 
results are not possible here due to the differences between the samples used. Despite this 
all markers showed an inter-assay variation of <15%. As seen in Table 3.5, all intra- and 
inter-assay variations were in reasonable agreement with the manufacturer's reported 
results, with the exception of sCD40L in the inter assay results (14.9% versus ~7%). This 
discrepancy may be attributable to two outliers in the in-house sCD40L inter-assay 
results (CV>20%) or it may reflect a higher concentration of standard used by the 
manufacturers to report inter-assay CV (levels not reported). 
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Table 3.4 Intra-assay variation in the four inflammatory markers 
SD; standard deviation, CV; coefficient of variation (%), n; number; NR not reported 
 
 
Table 3.5 Inter-assay variation in the four inflammatory markers 
 n Mean SD CV (%) 
Manufacturer 
reported CV 
(%) 
IL-18 (pg/ml) 17 196 20.3 10.4 ~7 
TNFα (pg/ml) 17 1.41 0.177 12.5 ~11 
MMP-9 (pg/ml) 17 543 56.5 10.4 ~8 
sCD40L (pg/ml) 17 2033 303.8 14.9 ~7 
SD; standard deviation, CV; coefficient of variation (%), n; number 
 
 
 
 
 
 
 
 
 
 
 
 
 
n Mean SD CV (%) 
Manufacturer’s 
reported CV 
(%) 
IL-18 (pg/ml) 10 356 19.9 5.6 ~10 
4 1716 74 4.5 ~5 
TNFα (pg/ml) 10 1.96 0.164 8.4 ~8.5 
20 0.33 0.117 36 NR 
MMP-9 (pg/ml) 10 551 24 4.4 ~2 
 5 878 32 3.6 NR 
sCD40L (pg/ml) 10 2228 87 2.9 ~5.5 
 5 2068 78 3.8 ~5.5 
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3.3.3 Discussion 
 
Intra- and inter-assay variation ranges for each marker were comparable to most other 
inflammatory markers within the normal healthy population range, and hence the assays 
were deemed appropriate for epidemiological use in terms of sensitivity. 
 
3.4 SAMPLE PROCESSING 
 
Sample processing is an important step in blood collection, since the length of time 
plasma or serum is left in contact with blood cells may alter subsequent levels of 
variables due to cell or platelet lysis and/or activation and may also influence levels of 
less biochemically stable markers left at room temperature. The epidemiological studies 
used in this thesis were all carried out employing reasonably prompt handling procedures, 
as detailed in each individual chapter. Since my laboratory had little input into the design 
of most of these studies prior to blood letting, sample processing is not investigated in 
this thesis. Previous studies have shown that TNFα is unaffected if left un-processed in 
whole blood for up to 4 hours (Flower et al, 2000). MMP-9 and sCD40L have been 
shown to be relatively stable for a number of hours in serum after centrifugation and 
sample separation (Weber et al, 2006; Makowski et al, 2003). There are no known studies 
of this type for IL-18. 
 
3.5 SAMPLE STORAGE AND FREEZE THAW 
 
3.5.1 Sample Storage Time Introduction 
 
Degradation of stored blood samples is an important issue to assess, and can be caused by 
either time in storage itself, or increasing numbers of freeze-thaw cycles.  
 
The time samples are kept frozen in storage is primarily a concern for large 
epidemiological studies rather than clinical processing and the testing of blood samples 
for individual patients, which are usually performed on fresh samples in clinical 
biochemistry departments. Blood samples from large cohort studies may be stored frozen 
for decades (such as the British Regional Heart Study samples; Walker et al, 2004) and 
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this may have a bearing on different markers of variable stability. Due to time constraints 
of this thesis, it is obviously not possible to study the effects of storage over such long 
periods.  
 
In the literature, storage of frozen serum for 1 month has been reported to have no effect 
on MMP-9 (Souza-Tarla et al, 2005). Interestingly, however, in plasma MMP-9 may be 
unstable even when frozen at -80OC, perhaps partially accounting for the relatively low 
circulating levels reported in most studies of plasma. One study found that, after 2 years, 
the detectable total MMP-9 dropped by 65% in plasma (Rouy et al, 2005). A literature 
search revealed no such studies for IL-18, TNFα or sCD40L, and none are reported by 
the manufacturers (R&D Systems).  
 
In designing this study, it was important to define what information it was important to 
glean from the data. Plans for future studies involved comparing markers by thirds of the 
population in prospective studies, and this required us only to show that rank correlations 
of marker data sets were maintained across storage time (i.e. the actual information 
within the data sets are maintained as opposed to absolute values). For performing 
possible meta-analysis the marker requires to demonstrated more resistance to decay with 
time in storage in terms of absolute values (so studies may be combined without 
“experimental” heterogeneity in the pooled results).  
 
In this experiment I aimed to study the effects of storage at -50oC over 12-15 months on 
all four inflammatory markers in the plasma or serum of ten individuals. Storage at -50oC 
will generally be the highest temperature epidemiological samples are stored at in modern 
laboratories. Data sets were analysed as outline in the relevant section. 
 
3.5.2 Freeze-Thaw Cycles Introduction 
 
Freeze/thaw cycles, like frozen storage, is primarily a concern for large epidemiological 
studies, rather than clinical processing and the testing of blood samples for individual 
patients. For the inflammatory markers in this thesis the manufacturer’s instructions only 
state a non-committal recommendation of “avoid repeat freeze-thaw cycles” for each 
marker.  
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Some peer-reviewed studies suggest inflammatory markers are surprisingly robust, and 
show that 3 freeze thaw cycles had no effect on TNFα (or other cytokines such as IL-1β, 
IL-6 and IFNγ) or plasma sCD40L (Thavasu et al, 1992; Varo et al, 2006), and up to five 
freeze-thaw cycles for MMP-9 (Souza-Tarla et al, 2005) also had no effect. Again, no 
specific studies of IL-18 were found in the literature although the manufacturer of an  
ELISA kit for swine IL-18 has reported that 5 freeze-thaw cycles had no effect on 
detectable levels: 
(www.biosource.com/content/catalogcontent/tds3/moreinfo/KSC0181%20pr272%20rev
A2%20nov706%20(Sw%20IL-18)(BMS672).pdf ).   
The surprising resistance of these inflammatory markers to freeze/thaw cycles may 
reflect the measurement by ELISA techniques in these studies; ELISA antibody detection 
only requires the antigenic site to be intact, rather than the marker to be biologically 
active.   
 
As with the section on storage stability, I required to ascertain whether markers 
maintained rank correlation with freeze-thaw biochemical stress, and whether absolute 
values were stable. In this study the aim was to examine the effect of 4 freeze-thaw 
cycles on each of the four inflammatory markers in the plasma or serum of ten 
individuals. 
 
3.5.3 Subjects and Methods 
 
The same subjects in the same blood let were used to study both storage and freeze-thaw 
variables.10 healthy laboratory volunteers (5 males: 5 females, age range 21-59 years) 
donated venous blood which was collected in a citrated vacutainer (BD, Oxford) (0.11M; 
9:1 v:v) (IL-18 and TNFα assay) and in a serum clot accelerator vacutainer (MMP-9 and 
sCD40L) in the same venipuncture. Blood samples were left on the bench for 30 minutes 
(precisely) before centrifugation at 2000g for 10 mins, and then were separated into 
plasma or serum aliquots, which were snap-frozen at -80oC. Appropriate aliquots were 
thawed as required.  
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In the storage study, baseline was defined as 3 weeks after freezing to allow for initial 
freezing effects on the samples. Due to limitations in the ELISA kits available in the 
laboratory at any given time point after setting up this study, IL-18 and TNFα were 
assayed at different time points from MMP-9 and sCD40L. IL-18 and TNFα were 
assayed at baseline, 6 and 15 months, and MMP-9 and sCD40L at baseline, 9 and 12 
months. Due to unforeseen changes in the manufacture of the hs-TNFα assay by R&D 
Systems early in 2007, the ability to complete this experiment for TNFα has been 
restricted. The newly manufactured kit claims to have superior sensitivity and to resolve 
some “minor technical issues” with the previous lots. The newly manufactured kit has a 
linear r =0.82 correlation when results are compared directly with the older kit lot, but the 
conversion is non-linear at more extreme high and low observations. It is therefore hard 
to justify adjustment for these changes in a study of this small scale. Therefore the last 
study point at 15 months cannot be used in the storage study of TNFα. The storage study 
is the only study in this thesis affected by this kit change. 
 
In freeze-thaw, after taking appropriate aliquots and initially snap-freezing at -80oC, each 
aliquot from an individual was repeatedly thawed at 37oC, assayed, and re-frozen at -
80oC (n= 4 cycles for all markers) leaving a minimum of 2 days in between freeze-thaw 
cycles. 
 
Since the results of these experiments are very sensitive to inter-assay variations, each 
assay in both experiments was adjusted on the in-house QC result to give the average QC 
reading. This was a simple process of adjusting the data by the proportion:  
(obtained QC value - mean QC value)/mean QC value  
 
From this adjustment, the average magnitude of correction was ± 7.8% for all markers 
across 12 assays in total in the storage study (which is in broad agreement with the 
expected correction for the inter-assay CV range: table 3.5), and the median correction 
was 0.15%, suggesting random fluctuation in inter-assay variation. In the freeze-thaw 
study, the average magnitude of correction was ± 6.9% for all markers across a total of 16 
assays and the median correction was ~0.1%, also suggesting random fluctuation in inter-
assay variation. 
 
  142
Pairs of results from different storage points and freeze-thaw cycles were compared by 
Bland-Altman plot analysis (Bland & Altman, 1986) on a log or power-transformed scale 
(Woodward, 2005). The plots test the consistency of the effects of storage and freeze-
thaws across different baseline marker levels by illustrating any trends in the data (a 
random scatter suggesting consistent effects independent of marker levels). Differences 
between transformed data sets were also tested by paired t-test and Spearman 
correlations. 
 
3.5.4 Storage Results 
 
Data on the effects of storage at -50oC on the four markers are summarised in Table 3.6. 
Baseline measurements were not made until samples had been stored for three weeks. 
 
The Bland-Altman analysis in Figure 3.4 shows that, after data transformation, the effects 
of storage on IL-18 levels are independent of mean IL-18 levels. There is an outlying 
point of relatively high IL-18 levels for which there appears to be more significant 
storage affects, however, it is a single point and possibly a chance finding. In agreement 
with this, the effect of 9 versus 15 month storage does not appear to have any additional 
degradative effect on the point. There is no significant change in mean IL-18 levels 
across storage points, although the rank correlation is not as high as for other markers (r = 
0.71), but this does not worsen with further time in storage (9 versus 15 months). TNFα 
levels (Figure 3.5) were also stable across the single extra time-point measured at 6 
months (p=0.86), and the correlation between points was high (r = 0.90). In contrast to 
IL-18 and TNFα, mean levels of serum MMP-9 (Figure 3.6) decreased substantially at 
each time point compared to baseline (22.9% and 28.5% at 9 and 12 months 
respectively). Despite this however, the rank order of the data is well maintained (r≥0.84 
for both time-points), suggesting a uniform decay with time in storage, and this is 
confirmed by a random scatter of the Bland-Altman plot, showing a constant decay 
independent of MMP-9 levels.. For sCD40L (Figure 3.7), the 9 month time-point shows 
no decay compared to baseline, although the difference is significant by 12 months 
(5.4%, p=0.03). Again, the data suggests the effect of decay on detectable levels of 
sCD40L was uniform (r =0.96), and the data scatter on the plot was random, suggesting 
any decay is constant over all sCD40L levels. 
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Table 3.6 Summary of data for the four inflammatory markers after storage at -50oC at 
three time points; Baseline, time point 2 (12 months for IL-18 and TNFα, 9 months for 
MMP-9 and sCD40L), and time point 3 (15 months for IL-18, 12 months for MMP-9 and 
sCD40L).  
 
 
 
 
 
 
 
 
 
n/a – Not applicable 
 
 
 
 
 Median 
baseline 
Median 
time 
point 2 
Median 
time 
point 3 
IL-18 
(pg/ml) 
351 352 363 
TNFα  
(pg/ml) 
1.86 1.96 n/a 
MMP-9 
(pg/ml) 
1608 1239 1150 
sCD40L 
(pg/ml) 
6416 6469 6091 
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Figures 3.4-3.7 Bland-Altman plots showing the effect of minus 50oC storage at various time points (compared to baseline) for each of the 
four inflammatory markers. 
Figure 3.4 IL-18  
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Figure 3.5 TNFα 
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Figure 3.6 MMP-9 
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Figure 3.7 sCD40L 
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3.5.5 Freeze-Thaw Results 
 
The effects of freezing and thawing cycles on the four markers are summarised in Table 
3.7. The first thaw was at taken as a baseline value, since fresh plasma or serum was not 
assayed in this study. 
 
As seen in the Bland-Altman plot in Figure 3.8, IL-18 levels dropped 28.8% on the 
second compared to first thaw. Interestingly, this observation of decreasing detectable 
levels was not exacerbated on subsequent thaws. Spearman rank correlations of IL-18 
data sets across thaws were maintained throughout (r≥0.75). Random data scatter shows 
that the effects of freeze-thaw were proportionately constant across IL-18 levels. TNFα 
levels (Figure 3.9) did not show any significant decreasing trend across the four thaws. 
The second thaw was significantly lower than the first (14.5%), but the equality of 
subsequent thaws to baseline suggest that this was a chance finding. Again, all data sets 
were correlated (r≥0.78). MMP-9 levels (Figure 3.10) decreased on the third and fourth 
thaws (27.1% and 27.6%, p≤0.002), and although the effect of thawing was constant 
across thaws, the data correlation was poor on the third thaw (r 0.59). This may be an 
outlier, since the correlation with baseline was better on the fourth thaw (r = 0.77). 
sCD40L levels did not decrease on the second thaw, but levels dropped significantly on 
the third thaw (8.2%) and dramatically on the fourth thaw (41.7%). The effect of these 
thaws was constant, and even on the fourth thaw there was very strong correlation with 
baseline values (r = 0.94). 
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Table 3.7 Summary of data for the four inflammatory markers after 4 freeze-thaw cycles. 
 
  Median 
1st thaw 
Median 
2nd thaw 
Median 
3rd thaw 
Median 
4th thaw 
IL-18 
(pg/ml) 
351 250 269 267 
TNFα  
(pg/ml) 
1.86 1.59 2.07 2.19 
MMP-9 
(pg/ml) 
1608 1634 1172 1164 
sCD40L 
(pg/ml) 
6416 6994 5889 3743 
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Figs 3.8-3.11 Bland-Altman plots showing the effect of four freeze-thaw cycles (compared to baseline [thaw 1]) on each of the four 
inflammatory markers 
Figure 3.8 IL-18 
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Figure 3.9 TNFα 
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Figure 3.10 MMP-9 
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Figure 3.11 sCD40L 
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3.5.6 Storage and Freeze-Thaw Discussion 
 
In this experiment it is important to consider that the samples were taken from healthy 
participants with only small inter-individual differences in circulating levels of each 
marker. This may have important bearings on results, particularly the rank correlation 
analysis. For instance, for IL-18 and TNFα the baseline CV between all participants is 
<25%. Even though attempts were made to adjust for inter-assay variation effects, it is 
perfectly conceivable that residual intra-assay variation has a CV>5%, and this may have 
significant effects on the rank correlation between assays. Selection of only young and 
healthy individuals, therefore, may give an extreme view of the effects of storage and 
freeze-thaw conditions on these markers, and consequently results may be cautiously 
viewed as a possible exaggeration compared to the effects one would expect to observe in 
usual epidemiological studies of a general population including older subjects where the 
data set would have a higher CV. 
 
Bearing in mind this limitation, the storage analysis study shows generally that keeping 
the samples frozen at -50oC for over a year has little material impact, in terms of the rank 
order of the data sets, on the measurement of any of the four inflammatory markers. A 
previous study of MMP-9 has shown that storage for 2 years leads to a 65% fall in 
detectable levels (Rouy et al, 2005) and these results are consistent, demonstrating a fall 
of 28.5% of the median levels over 12 months. Despite this, the current study broadly 
found that the rank order of the data set is maintained since the effects appear to be 
uniform across all samples.  
 
MMP-9 and sCD40L are most heavily affected in terms of absolute loss in detectable 
levels with each incremental freeze-thaw cycle, particularly sCD40L, which dropped by 
41.7% of median baseline values after 4 cycles. A previous study of MMP-9 
zymographic activity in EDTA plasma has shown no effect of several freeze-thaws, 
suggesting chelation of the molecule may confer some biochemical stability and allow it 
to maintain enzymatic potency (Souza-Tarla et al, 2005). This was clearly not the case 
here in serum measured by ELISA, since MMP-9 levels decreased on the third and fourth 
thaws.  
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Interestingly, sCD40L levels have recently been shown to be resistant to freeze-thaw 
cycles in platelet poor plasma, but levels may increase slightly in platelet rich plasma 
after freeze thaws (Varo et al, 2006). The ELISA used in that study (Varo et al, 2006) had 
a reported sensitivity of 10pg/ml, but the study reports values of up to ~16 ng/ml in 
serum; it is inherently unlikely the assay is sensitive over a range of ~2000-fold 
increases, and the sensitivity claim has not been peer-reviewed to my knowledge. Taken 
together the evidence suggests that in plasma samples any residual platelets (in platelet 
rich or poor plasma) are able to maintain or indeed elevate sCD40L levels due to the 
generally low levels already present being around the limit of detection for the technique. 
This is therefore experimental artefact, and further suggests that plasma samples are 
problematic in the measurement of sCD40L. The evidence presented here suggests that 
stored serum samples, or samples subjected to up to 4 freeze-thaw cycles, do not affect 
sCD40L or MMP-9 to the detriment of the integrity of the data set so long as all samples 
are prepared and treated in the same manner. This finding is important for 
epidemiological studies. Cross-study comparison of levels of the markers may prove 
more problematic. 
 
In contrast, despite storage of samples or freeze-thaw cycles having little material effect 
on median IL-18 levels overall (which is in agreement with reported results from 
Biosource, the manufacturer of a swine IL-18 ELISA [see introduction]), I observed that 
IL-18 rank correlation within the data set was more substantially affected by storage for 
15 months (r = 0.70 versus baseline) and 4 freeze thaw cycles (r = 0.75 versus baseline) 
than the other markers. Bearing in mind the limitations of this study, and the fact that the 
correlations were still significant, the conclusion is that IL-18 is suitable for use in 
epidemiological studies with the proviso that it be measured at the first thaw (within 
studies for this thesis) as the priority marker in order to minimise any possible effect of 
these pre-analytical variables. 
 
This study has also shown that 4 freeze thaw cycles (and probably storage for up to a 
year; although this evidence is hampered by technical problems) has minimal impact on 
measurements of TNFα in terms of overall change in levels, which is in agreement with 
previous findings (Thavasu et al, 1992). It seems probable that TNFα is the most robust 
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of these inflammatory markers in terms of resistance to storage decay and freeze-thaw 
cycles, despite the very low circulating levels in healthy individuals. 
 
In terms of epidemiological use, I conclude that all four markers are suitable to be 
examined as risk markers in prospective epidemiological studies, but based on the 
evidence here, it is possible only IL-18 and TNFα are suitable for meta-analysis of 
prospective studies, due to the increased labile nature of MMP-9 and sCD40L. Pooling of 
data sets for these markers may not be a suitable methodology. More data is required for 
all of the markers using a larger, wider population in order to confirm and expand on 
these findings. 
 
 
3.6 SHORT-TERM BIOLOGICAL VARIATION 
 
3.6.1 Short-Term Biological Variation 
 
Normal fluctuations in the expression of circulating inflammatory and haemostatic 
markers occur within the time frame of weeks, days, and hours. For instance, there are 
diurnal and seasonal variations in circulating haemostatic factors (activated factor VII, 
tissue plasminogen activator, prothrombin fragment F1+2, plasmin–plasmin inhibitor 
complex, fibrin D-Dimer, t-PA, vWF) and inflammatory markers (fibrinogen and CRP) 
(Kapiotis et al, 1997; Rudnicka et al, 2007). To some extent variation in circulating 
variables is caused by predictable external factors (e.g. physiological response to seasonal 
weather, activity, or eating patterns over 24 hours), and hence consequent variation is 
predictable at a population level. However, there are also less predictable fluctuations in 
short-term variation that are more prominent on the scale of individual patients (e.g. 
response to (sub)clinical infection or physical exertion). This source of biological 
variation could have implications for a marker’s clinical utility, as well as perceived risk 
associations in epidemiological studies. In most clinical situations or epidemiological 
studies, only one blood sample from each subject is taken, but ideally multiple sampling 
would be required for more reliable estimation of the individual’s habitual plasma level. 
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According to the literature, biological variation in inflammatory markers can be 
surprisingly large. For instance, CRP has been estimated to have an intra-person CV of 
34 – 49.8% (Macy et al, 1997; Wilkins et al, 1998; Sakkinen et al, 1999; Ockene et al, 
2001; at least 5 repeat measurements at a maximum of 1 month intervals). One of these 
studies has suggested that CRP has similar CV to that seen in total cholesterol (Ockene et 
al, 2001) although this claim has been refuted (Campbell et al, 2002 & 2003). The 
biological variability study from the British Regional Heart Study cohort (1 week repeat 
measurement in 297 men) reports a regression dilution ratio of 0.87 for total cholesterol, 
0.74 for CRP, 0.84 for fibrinogen and 0.69 for systolic blood pressure (Emberson et al, 
2004). 
 
For more precise measurement of biological variability, markers should be repeatedly 
measured in a small number of individuals with the aim of ascertaining the number of 
repeat measurements required to estimate reliable usual level (or to minimise risk of mis-
classification in individuals). The aim of this study was to examine the effect of short-
term biological variability on IL-18 and TNFα in comparison to other new CVD risk 
predicotors (CRP, IL-6, fibrinogen). In doing this the aim was to estimate the number of 
blood samples which would be required for 75% and 90% reliability of such estimates in 
individuals (Fleiss et al, 1987), as well as estimating the effects of biological variation on 
observed risk associations in cohort studies. Due to a lack of serum samples, sCD40L and 
MMP-9 were not analysed. The results of the haemostatic markers, fibrinogen, CRP and 
IL-6 in this study have previously been reported elsewhere (Poorhang, MSc thesis, 2005), 
and are also reported here in a revised statistical analysis to compare with IL-18 and 
TNFα. 
 
3.6.2 Subjects and Methods 
 
14 healthy non-fasted volunteers, 7 men and 7 women aged between 37 and 56, all gave 
informed consent to repeated venipuncture for up to 21 weeks, and the study was 
approved by the Local Research Ethics Committee. 20 ml blood was drawn weekly into 
citrated (0.109M trisodium citrate) vacutainers. All samples were taken in the morning 
before 12MD, which minimises the effect of diurnal variation (Rudnicka et al, 2007). Due 
to subject withdrawal at various stages, the average number of visits was 17 (range 4-21). 
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Blood samples were centrifuged at 2000g, the plasma separated, and aliquots frozen at -
80°C. Each sample was snap-thawed at 37oC as required, and each aliquot was thawed 
for assay on a maximum of two occasions. All the time points for a given individual were 
assayed on the same ELISA (for each marker) to minimise inter-assay variation in the 
study, and each set of samples for an individual had experienced the same storage/freeze-
thaw history. All available data was analysed. 
 
Total within person variation (CV) in this study can be seen as the composite effect of 
biological CV and methodological CV (which is a constant; intra-assay CV). Therefore 
biological variation is given by the equation: 
 
 
 
 
 
(Ernst et al, 1985) 
 
More complex statistical analysis was performed in Excel in accordance with Fleiss 
(1986) after log-transformation to normalise the data. However, the Fleiss method is 
prone to statistical biases with decreasing number of values due to estimations of 
variance in components of random error and intra-subject error (Fleiss, 1986). Although 
this study is sizeable, it was deemed prudent to cross-examine the data with another 
statistical method. The “Random effects model” (a mixed model) removes these inherent 
biases, although the statistical analysis entailed is more complex. Therefore this analysis 
of the data was performed by using a random effects model (Hankinson et al, 1995). This 
involved regressing the correlated sets of values, all observations on all individuals taken 
together, against a random intercept. An unstructured correlation set was assumed, and 
log transformed used to induce approximate normality. 
 
On comparison of both the Fleiss and the random effects models, the data were shown to 
be highly comparable (suggesting sufficient N to estimate variances in the Fleiss model). 
Due to high comparability, only the data from the random effects model is included here. 
 
Biological CV = 
Total CV – Methodological CV 
1 – Total CV 
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Key output data is presented with the following index: 
 
R Reliability (the intra-class correlation coefficient); the proportion of variance due 
to within subject error. Calculated by the ratio of the within-subject mean square 
(also the within subject variance) to between subject mean square (from one-way 
ANOVAs). 
nrep Number of replicates required to achieve desired reliability. 
 
The reliability coefficient (R) obtained was used to determine the expected effect of 
short-term variation on marker associations with outcome in epidemiological studies. 
This means a hypothetical “true” association between a marker and a study outcome can 
be used to infer what the expected observed association will be when considering data 
“lost” to short-term variation (Hankinson et al, 1995). 
 
Data examining all other inflammatory markers (than IL-18, TNFα, MMP-9 and 
sCD40L) in this section are from Poorhang, MSc thesis, 2005. The results presented here 
for those markers are analysed in a novel form (not used by Poorhang) are included for 
comparison. 
 
3.6.3 Results 
 
In total there were 243 time-points where blood samples were taken from 14 individuals. 
For technical reasons IL-18 and TNFα were assayed in fewer samples than the other 
markers (99% and 91% respectively), but all available data was analysed. 
 
Table 3.8 shows the total variability in the 14 individuals over the period of the study. 
Total CV is broken down into methodological and biological CVs. As expected, by far 
the greatest proportion of total CV was biological in origin. Intra-person biological CV 
was lowest for fibrinogen (6.2%), greater for IL-18 (25.0%) and TNFα (24.8%), and 
highest for the acute phase response associated cytokines IL-6 (50.1%) and CRP (55.7%).  
 
Despite the interesting observation that IL-6 and CRP as well as IL-18 and TNFα had 
highly comparable overall biological CVs, this belied considerable inter-individual 
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variation in observed CVs. Illustrating this, IL-6, CRP, IL-18 and TNFα CVs in 
individuals are shown as a function of plasma antigen level in Figure 3.12. As seen in the 
figure, although the average overall CV for IL-6 was ~54% the range spread from ~25% 
to ~150%. There were no significant interactions of CVs with circulating plasma levels of 
the marker. This means the CV is independent of plasma level of the marker in each case. 
 
Expanding this theme, it would be ideal to compare biological CV between individual 
people; i.e. do some people display tendencies towards variability/stability across all 
inflammatory markers than others? Rank orders of CVs for all people in each marker are 
displayed in Table 3.9. As can be seen in this table, person 4 displayed consistently high 
biological variability (relative to the group), whereas there were others who were 
relatively stable across markers. There were too few people and too many variables to 
apply statistical models to this question reliably here, although the general trends are 
interesting to note. Thus, overall, some individuals appear to display greater propensity to 
a high degree of variation. It is hard to attribute this to a specific biological cause. The 
individual may have only had a cold(s) over a significant period of the study. Also 
interesting in Table 3.9, but as expected, IL-6 and CRP/fibrinogen demonstrated high 
correlations with each other throughout the data in terms of intra-individual CV. Other 
markers were relatively less well correlated.  
 
Further illustrating differences in variation between individuals, Figure 3.13 shows two 
individuals at opposite ends of biological variability spectrum for CRP and fibrinogen. 
Note that even after 5 months it is hard to discern a “habitual” level of either marker for 
the variable individual. In Figure 3.14 the biological CV of fibrinogen (low overall CV) 
and IL-6 (high CV, although the correlation in CV between persons for the two markers 
is high) for two individuals is shown. Interestingly, erratic circulating IL-6 levels can be 
associated with concomitant erratic fibrinogen levels (person 1). In contrast, as seen in 
person 2, sharp peaks in IL-6 expression may also have no observed effect on fibrinogen 
(or any other inflammatory marker; data omitted for clarity). This is despite roles in the 
acute-phase response common to IL-6 (promoter) and fibrinogen (reactant), and a 
relatively strong correlation (r = 0.49). IL-18 and TNFα demonstrated no particularly 
strong association in variation with each other or any other inflammatory marker. 
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Using the random effects model, Table 3.10 was generated, and shows estimates of the 
coefficient (R) for each marker. According to study estimates, in order to achieve a 
reliability of 75% for an individual’s true mean value, 1 measurement of fibrinogen 
(rounded whole number 95% confidence intervals; 1-2) is sufficient, while 2 
measurements are required for IL-18 (1-3), CRP (1-4), and TNFα (1−4), although 8 
measurements are required for IL-6 (1-14). To achieve a reliability of 90% it is estimated 
that 3 measurements are required for fibrinogen (1-6), 4 measurements for IL-18 (1-8), 6 
measurements for CRP (1-12) and TNFα (1-12), and 22 measurements for IL-6 (2-43). 
 
In addition to this analysis, the probable observed OR in prospective studies for each 
marker, based on a hypothetical “true” OR of 1.50 for each marker was estimated. These 
“expected/observed” ORs are also summarised in Table 3.10. Due to each marker being 
assigned the same hypothetical OR, the rank order of relative underestimations of the 
markers due to biological variation is the same as the rank order for the coefficient R. As 
can be seen from the table, estimates suggest the marker with the lowest biological CV, 
fibrinogen, would have an OR of 1.36 (a 28% underestimation of risk). In contrast the 
more variable markers would lose much of their associations with events in prospective 
studies: CRP OR 1.27 (46% underestimation) and IL-6 OR 1.12 (76% underestimation). 
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Table 3.8 Total short-term CVs for each marker and proportions thereof that are 
methodological (intra-assay) or biological in origin. CVs are obtained from 243 
observations from 14 people (except IL-18 and TNFα; 221 observations from 13 people, 
240 observations from 14 people respectively). 
SD: standard deviation, CV: coefficient of variation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Mean of 
intra-person 
means 
Mean of 
intra-
person SDs 
Mean of 
intra-person 
CVs (%) 
Methodological 
CV % 
Biological 
CV % 
Fibrinogen (g/L) 3.05 0.25 8.31 2.6 6.2 
CRP (mg/L) 1.31 0.7 57.8 4.7 55.7 
IL-6 (pg/ml) 1.46 0.84 53.8 7.5 50.1 
IL-18 (pg/ml) 299 91 29.2 5.6 25.0 
TNFα (pg/ml) 0.71 0.21 31.1 8.4 24.8 
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Figure 3.12 Range of inter-individual CVs of inflammatory markers (CRP, IL-6, IL-18 and TNFα) as a function of circulating plasma level. 
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Table 3.9 Rank order of magnitude of CV for each person in each marker (1=highest CV 
for given marker). Table illustrates inter-individual differences in global inflammatory 
trends for variability. Correlation values displayed below are rank correlations comparing 
data sets for given markers in selected pairs.  
 
 
 
 
 
 
 
 
 
 
 
n/a, data missing. 
 
CRP vs Fibrinogen  r = 0.78 
IL-6 vs CRP  r = 0.72 
IL-6 vs Fibrinogen r = 0.49 
IL-18 vs TNFα r = 0.23 
TNFα vs CRP  r = 0.17 
IL-18 vs CRP  r = 0.04 
 
 
 
 
 
 
 
 
 
 
 IL-18 TNFα IL-6 CRP Fib Average 
Person 1 2 13 11 14 9 10 
Person 2 4 15 13 10 8 10 
Person 3 13 2 14 13 14 11 
Person 4 3 1 2 1 1 2 
Person 5 11 12 6 5 5 8 
Person 6 6 5 4 3 4 4 
Person 7 1 11 1 8 12 7 
Person 8 9 7 7 12 13 10 
Person 9 8 4 5 6 3 5 
Person 10 5 8 3 2 2 4 
Person 11 12 10 8 4 10 9 
Person 12 7 6 12 9 7 8 
Person 13 n/a 3 10 11 11 9 
Person 14 10 9 9 7 6 8 
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Fig 3.13 Graphical comparison of CRP and fibrinogen in a person with high CV (person 
4 in Table 3.9) and a person with low CV (person 8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Graphical comparison of biological CV in fibrinogen (lowest biological CV) 
and IL-6 (highest biological CV) for two people over the course of the study. 
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Table 3.10 Random Effects model statistics for reliability measurements in short-term 
variation. 
 CI: confidence intervals, n rep: number of required repeat measurements, OR: Odds 
ratio. 
 * Observed OR estimated to be found in prospective studies (assuming correct value for 
R coefficient). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intra-class 
correlation 
coefficient (R) 
n required 
measurements for 
75% reliability 
n required 
measurements for 
90% reliability 
Hypothetical 
OR 
Observed 
OR* 
 R (95% CI) nrep (95% CI) Nrep (95% CI)   
Fibrinogen 0.73 (0.60-0.94) 1 (1-2) 3 (1-6) 1.50 1.36 
CRP 0.58 (0.43-0.89) 2 (1-4) 6 (1-12) 1.50 1.27 
IL-6 0.28 (0.17 – 0.83) 8 (1-14) 23 (2-43) 1.50 1.12 
IL-18 0.66 (0.52-0.93) 2 (1-3) 4 (1-8) 1.50 1.31 
TNFα 0.58 (0.43-0.89) 2 (1-4) 6 (1-12) 1.50 1.27 
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3.6.4 Discussion 
 
Overall, this study demonstrates the importance of considering the normal background 
biological variation in prospective studies of novel risk markers, and indeed in candidate 
markers for clinical risk assessment. From a clinical perspective, the risk of mis-
classifying an individual into hypothetical “high, intermediate, or low” risk categories 
increases with decreasing reproducibility of a marker, and hence detrimentally affects the 
clinical utility of the marker as a tool. Biological variation also has impact on prospective 
epidemiological studies, which often only use one baseline measurement of an individual, 
and can lead to gross under-estimation of “true” risk association. These statements are of 
course not new, but the finding of such dramatic differences in biological variation 
between similar “general inflammatory” markers within the same study is striking. 
 
Previous studies have shown similar biological variability in more conventional CVD 
risk markers. A meta-analysis of 30 studies published from 1970 to 1992 yielded 
estimates of biological CV of 6.1% for total cholesterol, 7.4% for HDL cholesterol, 9.5% 
for LDL cholesterol and 22.6% for triglycerides (Smith et al, 1993). Results presented 
here suggest that inflammatory markers are generally much more variable than serum 
lipids, although the CV of IL-18 and TNFα are comparable to the (by far) most variable 
lipid reported, triglycerides (Smith et al, 1993). This study further extends the exploration 
of biological CVs by examining implications of variability both at the epidemiological 
and clinical level. 
Fibrinogen, CRP and IL-6 
The finding that fibrinogen has a relatively low within-person CV over short time frames 
despite it being an acute phase reactant has been reported elsewhere (Sweetnam et al, 
1998; Rosenson et al, 1994 & 2001; de Maat et al, 1996). Rosenson et al (1994 & 2001) 
recommended that 4 measurements of fibrinogen be performed to characterise a healthy 
person’s “usual” level although due to a lack of comparison with other markers, this was 
concluded to be a high level of variability. According to study estimates, 4 replicates of 
fibrinogen would give a reliability ~90% (95% CI; 1-6 measurements). Fibrinogen was 
relatively less affected by short-term biological variability, and therefore appears to be a 
relatively reproducible marker in terms of biological variation. 
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In contrast, CRP shows considerable biological variability in healthy persons and hence 
appears to have more classical APR behaviour. In the present short-term biological 
variability study, results show a mean within-person CV of 55.7% for CRP, which is 
comparable to those obtained previously over similar time-frames (47.4% and 49.8%) 
(Macy et al, 1997; Sakkinen et al, 1999). These findings are in general agreement with 
previous studies, which recommended at least 3 sequential measurements of CRP (de 
Maat et al, 1996; Koenig et al, 2003) since our results suggest ~2 (1-4) measurements 
were required to attain only 75% reliability. According to these estimates, the 2 
measurements recommended by the American Heart Association guidance (Pearson et al, 
2003) would be insufficient to entirely counteract the inherent unreliability of CRP. 
  
Perhaps consistent with its role as a chief regulator of the APR, estimates showed a mean 
within-person CV of 50.1% for biological variability in IL-6 levels, which is comparable 
with that of CRP in our study. However, our statistical analysis shows IL-6 to be much 
more variable than CRP, with 8 measurements required to obtain a reliability coefficient 
of 0.75 and 23 (2-43) measurements for a reliability coefficient of 0.90. This finding calls 
into question recent conclusions in a study of brain naturetic peptide (BNP; a putative 
CVD risk marker) (Clerico et al, 2006). The authors of this study show that BNP has a 
CV of 30-50%, suggest that, due to high CV, only those with very high BNP levels 
within the population could have BNP considered as a risk marker due to inherent 
uncertainty. In contrast, these findings show that actually little weight can be given to 
more extreme observations within a population as they likely have little physiological 
significance in terms of “habitual” levels (e.g. person 8 in Figure 3.13).  
 
Assuming accuracy, our data suggest that prospective studies may be actually under-
estimating risk associations of IL-6 by around 76% due purely to biological variation. On 
the other hand, data presented here (for IL-6 in particular) requires further study in order 
to narrow the confidence intervals; the finding that IL-6 is particularly unreliable could 
be a chance finding, and confidence intervals for IL-6 do overlap with other markers.  
 
In some individuals, peaks of IL-6 and fibrinogen/CRP expression somewhat coincided, 
while in others they were dissociated (Figure 3.14). One interpretation of these 
observations may be that CRP and fibrinogen expression may be regulated by 
inflammatory factors other than IL-6 (e.g. leptin, adiponectin, oncostatin M; Hansson et 
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al, 2005) and conversely that aberrant expression of IL-6 need not result in simultaneous 
variability in expression of all acute phase response proteins. This may suggest that the 
APR is not an “absolute” event as seen in textbooks, although it is important to bear in 
mind data is lost even when individuals are examined at 1 week intervals.  
 
IL-18 and TNFα 
Consistent with pro-inflammatory roles somewhat removed from the acute-phase 
response, the cytokines IL-18 and TNFα had within-person CVs around half of that seen 
for CRP or IL-6 (25.0% and 24.8% respectively). The fact that they are highly 
comparable to each other is interesting considering the “upstream” pro-inflammatory Th1 
type role they both play in initiating and maintaining immune responses. Lower 
biological CVs than CRP and IL-6 is perhaps suggestive of tighter transcriptional 
regulation in normal healthy people consistent with important immunoregulatory roles. 
 
Analysis shows that IL-18 requires 1 measurement for 75% reliability and TNFα 2 
measurements, while the requirement increases to 4 measurements for IL-18 (1-8) and 6 
for TNFα (1-12) at 90%. According to our estimates, TNFα therefore is comparable to 
CRP in terms of reproducibility (despite having a CV around half that of CRP), while 
circulating IL-18 may be slightly better than either of these, and is the most reproducible 
of the pro-inflammatory cytokines in this study. Lower reproducibility of TNFα is 
probably at least partially due to the higher intra-assay CV in the normal range, and is 
hence partly a methodological issue. Both IL-18 and TNFα are estimated to have 
underestimated associations with risk in prospective studies by around 40-45%, which is 
similar to CRP. 
 
In conclusion, there is a range to the extent of biological variation in different 
inflammatory markers. Such biological variation in inflammatory markers demonstrate 
limited intra-person cross-marker associations, and intra-marker cross-person 
associations. Despite this there may be clear trends in variation at the population level. 
Generally, normal biological variation of inflammatory markers (and indeed classical risk 
markers; Emberson et al 2003 & 2004) in healthy people will lead to varying degrees of 
under-estimation of risk association in prospective studies, and this has important 
limitations for clinical utility of potential risk markers. On the other hand prospective 
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studies which utilise only one baseline sample may drastically under-estimate a marker’s 
risk associations. It is important therefore to consider these issues in such studies, 
particularly when considering novel risk markers.  
 
3.7 LONG-TERM REGRESSION DILUTION 
 
In addition to short-term biological variation, it has been shown for many classical risk 
markers that estimation of a baseline value based on one sample results in a long-term 
underestimate of the association with risk (Emberson et al, 2003 & 2004; Frost and 
White, 2005). For example, in middle-aged men taking a single measurement leads to an 
underestimate of all lipid measurements (25-35% on a log scale) and blood pressure (40-
50%) within 4 years (Emberson et al, 2004). This leads to an underestimate of risk 
association, and is a potential explanation of the “50% myth” of conventional risk factors. 
The British Regional Heart Study estimates that once “regression dilution” is accounted 
for, classical risk factors may account for 70-90% of incident CHD, not just 50% 
(Emberson et al, 2003 & 2004).  
 
The aim of this study was to assess the 4-year intra-individual variability and regression 
dilution in the inflammatory markers in a sizeable (>100 people) study, using the British 
Regional Heart Study stored plasma and serum samples. Use of the BRHS samples 
allows direct comparisons to be made with regression dilution results for other markers 
assayed in these samples, described in previous publications (1Emberson et al, 2004). 
 
Methods, results and discussion of this study are included in Chapter 6. 
 
3.8 GENERAL CONCLUSIONS 
 
IL-18, TNFα, were found to be suitable for use in citrate or EDTA-anticoagulated plasma 
as well as serum, whereas acceptably high detectable levels levels of MMP-9 and 
sCD40L (above background assay noise) were only seen in serum samples in normal 
people. Therefore only serum samples will be used with the latter two markers in this 
thesis. All 4 inflammatory markers displayed acceptable intra- and inter-assay variations 
for use in epidemiological studies. Although generally higher in terms of CV than 
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automated methods such as CRP nephelometry and von Clauss clotted plasma fibrinogen 
detection, the ELISA assays employed are sensitive enough to measure circulating 
concentrations reproducibly in the normal range.  
 
In further studies, TNFα was the most robust cytokine of the 4 markers, showing little 
variation over the six month period that the study was able to be used, or over 4 freeze-
thaws. IL-18 was also relatively robust, although the data sets tended to show lower 
correlations after storage or freeze-thaws (more observations are required). MMP-9 and 
sCD40L were less robust and decayed faster in storage and with increasing freeze-thaw 
cycles. Larger studies in more varied populations are required to confirm and expand on 
these findings, although the possibility of accurately performing storage studies over 
decades is almost impossible in technical terms. In the meantime, I recommend that only 
IL-18 and TNFα can be used in meta-analysis, until such a time that there is sufficient 
evidence that statistical adjustment of pooled MMP-9 and sCD40L datasets will yield 
results suitable for meta-analysis.. 
 
Biological variability of risk markers is an area of current interest in the literature. The 
study presented here suggests that although many inflammatory markers display similar 
degrees of biological variability in the short-term (in terms of the reliability coefficient), 
such variability is clearly important to consider in epidemiological and clinical terms. In 
epidemiological studies these estimates predict that IL-18 risk associations will be 
underestimated by 38%, and TNFα by 46%. In clinical terms the estimates suggest that 
IL-18 and TNFα require at least 2 repeat measurements to achieve a reliability of 75%, 
and 4 and 6 measurements respectively to achieve reliability of 90%. The effect of 4-year 
regression dilution will be examined in Chapter 6. 
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CHAPTER 4 
 
DISTRIBUTIONS OF IL-18, TNFα, AND IL-6 AND ASSOCIATIONS WITH CVD 
RISK FACTORS IN A RANDOM POPULATION SAMPLE: THE GLASGOW 
MONICA STUDY 
 
4.1 INTRODUCTION 
 
4.1.1 Population Distributions and Associations of IL-6, IL-18 and TNFα 
 
Random cross-sectional studies of general populations provide the least bias-prone 
method of examining distributions of risk markers and their associations with other CVD 
risk factors, and data from large studies of this kind can potentially be used as reference 
ranges. I am not aware of any such studies examining IL-18 or TNFα published before 
commencing this thesis.  
 
Despite lack of cross-sectional data from general populations before commencing this 
thesis, some studies had demonstrated trends suggesting inflammatory risk markers have 
associations with some classical CVD risk factors. TNFα is associated with age (Belmin 
et al, 1995; Paolisso et al, 1998) and is thought to correlate with BMI, and symptoms of 
the metabolic syndrome (Ziccardi et al, 2002; Samuelsson et al, 2003) as is IL-18 
(Esposito et al, 2003). Previous prospective publications have reported that IL-18 shows 
relatively weak associations with HDL cholesterol (inversely) and triglycerides (but not 
total cholesterol), as well as weak but statistically significant associations with CRP and 
IL-6, but not with age, BMI, or fibrinogen levels (Blankenberg et al, 2002, 2003). 
Likewise in similar publications TNFα shows weak but statistically significant 
associations with triglycerides, HDL cholesterol (inversely), and other inflammatory 
markers (IL-6, IL-18 and CRP [moderate], although not fibrinogen) (Ridker et al, 2000; 
2Cesari et al, 2003). The ABC study found no gender-specific interactions with TNFα (or 
IL-6) concentrations (2Cesari et al, 2003), although there are reported mechanistic 
differences in TNFα expression between the sexes in this cytokine’s association with 
BMI (Hube et al, 1999; Orel et al, 2004) 
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IL-6 has been investigated in a small cross-section (196 men and 221 women) of the 
Third Glasgow MONICA survey (Woodward et al, 1999) and was found to correlate 
significantly with age, fibrinogen, and current smoking, but not with other major risk 
factors or with prevalent cardiovascular disease. Clearly more cross-sectional data is 
needed to confirm and expand on these findings, preferably in a cohesive study of a range 
of inflammatory markers. 
 
Some studies have reported that inflammatory markers in general (e.g. CRP, IL-6 and 
fibrinogen: Woodward et al, 2003; Mennen et al, 1999; Mukalmal et al, 2004; Volpato et 
al, 2004) but not TNFα (Volpato et al, 2004) have a relationship with alcohol 
consumption, perhaps reflecting alcohol consumption’s J-shaped relationship with CVD 
risk (Emberson & Bennet, 2006). Although there are credible biological pathways to 
substantiate evidence that low alcohol consumption is associated with lower CVD risk 
(Emberson & Bennet, 2006), if inflammation is potentially a partial explanatory factor for 
the J-shaped relationship of alcohol consumption with CVD, this would be of obvious 
interest. In addition to these observations, inflammatory markers in general are known to 
be related to smoking habits (Woodward et al, 1997 & 2003, 2Wannamethee et al, 2005). 
A potential relationship of IL-18 and TNFα with smoking requires clarification, since it 
would be a potential confounder of relationships with CVD. 
 
Cross sectional data on inflammatory marker associations with socioeconomic status 
(SES) were sparse at the outset of this thesis, with one small (n=230) study showing that 
IL-6 and TNFα were weakly associated with SES in women (Steptoe et al, 
2002), although there was a general association between IL-6 and CRP and SES in the 
Whitehall II study (Hemingway et al, 2003). In contrast, fibrinogen has long been known 
to be associated with social position (Markowe et al, 1985; Brunner et al, 1996, 
2Woodward et al, 2003). There were no published data linking IL-18 with SES at the 
outset of this thesis. It is possible that inflammation per se may be one plausible 
mechanism for the association between conventional risk markers, and social deprivation, 
as risk factors for CHD. This is of particular interest in Scotland. The ASSIGN score was 
recently introduced in Scotland to include social deprivation as a marker in risk 
assessment of CHD, since the association between social deprivation and CHD risk is not 
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explained fully by confounding from conventional risk factors (Brunner et al, 1996; 
2Woodward et al, 2003; Tunstall-Pedoe et al, 2006; 1Ramsay et al, 2007; Woodward et al, 
2007).  
 
4.1.2 Aims of the Study 
 
In this study, the aim was to use stored plasma samples from the fourth Glasgow 
MONICA survey as a cross-sectional study to study IL-18 and TNFα (and also CRP, 
fibrinogen and IL-6 for comparison), specifically 
 
1. Reporting reference ranges of these cytokines. 
2. Reporting their associations with each other. 
3. Reporting their associations with some classical CVD risk markers (age, sex, BP,   
cholesterol, BMI, hormone use). 
4. Investigating inflammatory marker associations with smoking, alcohol 
consumption, social deprivation scores - areas of current interest in the literature – 
and also analysing for sex-specific interactions with these factors. 
 
 
4.2 METHODS 
 
4.2.1 The World Health Organisation MONICA Study 
 
It was realised, in the 1970s and 1980s, that more data were needed to explain rapidly 
changing incidence rates of cardiovascular disease across the globe, above and beyond 
data on death certificates (Havlik & Feinleib 1979). The Framingham study had already 
deduced the major conventional risk factors for coronary and stroke events, but the ways 
in which these and other risk factors contributed to global changes in incidence rates were 
unclear. Particularly still to be resolved were the reasons for the decline in mortality from 
both coronary heart disease and stroke in many countries, despite the continuing increase 
in prevalence in the countries of eastern and central Europe and the USA (Uemura et al. 
1988). 
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The MONICA project was conceived in the early 1980s to MONItor the trends and 
determinants of CArdiovascular disease (Tunstall-Pedoe, 1989; WHO, 1989). In contrast 
to traditional cross-sectional studies of populations, the MONICA study aimed to 
longitudinally investigate the dynamic causes of change in incidence and mortality of 
cardiovascular disease and used a multitude of national research centres. It aimed to 
examine changes in six possible associations between four factorial categories: 
 
1. Risk factors versus incidence 
2. Medical care versus case fatality 
3. Incidence versus case fatality 
4. Medical care versus incidence 
5. Risk factors versus case fatality 
6. Medical care versus risk factors. 
 
The study quickly became the largest study of cardiovascular disease in history, with 32 
collaborating centres in 21 countries monitoring around 10 million people worldwide.  
 
Details of the MONICA study population, methods, and publications are available on the 
MONICA manual website: http://www.ktl.fi/monica 
 
In Scotland four MONICA surveys were performed in North Glasgow (1987, 1989, 1992 
and 1995) obtaining age (10 year) and sex-stratified samples from GP registers.  
Previously, the first MONICA survey in Glasgow conducted a preliminary study of 
whole-blood viscosity, haematocrit, plasma viscosity and fibrinogen (Lowe et al, 1988) 
and the second survey conducted a preliminary study of haematocrit, red cell aggregation, 
white cell count and fibrinogen (Lowe et al, 1992).  These studies suggested these 
rheological variables had associations with conventional cardiovascular risk factors, and 
with prevalent CVD, but lacked statistical power, partly due to insufficient prevalent 
CVD in the 25–64-year age range studied. The third Glasgow MONICA survey therefore 
extended the age range up to age 74 years (1992) and was used to examine the reference 
ranges and the demographic distributions of haemostatic and inflammatory (IL-6, CRP 
and fibrinogen) risk markers and their associations with each other and with conventional 
risk factors (Lowe et al, 1997; Woodward et al 1997, 1999, 2003). In the fourth Glasgow 
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MONICA survey, conducted in 1995, fibrinogen, plasma viscosity, and CRP were 
measured (Rumley et al, 2003; Woodward et al, 2003).  
 
Stored plasma samples were available in the laboratory for measurement of newer 
inflammatory markers, hence it was a good opportunity to measure TNFα and IL-18 and 
establish their population distributions and associations in a cross-sectional study. 
Consent to assay new potential cardiovascular risk markers had been obtained at the time 
of the survey, which was approved by the local research ethics committee. Because 
stored serum was not available, sCD40L and MMP-9 could not be measured in this study. 
 
4.2.2 Subjects and Methods: 
 
The fourth MONICA Survey in North Glasgow was carried out in 1995 as one of a series 
of cross-sectional random samples of this community conducted as part of the 
international MONICA  project (World Health Organisation Principal Investigators, 
1988). In this survey, 1836 men and women aged 25 – 64 years old were randomly 
sampled from general practice registers and asked to attend a health screening clinic in a 
non-fasting state between 09.00 and 16.00 hours, where a blood sample was taken. 
Information on oral contraceptive use, menopause and hormone-replacement status as 
well as social class and alcohol use was obtained through the MONICA questionnaire 
and by interview. Smoking exposure was measured objectively by cotinine levels (a 
nicotine metabolite) (Woodward et al, 1991). 
 
Subjects were rested for at least 20 minutes before venepuncture by trained nurses. One 
blood sample was anticoagulated with 0.11M trisodium citrate (9:1 v:v) and one with 
EDTA (K2 EDTA 7.2mg) and samples were immediately centrifuged at 2000g for 5 min 
at room temperature. The middle layer of plasma was removed, aliquoted, and snap-
frozen at -70oC until assay. Citrated plasma was used for all analysis in this study. 
 
IL-18, TNFα, IL-6, CRP, and fibrinogen were all assayed as described in Chapter 2. 
Aliquots used in this study were previously unthawed. 
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4.2.2 Statistical analysis 
 
All analyses were, where appropriate, sex-specific. The distribution of each inflammatory 
variable was summarised through five percentiles: the point of central tendency (50th 
percentile), the 25th and 75th percentiles, which indicate the spread, and the 5% and 95% 
percentiles, which show the range within which 90% of values lie, not influenced by 
outliers.  
 
Each of the inflammatory variables included in this study had skewed distributions, and 
in each case a log transformation was found to induce approximate normality. 
Consequently, all tests on these variables were carried out after log transforms. These 
tests arose from comparisons of demographic groups, involving t-tests, tests of Spearman 
correlation coefficients and tests of trend from age-adjusted general linear models. The 
latter were used to test associations of inflammatory variables with alcohol drinking, 
cotinine levels and social deprivation, each defined as a four-grade ordinal variable, 
coded 1-4. Drinking was the number of units of alcohol drunk in the past week, divided 
into groups by UK national guidelines and, in subsequent analyses, into four equal parts 
by the sample distribution; cotinine was also divided into its observed quarters; and the 
level of social deprivation was defined from the Carstairs and Morris deprivation scores 
for the address at which the subject lived. Once again, deprivation was coded into its 
quarters, this time defined as the quarters for the north Glasgow population (Morrison et 
al, 1997). Further tests on the associations between inflammatory variables and social 
deprivation adjusted for classical CVD risk factors, and cross-adjusted all those 
inflammatory variables which had residual independent associations for each other. 
 
4.3 RESULTS 
 
4.3.1 Sample Availability 
 
1836 men and women aged 25 – 64 years old were randomly sampled from general 
practice registers in North Glasgow in 1995. Due to refusal to consent and failed 
venepunctures, 1698 (92%) of the 1836 participants in this MONICA-4 survey had 
available plasma samples. This 92% differed significantly from the remaining 8% in that 
there were fewer females (52% v 67%; p=0.0007). There were no differences (p>0.05) in 
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age, systolic blood pressure, serum total cholesterol, body mass index, cotinine, alcohol 
drinking or social deprivation between those who gave plasma and those who did not. 
Due to these samples being residual, there was only a small amount of plasma available 
in some aliquots, and consequently the number of tests performed for each marker varied 
from 1136 to 1666 (Table 4.1).  
 
4.3.2 Population Correlations 
 
Table 4.1 shows the inter-correlations between inflammatory variables (adjusted for age) 
and their associations with age in both men and women. As expected, in general all 
inflammatory variables correlated strongly with each other. Particularly strong 
correlations were noted in both sexes for CRP and fibrinogen (male/female r = 
0.55/0.47), CRP and IL-6 (M/F  r = 0.53/0.47), and fibrinogen and IL-6 (M/F r = 
0.35/0.31). These observations are consistent with these markers’ respective roles in the 
acute phase response. Notable exceptions to strong inflammatory marker inter-
associations were seen for TNFα and fibrinogen; (M/F r = 0.12/0.10). IL-18 was also 
more weakly correlated with fibrinogen than other inflammatory markers in both sexes 
(M/F r = 0.18/0.17). Inflammatory marker associations with age were all strong (r≥ 0.20), 
with the exception of IL-18 (M/F r = 0.16/0.14). There were, hence, no particularly 
notable sex-specific interactions of inflammatory markers with each other. 
 
Table 4.2 shows the correlations of inflammatory markers with conventional risk markers 
measured in this study (with the exception of smoking and alcohol consumption, which 
are subsequently analysed in greater detail). Although none of the inflammatory markers 
correlated particularly strongly with total cholesterol (r<0.11), all showed strong inverse 
correlations with HDL cholesterol, IL-18 and TNFα being particularly strong in this 
respect (r= -0.19 and -0.21 respectively). Only IL-6 and CRP demonstrated strong 
associations with systolic BP (r =0.15). Inflammatory associations with BMI were strong, 
particularly for CRP and IL-6 (r = 0.31 and 0.21 respectively), and although IL-18 and 
TNFα correlated significantly, the association with BMI was considerably weaker than 
for the other inflammatory markers (r =0.10 and 0.13 respectively). Considering age- and 
sex- adjusted waist size measurement or waist-hip ratio (WHR) as measures of visceral 
fatness improved associations of IL-18 with “fat mass” compared with BMI (r =0.20 for 
  179
 
WHR) and also marginally improved similar associations of TNFα (r =0.16). In contrast, 
considering waist size and WHR had little impact on the association of IL-6, CRP or 
fibrinogen with “fatness” compared with BMI. 
 
4.3.3 Distributions by Age and Sex of Inflammatory Markers 
 
Table 4.3 shows the medians, three quartiles, and 5-95% ranges for inflammatory 
variables in men and women. Median levels of fibrinogen, CRP, IL-6, IL-18, and TNFα 
all showed increasing trends with age in both men and women (see Table 4.1 for 
correlations) across groups as expected. Comparing men and women in age adjusted 
analysis, IL-18 and TNFα medians were significantly higher in men than in women 
(p<0.0001 for both), but CRP (p=0.55), IL-6 (p=0.33), and PV (p=0.85) are not, while 
fibrinogen levels were lower in men (p<0.0001).  
 
4.3.4 Effects Oral Contraceptive Use, Menopausal Age, and HRT in Women 
 
Table 4.4 shows the effect of current oral contraceptive use on inflammatory markers in 
young (25-34 years) non-pregnant women still having periods, and Table 4.5 shows the 
effect of menopause and hormone replacement therapy (HRT) status among women aged 
45-54 years. Current oral contraceptive use was associated with a very significant rise in 
circulating CRP levels, although this was highly specific to CRP and did not extend to 
any of the other inflammatory markers, including fibrinogen.  
 
Post-menopausal women without HRT had significantly higher levels of IL-18 compared 
with the pre-menopausal group. Furthermore, women taking HRT had this menopause-
associated effect of increased IL-18 levels reversed, so that circulating levels of IL-18 
became comparable to the levels seen in the pre-menopause group (p=0.84). A similar 
pattern was seen for TNFα, for which there was a non-significant trend to higher median 
levels in post-menopausal women, an effect reversed by HRT (p<0.07). Menopausal 
status and HRT use had no effect on IL-6, CRP or fibrinogen. 
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4.3.5 Associations of Inflammatory Markers with Alcohol 
 
Tables 4.6-4.8 show the effect of exposure to the categorical variables (alcohol, smoking, 
and social deprivation respectively) on the inflammatory risk markers. In this population 
17.3% were teetotallers, 35.8% had never smoked any form of tobacco, and 45.6% were 
in non-manual employment. 
 
As seen in Table 4.6, significant inflammatory marker associations with alcohol 
consumption (by groups according to UK guideline limits) were observed after 
adjustment for age, although many of these interactions were sex-specific (IL-6 
p=0.0002; IL-18 p=0.08; TNFα p=0.02; CRP p=0.07; fibrinogen p=0.43). Results from 
analysis showed increased IL-6 expression with increased alcohol consumption only in 
men (median IL-6 1.56 versus 2.15 pg/ml in group 1 versus group 4; p for trend 
<0.0001), while there was a non-significant decreasing trend of IL-6 expression in 
women. This observation of increasing levels of inflammatory markers in men and 
decreasing levels in women with greater alcohol consumption was also mirrored for IL-
18, TNFα, and CRP, although none of these trends reached significance (trends for IL-18 
in men, TNFα in women and CRP in women were all borderline significant). Decreasing 
fibrinogen levels with increasing alcohol consumption was also seen in women (median 
fibrinogen 3.10 versus 2.96 g/l in group 1 versus group 4; p for trend 0.008) although the 
effect was nonlinear, and no significant trends were seen in men.  
 
4.3.6 Associations of Inflammatory Markers with Smoking 
 
Associations of smoking exposure, as measured objectively by the biochemical marker 
cotinine, with inflammatory markers are illustrated in Table 4.7. In this analysis there 
were fewer sex-specific differences (IL-6 p=0.05; CRP p=0.03; fibrinogen p=0.07) in 
terms of inflammatory marker association with cotinine levels, and IL-6, IL-18, and 
fibrinogen all had highly significant age-independent associations with cotinine levels 
both in men and women (p for trend <0.0002 for all). CRP had highly significant 
associations with cotinine levels in men (p for trend <0.0001), although the trend was 
slightly less strong, but still statistically significant in women (p for trend 0.04). There 
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were no strong associations between TNFα levels and cotinine in either sex after age 
adjustment, although there was a non-significant increasing trend in men. 
 
4.3.7 Associations of Inflammatory Markers with Social Deprivation 
 
As seen in Table 4.8, increasing social deprivation was significantly associated with 
increases in most of the inflammatory risk makers measured, and only CRP demonstrated 
a borderline sex-specific interaction after age adjustment (p=0.09). IL-6, IL-18 and TNFα 
all increased significantly in both men and in women with increasing deprivation 
(p≤0.05), while both sexes showed generally weaker increasing trends for fibrinogen. For 
CRP there was a linear increasing trend only in women (p=0.0004), while in men there 
was a non-linear non-significant increasing trend. 
 
The association between inflammatory variables and social deprivation may be 
confounded by the relationship of inflammatory markers with sex, age, smoking, blood 
pressure, BMI, and cholesterol measurements since these variables (among others) are 
related to social deprivation. We therefore corrected the associations between the 
inflammatory variables and social deprivation for these potential confounders. This 
represents correction for all the ASSIGN cardiovascular risk markers (with the exception 
of social deprivation itself). In this analysis, the only inflammatory variables to show 
trends of association across quarters of social deprivation were 3 of the cytokines in men 
only; IL-6 (p for trend =0.004), IL-18 (p for trend =0.003), and TNFα (p for trend 
=0.008). After additional adjustment to correct for each other, these three cytokines 
remained independently associated with social deprivation in men (p for trend = 0.05, 
0.01, 0.04 respectively). Only IL-18 had a borderline association with social deprivation 
in women in the fully adjusted model (p for trend across quarters= 0.07). 
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Table 4.1 Spearman correlations of inflammatory factors with age and correlations 
between inflammatory factors adjusted for age (bold p<0.0001; italic p>0.05; else 
0.0001<p<0.05). 
  IL-18 TNFα CRP Fibrinogen Age 
IL-6 M 0.23 0.33 0.53 0.35 0.43 
 F 0.19 0.24 0.47 0.31 0.35 
IL-18 M  0.19 0.23 0.18 0.16 
 F  0.22 0.20 0.17 0.14 
TNFα M   0.27 0.12 0.21 
 F   0.24 0.10 0.28 
CRP M    0.55 0.27 
 F    0.47 0.18 
Fibrinogen M     0.30 
 F     0.22 
M: males; F: females 
 
 
Table 4.2 Spearman correlations of inflammatory factors other with conventional risk 
markers (age- and sex-adjusted) (bold p<0.0001; italic p>0.05; else 0.0001<p<0.05). 
WHR, Waist-hip ratio; BMI, body mass index 
 
 
 
 
 
 Total 
cholesterol 
HDL 
Cholesterol Systolic BP BMI Waist Size WHR 
IL-6 0.03 -0.18 0.15 0.21 0.23 0.23 
IL-18 0.06 -0.19 0.07 0.10 0.15 0.20 
TNFα 0.05 -0.21 0.03 0.13 0.13 0.16 
CRP 0.11 -0.18 0.15 0.31 0.32 0.30 
Fibrinogen 0.10 -0.15 0.03 0.15 0.17 0.16 
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Table 4.3 Age-specific reference ranges for inflammatory factors. Values shown are 
median (first quartile, third quartile) and 5%-95% range. 
M: males; F: females 
 
 
 
 
Age (years) 
 n 25-34 35-44 45-54 55-64 
IL-6 (pg/ml)      
M 698 1.28 (0.95, 1.97) 
0.64-3.60 
1.52 (1.12, 2.27) 
0.71-4.78 
1.98 (1.40, 2.76) 
0.79-6.47 
2.63 (1.92, 3.81) 
1.18-9.39 
F 739 1.32 (0.89, 2.11) 
0.57-4.52 
1.41 (1.03, 2.03) 
0.66-3.82 
1.87 (1.37, 2.89) 
0.82-7.89 
2.43 (1.49, 4.26) 
1.00-9.85 
IL-18 (pg/ml)      
M 715 205 (163, 246) 
122-407 
254 (189, 323) 
128-460 
251 (191, 332) 
132-443 
251 (191, 340) 
132-469 
F 769 187 (144, 247) 
95-435 
197 (141, 262) 
94-429 
213 (172, 283) 
116-461 
228 (186, 303) 
112-418 
TNFα (pg/ml)      
M 715 1.49 (1.30, 1.86) 
1.05-2.64 
1.60 (1.31, 2.00) 
1.00-3.00 
1.65 (1.35, 2.11) 
1.03-2.91 
1.90 (1.50, 2.35) 
1.10-4.26 
F 769 1.38 (1.12, 1.69) 
0.79-2.77 
1.39 (1.12, 1.75) 
0.80-2.54 
1.63 (1.19, 2.05) 
0.87-2.05 
1.83 (1.51, 2.17) 
1.06-3.40 
CRP (mg/L)      
M 538 0.88 (0.40, 1.89) 
0.25-5.82 
1.05 (0.59, 2.78) 
0.21-7.90 
1.32 (0.77, 2.87) 
0.30-6.90 
1.96 (0.99, 4.47) 
0.40-10.59 
F 598 1.29 (0.55, 2.94) 
0.17-7.75 
0.94 (0.49, 2.79) 
0.22-7.47 
1.58 (0.67, 3.32) 
0.22-8.83 
2.35 (0.98, 5.02) 
0.36-14.30 
Fibrinogen (g/L)      
M 799 2.54 (2.29, 2.96) 
1.83-3.71 
2.67 (2.28, 3.11) 
1.96-4.30 
2.90 (2.40, 3.57) 
2.00-4.77 
3.11 (2.57, 3.92) 
2.10-5.54 
F 862 2.87 (2.47, 3.49) 
1.93-4.48 
2.96 (2.50, 3.62) 
2.08-4.48 
3.02 (2.59, 3.67) 
2.13-4.92 
3.43 (2.84, 4.25) 
2.24-6.05 
  184
 
Table 4.4 Inflammatory factors in non-pregnant women aged 25-34 years who are still 
having periods, by current use or non-use of oral contraceptives. Values shown are 
median (first quartile, third quartile) and 5%-95% range. p-values are after log 
transformation. 
OC, oral contraceptives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Current OC use 
 Yes (n=85) No (n=124) p-value 
IL-6 (pg/ml) 1.13 (0.78, 2.00) 
0.48-7.43 
1.33 (0.91, 2.07) 
0.61-3.43 
0.71 
IL-18 (pg/ml) 180 (145, 247) 
106-566 
190 (143, 246) 
95-369 
0.57 
TNFα (pg/ml) 1.39 (1.01, 1.74) 
0.81-2.78 
1.37 (1.15, 1.66) 
0.78-2.71 
0.66 
CRP (mg/L) 1.78 (0.80, 4.62) 
0.20-10.0 
0.84 (0.40, 1.71) 
0.17-4.50 
0.0001 
Fibrinogen (g/L) 2.99 (2.52, 3.54) 
1.88-4.36 
2.75 (2.43, 3.32) 
1.84-4.43 
0.27 
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Table 4.5 Inflammatory factors in non-pregnant women aged 45-54 years, by menopausal 
status and use of HRT. Values shown are median (first quartile, third quartile) and 5%-
95% range. p values are after log transformation. 
 Pre-menopausal 
(1) (periods, no 
HRT) (n=86) 
p value 
(1 v 2) 
Post-menopausal 
(2) (no periods, no 
HRT) (n=81) 
p value 
(2 v 3) 
All HRT (3) 
(n=42) 
IL-6 (pg/ml) 1.70 (1.25, 2.76) 
0.68-7.77 
0.13 2.10 (1.49, 3.34) 
1.01-7.88 
0.11 1.70 (1.30, 2.40) 
0.79-7.89 
IL-18 (pg/ml) 188 (164, 238) 
116-480 
0.0002 268 (213, 361) 
140-461 
0.006 195 (144, 267) 
105-533 
TNFα (pg/ml) 1.59 (1.18, 2.00) 
0.86-3.40 
0.51 1.76 (1.36, 2.19) 
0.71-3.91 
0.07 1.35 (1.10, 1.86) 
0.87-2.70 
CRP (mg/L) 1.10 (0.46, 3.08) 
0.21-8.85 
0.27 1.27 (0.71, 3.24) 
0.28-7.68 
0.11 2.09 (1.23, 5.45) 
0.43-8.83 
Fibrinogen (g/L) 3.05 (2.49, 3.75) 
1.92-4.92 
0.30 2.93 (2.60, 3.86) 
2.34-5.84 
0.41 3.12 (2.81, 3.49) 
2.14-4.23 
HRT, hormone replacement therapy 
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Table 4.6 Medians of inflammatory markers in groups according to alcohol consumption. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups are defined by alcohol consumption by quarters of the population (Quarters are, M: 1 = 0-7; 2 = 8-17; 3 = 18-32; 4 = 33+, F: 1 = 0; 2 
= 1-4; 3 = 5-11; 4 = 12+ units per week.) 
p-values after log-transformations. Male and female p-trends after age-adjustment. 
 
 
 
 
 
 
 
 
 
 
 
  Group 1 
(n=) 
Group 2 
(n=) 
Group 3 
(n=) 
Group 4 
(n=) 
p-value for 
trend 
p-value group 
1 vs group 4 
IL-6 (pg/ml) M 1.56 1.70 1.69 2.15 <0.0001 0.0002 
 F 1.78 1.63 1.51 1.51 0.12 0.12 
IL-18 (pg/ml) M 230 230 239 250 0.07 0.06 
 F 217 196 205 207 0.46 0.21 
TNFα (pg/ml) M 1.58 1.56 1.65 1.74 0.17 0.37 
 F 1.59 1.58 1.5 1.36 0.08 0.10 
CRP (mg/L) M 1.16 1.03 1.28 1.21 0.41 0.56 
 F 1.43 1.71 1.16 1.19 0.09 0.18 
Fibrinogen (g/L) M 2.76 2.85 2.76 2.78 0.12 0.48 
 F 3.10 3.34 2.9 2.96 0.008 0.13 
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Table 4.7 Medians of inflammatory markers in groups according to smoking exposure (cotinine levels). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups are defined by levels of cotinine in quarters according to the population distribution of cotinine.  
p-values after log-transformations. Male and female p-trends after age-adjustment 
 
 
 
 
 
 
 
 
 
 
 
Group 1 
(n=504) 
Group 2 
(n=533) 
Group 3 
(n=412) 
Group 4 
(n=386) 
% increase in 
median; group1 
vs group 4 
p-value 
for trend 
IL-6 (pg/ml) M 1.47 1.88 2.09 2.01 36.7 <0.0001 
 F 1.52 1.55 1.58 1.86 22.4 0.0002 
IL-18 (pg/ml) M 207 242 228 265 28.0 <0.0001 
 F 191 194 207 246 28.8 <0.0001 
TNFα (pg/ml) M 1.53 1.71 1.69 1.62 5.9 0.06 
 F 1.49 1.52 1.53 1.62 8.7 0.17 
CRP (mg/L) M 1.02 1.00 1.39 1.88 84.3 <0.0001 
 F 1.21 1.17 1.53 1.84 52.1 0.04 
Fibrinogen (g/L) M 2.67 2.64 2.84 3.11 16.5 <0.0001 
 F 3.02 2.90 3.07 3.30 9.3 <0.0001 
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Table 4.8 Medians of inflammatory markers in groups according to social deprivation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups are defined by Carstairs social deprivation scale in quarters; increasing group number implies increased deprivation.  
p-values after log-transformations. Male and female p-trends after age-adjustment. 
* Smoking, blood pressure, BMI, and HDL cholesterol, and total cholesterol 
 
 
 
 
 
 
 
 
Group 1 
(n=504) 
Group 2 
(n=533) 
Group 3 
(n=412) 
Group 4 
(n=386) 
% increase in 
median; group1 
vs group 4 
p-value 
for trend 
p-trend after 
full 
adjustment* 
IL-6 (pg/ml) M 1.61 1.79 2.05 1.88 16.8 <0.0001 0.004 
 F 1.47 1.60 1.81 1.72 17.0 0.05 0.74 
IL-18 (pg/ml) M 219 223 245 262 19.6 <0.0001 0.003 
 F 191 215 212 222 16.2 0.0001 0.06 
TNFα (pg/ml) M 1.52 1.65 1.68 1.74 14.5 0.002 0.008 
 F 1.41 1.56 1.55 1.63 15.6 0.01 0.09 
CRP (mg/L) M 1.12 1.27 1.54 1.31 17.0 0.19 0.85 
 F 1.11 1.35 1.70 1.85 67.0 0.0004 0.15 
Fibrinogen (g/L) M 2.66 2.84 2.89 2.87 7.9 0.06 0.95 
 F 2.94 3.15 3.05 3.18 8.2 0.02 0.81 
188 
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4.1 DISCUSSION 
 
4.4.1 Population Distribution 
 
No previous data in the literature has thus far established similar distribution ranges to 
those illustrated here for IL-18 or TNFα. In the absence of other published studies for 
comparison these data may be potentially useful as reference ranges. In this regard there 
are several positive and negative aspects of this study to take into account. The study was 
performed in a large random sample of the local population thought to be representative 
of the general population in the West of Scotland, it included a wide age range (25-64 
years) of roughly equal numbers of men and women, and there was little in the way of 
selection criteria (subjects had to be registered with a GP). In addition to this, all markers 
measured were assayed with reagents calibrated against international standards (by the 
manufacturers) with the exception of IL-18, for which there is no recognised standard. 
The West of Scotland region is an area of relatively high cardiovascular risk (Scottish 
Health Survey, 2003 [Cardiovascular disease report]). 
 
 There were discrepancies with previous MONICA survey results, for fibrinogen, CRP 
and IL-6. CRP and fibrinogen levels in MONICA-4 were much higher in each age group 
(~10%) than in the MONICA-3 survey (Lowe et al, 1997, Woodward et al, 1997 & 
2003). IL-6 levels reported here are also much higher than those previously reported in 
similar age groups (~2-fold) (Woodward et al, 1999) although the ~2-fold increase in 
circulating levels between age extreme groups in both sexes in this study is a consistent 
observation (Woodward et al, 1999). This change is probably due to change in the 
available IL-6 kit technologies (the new high-sensitivity kit) and in the international 
calibrants for these assays, rather than a genuine increase in circulating levels of these 
markers in the population over the last few years (3 years since MONICA-3), but these 
findings require further investigation.  
 
4.4.2 Age Associations 
 
In general, all markers of inflammation had positive associations with age, in agreement 
with previous MONICA-3 findings for IL-6, CRP and fibrinogen (Lowe et al, 1997, 
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Woodward et al, 1999, 2003) and findings elsewhere (Gimeno et al 2007; Miles et al, 
2006; Fibrinogen Studies Collaboration, 2005). Recent cross sectional data from 1111 
men and women (aged 27-77) in the Perth Carotid Ultrasound Disease Study (CUDAS) 
has shown that, similar to the present study, the Spearman association between IL-18 and 
age was weaker (r2=0.10) than IL-6 or CRP (0.20 and 0.22 respectively) (Hung et al, 
2005), a result also seen in the MONICA/KORA study (Thorland et al, 2005). It appears, 
therefore, that IL-18 levels in the general population may not be confounded by age to the 
same extent as other inflammatory markers. TNFα has long been known to increase with 
age in both mice and man (Belmin et al, 1995; Paolisso et al, 1998) and results presented 
here reflect this, TNFα being generally associated with age to a similar extent as CRP 
and fibrinogen. 
 
4.4.3 Sex 
 
Of the markers studied, only IL-18 and TNFα were significantly higher in men than in 
women. This difference in IL-18 between the sexes has been commented on in the 
CUDAS study (Chapmen et al, 2006), and the result is also confirmed in smaller studies 
(Yamagami et al, 2005). For TNFα there is the possibility that metabolic differences in 
male and female fat storage may contribute to sex-specific differences in circulating 
TNFα levels in the general population (see 4.4.4). The MONICA/KORA study group 
(Thorland et al, 2006) observed in a study of similar size to the present one that while 
CRP levels showed no sex-specific interactions, fibrinogen was lower and IL-6 was 
higher in men. Indeed, the present study showed non-significant trends towards 
confirming the association of IL-6 with male gender, and also found fibrinogen to be 
higher in women, which is confirmed in meta-analysis (Fibrinogen Studies Collaboration, 
2005). 
 
4.4.4 Metabolic Syndrome Components 
 
IL-18 and TNFα have been suggested to be strongly associated with aspects of the 
metabolic syndrome in population studies (Hotamisligil et al, 1995; Kern et al, 1995; 
Jovinge et al, 1998; Ziccardi et al, 2002; Hotamisligil et al 2006). IL-18 was found to 
correlate with BMI, waist circumference, triglycerides, HDL cholesterol (inversely), and 
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fasting glucose and insulin levels in the CUDAS study (Hung et al, 2005), Some recent 
studies (Villarrasa et al, 2006; Herder et al, 2006) have suggested that IL-18 may not be 
associated with fat mass, however it does seem to be associated with type II diabetes and 
the metabolic syndrome (Thorland et al, 2005 & 2006; Hung et al, 2005) as does TNFα 
(Hotamisligil et al, 1995 & 2006). It is interesting to speculate that higher levels of these 
cytokines in men may reflect the generally higher prevalence of metabolic syndrome in 
UK men than in women (Tillin et al, 2005), although epidemiological studies cannot infer 
causality on the basis of an association.  
 
The present study of a general population shows that IL-18 and TNFα are strongly 
associated inversely with HDL cholesterol levels, but are less strongly associated with 
BMI than other inflammatory markers. The latter observation is interesting, since both 
cytokines are thought to be produced in visceral adipose tissue (perhaps by infiltrating 
macrophages) and are often described as adipokines (Hotamisligil, 2006). Indeed, TNFα 
was described in vitro as the archetypal adipokine (Hotamisligil et al, 1993). The present 
discrepant observation may be explained by the often debated potentially “weak” 
association between BMI and visceral fat mass (3Wannamethee et al, 2005), but strong 
associations of IL-6 and CRP with BMI may conflict with this argument. However, when 
the study considered WHR instead of BMI as a marker of central adiposity, the 
associations of both IL-18, and to a lesser extent TNFα (although not IL-6 or CRP), with 
fatness improved. This is in line with previous observations (Hung et al, 2005; Thorland 
et al, 2005). It is likely, according to previous studies, that TNFα is associated relatively 
more strongly with subcutaneous fat in women than in men (and hence overall BMI) 
whereas in men TNFα is produced from visceral and subcutaneous fat in equal amounts 
(Hube et al, 1999; Orel et al, 2004).  
 
Combined, these results may suggest that although inflammation in general is associated 
with relative body mass (i.e. muscle plus fat mass; BMI), some adipokines (e.g. IL-18) 
are more strongly associated with visceral fat (but perhaps only in a sex-dependant 
manner). TNFα is the prototypic pleiotropic cytokine, and is produced almost 
ubiquitously, even by muscle cells (Saghizadeh et al, 1996) which are often considered to 
be the metabolic antithesis of fat mass. It is hence possible that the association of TNFα 
with adipose tissue has been somewhat overestimated in some studies in terms of impact 
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on systemic concentrations of the cytokine. This speculation does not preclude a role for 
either marker in metabolic syndrome since they may be associated with other crucial 
factors such as insulin resistance. Whether low localised expression levels of TNFα and 
perhaps other cytokines are sufficient for biologically important cross talk between 
adipocytes and leukocytes without significant effect on circulating cytokine 
concentrations (Skurk et al, 2005), requires verification. 
 
4.4.5 Female Hormones 
 
Consistent with previous findings both in MONICA-3 and elsewhere (Woodward et al, 
2003; Frohlich et al, 1999), we observed that modern oral contraceptives have a very 
specific effect of increasing circulating CRP levels ~2 fold in users aged 25-34 years, 
whilst not having any effect on fibrinogen, IL-6 or other inflammatory markers.  The 
physiological mechanism for this is not clear. Modern oral contraceptives carry much 
lower hormone doses than previously, however it is still recommended that older pre-
menopausal women with other cardiovascular risk factors avoid oral contraceptives due 
to slight excess risk of CVD (Vandenbroucke et al, 1998). The excess risk is found with 
haemostatic, as well as inflammatory, markers (Lowe et al, 1997, 2004) and hence cannot 
be solely attributed to inflammatory effects.  
 
Among women aged 45-54 years, being post-menopausal had the specific effect of 
increasing IL-18 levels, while taking HRT abrogated this effect. As far as we are aware 
this is a novel epidemiological finding, although one recent study reports oestrogen 
steroids downregulate endometrial expression of IL-18 (Ledee et al, 2006). These 
observations may suggest that natural levels of oestrogen and progesterone during child-
bearing pre-menopausal years attenuate the inflammatory environment of the 
endometrium, and possibly at other biological sites, and that these effects may be 
achieved exogenous dosages of oestrogen post-menopause. There is debate as to the 
requirements of the relative Th1/Th2 balance in the endometrium for successful 
reproduction (Chaouat et al, 2004), but IL-18 clearly has the potential to influence this 
balance via IFNγ, and the evidence in this report and in animals suggests oestro-
progestative hormones may directly influence IL-18 expression. In addition to this effect 
on IL-18, there may be a borderline inhibitory effect of HRT on TNFα expression, but 
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valididity of the observation is hampered by small numbers of post-menopausal women 
in this cross-sectional study. Supporting this observation however, it has previously been 
noted in vivo that TNFα levels in the human endometrium fall in the late secretory phase 
of the menstrual cycle, and withdrawal of oestrogen stimulation leads to a rise in TNFα 
expression (Tabibzadeh et al, 1999). There is, hence, a plausible biological pathway by 
which hormone replacement in post-menopausal women may dampen down expression 
of both IL-18 and TNFα. It is hence clear that both the reproductive cycle and the age of 
women may have implications for circulating levels of both IL-18 and TNFα in 
epidemiological terms, although to an extent age and sex adjustment in multiple 
regression analysis will correct for a proportion of this error during epidemiological 
studies. If there were ever to be a case for IL-18 or TNFα being used clinically as any 
sort of biomarker, this subject would require more detailed analyses. 
 
4.4.6 Alcohol 
 
It is thought that suppression of inflammation may partly explain the cardiovascular 
benefits of moderate alcohol consumption. Associations between alcohol consumption 
and inflammatory markers have been previously reported (Lee et al, 1990; Krobot et al, 
1992; Woodward et al, 1997; Imhov et al, 2001; Woodward et al, 2003; Mennan et al, 
1999; Mukamal et al, 2004; Volpato et al, 2004; Levitan et al, 2005; Pai et al, 2006). The 
effect of alcohol consumption on inflammatory markers is open to a number of subjective 
biases in terms of how data is analysed, including how the population is divided based on 
drinking habits, and how those drinking habits are reported (although self-reporting may 
be the most effective method; Miadnik, 1988). Many studies examining both men and 
women report J-shaped dose response curve (Krobot et al, 1992; Woodward et al, 1997; 
Imhov et al, 2001; Volpato et al, 2004; Pai et al, 2006), however, by dividing the 
population into quarters there is a gain in statistical power over the range of alcohol 
intakes (as opposed to small numbers of observations in very low and very high alcohol 
intake groups), and by examining men and women separately there is evidence of sex-
specific interactions in this study.  
 
The finding of an age-independent reduction of circulating fibrinogen levels with 
increasing alcohol consumption in women only is consistent with previous findings (Lee 
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et al, 1990; Mennan et al, 1999) as are observations of inverse associations of CRP with 
alcohol consumption in women (Levitan et al, 2005). It may still be true that those with 
the highest alcohol consumption have increased fibrinogen levels, but such observations 
depend on cut-off points used for observation at the extremes of drinking habits (which 
may require a large study to gain adequate power), and adjustment for potential 
confounders in the population (Mennen et al, 1999; Volpato et al, 2004; Pai et al, 2006).  
 
This cross-sectional study found that most inflammatory markers were differently 
associated with alcohol consumption in men and women when the data was viewed not 
adjusting for smoking or other potential confounders (apart from age). All cytokines 
followed the broad pattern of increasing trends among men, and decreasing trends among 
women (comparing extreme groups), although few of these patterns attained significance. 
One diet study has reported that moderate alcohol consumption reduces CRP and 
fibrinogen levels in men and in women (Sierksma et al, 2002), although all the 
participants were healthy non-smokers and numbers were small.  
 
The results reported here confirm a previous study (Volpato et al, 2004) showing that 
alcohol intake has superficially minimal effect on circulating TNFα levels in either sex. 
Biological mechanisms supporting these observations have not been reported. Indeed, 
p55 TNFR is required for alcohol induced liver injury (Yin et al, 1999), as is biological 
TNFα action (Ponnappa et al, 2005), and one would hypothesise therefore that TNFα 
may be an important biological determinant of downstream physiological consequences 
of alcohol intake. Although TNFα may be required for such pathophysiological 
processes, it may still be the case that circulating levels of the cytokine are relatively 
unaffected by alcohol intake, and that hepatocytes (and other cellular systems) are primed 
to react pathophysiologically to it by separate signalling processes downstream of alcohol 
consumption. 
 
4.4.7 Smoking 
 
Inflammatory markers are known to be associated with lifetime smoking status 
(Woodward et al, 1997 & 2003; 2Wannamethee et al, 2005), and results here reflect this, 
showing that in particular CRP levels are strongly positively associated with current 
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levels of cotinine in individuals, despite previous results suggesting increases in CRP 
levels are independent of the amount actually smoked (Ohsawa et al, 2005). This may be 
a facet of using cotinine as an objective biomarker. In the case of TNFα, a borderline 
positive association was also observed, but this was somewhat weaker than CRP, IL-6 or 
IL-18 due to plateau of the curve between group 2 and group 4 in both sexes, which is 
consistent with in vitro observations that high levels of nicotine may inhibit mononuclear 
cell TNFα production (Madrestma et al, 1996). IL-18 showed increases in expression 
comparable to IL-6 across quarters with a highly significant trend (p<0.0001). As far as I 
am aware this is the first time a relationship between IL-18 and cotinine (or similar 
smoking exposure measurements) has been observed in a large cross-sectional study. 
 
4.4.8 Social Deprivation 
 
Univariate analysis demonstrated that levels of all inflammatory markers were very 
strongly positively associated with social deprivation. These findings are in broad 
agreement with the published literature. In the Whitehall study of British civil servants, 
fibrinogen levels were higher among women and men with indicators of deprived 
childhood socioeconomic circumstances (fathers in manual jobs or short physical 
stature), participated in less leisure-time activity, had lower job grades as adults and 
lower levels of job control; all demographic indicators of lifetime social deprivation 
(Brunner et al, 1996). In the Scottish Heart Health Study, fibrinogen was the strongest 
“non-classical” risk predictor in explaining social influence (as indicated by housing 
tenure) on CHD in men (although the relationship was weaker in women) (2Woodward et 
al, 2003). Likewise for other inflammatory markers, recent studies have shown that IL-6 
and TNFα are also biomarkers of lifetime socioeconomic status (education, income, and 
ownership of financial assets; Koster et al, 2006; Loukes et al, 2006). 
 
A recent study has shown that fibrinogen and CRP are associated with lifetime 
socioeconomic status in 3745 women. When using socioeconomic status, as well as other 
risk markers, to adjust associations of fibrinogen with incident CHD events, this 
attenuates the CHD risk associated with a 1g/L increase in fibrinogen from 1.29 (1.12, 
1.49) to 1.09 (0.93, 1.28) (Lawlor et al, 2005). In contrast, smoking was a risk factor for 
CHD (OR for ever smoking 2.27 [1.43, 3.58]), but adjusting associations with risk for 
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lifetime socioeconomic status and other conventional risk factors did not abrogate the risk 
association with CHD (1.63 [1.12, 2.36]). This suggests that smoking is far more likely to 
be a causal factor in CHD than fibrinogen and CRP, which may have confounding 
associations with socioeconomic status (Lawlor et al, 2005).  
 
Although socioeconomic markers may confound the relationship of inflammatory 
markers with CHD this does not mean the association with inflammatory markers is 
unimportant; it may still represent a plausible biological pathway by which deprivation 
causes CHD. Contrary to this argument, recent data from older men (n=2682) in the 
British Regional Heart Study has shown that CRP, fibrinogen and IL- 
6 are associated with social class, but that these relationships are attenuated to null after 
adjusting for smoking, alcohol consumption, physical activity and BMI (2Ramsey et al, 
2007).  This would suggest that behavioural CVD risk factors are responsible for a 
confounded association between deprivation and inflammation, and argues against social 
deprivation per se resulting in elevated inflammatory markers.  
 
The relationship between inflammatory markers and socioeconomic status/social 
deprivation is hence an important issue to explore, particularly in Scotland, where the 
new ASSIGN score (Woodeard et al, 2007) incorporates social deprivation (by postcode) 
as a marker of CVD risk due to the fact that conventional risk markers do not fully 
explain the greater cardiovascular risk experienced among the more socially deprived 
(Brunner et al, 1996; Tunstall Pedoe et al, 2006; 1Ramsay et al, 2007). In the present 
study, after adjustment for conventional risk markers, which may confound associations 
with social deprivation (age, gender, smoking, blood pressure, BMI, total cholesterol, 
HDL-cholesterol – all ASSIGN risk markers), we found that IL-6, IL-18 and TNFα 
retained significant associations with social deprivation only in men across quarters of the 
population by Carstairs scores (p for trend <0.008 for all). IL-18 and TNFα had only 
borderline association with deprivation in women (p<0.09). Further cross adjustment of 
each of the three markers for each other left each independently associated with 
deprivation across quarters in men, with IL-18 most strongly associated (p for trend 
<0.01). The results suggest that fibrinogen and CRP are weakly (if at all) associated with 
Carstairs score in this population after only age and sex adjustment, and not at all after 
adjustment for other risk factors. This may reflect that the Carstairs score is a more 
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“immediate” reflection of social deprivation rather than lifetime socioeconomic status 
measured elsewhere (e.g. British Women’s Heart and Health Study; Lawlor et al, 2005). 
Although lifetime socioeconomic status is probably, by definition, a better marker of 
long-term exposure to social CHD risk factors than Carstairs, the Carstairs score is a 
more accurate reflection of the postcode measurement used in the ASSIGN score (i.e. 
“current social class”), and is hence better placed to assess associations with relevance to 
the Scottish system. It is hence possible that lifetime socioeconomic status and immediate 
social deprivation scores are associated with different risk factors to different extents. 
Despite this, our observations are consistent with other observations that IL-6, IL-18, and 
TNFα are associated with lifetime education, income, and ownership of financial assets 
(Koster et al, 2006; Loukes et al, 2006) independently of other risk markers. This may 
suggest that IL-18, TNFα, and IL-6 are more strongly related to “current” deprivation 
than fibrinogen and CRP. 
 
In this study, the discrepancy between socioeconomic status in men and women may 
reflect the long standing epidemiological problem of accurately measuring a women’s 
social class (without using a lifetime questionnaire), since female socioeconomic position 
may (traditionally) vary over the course of her life to a greater extent than male; the 
social class a women marries into is often her reported social class in these studies and 
does not necessarily reflect lifetime social class. This is particularly true of the Carstairs 
score, which includes measurements of local male unemployment, households with no 
car, overcrowding (over 1 person per room), and head of household's social class 
categories IV and V. It is perhaps the case, then, that a more accurate picture of 
inflammatory associations with deprivation would be gleaned in females with a lifetime 
socioeconomic questionnaire. Indeed, this may be relevant to in the borderline 
associations of IL-18 and TNFα in the fully adjusted models in women, suggesting the 
difference between men and women in this respect is due to inability to measure 
deprivation as accurately in women as in men. 
 
 
4.4.9 Conclusions 
 
Inflammatory markers, in general, showed associations with CHD risk factors (age, sex, 
smoking, alcohol, social deprivation, metabolic syndrome, use of hormones). Although 
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IL-18 and TNFα do not show associations with BMI that would generally be expected of 
adipokines, the association with “fatness” was marginally improved by considering WHR 
instead of BMI. Inflammatory markers in general, including IL-18 and 
TNFα, demonstrated strong positive associations with smoking in this study. Increasing 
alcohol consumption was associated with divergent effects in the sexes, generally 
resulting in increased levels in men and decreased levels in women after age-adjustment 
although the trends were only strongly significant for IL-6 in men and for fibrinogen in 
women. All inflammatory markers had highly significant, but confounded, associations 
with social deprivation, which remained significant for IL-18 and TNFα and IL-6 (in 
men only) after full adjustment for the ASSIGN risk markers. This study suggests that 
IL-18 and TNFα are likely to have interesting and potentially informative associations 
with CHD risk in the general population, at the very least by proximal relationships with 
other cardiovascular risk markers, and these associations require further study. 
 
The next 4 chapters report associations of IL-18, TNFα, sCD40L and MMP-9 with CHD 
risk. 
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CHAPTER 5 
 
ASSOCIATIONS OF IL-18 AND TNFα WITH PREVALENT MYOCARDIAL 
INFARCTION: GLASGOW MYOCARDIAL INFARCTION STUDY (GLAMIS) 
 
5.1 INTRODUCTION 
 
5.1.1 Prevalent Case-Control Studies 
 
When investigating the associations of new potential risk markers with CVD, case-
control studies of prevalent CHD are a quick and relatively inexpensive useful first step, 
prior to assessment of the markers in prospective studies. Prevalent case-control studies 
are generally seen as far weaker in terms of proof of a statistical association of a 
biomarker with an event than prospective studies are. This is due to the various sources of 
bias additional confounding effects (such as reverse causality) that they entail. 
(Woodward, 2005). 
 
The first use of the Glasgow ECTIM (Etude Cas-Témoin de l'Infarctus du Myocarde) 
study was to examine socioeconomic associations with prevalent MI in Glasgow, 
socioeconomic position being relatively unaffected by reverse causality bias. The study 
found, importantly, that social deprivation not only vastly increased likelihood of 
experiencing an event, but also lessened chance of survival at, and beyond, admission 
(Morrison et al, 1997). Using the Carstairs deprivation score, MI rate increased 1.7-fold 
in men and 2.4-fold in women from the least (Q1) to the most (Q4) deprived 
socioeconomic quarter (Morrison et al, 1997). 
 
GLAMIS was used to assess the relative associations of the fibrinogen assays, CRP and 
IL-6 with CHD (Lowe et al, 2003). In a separate study, GLAMIS also demonstrated 
associations of homocysteine with prevalent MI, independent of conventional and 
inflammatory risk markers (Woodward et al, 2006).  
 
The availability of stored plasma in this study provided the opportunity to investigate the 
associations of TNFα and IL-18 with other risk markers and with prevalent CHD in the 
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population. As there were no serum samples available in the Glasgow MONICA study, 
MMP-9 and sCD40L were not measured here. 
 
5.1.2 Previously Published data on associations of IL-18 and TNFα with Prevalent 
Cardiovascular Disease                                                                                             
TNFα correlates well with the ankle-brachial index (ABI) (Bruunsgaard et al, 2000 & 
Skoog et al, 2002), an established marker of underlying atherosclerosis (Fowkes et al, 
2006) and a CVD risk marker (Heald et al, 2006). Associations of TNFα with the degree 
of atherosclerosis in imaging studies have been weak. Several studies have suggested that 
TNFα is not associated with carotid IMT or maximal plaque thickness (MCPT) in a cross 
section of stroke-free people (Elkind et al, 2002 & 2005) or angiographic CAD degree of 
stenosis in people with prevalent CHD (Sukhija et al, 2007). Strong correlations between 
ABI and IMT have been reported (McDermott et al, 2005). The reasons for these 
discrepant results in studies of TNFα are not clear. Several studies have reported that in 
patients with prevalent CVD, IL-18 levels are correlated with the extent of CAD, as 
measured by degree of stenosis, number of affected vessels, and to some extent the 
coronary plaque area (Yamashita et al, 2003; Yamaoko et al, 2003; Suchanek et al, 2005). 
However, a larger study (n=1111) recently suggested that only the univariate association 
was significant (Chapman et al, 2006). In addition, a recent study (Espinola-Klein et al, 
2007) found in 720 patients that IL-18 levels were not different in patients with no 
significant CAD, those with CAD, or those with clinically relevant multi-vessel disease. 
Although the latter study, in categorizing patients will lose a lot of power by categorizing 
(instead of measuring CAD as a continuous variable), any possible association of IL-18 
with CAD (Yamashita et al, 2003; Yamaoko et al, 2003; Suchanek et al, 2005) would 
seem likely to be small overall. 
 
Given these results, one would, therefore, expect significantly higher levels of both 
markers in patients with recent previous MI (since they would have greater prevalence of 
diffuse atherosclerosis and CAD). In line with this hypothesis, previous studies have 
suggested that circulating TNFα and IL-18 are increased in patient populations with 
previous MI (Jovinge et al, 1998; Bennett et al, 2006; Hulthe et al, 2006).  
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The first study to show this for TNFα examined young (<45 years) male postinfarct 
patients, but only described univariate differences between cases (n=153) and age-
matched controls (n=63); 4.1pg/ml (±1.6) vs 2.5pg/ml (±0.4) p < 0.0001 (Jovinge et al, 
1998). Another study (n cases = 1213) recently reported associations, this time in terms 
of odds ratios of MI risk in the top versus bottom quartile, but did not adjust for 
confounders; OR [95% CI]: 1.7 [1.1; 2.6] n cases=1213 (Bennet et al, 2006).  
 
Univariate comparisons between retrospective cases (n=387) and controls (n=387) have 
also been made for IL-18; 309.6pg/ml (±138.6) vs 285.4pg/ml (±115.7) p<0.01 (Hulthe et 
al, 2006). Due to a lack of studies examining both inflammatory markers as well as 
classical and other inflammatory risk factors in the same cohort, data directly comparing 
the associations with prevalent CHD and the extent of confounding by other markers 
comparing IL-18 and TNFα are not known. 
 
5.1.3 Aims 
 
Hypothesising that IL-18 and TNFα levels would be higher in the survivors of MI than 
age-matched controls, the aim was to directly compare IL-18 and TNFα and their 
relationships with retrospective risk of MI in a case-control study, as well as with 
classical and inflammatory risk factors. 
 
5.2 METHODS 
 
5.2.1 Patient Recruitment 
 
It was noted during the MONICA study that the incidence of CHD in middle-aged men is 
more than three times higher in Northern Ireland than in Northern France. The ECTIM 
(Etude Cas-Témoin de l'Infarctus du Myocarde) study was set up to investigate the 
demographic, clinical, genetic and biomarker differences between these populations in an 
attempt to explain this striking discrepancy (Moreel et al, 1992; Parra et al, 1992). 
Participants in the MONICA trials in Belfast, Toulouse, Lille, or Strasbourg who, 
according to MONICA databases, survived MI after 1992 were contacted and asked to 
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participate in the retrospective ECTIM case-control study (Parra et al, 1992). A high 
prevalence of CVD events were also (as expected) found in Glasgow in the MONICA 
study, and the Glasgow ECTIM study was subsequently set up as an extension of 
ECTIM. The Glasgow MONICA coronary event register contains all cases of MI and 
coronary death occurring in men and women aged 25-64 years resident in North Glasgow 
from the 1980s. Individuals surviving an MI event after July 1994 were asked to 
participate, and consequently a prevalent case-control study was set up. Although 
originally set up to overlap the ECTIM study of genetic markers, the Glasgow 
Myocardial Infarction Study GLAMIS was subsequently also established as a stand-alone 
case-control study of plasma markers which were not studies in ECTIM (Lowe et al, 
2003). Some controls rejected by the ECTIM study due to genetic exclusion criteria were 
accepted in GLAMIS. 
 
The aim of the Glasgow Myocardial Infarction Study (GLAMIS) was to recruit all men 
and women with MI in the North Glasgow MONICA study (Morrison et al, 1997), 
diagnosed by MONICA criteria (Tunstall-Pedoe et al, 1988) from July 1994-5, between 3 
and 9 months after the event when acute-phase protein reactions due to myocardial 
trauma had settled. Cases were patients with MI in this population survey who were still 
alive, contactable and gave consent (75% response rate, n=490). Controls were selected 
from a random sample of the same North Glasgow population, obtained from general 
practice registers, who had no history or electrocardiograph evidence of MI, and who 
were frequency-matched for sex and age (within 1 year). Written informed consent was 
obtained from all participants, and the study was approved by the local research ethics 
committee. 
Participants completed a detailed general health questionnaire including the Rose chest 
pain questionnaire, as well as questions on smoking (current/ex-smoker/never smoked 
cigarettes) and diabetes (yes/no) history. Weight and height were measured for 
calculation of BMI and an ECG and blood pressure were also recorded by a trained nurse. 
A forearm venous blood sample was taken after a full overnight fast; one serum and one 
citrated sample (0.11 mol/L, 9:1 v/v). Blood samples were centrifuged at 2000 × g for 10 
min at room temperature within two hours of sampling, and aliquots stored at -70 °C until 
assay.  
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IL-18, TNFα, fibrinogen, CRP and IL-6 were assayed as described in Chapter 2. Aliquots 
used in this study were previously unthawed. 
 
5.2.2 Statistical Analysis                                                                                               
Each of the inflammatory variables (IL-18, TNFα, CRP, IL-6 and fibrinogen) and 
continuous conventional cardiovascular risk factors considered (age, systolic blood 
pressure, serum total cholesterol and carbon monoxide in expired air) was compared 
between MI cases and controls using general linear models that adjusted for age and sex 
(Woodward et al, 2006). Skewed continuous variables (including all inflammatory 
markers) were log-transformed to approximate normality, or if normality was not 
achieved by these methods, were power-transformed as stated in the text. Spearman rank 
correlations were used to explore monotonic relationships, again adjusting for age and 
sex, between IL-18 and TNFα and all the continuous variables. Multivariable logistic 
regression models were used to obtain odds ratios for MI by the thirds of both IL-18 and 
TNFα in total population, adjusting both for age and sex, and additionally adjusting for 
all inflammatory variables and CVD risk factors considered in subsequent models. 
 
5.3 RESULTS 
5.3.1 Sample Availability                                                                                         
 From the 75% response rate to the GLAMIS recruitment procedure, there were a total of 
490 cases and 505 controls entered into the study. Of these, 446 cases (445 for TNFα) 
and 477 controls had citrated blood samples available for measurement of novel 
inflammatory variables due to previous sample attrition (93% of the total available). The 
baseline characteristics of subjects for whom samples were and were not available for the 
present study were not appreciably demographically different and were hence missing at 
random (p>0.1 for all). 
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5.3.2  Population Characteristics                                                                                
 
Table 5.1 shows baseline demographic data for cases versus controls. As anticipated by 
design, there were no significant differences in age between cases and controls. Cases 
and controls were matched for age and sex (cases 74.4% male vs controls 72.6% male 
p>0.5). Cases and controls had similar percentages of current smokers (cases 46.9% vs 
controls 45.6% p = ns) but a higher percentage people who had ever smoked in the case 
population (cases 89.4% vs controls 74.4% p <0.0001). This is due to the fact that of 161 
cases who were ex-smokers, 46% had given up in the last year compared with 6% in the 
controls. Cases were more likely to be diabetic (12% vs 2%; p<0.0001) and more likely 
to be taking prescribed medications for high blood pressure (39% vs 17%; p<0.0001) or 
high cholesterol (28% vs 1%; p<0.0001). 
Cases had lower levels of blood pressure compared to controls, an effect probably 
attributable to treatment with medication following index MI. Cases and controls were 
significantly different for HDL cholesterol and triglyceride lipid measurements 
(p<0.0001) (although not total cholesterol) and body mass index (BMI) (p=0.0007) in the 
expected directions. Cases had very significantly higher levels of the APR associated 
inflammatory markers IL-6, fibrinogen, and CRP (p<0.0001 for all). In univariate 
comparisons of cases and controls both TNFα and IL-18 were also significantly higher in 
cases than in controls (29%; p<0.0001 and 6%; p<0.01 respectively).  
5.3.3 Correlations of IL-18 and TNFα with Other Cardiovascular Risk Markers   
TNFα levels in those who had ever smoked compared to those who had never smoked 
were not significantly higher in the case or in the control population (non-significant 
trend in control populations:  median 0.69 vs 0.79pg/ml p= 0.38). For continuous 
variables, Tables 5.2 and 5.3 respectively show age- and sex-adjusted correlations of 
TNFα and IL-18 with classical and inflammatory risk markers. TNFα showed few strong 
correlations with classical risk factors, even in the control population (Table 5.2). TNFα 
had a moderate associations with age (r2 = 0.14) triglycerides (r2 = 0.10) and HDL 
cholesterol (r2 = -0.12) in the control population, although these were absent in the cases 
(for lipid measurements this is probably attributable to fibrate prescription). In the group 
of haemostatic markers measured there were moderate associations of TNFα with t-PA 
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and D-dimer in case and control populations (r range =0.11-0.18), although not with vWF 
or PAI antigens. TNFα had expected strong associations with the other cytokines (IL-6 
and IL-18) and with PV in both case and control populations, but surprisingly 
associations were not observed with the acute phase reactants (fibrinogen and CRP).  
 
Similarly to TNFα, IL-18 levels showed no significant relationship with smoking, 
although there was a non-significant trend for controls who had ever smoked to have 
higher IL-18 levels (median 249 vs 277 pg/ml p=0.19). IL-18 showed strong associations 
with HDL cholesterol (r = -0.22) and associations with triglycerides (r = 0.16), although, 
similarly to TNFα, relationships with lipids were absent in the cases (Table 5.3). IL-18 
also had modest associations with BMI (r = 0.14) and carbon monoxide expiration (r = 
0.11), although these were also absent in case populations (probably due to weigh loss 
and altered smoking patterns following MI). IL-18 had significant associations with all 
haemostatic markers measured in the controls, and in particular associations with D-
dimer and t-PA were strong (r = 0.25 for both). IL-18 also had expected strong 
associations with other cytokines in both case and control populations (IL-6 and TNFα), 
and a strong association with markers of the acute phase response (CRP and fibrinogen) 
as well as plasma viscosity, although again these associations were weakened or absent in 
the case population. 
 
5.3.4 TNFα and IL-18 Associations with History of MI                                                     
Table 5.4 shows the risk of MI in the population by thirds of TNFα and IL-18 expression, 
and both cytokines are analysed by adjusting in three different models. After adjustment 
for matched variables (age and sex), those in the top third for TNFα expression had an 
elevated risk of MI (Odds ratio [OR] 2.19: 95% confidence intervals [CI] 1.58 – 3.03). 
After adjustment for classical risk factors the association attenuated to 1.66, and after 
further adjustment for acute phase reactants the relationship marginally attenuated to 
borderline significant 1.47 (95% CI 0.91 – 2.37).  
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In contrast, IL-18 showed a weak association with risk after adjustment for only matched 
variables (OR 1.38; 95% CI: 1.00 – 1.90). This relationship was attenuated to a null 
association after adjustment for classical risk factors (1.07), and classical risk factors and 
acute phase reactants (0.87). This loss of statistical association with outcome is broadly in 
agreement with the greater level of correlations IL-18 displayed with conventional and 
inflammatory risk markers than did TNFα. 
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Table 5.1 Baseline age- and sex-adjusted summary statistics for TNFα, IL-18 and continuous conventional risk factors in case and control 
populations. 
 
 
 
 
 
 
 
 
* Adjusted for sex only 
For transformed values summery statistics are shown after back transformation: 
† Values computed on log scale 
‡ Computed after power -0.1 transformation 
§ Computed after power -0.5 transformation 
 
 
 
            Cases             Controls  
 
n 
Medians 
(IQR) 
 
n 
Medians 
(IQR) p-value 
Age (years) * 490 57 (50 -61)  505 57 (51 – 61) 0.57 
Systolic blood pressure (mmHg) 489 120 (105 – 137)  505 130 (116 – 143) <0.0001 
Diastolic blood pressure (mmHg) 489 77 (69 - 86)  505 83 (75 – 90) <0.0001 
Total cholesterol (mmol/L) 477 5.70 (4.95 – 6.48)  493 5.70 (5.01 – 6.42) 0.59 
HDL cholesterol (mmol/L) † 477 1.08 (0.90 – 1.29)  492 1.29 (1.06 – 1.55) <0.0001 
Triglycerides (mmol/L) † 477 1.88 (1.35 – 2.63)  493 1.44 (1.05 – 2.11) <0.0001 
Body mass index (Kg/m2) † 487 27.3 (24.7 – 30.4)  505 26.3 (23.8 – 29.7) 0.0007 
Carbon monoxide (ppm) † 486 6 (3 – 15)  504 4 (3 – 15) 0.03 
Fibrinogen (g/L)† 387 4.46 (3.80 – 5.26)  378 4.03 (3.44 – 4.69) <0.0001 
CRP (mg/L)† 391 2.92 (1.31- 6.32)  370 1.79 (0.80 – 4.23) <0.0001 
IL-6 (pg/ml) § 379 2.08 (1.42 – 3.17)  360 1.42 (1.07 – 2.16) <0.0001 
IL-18 (pg/ml) † 446 287 (212 – 404)  477 271 (200 – 373) 0.01 
TNFα  (pg/ml) ‡ 445 0.99 (0.65 – 1.64)  477 0.77 (0.52 – 1.22) <0.0001 
 
207 
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Table 5.2 Age and sex-adjusted Spearman correlations of continuous variables with 
TNFα for MI cases and controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cases  Controls 
 r p-value  r p-value 
Age 0.05 0.29  0.14 0.002 
Systolic blood pressure -0.008 0.86  -0.03 0.49 
Diastolic blood pressure 0.00 0.94  -0.01 0.85 
Total cholesterol -0.03 0.51  -0.05 0.29 
HDL cholesterol 0.06 0.17  -0.12 0.01 
Triglycerides 0.06 0.21  0.10 0.03 
Body mass index 0.08 0.08  0.06 0.18 
Carbon monoxide -0.09 0.05  0.04 0.37 
Haematocrit -0.02 0.62  0.03 0.51 
PAI 0.03 0.51  0.05 0.30 
t-PA 0.11 0.06  0.12 0.06 
D-dimer 0.14 0.01  0.18 0.003 
vWF 0.06 0.18  0.06 0.20 
PV 0.11 0.02  0.11 0.01 
Fibrinogen 0.07 0.19  0.09 0.08 
CRP 0.05 0.30  0.07 0.17 
IL-6 0.24 <0.0001  0.21 <0.0001 
IL-18 0.24 <0.0001  0.23 <0.0001 
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Table 5.3 Age and sex-adjusted Spearman correlations of continuous variables with IL-18 
for MI cases and controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cases  Controls 
 r p-value  r p-value 
Age 0.01 0.77  0.00 0.97 
Systolic blood pressure 0.00 0.96  0.04 0.41 
Diastolic blood pressure 0.04 0.39  0.04 0.41 
Total cholesterol 0.00 0.97  0.02 0.61 
HDL cholesterol 0.09 0.06  -0.22 <0.0001 
Triglycerides 0.07 0.12  0.16 0.0005 
Body mass index 0.09 0.06  0.14 0.003 
Carbon monoxide 0.04 0.46  0.11 0.01 
Haematocrit 0.01 0.77  0.14 0.003 
PAI 0.10 0.04  0.14 0.004 
tPA 0.10 0.08  0.25 <0.0001 
D-dimer 0.16 0.004  0.25 <0.0001 
vWF 0.13 0.01  0.18 0.0004 
PV 0.02 0.63  0.15 0.001 
Fibrinogen 0.07 0.18  0.25 <0.0001 
CRP 0.15 0.005  0.21 <0.0001 
IL-6 0.22 <0.0001  0.25 <0.0001 
TNFα 0.24 <0.0001  0.23 <0.0001 
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Table 5.4 Odds ratios (OR) of myocardial infarction for TNFα and IL-18, adjusted for 
three sets of risk factors. Analyses are by thirds (bottom third OR=1) based on 
distribution in the GLAMIS population. 
 
* Age, sex, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL 
cholesterol, triglycerides, diabetes, smoking (current/ex/never), body mass index, use of 
medications for high blood pressure and total cholesterol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Odds ratio (95% CI) adjusted for: 
 
 
 
Matched variables 
only 
 
Classical risk factors* 
 
Classical risk 
factors, fibrinogen, 
and CRP 
TNFα    
Bottom third 1 1 1 
Middle third 1.46 (1.06, 2.01) 1.06 (0.70, 1.59) 1.06 (0.66, 1.70) 
Top third 2.19 (1.58, 3.03) 1.66 (1.10, 2.50) 1.47 (0.91, 2.37) 
    
IL-18    
Bottom third 1 1 1 
Middle third 1.28 (0.93, 1.76) 0.95 (0.62, 1.43) 0.75 (0.46, 1.21) 
Top third 1.38 (1.00, 1.90) 1.07 (0.70, 1.62) 0.87 (0.53, 1.42) 
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5.4 DISCUSSION 
5.4.1 Cytokine Expression Levels in the MONICA Study                                     
Median IL-18 levels among controls were 271pg/ml (inter-quartile range 200-373) and 
for TNFα the median was 0.77pg/ml (0.52-1.22). Comparing the present study to the 
MONICA-4 study, median IL-18 levels are very similar (271 pg/ml among ~57 year old 
controls versus 251pg/ml in the 45-64 year old males), which would suggest a high 
comparability between the studies in terms of sample condition and the populations 
(which is as expected since they are both North Glasgow studies). Despite this, the same 
cannot be said for TNFα, for which levels appears to be around half of those seen in 
MONICA-4 (0.77 pg/ml among controls versus 1.65-1.90pg/ml range in the 45-64 year 
old males). The inter-quartile ranges between the studies are also similarly discrepant 
(~2-fold comparing extreme values in the IQR) and therefore the difference is a 
population-wide “shift” of all TNFα values. The reasons for this discrepancy are not 
clear. It is possible that the difference is partially due to differences in kit lots and drift of 
the calibrant between them. This would be a worrying conclusion, yet it may be the 
simplest one. As described in Chapter 3, if anything TNFα is more robust than IL-18, and 
it is unlikely therefore that sample quality plays a role in the discrepancy. Likewise, 
EDTA levels of TNFα are similar to those in citrate (MONICA-4) and may if anything 
be slightly higher (Chapter 3). These important findings require further monitoring and 
explanation. 
 
5.4.1 Association of TNFα and IL-18 with Previous MI                                             
The present study investigated the associations of TNFα and IL-18 with classical risk 
factors, acute phase response markers, and risk of MI in a case – control study. Results 
reported here show that that both TNFα and IL-18 are significantly elevated in persons 
with previous MI, independently of sex and age. This study also finds that these 
associations with MI are dependant on confounding associations with classical risk 
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factors and are also confounded by markers of the acute phase response, and after 
adjustment for both of these TNFα, but not IL-18, remains significantly associated with 
MI. 
These patterns of association with MI for the two cytokines are in agreement with 
previous publications that studied the cytokines separately in case-control studies 
(Jovinge et al, 1998; Bennett et al, 2006, Hulthe et al, 2006) where it was observed in 
unassociated studies that IL-18 had a relatively weaker univariate association with MI 
than did TNFα. This study confirms these findings, and adds further data showing that 
after full adjustment for classical risk factors in multivariate analysis, TNFα remains 
associated with previous MI, whereas IL-18 does not. This result is slightly surprising, 
since in prospective studies in generally healthy populations (2Cesari et al, 2003; 
Blankenberg et al, 2003) as well as populations with prevalent CVD (3Ridker et al, 2000: 
Koukkunen et al, 2001; Blankenberg et al, 2002; Blankenberg et al, 2006; Table 
1.4&1.6), trends suggest that if anything IL-18 may be a stronger prospective risk marker 
of MI than TNFα.  
In the months immediately following index MI, and after acute-phase protein reactions 
have settled, physiological changes (such as cardiac cachexia and CHF), lifestyle changes 
(such as intentional weight loss and smoking cessation) and/or treatment with prescribed 
medication result may alter the relative circulating levels of IL-18 and TNFα, and hence 
there may be an alteration of observed associations with historical MI. For instance, 
although little is known of the role of IL-18 in cachexia, TNFα levels are known to be 
elevated in those with cardiac cachexia, and blockade of the cytokine may help normalize 
the anabolic response to overeating and allow fat-free mass to be gained (Marcora et al, 
2006). In addition smoking cessation will likely lower circulating concentrations of most 
cytokines (see Chapter 4; 2Wannamethee et al, 2005). Hence it is possible there are sub-
groups of MI survivors that will display longer-term physiological responses to MI, and 
these responses will impact on pro-inflammatory cytokines, which will have bearings on 
the observed magnitude of associations with outcome. 
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Despite a lack of observed independent associations with previous MI and IL-18 in this 
study, IL-18 may still be a prospective risk marker within populations with prevalent 
CHD independently of conventional risk markers (Blankenberg et al, 2002, 2006). 
Speculatively, this may suggest that although there are changes in the medications, 
physiology, and lifestyles of populations with history of MI that abrogate independent 
associations of IL-18 with historical MI (and essentially make these populations appear 
closer to “normal” in terms of IL-18 expression) IL-18 may still ultimately predict risk of 
recurrent CHD events in these populations. In contrast with IL-18, the association 
between TNFα and retrospective MI is attenuated after adjustment for classical risk 
factors and markers of the acute phase response, but remains borderline significant in 
populations with historical MI. This is consistent with the central role TNFα may play in 
post-MI left ventricle dilatation and subsequent congestive heart failure (Torre-Amione et 
al, 1999; Sarzi-Puttini et al, 2005), as well as its role in cardiac cachexia (Marcora et al, 
2006). 
 
5.4.2 Associations of IL-18 and TNFα with Conventional Risk Markers                      
In agreement with previous publications (Jovinge et al, 1999; Bennett et al, 2006) and 
with the MONICA-4 study (Chapter 4), TNFα showed weak to moderate associations 
with some lipid parameters in the control population (HDL cholesterol and triglycerides) 
but not with total cholesterol. There was also evidence of correlations with D-dimer and a 
borderline association with t-Pa which suggests that TNFα participates in the fibrinolysis 
cascade, consistent with observations in patients with lung cell carcinoma and TNFα 
infusion experiments (Guadagni et al, 2004; van Hinsbergh et al, 1990). However, also 
consistent with MONICA-4 (chapter 4), TNFα did not demonstrate firm associations 
with other classical risk markers, such as blood pressure and BMI, although there was a 
correlation with age in the controls. Lack of association between BMI and TNFα 
contradicts proposed associations between obesity and TNFα (Ziccardi et al, 2002; 
Samuelsson et al, 2003), although the present study may biased by the poor general 
health of the north Glasgow control group, reflected by the high prevalence of smoking, 
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and the suboptimal average values of risk factors such as BMI and blood pressure. 
Interestingly, although ΤΝFα showed expected associations with IL-18 and IL-6, it had 
no statistical association with the downstream markers of the APR; CRP and fibrinogen.  
IL-18 had moderate associations with markers of the metabolic syndrome in the control 
population (HDL cholesterol, triglycerides, and BMI) and this is consistent with previous 
studies, which suggest it may also be associated with insulin levels (Esposito et al, 2003; 
Hung et al, 2005; Hulthe et al, 2006), although studies exist which also contradict this 
apparent association (1.4.7). Less controversially, associations with haemostatic markers 
in the control population (D-dimer, vWF, PAI and t-PA) as well as other inflammatory 
markers and markers of the acute phase response were observed for IL-18. These 
associations were generally absent or heavily attenuated in the case population and this is 
probably due to previously described changes in lifestyle, secondary consequences of MI 
such as cachexia, and prescribed medication.  
Lack of an association of either cytokine with smoking is contradictory to results in the 
MONICA-4 study. This is likely due to the previously described recent cessation of 
smoking (and perhaps denial of previous/current smoking habits) in a population with a 
recent CVD event history. 
 
5.4.3 Study Strengths and Limitations                                                                                           
This study comprised a relatively large number of patients (n=490) procured from a 
focused geographic area within a relatively short time-frame. This makes the study a 
statistically powerful resource. Despite this limitations of the study require consideration. 
As previously discussed, the North Glasgow population may be considered to be of 
generally sub-optimal cardiovascular health as reflected by the high-normal blood 
pressure, BMI and cholesterol levels of the control population in this study. Also, the 
present case-control study has the disadvantage of using a study design which, as 
previously discussed, is relatively weak for estimating causality (Woodward et al, 2005). 
In particular survivor bias may have had some effect on the results (cases had to be alive 
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several months after their MI), for instance lack of association between IL-18 and 
historical MI may imply that those with high IL-18 levels who experienced MI were less 
likely to survive. There is currently no causal evidence in favour of this argument, but it 
is important to highlight the potential confounding implicated by survivor bias in the 
interpretation of results.  
The necessary lag between the event and recruitment into the study allowed time for 
changes to lifestyle and treatment that will usually occur after surviving a significant 
medical event. This is manifested here by the lower blood pressures in the case group, the 
lack of difference between the cases and controls in average cholesterol levels and the 
same percentage (45%) of current smokers amongst cases and controls at the time of 
surveying. Despite this a higher BMI was observed among cases, but IL-18 and TNFα 
were not associated with this variable among cases. These results reflect that that a lag 
time of a few months is not entirely sufficient for some risk factors to become attenuated, 
resulting in superficially disparate observations. Statistical correction measures included 
are that correlations and binary relationships with TNFα and IL-18 are presented 
separately for cases and controls, medication use is included as an adjustment variable in 
the analyses of association with MI, and smoking status is dichotomised as ever or never 
smoked cigarettes. 
 
5.4.4 Conclusions                                                                                                   
Despite these limitations, this study has shown that IL-18 is associated with classical risk 
markers for CHD that are also associated with the metabolic syndrome (HDL cholesterol, 
triglycerides and BMI), haemostatic markers, and other inflammatory markers, including 
markers of the APR in a control population. Heavy confounding may have implications 
limiting IL-18 utility as a risk marker (potentially even in prospective studies), but does 
not preclude (and may even allude to) a role for it in the development of incident CHD, 
particularly with reference to its associations with markers of the metabolic syndrome. 
This study also suggests that lifestyle changes and medical treatment following MI may 
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have profound effects on IL-18 associations with other risk markers, and indeed perhaps 
its association with risk.  
In contrast, TNFα has few firm associations with classical risk markers (borderline 
associations with HDL cholesterol and triglycerides in controls) and although it 
associates with other cytokines (IL-6 and IL-18) it shows no association with markers of 
the APR, and hence multivariate adjustment leads to only moderate attenuation of the 
association with risk. This suggests that not all inflammatory markers associated with risk 
of CHD are acting as distal markers of the APR, although TNFα is undoubtedly at least 
partially confounded by it. Hence there is scope for inflammatory markers to play 
differential roles in both the conventional risk factor dependant and independent of the 
process of atherogenesis. 
Further studies are needed to confirm these findings and to expand on them, particularly 
to elucidate reasons for cross-study discrepancies in IL-18 associations with conventional 
risk markers and TNFα's associations with degree of atherosclerosis (IMT or ankle 
brachial index). Prospective studies are required which can directly compare IL-18 and 
TNFα as prospective risk markers of CHD. Such studies are reported in Chapters 6 and 7. 
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CHAPTER 6 
 
ASSOCIATIONS OF IL-18, TNFα, MMP-9 AND sCD40L WITH RISK OF CHD 
IN A NESTED CASE CONTROL STUDY OF MIDDLE-AGED MEN AND THE 
EXTENT OF 4-YEAR REGRESSION DILUTION IN THOSE MEN:  
THE BRITISH REGIONAL HEART STUDY 
 
6.1 INTRODUCTION 
6.1.1 Prospective Study of Risk Associations of Novel Inflammatory Risk Markers in 
Middle-Aged Men                                                                                                                                  
Having examined associations of IL-18 and TNFα with retrospective risk of CHD, the 
logical next step was to further examine such associations in prospective studies, which 
are subject to less reverse-causality bias (GLAMIS: Chapter 5). 
We had stored baseline serum samples in our laboratory from the British Regional Heart 
(BRH) Study, which were originally drawn in 1978-1980. The BRH study was set up to 
examine the factors responsible for the regional variation in coronary heart disease, 
hypertension, and stroke in Great Britain, and to determine the causes of these conditions 
(at both individual and regional levels) in order to provide a rational basis for 
recommendations towards their prevention. The focus of the study was on the prevalence 
and incidence of cardiovascular disease and their relations to established behavioural and 
biological risk factors (Walker et al, 2004). 
Although these samples had been stored for a long period (~25 years), the cohort is large, 
well established, has had many conventional and novel risk factors measured, and follow-
up of participans has been excellent (see methods). This well defined cohort therefore 
represents an ideal resource for the measurement of novel potential risk markers of CHD. 
It is a random sample of the 1980 UK general population of middle-aged men, with 
relatively few selection criteria, and over the 16 year follow-up the cohort yielded 643 
incident coronary heart disease cases making it a powerful resource. The availability of 
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serum samples also allowed for the measurement of sCD40L and MMP-9 as novel risk 
markers, as well as IL-18 and TNFα. For these reasons the BRH study was considered 
one of the key studies of this thesis. 
 
6.1.2 Previously Published Prospective Data Linking the Inflammatory Markers with 
Risk of CHD                                                                                                                   
Summary tables of all published prospective data examining IL-18, TNFα, MMP-9, 
sCD40L, and CHD risk are shown in Tables 1.4, 1.6, 1.8 and 1.10. At the outset of this 
thesis there was only very limited data examining associations of IL-18, TNFα, sCD40L 
and MMP-9 markers with incident CHD.  Several studies had shown IL-18 (Blankenberg 
et al, 2002), TNFα (Ridker et al, 2001; Koukkunen et al, 2001), MMP-9 (2Blankenberg et 
al, 2003), and sCD40L (2Varo et al, 2003, Kinlay et al, 2004) were associated with risk of 
CHD in people with varying severities and degrees of prevalent vascular disease. 
However, these populations do not include “healthy” people and may be subject to 
reverse causality bias or selection bias compared to generally healthy populations.  
The ABC nested case-control study of TNFα as a risk marker in healthy elderly people 
(2Cesari et al, 2003) indicated that TNFα was a moderate risk predictor of CHD (OR 1.6 
[95% CI 1.23-2.26]) (Table 1.4). The PRIME Study of IL-18 in middle-aged men found a 
relatively strong association of IL-18 with risk of CHD among men in the top tertile 
(~80%) (Blankenberg et al, 2003) and the risk was independent of potential confounders. 
At the outset of this thesis there were no general or healthy populations studies for MMP-
9 (Table 1.8), and the small Women’s Health Study (n cases=130) was the only available 
data for sCD40L, which suggested significant associations with risk only at the 95th 
percentile (although the study was performed on plasma: see Chapter 3) (3Schonbeck et 
al, 2001).  
 
Thus, data in general examining these inflammatory markers are suggestive of 
moderately strong associations with risk of CHD, although the data are limited. An 
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additional concern is that recent history suggests that the literature on novel biomarkers 
may be subject to publication bias in the early stages of investigation (e.g. CRP; Danesh 
et al, 2004). These markers therefore required further investigation on their association 
with risk of CHD. 
 
6.1.3 Aims                                                                                                                                      
The aim of this study was to establish the associations of serum IL-18, TNFα, MMP-9 
and sCD40L with conventional risk markers and with risk of incident CHD in a long-
term nested case-control study in a general population of middle-aged men. In addition, I 
aimed to use the cohort to estimate the 4-year regression dilution ratios of all four 
inflammatory markers (Chapter 3), to compare these with previously published findings 
for other risk markers in this cohort (Emberson et al, 2004) and to use them to assess the 
potential strength of associations once the bias is taken into account. 
 
6.2 METHODS 
6.2.1 Establishment of the British Regional Heart (BRH) Study 
During the 1970s the epidemic of CHD was well-established in Britain. Pronounced 
regional variations in CVD prevalence were noted in epidemiological studies. Indeed, it 
is well known that the geographical phenomenon of a general South-North and East-West 
gradient in CHD is still evident in the UK today (see fig 6.1). For a time there was 
interest in the possibility that 'soft' drinking water was a risk factor for CHD and that 
variations in water hardness/softness, or the weather gradient, across Britain might 
account for these geographical variations. The study demonstrated that although water 
softness was not associated with incident CHD after adjustment for confounders (Pocock 
et al, 1980), classical risk factors accounted for 77% of the geographical variance in 
incident CHD levels (Morris et al, 2001). The BRH study has also contributed much 
valuable data  on the associations of classical risk factors with incident CHD (Shaper et 
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al, 1985, 1986, 1991, 1994, 1997, 1998; Walker et al, 1987, 1995; Wannamethee et al, 
19981&2, 2002), data on British CHD risk assessment (Brindle et al, 2003) and novel risk 
markers (Danesh et al, 20002, 2001; Whincup et al, 2000; Homocysteine Studies 
Collaboration, 2002) as well as the regression dilution effect for conventional and novel 
cardiovascular risk markers (Emberson et al, 2003 & 2004). An exhaustive list of 
publications up until 2004 has been published and discussed elsewhere (Walker et al, 
2004). 
The study included 24 towns and boroughs with populations >50 000 in 1978-80 (see fig 
6.2) and various selection criteria including ranges of CVD prevalence (Walker et al, 
2004). Initially almost 10 000 middle-aged men aged 40–59 were drawn at random age 
bands of each practice register and invited to take part. The cohort is socio-economically 
representative of British middle-aged men in 1980 (Table 6.1) and of senior citizens in 
the 2000s. Since then a wide range of personal, behavioural, risk factor exposure, and 
clinical data has been collected on follow up as the cohort moved from middle to old age 
(blood samples at baseline, 4, 16 and 20 years; Walker et al, 2004, Emberson et al, 2004). 
This makes the cohort a powerful epidemiological resource and longitudinal study. 
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Fig 6.1 Age-standardised death rates per 100,000 of the population from CHD in men 
aged under 65 years by local authority 2002/2004 illustrating a general South East-North 
West gradient in incidence. From The British Heart Foundation: www.heartstats.org 
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Fig 6.2 Illustration of towns involved in the BRHS. From Walker et al, 2004 
 
Table 6.1 Social class distribution of participants in the British Regional Heart Study 
(BRHS) in relation to Census data. From Walker et al, 1987. 
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6.2.2 Subject recruitment and establishment of a case/control study 
 
In 1978-1980, 7735 males aged 40-59 were randomly selected from general practice 
registers in each of 24 British towns and invited to take part in the British Regional Heart 
Study (response rate 78% from ~10,000 invitations). Nurses administered questionnaires, 
made physical measurements including blood pressure and body mass index (BMI), 
recorded an ECG and collected non-fasting venous blood samples. In 5661 men in 18 of 
the study towns, serum was initially stored at -20oC for subsequent analysis (Shaper et al, 
1981), and at -50oC and –80oC once the facility was available.  In the cohort assessments, 
pre-existing CHD was defined on the basis of a history of a doctor diagnosis of CHD, a 
positive history of angina or possible MI on the Rose (WHO) chest pain questionnaire or 
an ECG consistent with definite or possible CHD.  
 
All men were followed-up for all-cause mortality and for cardiovascular morbidity, with 
a follow up loss of <1% (Walker et al, 2004).  Fatal CHD cases were ascertained through 
National Health Service Central Registers on the basis of a death certificate with ICD-9 
codes 410-414.  The diagnosis of non-fatal myocardial infarction was based on reports 
from general practitioners, supplemented by regular reviews of general practice records, 
and diagnosed in accordance with World Health Organisation criteria (Walker et al, 
2004).  After an average of 16 years follow-up, a nested case-control study was 
established, based on all 643 coronary heart disease cases (279 coronary heart disease 
deaths and 364 cases of non-fatal myocardial infarction) occurring between 1978 and 
1996 and a total of 1278 controls (2 per case) were “frequency matched” to cases on town 
of residence and age in 5-year bands. These controls were randomly selected from among 
men who had survived to the end of the study period free from incident coronary heart 
disease, but could include a random sample of those with baseline CHD presuming no 
further incidents at follow-up. Emerging risk markers previously studies include CRP 
(2Danesh et al, 2000), soluble adhesion molecules (Malik et al, 2001), vWF (Whincup et 
al, 2002), t-PA (Lowe et al, 2004), D-Dimer (Danesh et al, 2001), and IL-6 (Mann et al, 
submitted). 
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IL-18, TNFα, MMP-9 and sCD40L were all measured as described in Chapter 2. 
Samples used in this thesis had been stored for ~25 years and had been thawed on ~4-5 
previous occasions. 
 
6.2.3 Statistical analysis 
 
Highly skewed variables were log transformed where necessary, and this included all the 
four novel markers. Analysis of case-control samples was pre-specified by thirds of IL-
18, TNFα, MMP-9 or sCD40L values in controls.  Unmatched stratified logistic 
regression was fitted using unconditional maximum likelihood methods (SAS version 
8.1).  For associations between inflammatory markers and a variety of known and 
suspected CHD risk factors, trends across thirds of the population distribution for each 
inflammatory marker were analysed, and emphasis was mainly given to differences more 
extreme than 2.6 SD (2P>0.01) to make allowance for multiple comparisons. 
 
6.2.4 Regression Dilution Ratio Study 
 
The samples used to examine this pre-analytical variable were follow-up samples from 
the same cohort at 16 and 20 years (in towns Dewsbury and Maidstone; as per Emberson 
et al, 2004), hence this is a 4 year study of regression dilution in older (60 – 79 years at 
20 year clinic attendance) males. These samples were therefore less old than the baseline 
samples, and had been subjected to fewer freeze-thaws (which is important with regard to 
pre-analytical variables; Chapter 3). The re-attendance and follow-up of the cohort is 
described in detail elsewhere (Walker et al, 2004). sCD40L and MMP-9 measurements 
were made on 139 pairs of serum samples, whilst IL-18 and TNFα were measured on 
159 pairs of citrated plasma samples, each set of pairs representing a random selection of 
available samples. This was fewer samples than previously reported (Emberson et al, 
2004) due to sample attrition (samples at both 16 and 20 years had to be adequate to 
assay). 
 
  225
 
The regression dilution ratio (RDR) is an estimate of the ratio of the uncorrected 
association (on a log scale) to the corrected association. Various methods have been 
described that measure this index (Frost et al, 2000). In this study the ratio was analysed 
using the Rosner method (Rosner et al, 1990) as in the original BRH study of regression 
dilution (Emberson et al, 2004), and the method estimates the RDR by regressing the 
follow-up measurement on the baseline, and obtaining the regression slope (regression 
dilution coefficient). As with the relative risk statistical analysis, this statistical work was 
performed by Professor P Whincup and colleagues.  
 
6.3 RESULTS 
 
6.3.1 Sample Availability 
 
Due to the attrition of stored samples as a result of use in a number of previous studies 
(Danesh et al, 20002, 2001; Malik et al, 2001; Whincup et al, 2002; Lowe et al, 2004) a 
reduced number of residual serum samples were available for cytokine assays in 2004-5; 
IL-18 (595 cases, 1238 controls), ΤΝFα (535 cases, 1155 controls), MMP-9 (465 cases, 
1067 controls), and sCD40L (464 cases, 1063 controls). IL-18 and TNFα were assayed 
as the priority, and hence have a greater amount of data. The baseline characteristics of 
subjects for whom serum samples were and were not available for the present study were 
not appreciably different from the original case-control study (p>0.10 for case-control 
proportion, age distribution, residential town proportions, social class proportions). 
 
6.3.2 IL-18 - Associations with Conventional Risk Markers, and with CHD Risk 
 
The set of samples on which IL-18 levels were measured (the largest) were used to 
compare established vascular risk factors between cases and controls. The established 
factors showed highly significant differences between cases and controls in the expected 
directions (Table 6.2), although diabetes was not associated with CHD events. This could 
be due to very small numbers of diabetics (total <2% of the population) and undiagnosed 
latent cases within the population. This configuration of conventional risk factor 
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associations with outcome was also evident in the sets of case and control samples used 
to measure the other inflammatory markers (data not shown). 
 
Table 6.2, shows that geometric mean IL-18 levels were significantly higher among cases 
than controls (proportional difference 9%, 95% CI 4 to 14% after age adjustment; 
p<0.001).  
 
Examining possible associations of IL-18 with conventional risk markers (which may 
confound the association of IL-18 with risk), Table 6.3 illustrates correlations of IL-18 
with other risk markers. Unsurprisingly, baseline IL-18 levels in the control population 
were strongly related to other inflammatory markers (CRP, IL-6 [both associations 
particularly strong], serum amyloid A, globulin, white cell count) and homocysteine as 
well as soluble cellular adhesion molecules (ICAM-1, VCAM-1, E-selectin, P-selectin) 
and haemostatic markers (vWF, fibrin D-dimer and t-PA), but not haematocrit (Table 
6.3). IL-18 levels were also related to components of the metabolic syndrome such as 
dyslipidaemia (triglycerides and HDL cholesterol), as well as demonstrating weak 
associations with BMI and insulin levels. Among other classical risk markers IL-18 was 
not related to age but was strongly related to smoking, and weakly with diastolic and 
systolic BP as well as socioeconomic markers (non-manual occupation) (Table 6.3). IL-
18 was not associated with evidence of CHD at entry to the study.  
 
In comparisons of men in the top third compared with those in the bottom third of 
baseline IL-18 levels, the age-adjusted odds ratio for coronary heart disease was 1.55 
(95% CI 1.21, 1.98) (Table 6.7).  Adjustment for cigarette smoking slightly attenuated 
this odds ratio, while additional adjustment for other vascular risk factors reduced the 
odds ratio to borderline significance: 1.30 (95% CI 0.99, 1.69).  Additional adjustment 
for other inflammatory markers (CRP and IL-6) attenuated the odds ratio to 1.12 (95% CI 
0.84, 1.49) and hence nearly abrogated the association.  The trend across thirds of IL-18 
distributions was highly significant in the unadjusted model (p=0.003), but was 
attenuated with each extra step in the analysis models due to decreasing association of IL-
18 with CHD, until the trend became non-significant in the final fully-adjusted model 
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(p=0.19). Repeating the analysis excluding men with established CHD had little material 
impact on the results, which is consistent with the absence of association with evidence 
of CHD at study entry (Table 6.3). 
 
6.3.3 TNFα - Associations with Conventional Risk Markers, and with CHD Risk             
Geometric mean TNFα levels were significantly lower among cases than controls 
(proportional difference -9%, 95% CI -2 to -16% after age adjustment; p=0.001) (Table 
6.2).  
As illustrated in Table 6.4, TNFα values showed positive associations with other 
inflammatory markers (CRP, IL-6, serum amyloid A, globulin, white cell count) 
homocysteine, and adhesion molecules (P-selectin, E-selectin, VCAM-1 and ICAM-1). 
Positive associations with haemostatic markers were limited to D-dimer and a borderline 
association with t-PA. There was a borderline inverse association with total cholesterol, 
although no association with other lipid markers was observed, or with other markers of 
the metabolic syndrome. TNFα had no associations with conventional risk markers: age, 
blood pressure, smoking, or evidence of baseline CHD. 
 
In comparisons of men in the top third versus the bottom third of the TNFα control 
distribution, the age-adjusted odds ratio for CHD was inverse; 0.74 (95% CI 0.57 – 0.95) 
(Table 6.8). Adjustment for smoking status and other conventional risk factors did not 
significantly attenuate the inverse relationship: 0.74 (95% CI 0.57 – 0.98), an observation 
consistent with an absence of TNFα associations with such markers (Table 6.4). Further 
adjustment for IL-6 and CRP levels strengthened the inverse relationship with CHD, due 
to positive associations of TNFα with these inflammatory risk markers; 0.66 (0.49 – 
0.88). None of the analysis models yielded a significant trend across thirds of the TNFα 
distribution (data not shown), with the top two thirds giving very similar odds ratios. 
Exclusion of men with evidence of baseline CHD had minimal effect on the odds ratio, 
but the inverse association became only borderline significant, due to widening of the 
confidence intervals with loss of statistical power. 
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6.3.4 MMP-9 - Associations with Conventional Risk Markers, and with CHD Risk           
Geometric mean MMP-9 levels were higher among cases than controls (proportional 
difference 7%, 95% CI 1 to 13% after age adjustment; p<0.03) (Table 6.2).  
Baseline MMP-9 levels in the control population were significantly positively associated 
with markers of systemic inflammation (CRP, IL-6, serum amyloid A, white cell count, 
and borderline with albumin) although not with homocysteine, most vascular adhesion 
molecules (E- and P-selectin, and ICAM-1, although not VCAM-1), and some 
haematological variables (haematocrit and fibrin D-dimer, but not t-PA or vWF) (Table 
6.5).  MMP-9 levels were inversely related to FEV1 and strongly related to smoking as 
well as showing increasing trends with alcohol intake. Although it was weakly related to 
non-fasting glucose, MMP-9 showed no relationship to any other markers of the 
metabolic syndrome, and was not associated with other established risk factors such as 
age, evidence of CHD at entry, body mass index, blood pressure, physical activity, or any 
lipid measurements (Table 6.5).  
 
In comparisons of men in the top third versus the bottom third of MMP-9 control 
distribution, the age-adjusted odds ratio for coronary heart disease was 1.37 (95% CI 1.04 
- 1.82) (Table 6.9). Adjustment for smoking status attenuated the result to borderline 
significance: 1.28 (95% CI 0.95 - 1.74), although further adjustment for other vascular 
risk factors did not attenuate the result further.   After further adjusting for CRP and IL-6 
levels in the final model the association was attenuated to null: 1.13 (95% CI 0.82 – 
1.56). None of the analysis models yielded a significant trend across thirds of the MMP-9 
distribution, including in the unadjusted model (data not shown). Exclusion of men with 
evidence of baseline CHD had little material effect on the odds ratios observed, although 
the confidence interval was wider with the lower numbers of subjects. 
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6.3.5 sCD40L - Associations with Conventional Risk Markers, and with CHD Risk              
Geometric mean sCD40L levels were borderline significantly lower among cases than in 
controls (proportional difference -7%, 95% CI -14% to +1% after age adjustment; 
p=0.068).  
As illustrated in Table 6.6, baseline sCD40L levels in the control population were 
significantly positively associated with white blood cell count (although not CRP, IL-6, 
serum amyloid A, albumin, or homocysteine) and were strongly associated with the 
haemostatic markers t-PA and D-dimer (Table 6.6). There was also a strong positive 
association with p-selectin levels (but not other adhesion molecules). Serum sCD40L had 
inverse associations with age, vWF, fasting glucose, and triglycerides, as well as a 
positive association with HDL cholesterol. Serum levels of sCD40L showed no 
associations with other established risk factors such as age, evidence of CHD at entry, 
BMI, blood pressure, physical activity, or smoking, although there was a slight positive 
relationship with alcohol consumption (Table 6.6).  
 
In comparisons of men in the top third versus the bottom third of sCD40L control 
distribution, the age-adjusted odds ratio for coronary heart disease was inverse; 0.75 
(95% CI 0.57 – 0.99) (Table 6.10). Adjustment for smoking status and other conventional 
risk factors attenuated this relationship to borderline significance: 0.77 (95% CI 0.57 - 
1.04). Further adjustment for CRP and IL-6 levels did not attenuate the odds ratio further: 
0.77 (95% CI 0.57 – 1.05). None of the analysis models yielded a significant trend across 
thirds of the sCD40L distribution (data not shown). Exclusion of men with evidence of 
baseline CHD had little material effect on the odds ratios observed, although the 
confidence interval was wider with the lower numbers of subjects: 0.83 (95% CI 0.54 – 
1.27). 
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6.3.6 4-Year Regression Dilutions Coefficients and Ratios of all Four Inflammatory 
Markers in Comparison to Previously Published Data 
As seen in Table 6.11, regression dilution coefficients ranged from 0.25 for TNFα 
(corresponding to 4-fold underestimate of risk associations on the log scale), while IL-18 
was more stable over the four years with a regression dilution coefficient of 0.71 
(corresponding to a 1.41-fold underestimate). Coefficients for MMP-9 and sCD40L were 
intermediate and very similar (0.46 and 0.47 respectively). Overall therefore, IL-18 was 
the least prone to drift in expression levels over the 4 years compared to any other 
inflammatory risk marker, including CRP or fibrinogen (Table 6.1), and demonstrated a 
regression dilution ratio comparable to that of the total:HDL cholesterol ratio (Emberson 
et al, 2004). Regression dilution coefficients for MMP-9 and sCD40L were comparable 
to CRP. TNFα was the least stable marker measured, with a coefficient similar to that of 
clinical measurements of non-fasting insulin (Emberson et al, 2004). Despite this, TNFα 
had an overall correlation at 4 years compared to baseline that was similar to both MMP-
9 and sCD40L.  
As a very crude illustration of the possible implications of the impact of regression 
dilution on risk associations, I include adjusted odds ratios (based on this BRH cohort) 
for regression dilution. It should be noted that because the study is prospectively followed 
up for 16 years (not 4 years), these estimates are still likely to be underestimates, and no 
95% confidence intervals are included for this reason; the figures are intended only as 
illustration as to the possible impact of regression dilution. 
Age- and sex- adjusted odds ratios in the top tertiles become: 
IL-18   OR 1.55 (1.21, 1.98)                                      OR 1.86 (1.31-2.62) 
TNFα   OR 0.74 (0.57, 0.95)                                      OR 0.30 (0.30-0.89) 
MMP-9  OR 1.37 (1.04, 1.82)                                      OR 1.98 (1.09-3.67) 
sCD40L  OR 0.75 (0.57, 0.99)                                      OR 0.54 (0.30-0.98) 
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Hence, correction for regression dilution suggests that IL-18 and MMP-9 may be 
positively associated with CHD risk, and TNFα and sCD40L negatively associated. 
Ideally, the effect of regression dilution would be assessed in fully adjusted models, 
although for these inferences to be correct, adjustments would be made for conventional 
risk factors also adjusted for regression dilution over the same period. This has not been 
possible here. 
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Table 6.2 Baseline characteristics of the case and control populations. Values are means (standard deviation) unless otherwise 
specified. Case control numbers for TNFα, MMP-9 and sCD40L are stated in the text 
 
 
 
 
 
 
 
 
 
* Indicates geometric mean after log transformation and back-transforming (95% CI) 
 
                                                                                                                                                                                                                               
 Cases (n=595) Controls (n=1238) p-value 
    
Age (years) 52.6 (5.2) 52.5 (5.3) matched 
Current smoker (n,%) 304 (51.2) 521 (42.2) 0.0003 
Evidence of coronary disease (n,%) 247 (41.5) 327 (26.4) <0.0001 
History of diabetes (n,%) 16 (2.7) 18 (1.5) 0.09 
>2 drinks alcohol/day (n,%) 120 (20.2) 278 (22.5) 0.26 
Non-manual occupation (n,%) 184 (32.3) 465 (38.7) 0.009 
Physical activity (inactive/occasional) (n,%) 275(46.7) 493(40.4) 0.011 
    
Physical measurements    
Body mass index (kg/m2) 25.9 ( 3.4) 25.4 ( 3.3) 0.0008 
Systolic blood pressure (mmHg) 151.8 (21.8) 146.7 (20.9) <0.0001 
Diastolic blood pressure (mmHg) 85.7 (13.8) 82.8 (13.2) <0.0001 
FEV1 (L/min) (adjusted for age & size) 3.10 (0.65) 3.21 ( 0.71) 0.002 
    
Blood sample    
Total cholesterol (mmol/L) 6.64 (1.06) 6.20 (0.99) <0.0001 
HDL cholesterol (mmol/L) 1.09 (0.27) 1.15 (0.27) <0.0001 
Triglyceride (mmol/L)* 1.95(0.69, 5.51) 1.70(0.57, 5.02) <0.0001 
C-reactive protein (mg/L)* 2.51(0.30, 20.95) 1.45(0.14, 15.11) <0.0001 
Interleukin-6 (pg/ml)* 2.75(0.81, 9.32) 2.29(0.65, 8.11) <0.0001 
Interleukin-18 (pg/ml)* 302 (117,  779) 275 (107, 711) 0.0007 
TNFα (pg/ml)* 0.93(0.22, 3.96) 1.02(0.25, 4.15) 0.01 
MMP-9 (pg/ml)* 741 (275,  2001) 692 (245, 1953) 0.026 
sCD40L (pg/ml)* 257 (63, 1041) 275 (65, 1167) <0.0001 
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Table 6.3 Relation of IL-18 (thirds) with other cardiovascular risk factors in controls 
                                                                                                                   Tertiles of IL-18 
Tertile Low  Middle  High   
Range (pg/ml) 
 
(29-233) 
n=411 
 
(234-345) 
n=413 
 
(346-2068) 
n=414 
  
 Mean se Mean se Mean se p-trend 
Age 52.5 0.3 52.1 0.3 52.8 0.3 0.61 
current smoker (n) 133 32.4 188 45.7 200 48.3 <0.0001 
>2 drinks alcohol/day (n) 98 23.8 86 20.9 94 22.7 0.56 
Evidence of CHD at entry (n) 106 25.8 113 27.4 108 26.1 0.77 
History of diabetes at baseline (n) 7 1.7 6 1.5 6 1.5 0.77 
Non-manual occupations (n) 181 45.1 145 36.4 139 34.3 0.02 
Physical Activity (inactive/occasional) (n) 152 37.7 169 41.6 172 41.8 0.66 
Body mass index (kg/m2) 25.1 0.2 25.5 0.2 25.6 0.2 0.05 
Systolic blood pressure (mmHg) 144.6 1.0 146.9 1.0 148.4 1.0 0.03 
Diastolic blood pressure (mmHg) 81.0 0.6 83.8 0.6 83.4 0.6 0.02 
FEV1 (L/min) (adjusted for age & size) 3.26 0.04 3.20 0.04 3.16 0.04 0.62 
Total cholesterol (mmol/L) 6.14 0.05 6.23 0.05 6.21 0.05 0.39 
HDL cholesterol (mmol/L) 1.20 0.01 1.15 0.01 1.11 0.01 <0.0001 
Triglyceride (mmol/L)* 0.19 0.01 0.22 0.01 0.26 0.01 0.0001 
Insulin (mU/L) 1.07 0.02 1.05 0.02 1.13 0.02 0.03 
Glucose (mmol/L) 0.74 0.004 0.74 0.004 0.74 0.004 0.69 
von Willebrand Factor (IU/dL) 2.00 0.01 2.01 0.01 2.05 0.01 <0.0001 
Fibrin D-dimer (ng/ml) 1.86 0.02 1.88 0.02 1.93 0.02 0.01 
t-PA (ng/ml) 0.97 0.01 1.01 0.01 1.06 0.01 <0.0001 
Haematocrit (%) 41.91 0.45 42.79 0.45 42.45 0.45 0.7 
Albumin (g/L) 44.7 0.1 44.6 0.1 44.3 0.1 0.003 
Globulin (g/L) 28.9 0.2 28.9 0.2 29.3 0.2 0.1 
White cell count (109/L) 0.81 0.02 0.83 0.02 0.88 0.02 0.003 
Serum amyloid A protein (mg/L) 0.83 0.01 0.85 0.01 0.85 0.01 0.01 
Homocysteine (mmol/L) 1.10 0.01 1.12 0.01 1.16 0.01 0.01 
E-selectin (ng/ml) 1.74 0.01 1.77 0.01 1.82 0.01 <0.0001 
P-selectin (ng/ml) 2.00 0.01 2.01 0.01 2.07 0.01 0.001 
ICAM-1 (ng/ml) 2.43 0.01 2.47 0.01 2.52 0.01 <0.0001 
VCAM-1 (ng/ml) 2.62 0.01 2.64 0.01 2.66 0.01 0.01 
C-reactive protein (mg/L) 0.05 0.03 0.15 0.03 0.30 0.03 <0.0001 
IL-6 (pg/ml) 0.31 0.01 0.36 0.01 0.41 0.01 <0.0001 
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Table 6.4 Relation of TNFα (thirds) with other cardiovascular risk factors in controls  
 
                                                                                                                   Tertiles of TNFα 
Tertile Low  Middle  High   
Range (pg/ml) 
 
(0.05-0.76) 
n=389 
 
(0.77-1.16) 
n=384 
 
(1.17-30.0) 
n=382 
  
 Mean se Mean se Mean se p-trend 
Age 52.4 0.3 52.6 0.3 52.5 0.3 0.92 
current smoker (n) 159 41.0 160 41.7 164 43.0 0.53 
>2 drinks alcohol/day (n) 83 21.3 90 23.5 88 23.0 0.99 
Evidence of CHD at entry (n) 87 22.4 107 27.9 107 28.0 0.16 
History of diabetes at baseline (n) 5 1.3 7 1.8 5.0 1.3 n/a 
Non-manual occupations (n) 158 41.9 138 36.7 138.0 37.3 0.32 
Physical Activity (inactive/occasional) (n) 143 37.3 154 41.1 160.0 42.1 0.25 
Body mass index (kg/m2) 25.2 0.2 25.5 0.2 25.4 0.2 0.45 
Systolic blood pressure (mmHg) 145.4 1.1 146.9 1.1 147.3 1.1 0.26 
Diastolic blood pressure (mmHg) 82.1 0.7 83.0 0.7 83.3 0.7 0.24 
FEV1 (L/min) (adjusted for age & size) 3.25 0.0.4 3.16 0.04 3.23 0.04 0.96 
Total cholesterol (mmol/L) 6.26 0.05 6.18 0.05 6.14 0.05 0.07 
HDL cholesterol (mmol/L) 1.16 0.01 1.16 0.01 1.15 0.01 0.33 
Triglyceride (mmol/L)* 0.21 0.01 0.23 0.01 0.23 0.01 0.40 
Insulin (mU/L) 1.06 0.02 1.08 0.02 1.09 0.02 0.38 
Glucose (mmol/L) 0.743 0.004 0.740 0.004 0.737 0.004 0.23 
von Willebrand Factor (IU/dL) 2.01 0.01 2.03 0.02 2.00 0.01 0.26 
Fibrin D-dimer (ng/ml) 1.85 0.02 1.90 0.02 1.92 0.02 0.01 
t-PA (ng/ml) 1.00 0.01 1.02 0.01 1.03 0.01 0.09 
Hematocrit (%) 42.50 0.50 42.90 0.50 41.8 0.50 0.22 
Albumin (g/L) 44.6 0.1 44.5 0.1 44.3 0.1 0.14 
Globulin (g/L) 28.5 0.2 29.1 0.2 29.5 0.2 <0.0001 
White cell count (109/L) 0.83 0.01 0.84 0.01 0.86 0.01 0.0002 
Serum amyloid A protein (mg/L) 0.81 0.02 0.86 0.02 0.87 0.02 0.03 
Homocysteine (mmol/L) 1.09 0.01 1.23 0.01 1.16 0.02 0.01 
E-selectin (ng/ml) 1.75 0.01 1.76 0.01 1.81 0.01 <0.0001 
P-selectin (ng/ml) 1.98 0.01 2.02 0.01 2.08 0.01 <0.0001 
ICAM-1 (ng/ml) 2.45 0.01 2.48 0.01 2.49 0.01 0.001 
VCAM-1 (ng/ml) 2.62 0.01 2.64 0.01 2.64 0.01 0.01 
C-reactive protein (mg/L) 0.06 0.03 0.180 0.03 0.22 0.03 0.001 
IL-6 (pg/ml) 0.30 0.01 0.36 0.01 0.42 0.01 <0.0001 
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Table 6.5 Relation of MMP-9 (thirds) with other cardiovascular risk factors in controls 
                                                                                                                   Tertiles of MMP-9 
Tertile Low  Middle  High   
Range (ng/ml) 
 
(70-555) 
n=358 
 
(556-872) 
n=359 
 
(873-3500) 
n=359 
  
 Mean se Mean se Mean se p-trend 
Age (years) 52.1 0.3 52.6 0.3 52.5 0.3 0.27 
Current smoker (n) 123 34.4 134 37.3 194 54.2 <0.0001 
>2 drinks alcohol/day (n) 74 20.7 71 19.8 94 26.3 0.04 
Evidence of CHD at entry (n) 91 25.4 81 22.6 104 29.0 0.40 
History of diabetes at baseline (n) 2 0.6 7 2.0 7 2.0 n/a 
Non-manual occupation (n) 137 39.3 133 37.7 130 37.7 0.44 
Physical activity (inactive/occasional) (n) 138 38.9 143 40.4 149 42.5 0.51 
Body Mass index (kg/m2) 25.5 0.2 25.5 0.2 25.1 0.2 0.11 
Systolic blood pressure (mmHg) 146.9 1.1 147.6 1.1 145.0 1.1 0.41 
Diastolic blood pressure (mmHg) 83.5 0.7 83.2 0.7 81.9 0.7 0.23 
FEV1 (L/min) (adjusted for age & size) 3.30 0.04 3.25 0.04 3.09 0.04 0.002 
Total cholesterol (mmol/L) 6.24 0.05 6.18 0.05 6.14 0.05 0.18 
HDL cholesterol (mmol/L) 1.15 0.01 1.15 0.01 1.16 0.01 0.63 
Triglyceride (mmol/L) 0.21 0.01 0.22 0.01 0.24 0.01 0.12 
Insulin (mU/L) 1.08 0.02 1.10 0.02 1.05 0.02 0.21 
Glucose (mmol/L) 0.745 0.004 0.743 0.004 0.73 0.004 0.032 
Von Willebrand factor (IU/dL) 2.01 0.01 2.02 0.01 2.02 0.01 0.49 
Fibrin D-dimer (ng/ml) 1.83 0.02 1.86 0.02 1.96 0.02 <0.0001 
t-PA (ng/ml) 1.00 0.01 1.00 0.01 1.03 0.01 0.61 
Haematocrit (%) 43.10 0.17 44.20 0.17 44.70 0.17 <0.0001 
Albumin (g/L) 44.7 0.1 44.5 0.1 44.3 0.1 0.07 
Globulin (g/L) 29.1 0.2 29.0 0.2 29.0 0.2 0.48 
White cell count (‘109/L) 0.79 0.01 0.84 0.01 0.90 0.01 <0.0001 
Serum amyloid A protein (mg/L) 0.80 0.02 0.85 0.02 0.90 0.02 <0.0001 
Homocysteine (mmol/L) 1.12 0.01 1.13 0.02 1.12 0.02 0.61 
E-selectin (ng/ml) 1.76 0.01 1.77 0.01 1.80 0.01 0.002 
P-selectin (ng/ml) 1.94 0.01 2.04 0.01 2.09 0.01 <0.0001 
ICAM-1 (ng/ml) 2.45 0.01 2.46 0.01 2.50 0.01 <0.0001 
VCAM-1 (ng/ml) 2.64 0.01 2.63 0.01 2.62 0.01 0.14 
CRP (mg/L) 0.09 0.03 0.13 0.03 0.28 0.03 <0.0001 
IL-6 (ng/ml) 0.27 0.01 0.36 0.01 0.44 0.01 <0.0001 
235 
  236
 
Table 6.6 Relation of sCD40L (thirds) with other cardiovascular risk factors in controls  
                                                                                                                   Tertiles of sCD40L 
Tertile Low  Middle  High   
Range (ng/ml) 
(9-206) 
n=359 
 
(207-386) 
n=356 
 
(387-2500) 
n=358 
  
 Mean se Mean se Mean se p-trend 
Age (years) 52.8 0.3 52.4 0.3 52.1 0.3 0.06 
Current smoker (n) 144 40.1 147 41.4 158 55.9 0.39 
>2 drinks alcohol/day (n) 64 17.9 78 21.9 95 26.5 0.02 
Evidence of CHD at entry (n) 87 24.2 94 26.4 94 26.3 0.68 
History of diabetes at baseline (n) 5 1.4 6 1.7 5 1.4 n/a 
Non-manual occupation (n) 133 37.9 140 40.8 126 36.0 0.79 
Physical activity (inactive/occasional) (n) 134 37.6 153 43.7 142 40.3 0.62 
Body Mass index (kg/m2) 25.4 0.2 25.1 0.2 25.6 0.2 0.78 
Systolic blood pressure (mmHg) 146.4 1.1 147.1 1.1 146.0 1.1 0.69 
Diastolic blood pressure (mmHg) 83.0 0.7 82.9 0.7 82.6 0.7 0.77 
FEV1 (L/min)(adjusted for age & size) 3.23 0.04 3.27 0.04 3.15 0.04 0.27 
Total cholesterol (mmol/L) 6.19 0.05 6.21 0.05 6.16 0.05 0.62 
HDL cholesterol (mmol/L) 1.13 0.01 1.15 0.01 1.18 0.01 0.01 
Triglyceride (mmol/L) 0.24 0.01 0.22 0.01 0.21 0.01 0.01 
Insulin (mU/L) 1.10 0.02 1.04 0.02 1.09 0.02 0.27 
Glucose (mmol/L) 0.752 0.004 0.737 0.004 0.731 0.004 0.0002 
von Willebrand Factor (IU/dL) 2.04 0.01 2.01 0.01 2.01 0.01 0.02 
Fibrin D-dimer (ng/ml) 1.82 0.02 1.85 0.02 1.97 0.02 <0.0001 
t-PA (ng/ml) 0.98 0.01 1.00 0.01 1.05 0.01 <0.0001 
Hematocrit (%) 43.80 0.17 43.90 0.17 44.30 0.17 0.21 
Albumin (g/L) 44.4 0.1 44.4 0.1 44.6 0.1 0.18 
Globulin (g/L) 29.0 0.2 29.1 0.2 29.1 0.2 0.50 
White cell count (109/L) 0.83 0.01 0.84 0.01 0.86 0.01 <0.0001 
Serum amyloid A protein (mg/L) 0.85 0.02 0.83 0.02 0.86 0.02 0.92 
Homocysteine (mmol/L) 1.14 0.01 1.09 0.01 1.15 0.02 0.50 
E-selectin (ng/ml) 1.77 0.01 1.76 0.01 1.80 0.01 0.20 
P-selectin (ng/ml) 1.92 0.01 2.04 0.01 2.11 0.01 <0.0001 
ICAM-1 (ng/ml) 2.46 0.01 2.47 0.01 2.48 0.01 0.21 
VCAM-1 (ng/ml) 2.64 0.01 2.63 0.01 2.63 0.01 0.51 
C-reactive protein (mg/L) 0.16 0.03 0.11 0.03 0.22 0.03 0.17 
IL-6 (pg/ml) 0.37 0.01 0.37 0.01 0.36 0.01 0.88 
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Table 6.7 Odds ratio (95% CI) of coronary heart disease in men who had values of IL-18 in the top third of the distribution of controls 
relative to those who had values in the bottom third. 
 
All 595 cases and 1238 controls: 
 
 
267 cases and 798 controls without baseline evidence of coronary heart disease 
*blood pressure, total cholesterol, HDL cholesterol, body mass index, history of diabetes, baseline CHD, social class, physical activity 
† IL-6 and CRP fitted as logged variables 
‡ Only included where significant in unadjusted model in Tables 6.6-6.9 
Trends fitted using IL-18 as a continuous variable 
 
IL-18 values (pg/ml) Cases Controls Odds ratio (95% CI) adjusted for: 
Tertiles N N Age and town only 
Age, town and 
smoking status 
Age, town, smoking 
& risk factors* 
Age, town smoking, 
risk factors* and 
inflammation† 
346-2068 242 414 1.55 (1.21, 1.98) 1.48(1.15, 1.90) 1.30 (0.99, 1.69) 1.12 (0.84, 1.49) 
234-345 193 413 1.24 (0.96, 1.59) 1.19 (0.92, 1.54) 1.06 (0.81, 1.39) 1.04 (0.78, 1.38) 
29-233 160 411 1 1 1 1 
Total 595 1238     
p-trend‡   0.003 0.008 0.03 0.19 
IL-18 values (ng/ml) Cases Controls Odds ratio (95% CI) adjusted for: 
Tertiles N N Age and town only 
Age, town and 
smoking status 
Age, town, smoking 
& risk factors* 
Age, town smoking, 
risk factors* and 
inflammation† 
346-2068 150 306 1.63 (1.19 2.22) 1.53 (1.12, 2.10) 1.29 (0.92, 1.80) 1.11 (0.77, 1.50) 
234-345 105 300 1.16 (0.84 1.60) 1.09 (0.79, 1.52) 1.03 (0.73, 1.46 ) 1.05 (0.73, 1.51) 
47-233 93 305 1 1 1 1 
Total 348 911     
p-trend‡   0.03 0.06 0.34 0.76 
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Table 6.8 Odds ratio (95% CI) of coronary heart disease in men who had values of TNFα in the top third of the distribution of controls 
relative to those who had values in the bottom third. 
 
All 535 cases and 1155 controls: 
 
 
310 cases and 854 controls without baseline evidence of coronary heart disease 
 
*blood pressure, total cholesterol, HDL cholesterol, body mass index, history of diabetes, baseline CHD, social class, physical activity 
† IL-6 and CRP fitted as logged variables 
 
 
TNFα values (ng/ml) Cases Controls Odds ratio (95% CI) adjusted for: 
Tertiles N N Age and town only 
Age, town and 
smoking status 
Age, town, smoking 
& risk factors* 
Age, town smoking, 
risk factors* and 
inflammation † 
1.17-30.0 156 382 0.74(0.57, 0.95) 0.74 (0.57, 0.96) 0.74 (0.57, 0.98) 0.66 (0.49, 0.88) 
0.77-1.16 164 384 0.75 (0.59, 0.97) 0.75 (0.59, 0.97) 0.75 (0.57, 0.98) 0.72 (0.54, 0.95) 
0.05-0.76 215 389 1 1 1 1 
Total 535 1155     
TNFα values (ng/ml) Cases Controls Odds ratio (95% CI) adjusted for: 
Tertiles N N Age and town only 
Age, town and 
smoking status 
Age, town, smoking 
& risk factors* 
Age, town smoking, 
risk factors* and 
inflammation† 
387-2500 93 275 0.81 (0.59, 1.12) 0.82 (0.60, 1.13) 0.87 (0.62, 1.22) 0.77 (0.54, 1.10) 
207-386 91 277 0.79 (0.57, 1.09) 0.78 (0.57, 1.08) 0.80 (0.57, 1.12) 0.77 (0.55, 1.10) 
9-206 126 302 1 1 1 1 
Total 310 854     
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Table 6.9 Odds ratio (95% CI) of coronary heart disease in men who had values of MMP-9 in the top thirds of the distribution of 
controls relative to those who had values in the bottom third. 
 
All 465 cases and 1076 controls: 
 
 
 
268 cases and 800 controls without baseline evidence of coronary heart disease 
*blood pressure, total cholesterol, HDL, body mass index, history of diabetes, CHD, social class, physical activity 
† IL-6 and CRP fitted as logged variables 
MMP-9 values (ng/ml) Cases Controls Odds ratio (95% CI) adjusted for: 
Tertiles N N Age and town only 
Age, town and 
smoking status 
Age, town, smoking 
& risk factors* 
Age, town smoking, 
risk factors* and 
inflammation † 
873-3500 184 359 1.37 (1.04, 1.82) 1.27 (0.96, 1.69) 1.28 (0.95, 1.74) 1.13 (0.82, 1.56) 
556-872 146 359 1.03 (0.77, 1.38) 1.01 (0.75, 1.35) 1.00 (0.73, 1.36) 1.01 (0.74, 1.14) 
70-555 135 358 1 1 1 1 
Total 465 1076     
MMP-9 values (ng/ml) Cases Controls Odds ratio (95% CI) adjusted for: 
Tertiles N N Age and town only 
Age, town and 
smoking status 
Age, town, smoking 
& risk factors* 
Age, town smoking, 
risk factors* and 
inflammation † 
873-3500 104 255 1.29 (0.94, 1.84) 1.17 (0.81, 1.67) 1.24 (0.85, 1.82) 1.07 (0.72, 1.61) 
556-872 78 278 0.80 (0.55, 1.16) 0.79 (0.54, 1.14) 0.81 (0.54, 1.19) 0.82 (0.55, 1.23) 
70-555 86 267 1 1 1 1 
Total 268 800     
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Table 6.10 Odds ratio (95% CI) of coronary heart disease in men who had values of sCD40L in the top third of the distribution of 
controls relative to those who had values in the bottom third. 
 
All 464 cases and 1073 controls: 
 
 
 
 
*blood pressure, total cholesterol, HDL cholesterol, body mass index, history of diabetes, baseline CHD, social class, physical activity 
† IL-6 and CRP fitted as logged variables 
sCD40L values (ng/ml) Cases Controls Odds ratio (95% CI) adjusted for: 
Tertiles N N Age and town only 
Age, town and 
smoking status 
Age, town, smoking 
& risk factors* 
Age, town smoking, 
risk factors* and 
inflammation † 
387-2500 135 358 0.75(0.57, 0.99) 0.74 (0.56, 0.97) 0.77(0.57, 1.04) 0.77 (0.57, 1.05) 
207-386 150 356 0.87(0.66, 1.13) 0.87(0.66, 1.14) 0.86(0.65, 1.15) 0.88 (0.66, 1.18) 
9-206 179 359 1 1 1 1 
Total 464 1073     
sCD40L values (ng/ml) Cases Controls Odds ratio (95% CI) adjusted for: 
Tertiles N N Age and town only 
Age, town and 
smoking status 
Age, town, smoking 
& risk factors* 
Age, town smoking, 
risk factors* and 
inflammation † 
387-2500 78 264 0.77 (0.57, 1.10) 0.74 (0.54, 1.10) 0.80 (0.55, 1.16) 0.79 (0.54, 1.17) 
207-386 89 262 0.93 (0.66, 1.30) 0.95 (0.68, 1.34) 0.88 (0.61, 1.26) 0.90 (0.62, 1.30) 
9-206 100 272 1 1 1 1 
Total 267 798     
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Table 6.11 Comparison of 4-year regression dilution ratios of MMP-9, sCD40L, IL-18 and 
TNFα with previously published results for other inflammatory and conventional risk markers 
(Emberson et al, 2004). 
 
No of pairs 
observations 
Regression 
dilution 
coefficient 
Regression 
dilution ratio 
(1/RD coeff) 
Correlation 
(Spearman) r 
IL-18 158 0.71 1.41 0.74 
TNFα 158 0.25 4.00 0.36 
MMP-9 138 0.46 2.17 0.49 
sCD40L 138 0.47 2.13 0.32 
     
CRP 297 0.52 1.92 n/a 
Fibrinogen 297 0.61 1.64 n/a 
     
Total:HDL cholesterol 
ratio 
297 0.77 1.30 
n/a 
Systolic BP 297 0.61 1.64 n/a 
n/a – data not available 
 
 
 
 
 
 
 
 
 
  242
 
6.4 DISCUSSION 
6.4.1 Population Distributions of IL-18 and TNFα and Viability of Samples                                                          
The IL-18 levels among the control population (median 283 pg/ml [IQR 204-381]) were 
comparable to the median levels in the appropriate age groups of the MONICA-4 study 
(45-64 years ~251 pg/ml in men). This observation suggests that the BRH study samples 
are suitable for the measurement of IL-18 despite sample age and previous thaws. The 
comparison of this population with MONICA-4 also supports observations that the 
median IL-18 level among CHD cases in this study is higher than expected in middle-
aged men (308 pg/ml [224-406]). 
In contrast to IL-18, TNFα levels in this cohort (both cases and controls) were very much 
lower (around half) compared to those observed in the eldest age group of the MONICA-
4 study (median 0.92 pg/ml [IQR 0.69-1.36] among BRH study controls compared to 
1.90 pg/ml [1.50, 2.35] in MONICA-4). Despite this, the range of the 95% confidence 
intervals between in controls in the BRH study (0.25 – 4.15 pg/ml) is actually reasonably 
similar to the eldest age group in MONICA-4 (1.10 - 4.26 pg/ml). This suggests the data 
is skewed by an increased number of low observations in the current study. The reasons 
for this are not clear, but the possibility of sample degradation over time is hard to 
exclude. These observations are further discussed in Chapter 12.  
6.4.2 General Observations                                                                                                       
Before making general conclusions it is important to establish the relative strengths and 
limitations of the current study. Firstly, it is a large and powerful case - control study 
within a well-defined and established cohort of relatively unselected (male gender of age 
40-59 selected from GP practices in one of 24 selected towns, but no medical exclusion 
criteria), demographically representative middle-aged men. For this reason it was an 
ideal, powerful resource to assess inflammatory markers as potential novel risk markers. 
Indeed, at the outset of this thesis (and even to date), the number of cases in this study 
made it the most powerful case - control study performed on any of these markers, even 
including studies examining total CVD events as end-points.  
The potential limitations of the study lie in the quality of the serum samples used. While 
there is no question that the samples were obtained within rigorous guidelines, they are 
however old (>25 years) and have been thawed and re-frozen on a number of occasions 
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(~4-5 occasions), and the concession must be made that this may have unknown (and 
practically un-testable) effects on results obtained for any given marker dependant on its 
relative chemical stability. The thesis demonstrated in a preliminary study in Chapter 3 
that the effects of storage (and indeed freeze-thaw cycles), although not negligible, 
appeared uniform on all samples tested in 10 normal people. However, extrapolating 
these preliminary, limited results to the BRH study is quite a proposition. Supporting the 
validity of the study, it has been shown that the IL-18 levels within controls in this 
population is comparable to those in the appropriate age groups for men in the MONICA-
4 cohort, in which the plasma samples are much newer, and have been subjected to fewer 
freeze-thaws. The direct comparison of TNFα levels between the studies however shows 
different median values. There is no such opportunity for comparison for MMP-9 and 
sCD40L, although the levels obtained here are much lower (particularly for sCD40L) 
than those seen in the ten normal people in Chapter 3.  
6.4.3 IL-18, Risk Factor Correlations, and Risk of CHD in Middle-Aged Men                            
In the present study, circulating IL-18 was strongly related to cigarette smoking and with 
level of triglyceride and HDL-cholesterol (inversely) in the control population. It was 
also associated with the inflammatory markers IL-6, C-reactive protein and other acute 
phase markers (including haemostatic factors) and adhesion molecules. In contrast to 
MONICA-4 there was no correlation with age, which is probably due to the narrow age 
range of BRH study subjects. There were also only weak associations with BMI and non-
fasting insulin levels. IL-18 is generally thought to correlate with markers of the 
metabolic syndrome, although the present results and some more recent observations may 
question the strength of the association between IL-18 and BMI (see 4.4.2) and these 
men, were studied in 1978-80, when obesity was less prevalent in Great Britain compared 
to other recent studies. This weak association does not preclude a role for IL-18 in the 
metabolic syndrome, IL-18 may predict the risk of incident type II diabetes after 
adjustment for conventional CVD risk markers (Thorland et al, 2005). The association of 
IL-18 with metabolic syndrome markers will be considered in more detail in future 
chapters. 
The results of the present study suggest that any independent association between IL-18 
and CHD risk in middle-aged men is modest.  Baseline circulating IL-18 concentrations 
were positively associated with CHD risk on univariable analysis. The strength of 
independent association between IL-18 and CHD is (OR 1.3) is more marginal than the 
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increased risk of ~1.8  reported from a smaller previous nested case control study of 
middle-aged men (Blankenberg et al, 2003).  In our study (unlike that of Blankenberg) 
the association between IL-18 and CHD risk, although borderline after adjusting for 
conventional risk markers, was effectively abolished after adjustment for CRP and IL-6.  
IL-18 is, as previously discussed, pivotal in innate and adaptive Th1 inflammatory 
responses, and is present in human atherosclerotic lesions, and at higher concentrations in 
unstable plaques (Mallat et al, 2001).  In animal models, IL-18 administration leads to 
increases in atherosclerotic lesion size and promotes increased numbers of T-
lymphocytes in the lesion (Whitman et al, 2002).  Despite this, absence of independent 
association with risk of CHD here does not add strong evidence to a role for IL-18 in 
atherogenesis. Our results are in broad agreement with recent results in the 
MONICA/KORA study of men and women (see table 1.6), where IL-18 was associated 
with ~1.4 increased risk (top versus bottom tertile) of CHD in a healthy population, but 
the risk was abrogated on adjustment for confounders (Koenig et al, 2006). However, 
more data is needed in other population cohorts to explore these results further. 
 
6.4.3 TNFα, Risk Factor Correlations, and Risk of CHD in Middle-Aged Men      
Baseline circulating levels of serum TNFα in the control population were positively 
associated with markers of inflammation as expected. A borderline inverse association 
with total cholesterol was noted, although no association with other lipid markers, or 
indeed any other conventional risk factors was observed. This profile of associations with 
other markers is very similar to that noted by another recent study, including no 
association with conventional risk markers, and a weak inverse association with total 
cholesterol (Tuomisto et al, 2006), although they also reported an inverse association 
with HDL cholesterol (non significant trend noted in BRH Study). In general, absence of 
strong associations of TNFα with conventional risk factors have been reported elsewhere 
(Ridker et al, 2000, 2Cesari et al, 2003, Tuomisto et al, 2006). 
Considering the weight of evidence that TNFα is associated with adipose tissue and the 
metabolic syndrome (Kern et al, 1995; Hotamisligil et al, 1995; Jovinge et al, 1998; Borst 
et al, 2004) it may be somewhat surprising that there was no observed association with 
BMI, insulin resistance or fasting glucose levels. This lack of association with metabolic 
syndrome markers was also noted for IL-18. Similarly there was no association of TNFα 
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with age. As with IL-18, this may be due to the narrow age range of the subjects. The 
MONICA-4 study (Chapter 4) found significant but weak associations of TNFα with 
both BMI and WHR, and results in other prospective studies (Tuomisto et al, 2006) are 
generally in agreement with this. As discussed for IL-18, the BRH study men were 
studied in 1978-1980 when obesity was less prevalent in Great Britain compared to other 
recent studies, so within the “normal” weight range circulating TNFα levels are poorly 
related to fat mass (measured by BMI or WHR), despite it being the prototypic adipokine 
(Hotamisligil et al, 1993). 
Interestingly, this study has demonstrated an inverse association between thirds of TNFα 
levels and risk of incident CHD among middle aged men over a 20 year follow-up. The 
observation was only borderline significant on univariable analysis (0.74), but became 
stronger (0.66) after correcting for TNFα’s positive associations with inflammatory risk 
markers and limited associations with conventional risk markers. It is hard to reconcile 
this observation with previous data (Table 1.4). A previous study found that only those 
with very high TNFα expression (population top 10%) were at risk for recurrent MI 
(Ridker et al, 2000), and non-linear associations of TNFα with risk of CHD have been 
found recently elsewhere (Tuomisto et al, 2006). Other published data, both in people 
with prevalent CVD and in normal populations is conflicting, probably partially due to 
low statistical power generally. It remains possible that this is a chance finding, although 
the confidence intervals in the fully adjusted model are reasonably convincing to the 
contrary (0.49-0.88). These findings require further investigation, which will be 
performed in future chapters. 
6.4.4 MMP-9, Risk Factor Correlations, and Risk of CHD in Middle-Aged Men          
Baseline circulating levels of MMP-9 were positively associated with circulating markers 
of inflammation, inversely related to FEV1, and strongly associated with smoking. MMP-
9 did not associate with most major CVD risk factors (BMI, blood pressure and 
cholesterol). These results are in broad agreement with the other reasonably powered 
prospective published study to date (2Blankenberg et al, 2003). 
The elevated levels of MMP-9 observed in current smokers (who are at increased CHD 
risk) are of particular interest, because they may reflect greater expression of MMP-9 in 
tissues including arterial plaques, thus increasing the risk of plaque rupture.  A previous 
study of MMP-9 risk with CHD has also shown an association with smoking 
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(Blankenberg et al, 2003), and mouse models have shown MMP-9 to be increased with 
smoke exposure in a TNFα-dependant manner (2Wright et al, 2007).  
 
The univariable analysis showed that MMP-9 was associated with risk of incident CHD 
(OR 1.37, 95% CI 1.04-1.82), but this was heavily attenuated after adjusted for smoking 
(1.28, 95% CI, 0.95-1.74), although not by other conventional risk markers. The residual 
borderline association was nearly abrogated after adjustment for IL-6 and CRP.  These 
findings suggest that MMP-9 has a moderate association with incident CHD in the 
general population, which is largely dependent on smoking and is also confounded by 
markers of the acute phase response.  
 
The present study suggests a much more modest association of MMP-9 with incident 
CHD than that previously reported in a cohort of patients with unstable angina 
(2Blankenberg et al, 2003), possibly because such patients have a higher prevalence of 
unstable coronary artery plaques than the general population. The major hypothesized 
role of MMP-9 in CHD is in promoting plaque rupture, rather than directly in 
atherogenesis (see 1.5.4). It is interesting to speculate that MMP-9 may be a weaker 
marker of CHD risk in a generally healthy cohort than in those with established arterial 
disease who are often smokers. This is suggested in Table 1.8, where it is seen that one 
sizeable and one small study found significant independent associations in populations 
with prevalent disease (2Blankenberg et al, 2003; Eldrup et al, 2006) (although two other 
very small studies found no association), whereas the present study only finds a modest 
association dependant on smoking and classical risk markers a general population. These 
observations are consistent with a hypothesized role of MMP-9 to de-stabilise established 
plaques rather than to directly stimulate atherogenesis. They are also in agreement with 
other data showing that production of MMP-9 is higher in phenotypically unstable than 
stable plaques (Galis et al, 1994; Loftus et al, 2000; Sluijter et al, 2006). The BRH study 
shows some decrease in MMP-9 univariable risk associated with CHD when excluding 
those with baseline CHD (OR 1.29 vs 1.37), which would be consistent with this 
hypothesis, but the study is somewhat underpowered to make this observation. 
 
Alternatively, discrepancies in results in the current study (compared to 2Blankenberg et 
al, 2003) may reflect its greater size and hence more power and “regression to the mean”, 
or may reflect the use of serum here, which may, according to some sources, be a 
artefactual confounder of the association with CHD (Gerlach et al, 2007). As discussed 
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previously (see 1.5.5) Gerlach et al suggest that MMP-9 levels should not be measured in 
serum samples due to such measurements “not being representative of circulating plasma 
levels of MMP-9.” However, in the present study serum levels of MMP-9 still show an 
association with CHD and correlate with conventional risk markers, in a manner broadly 
similar to Blankenberg et al, 2003, suggesting serum levels are not merely an in vitro 
artifact.  
 
6.4.5 sCD40L, Risk Factor Correlations, and Risk of CHD in Middle-Aged Men 
 
Baseline circulating serum levels of sCD40L showed expected positive correlations with 
some other risk markers, particularly white blood cell count, and were also associated 
with circulating levels of P-selectin (Heeschen et al, 2003; Yan et al, 2004), which is a 
marker of platelet activation, as well as with D-dimer and t-PA. However, inverse 
associations were observed with some other CHD risk markers: vWF, fasting glucose, 
and triglycerides, as well as a positive association with HDL cholesterol. These 
associations are generally the reverse of that expected from a pro-inflammatory marker, 
and although the associations are not particularly strong, they are statistically significant. 
There were no associations with the more classical risk markers such as blood pressure, 
BMI, CHD at entry, physical activity, smoking or with age. 
 
sCD40L was inversely associated with incident CHD on univariable analysis, to a similar 
degree seen in TNFα, and the relationship was not attenuated by age, town and smoking 
adjustment (~26%). The relationship became borderline significant after adjustment for 
classical risk markers, but was not attenuated by further adjustment for inflammatory risk 
markers. These results showing a borderline inverse association between serum sCD40L 
and CHD are consistent with a recently published study of the serum of people with 
prevalent vascular disease (Tanne et al, 2006), which also found a non-significant inverse 
association. These are the only two prospective studies reported in serum; all other 
studies in plasma have shown a positive relationship with CHD risk (see Table 1.10). It is 
difficult to compare these results directly to publications of plasma samples, due to the 
generally smaller size and wider confidence intervals in previous studies. One hypothesis 
to explain the inverse association of serum sCD40L with incident CHD may be that 
circulating platelets, which are thought to be the major sCD40L reservoir (Henn et al, 
1998; Buchner et al, 2003), become “exhausted” during chronically elevated baseline 
inflammation. Hence, since extracting serum causes platelet degranulation, the measure 
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of total platelet pre-formed sCD40L is lower in those with low-grade chronic 
inflammation and hence propensity to experience CHD events. This would mean that 
although the measurement of risk is an in vitro artifact, it is a proximal marker of an in 
vivo phenomenon. This hypothesis is in line with a recent report that serum levels of 
sCD40L are lower and platelet mCD40L expression is higher in patients with unstable vs 
stable angina patients, whilst there was no difference between the groups in platelet poor 
plasma (Mason et al, 2005). This hypothesis has also been partially corroborated in other 
work using serum, where those with prevalent disease have lower serum levels of 
sCD40L (Aukrust et al, 1999; Tanne et al, 2006) and non-significant trends have been 
observed in other work with serum (Weber et al, 2007; Kiani et al, 2007). 
 
As discussed previously, platelet degranulation is undoubtedly a problematic issue, 
however, EDTA anti-coagulant also has undesirable and to some extent “unspecific” 
effects on platelet function (Golanski et al, 1996), and all pre-analytical study authors 
noted a trend towards higher sCD40L levels in EDTA anti-coagulated compared with 
citrated plasma, which is almost certainly an in vitro artifact (Ahn et al, 2004; Weber et 
al, 2006; Varo et al, 2006). Despite this, circulating levels of sCD40L in healthy subjects 
is often at, or below, the limit of detection in citrated samples (Malarstig et al, 2006) in 
ELISAs that are not high-sensitivity (~90pg/ml), and that which is detectable may well 
be due to in vitro artifact, just as is the case in serum (Ivandic et al, 2007). In light of this 
perhaps sCD40L is better measured in serum after end-point degranulation, as observed 
in this study. 
 
As with MMP-9, there is no reason to suspect that freeze-thaws or storage has adversely 
affected these results in terms of risk associations (although measured levels are certainly 
much lower than in Tables 3.3, 3.4, & 3.6 which are fresh samples from healthy people), 
but this is a possibility it is difficult to entirely exclude. 
 
Further studies are required to address these analytical issues. 
 
6.4.6 The Impact of 4-Year Regression Dilution on the 4 Inflammatory Markers 
 
This is the only reported study to my knowledge of regression dilution ratios in these four 
inflammatory markers. They illustrate the inherent systematic underestimation bias 
present for any prospective marker in conventional prospective studies. With the 
  249
 
exception of TNFα; these cytokines appear as stable over time as some conventional risk 
markers, despite the assertion that biological instability is higher for “other” 
inflammatory markers compared to CRP (Pearson et al, 2003). The present study 
suggests that IL-18, MMP-9, and sCD40L may be as temporally biologically stable as 
CRP.  
 
It is interesting to directly compare the data in this study of 4-year biological variation to 
that of the short-term biological variability in Chapter 3. Limited comparisons of these 
data are discussed in Chapter 12. 
 
In BRH study, further examination of the effects of regression dilution on these markers 
could be performed by expanding the study to examine 1 week, 16 year, and 20 year (as 
well as 4 year) regression slopes for all the markers (Emberson et al, 2004) 
 
6.4.7 Conclusions 
 
This case control study from a cross section of middle-aged British men has found that 
IL-18 and MMP-9 both have positive associations with risk of CHD on univariable 
analysis, although the risk association comparing extreme thirds is relatively weak 
(increased risk ≤55%). After adjustment for conventional risk markers and inflammatory 
markers (CRP and IL-6) these associations were significantly attenuated, and both only 
have a non-significant (~10%) association with risk. TNFα and sCD40L demonstrated 
inverse associations with CHD risk in this study on univariable analysis, and the 
association was not attenuated in multivariable analysis for sCD40L (23%), and became 
stronger for TNFα (34%). All these risk associations are relatively modest, and the 
previously hypothesised association between IL-18 and TNFα and markers of the 
metabolic syndrome was also relatively weak. As expected, adjustment for regression 
dilution improves the univariable risk associations of all four inflammatory markers, 
particularly for TNFα, for which the RDR was 0.25. It may also improve multivariable 
associations, although adjustment for regression dilution in conventional risk markers 
would also be required to assess this. These results require further analysis for 
confirmation (particularly TNFα, since the results appear inconsistent with previous 
literature and may be a chance finding) in wider cohorts and in newer samples to 
eliminate the possibility of bias and confounding from this study.  
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I therefore further examined the associations of IL-18 and TNFα in a nested case-control 
study of CHD from another general population cohort – the Fletcher Challenge Study. 
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CHAPTER 7 
 
ASSOCIATIONS OF IL-18, TNFα, AND IL-6 WITH RISK OF CHD IN A 
GENERAL POPULATION SAMPLE FROM NEW ZEALAND:  
THE FLETCHER CHALLENGE STUDY 
 
7.1 INTRODUCTION 
 
7.1.1 General Population Study of IL-18 and TNFα Risk Associations 
 
Having examined the 4 novel inflammatory markers in the BRH Study, further work was 
required to corroborate and to expand on these findings. As discussed in Chapter 6, there 
are many strengths to the BRH Study, but also several possible critisisms. These require 
to be balanced by observations in other studies with differing strengths and limitations. 
 
Stored plasma samples from the New Zealand Fletcher Challenge (FC) Study were 
available in our laboratory. New Zealand provides an interesting population for studying 
aetiology of cardiovascular disease. The population, like Scotland, has a high prevalence 
of CVD due to a generally high saturated fat diet, high smoking prevalence, and 
pronounced gradients in socioeconomic class across the population (with the native 
Maoris being generally more socially deprived) (Bell et al 1996; Bullen et al, 1996; 
Whitlock et al, 1997; Swinburn et al, 1998).  
 
Using the Fletcher Challenge Cohort to examine risk associations of TNFα and IL-18 
with CHD in a prospective case control study was an attractive possibility. Possible 
criticisms of the BRH study sample quality due to age and freeze-thaw cycles from the 
baseline samples, could be redressed by Fletcher Challenge plasma samples, which were 
more recently drawn, had always been stored at -80oC, and the aliquots used for this 
study had not been subjected to previous freeze-thaw cycles. The study was also a cohort 
of a general population, unselected initially for age or sex. It hence removes some 
potential confounders of the larger BRH study. The cohort also has epidemiological 
strengths similar to the BRH; i.e. it is a good demographic representation of the New 
Zealand population (MacMahon et al, 1995), which has a high prevalence of CVD, and 
the cohort is well defined in terms of measurement and publication of conventional risk 
marker data. The difference in length of follow-up also removes potential confounders of 
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the BRH study, which was subject to greater regression dilution bias (16 versus 5 years 
follow-up) (Emberson et al, 2004). The disadvantages include a smaller number of cases 
(although still reasonably powerful) because it is a general population cohort followed-up 
for only 5 years, as well as a high proportion of “missing” samples, the samples used here 
being the final unthawed aliquots from the study.  
 
The availability of stored plasma in this study provided the opportunity to investigate the 
associations of TNFα IL-18, as well as IL-6 for comparison in the population. As there 
were no serum samples available in the FC study, MMP-9 and sCD40L were not 
measured. 
 
7.1.2 Previously Published Data on Associations of IL-18 and TNFα, and IL-6 with Risk 
of CHD in Generally Healthy Populations 
 
As discussed in Chapter 1 & 6, at the outset of this thesis no study has examined risk 
associations for IL-18 and TNFα in healthy general populations. In contrast with these 
cytokines, IL-6 has been measured in a range of prospective studies, resulting in a meta-
analysis (Mann et al, submitted) which shows that IL-6 predicts risk of CHD: OR 1.67 
(1.35 – 2.05) in the top versus bottom tertile in fully adjusted models (see 1.2.8) 
 
7.1.3 Aims 
 
In using the Fletcher Challenge - University of Auckland Heart and Health Study we 
aimed to examine the associations of TNFα and IL-18, as well as IL-6, with conventional 
risk markers and with risk of incident CHD in a prospective nested case-control study of 
a general population. Since IL-6 is an established inflammatory CHD biomarker it forms 
a useful comparison to IL-18 and TNFα. 
 
7.2 SUBJECTS AND METHODS 
 
7.2.1 Establishment of Fletcher Challenge 
 
As in other developed countries, CHD and stroke are leading causes of morbidity and 
mortality in New Zealand despite declining incidence since the early 1970s, and most of 
the conventional and genetic causes of CVD are postulated to play the same role in New 
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Zealand as elsewhere. However relatively little accurate information was available in the 
1980s and early 1990s regarding the aetiology of heart disease and stroke in New Zealand 
populations, and the national Ministry of Health as well as the academic community in 
the country understandably required research into this, as well as data on the way in 
which risk factor demographics of the population were changing. At conception in 1991 
the aim of the Fletcher Challenge-University of Auckland Heart and Health Study (FC) 
(comprising more than 10,000 participants) was to investigate the causes of common 
chronic diseases (e.g. CHD and stroke) as well as acute injuries (e.g. motor vehicle 
accidents) in New Zealand (MacMahon et al, 1995).  
 
The FC Study has been used to determine the burden of many of these key risk factors 
within the population (Bell et al 1996; Bullen et al, 1996; Whitlock et al, 1997; Swinburn 
et al, 1998) and generally confirms similar findings to the CVD burden seen in Scotland 
and the UK. Further publications, data descriptions, and links can be found on the 
University of Auckland Heart and Health Study website: 
http://www.ctru.auckland.ac.nz/research/fletcher/index.html 
 
The principal results of the Fletcher Challenge Study hence provided necessary data for 
estimating CVD prevalence and absolute CVD risk distributions in the New Zealand 
population using the Framingham risk prediction equations. This data has been used in a 
wide variety of studies for estimating CVD risk burden in the New Zealand population 
(Wells et al, 2006). The data is now fairly outdated for this purpose (Wells et al, 2006) 
and more recent data has been published on monitoring trends in cardiovascular risk 
factors in the New Zealand populations in the last twenty years up until 2003 (Metcalf et 
al, 2006). However, the demographics of the population has little bearing on the present 
study. 
 
7.2.2 Subjects and Methods 
 
The participants of the Fletcher Challenge study derive from two baseline samples 
obtained using the same protocol: one from an occupational workforce in New Zealand 
(the Fletcher Challenge Company) and the other a random sample from metropolitan 
Auckland, New Zealand (MacMahon et al, 1995). The aim was to invite all Fletcher 
Challenge employees to participate, and to “top up” the participation to a target of 10,000 
  254
 
people using the electoral role. In total, 10,525 individuals were recruited (8011 from 
Fletcher Challenge) representing a response rate of 74% from invitations.  
 
Self administered questionnaires regarding medical histories were given to participants 
and physical examinations were carried out by qualified health professionals (MacMahon 
et al, 1995). Non fasting blood samples were taken at baseline, and serum and plasma 
samples (EDTA and citrate) were collected and stored at –70oC. These samples were 
used in a nested case-control study that derived from prospective follow-up of the 
Fletcher Challenge subjects, using national record linkage systems based on personal 
health identification numbers. Cases were all members of the study who had CHD, 
defined as a fatal coronary event or non-fatal hospital-diagnosed myocardial infarction, 
during the follow-up period (median 5.5 years). In total, 256 cases with available stored 
plasma samples were identified. Matched controls were randomly sampled as described 
for nested –case control studies (Woodward, 2005). Using this method, any case may be 
selected as a control for other cases for whom the CHD event predates their own, and 
cases may have common controls. This serves to give a more accurate random picture of 
the “control” population at the point when an incident case occurs, and hence minimises 
selection bias (i.e. it is unknown who from the general population of potentially eligible 
controls will become a case at the time of sampling – which should theoretically be when 
an incident occurs). Besides matching by time of the index case’s event, matching 
variables were age, sex and study population (occupational or general population). Age 
was matched, to the index case, within one year for all but 6 controls, these being 
matched within five years. In total, 703 controls were matched to cases; the minimum and 
maximum number of controls matched to any one case were 2 and 7, and the average 
control:case ratio was 2.75. Amongst the 703 matched controls were 615 separate 
individuals who were still free of CHD at the end of follow-up (“unique controls”).  
 
IL-18, TNFα and IL-6 were all measured as described in Chapter 2. Aliquots used in this 
study were previously unthawed. 
 
7.2.2 Statistical analysis 
 
Cases and unique controls were compared, for continuous variables, using t-tests after 
power transformations to better approximate normal distributions, where necessary and 
possible. Binary variables were compared through chi-square or Fisher’s exact tests. 
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Distributions of TNFα and IL-18 would not normalise, and so non-parametric Wilcoxon 
tests were used for these. Spearman rank correlations between the inflammatory variables 
were calculated for unique controls. Odds ratios for CHD were estimated from 
conditional logistic regression models (Woodward, 2005) using the matched sets as units 
of observation. In addition to unadjusted (except for matching variables) analyses, 
adjustments were made for classical cardiovascular risk factors, with and without CRP. 
 
7.3 RESULTS 
 
7.3.1 Sample Availability 
 
Due to sample attrition (these were residual unthawed samples), IL-18 and TNFα were 
assayed in 229 cases and 442 unique controls (77% of the total case-control study). IL-6 
was measured in 225 cases and 427 controls. Those included here were no different from 
those without available samples in terms of age, sex, smoking status, systolic blood 
pressure, total cholesterol or body mass index (all p>0.10).  
 
7.3.2 Baseline Characteristics of the Population 
 
The baseline characteristics of the study population are shown in Table 8.1. Lipids (total 
cholesterol, HDL cholesterol, and triglycerides) and acute phase reaction markers 
(fibrinogen, CRP and IL-6) were all significantly different in the expected directions 
(P<0.001 for all). Plasma IL-18 and TNFα were also significantly higher in cases 
compared to controls (10.9%; p=0.01 and 10.0%; p=0.024 respectively). Although there 
was a trend for both BMI and SBP to be higher in the cases than in the controls, the 
observation did not reach significance. After removing subjects with a previous doctor 
diagnosis of heart disease, the mean SBP (standard deviation) amongst cases increased to 
138.1 (21.2) mm Hg and BMI to 27.3 (4.0) kg/m2 (P<0.05 for both). 
 
7.3.3 Cytokine Correlations with Conventional Risk Factors 
 
Table 8.2 shows that, among controls, IL-6 had significant age and sex-adjusted 
associations with BMI, HDL cholesterol (inversely), fibrinogen, D-dimer, t-PA, and 
CRP. IL-18 showed significant associations with BMI, HDL cholesterol (inversely), 
triglycerides, t-PA, and CRP. TNFα showed no association with BMI, but was associated 
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with triglycerides and HDL cholesterol (inversely). Neither IL-18 nor TNFα showed 
significant associations with other haemostatic variables (fibrinogen, D-dimer, or vWF). 
IL-18 and TNFα were both associated with other inflammatory markers (CRP and IL-6) 
and with each other (r = 0.28).  
 
Both IL-18 (r=0.22) and TNFα (r=0.31) were significantly (p<0.0001) associated with 
age, after controlling for sex. Neither was significantly associated with current smoking 
(p≥0.26). 
 
7.3.4 Cytokine Associations with Absolute and Adjusted Risk of CHD 
 
29.0% of people in the bottom tertile of IL-18 expression were cases, whereas 40.6% 
were cases in the top tertile. There was a consequent stepwise increase in the odds ratio 
(OR) across thirds of IL-18 (p for trend 0.02) after controlling only for the matching 
variables (OR 1.63; 95% confidence interval [CI] 1.08 - 2.46) (Table 8.3). Adjustment for 
classical CHD risk factors marginally attenuated this result to below the threshold for 
statistical significance (OR 1.50; 95% CI 0.91 - 2.48).  Further adjustment for CRP did 
not attenuate the result. 
 
32.8% of people were cases in the bottom tertile of TNFα expression, and only 40.7% 
were cases in the top tertile. There was no significant stepwise increase in the ORs across 
thirds of TNFα after controlling for matching variables (OR 1.33; 95% CI 0.87 – 2.02), 
with, again, marginal attenuation on adjustment for classical CHD risk factors and no 
further attenuation after adjustment for CRP.  
 
When the 50 prevalent cases of CHD at baseline were deleted from the analysis, odds 
ratios comparing the extreme thirds all increased slightly, without altering the 
conclusions. For IL-18 the ORs (95% CIs) for CHD, top third v bottom third, were 1.79 
(1.12-2.84) controlling for matching variables only, 1.76 (0.99-3.14) adjusted for 
classical risk factors and 1.82 (0.94-3.52) after further adjustment for CRP. The 
corresponding results for TNFα were 1.35 (0.84-2.15), 1.33 (0.76-2.34) and 1.32 (0.69-
2.52). 
 
In comparison, IL-6 was a stronger marker of CHD risk than either IL-18 or TNFα. As 
seen in Table 8.3, 40.9% of people in the bottom tertile of IL-6 expression were cases, 
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whereas the figure was 68.5% in the top tertile. There was a stepwise increase in the odds 
ratio (OR) across thirds of IL-6 (p for trend 0.0003) and the risk in the top tertile after 
controlling only for the matching variables was 2.84 (1.73 - 4.68) (Table 8.3). 
Adjustment for classical CHD risk factors marginally attenuated this result to 3.01 (CI 
1.53 – 5.93), but largely only added noise to the signal.  Further adjustment for CRP did 
not materially affect the result either, and although the confidence intervals of the 
associations widened, the trend across thirds was still significant (p=0.03). 
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Table 7.1 Baseline characteristics: means (standard deviations) or percentages and p-
value for coronary heart disease cases and controls who were CHD free at end of follow-
up 
 P values compare cases and controls: (1) for categorical variables, from chi-square tests, 
except † when Fisher’s exact test was used; (2) for continuous variables, from t-tests, * 
after power transformations, except †† when Wilcoxon tests were used 
 
 
 
 
 
 
 
 
 
 Cases  
(n range: 215 - 246) 
Controls  
(n range: 410 - 472) 
p-value 
Questionnaire    
Age (yrs) 60.6 (16.5) 59.8 (16.2) matched 
Sex (% Male) 76.8 76.5 matched 
Baseline CHD (%)† 20.4 0 <0.0001 
Smoking (% Current)  25.2 17.4 0.01 
    
Physical measurements    
BMI (kg/m2) 26.9 (4.1) 26.4 (3.9) 0.16 
SBP (mmHg) 137.4 (21.4) 135.7 (20.3) 0.28 
    
Blood Sample    
Lipids:    
Total cholesterol (mmol/L) 5.96 (1.19) 5.59 (1.10) <0.0001 
HDL cholesterol (mmol/L) * 0.90 (0.30) 1.10 (0.31) <0.0001 
Triglyceride (mmol/L) * 2.11 (1.80) 1.69 (0.99) <0.0001 
Haemostatic variables:    
Fibrinogen (g/L)* 3.52 (0.81) 3.28 (0.62) 0.0003 
vWF (IU/dL) * 140.0 (60.8) 127.3 (51.9) 0.01 
Fibrin D-dimer (ng/ml) * 333.9 (260.1) 252.7 (176.6) <0.0001 
t-PA (ng/ml) * 5.29 (2.26) 4.68 (2.15) 0.002 
Inflammatory variables:    
C-reactive protein (mg/L) 3.82 (9.92) 2.02 (2.98) <0.0001 
Interleukin-6 (pg/ml) * 2.82 (3.54) 1.93 (2.28) <0.0001 
Interleukin-18 (pg/ml) †† 331.5 (167.8) 299.0 (175.2) 0.001 
TNFα (pg/ml) †† 2.74 (3.96) 2.49 (3.94) 0.024 
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Table 7.2 Age- and sex-adjusted Spearman correlations (r) of IL-6, IL-18 and TNFα with 
each other and established coronary risk factors in controls. p denotes the p-value for the 
test of a zero correlation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cytokines 
 IL-6 IL-18 TNFα 
Variable r p r p r p 
Body mass index 0.213 <0.0001 0.139 0.003 0.002 0.96 
Systolic blood pressure 0.097 0.045 -0.017 0.716 0.029 0.54 
Total cholesterol 0.006 0.90 -0.013 0.78 -0.073 0.13 
HDL cholesterol -0.174 0.0006 -0.312 <0.0001 -0.191 <0.0001 
Triglyceride 0.079 0.11 0.175 0.0003 0.114 0.018 
Fibrinogen 0.287 <0.0001 0.021 0.66 -0.032 0.502 
Von Willebrand factor  0.058 0.23 0.100 0.047 0.070 0.17 
Fibrin D-dimer 0.157 0.0014 0.071 0.17 0.088 0.09 
t-PA 0.182 0.0002 0.146 0.004 0.097 0.05 
C-reactive protein 0.461 <0.0001 0.206 <0.0001 0.124 0.015 
IL-6 n/a n/a 0.132 0.009 0.251 <0.0001 
IL-18 0.132 0.009 n/a n/a 0.282 <0.0001 
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Table 7.3 Odds ratios of coronary heart disease in men based on thirds of IL-18, TNFα and IL-6. Matching variables are age, sex, 
source of sample and time to event 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cases Controls Odds ratio (95% CI) adjusted for: 
 
 
 
n 
 
n 
 
Matched variables 
only 
 
Classical risk factors* 
 
Classical risk 
factors and CRP 
IL-18 (pg/ml)      
>331  89 130 1.63 (1.08, 2.46) 1.50 (0.91, 2.48) 1.69 (0.94, 3.03) 
236 - 330 73 148 1.15 (0.77, 1.73) 0.97 (0.60, 1.58) 1.04 (0.60, 1.82) 
< 235 67 164 1 1 1 
Total 229 442    
TNFα (pg/ml)      
>2.16  88 128 1.33 (0.87, 2.02) 1.23(0.75, 2.04) 1.25 (0.70, 2.25) 
1.57 – 2.15 64 156 0.81 (0.54, 1.23) 0.68 (0.41, 1.12) 0.64 (0.36, 1.15) 
< 1.56 77 158 1 1 1 
Total 229 442    
IL-6 (pg/ml)      
> 2.15 89 130 2.84 (1.73 - 4.68) 3.01 (1.53 - 5.93) 2.79 (1.11 - 6.99) 
1.16-2.15 73 148 2.10 (1.33 - 3.30) 2.62 (1.45 - 4.76) 2.13 (1.01 - 4.48) 
< 1.16 pg/ml 67 164 1 1 1 
Total 229 442    
* Systolic blood pressure, total cholesterol, HDL-cholesterol, triglycerides, body mass index and smoking status 
(never/ex/current cigarette smoker) 
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7.4 DISCUSSION 
 
7.4.1 Population Distribution of IL-18 and TNFα                                                                                        
 
Comparing the present study to the MONICA-4 study, median IL-18 levels in the present 
study are very similar to medians in the same age range in the North Glasgow Survey 
(271 pg/ml among ~60 year old controls vs 251 pg/ml in the 55-64 year old MONICA-4 
males) and are also highly comparable to those seen in the BRH study (Chapter 6).  
 
TNFα levels between the two studies were also comparable, although the median 
circulating level appears to be slightly higher in the present study (1.74 pg/ml among 
controls vs ~1.59 pg/ml in the 55-64 year old males). Due to the marginal magnitude of 
this difference, it is likely to be due to drift of the calibrants between TNFα kit lots over 
time, or simply due to improved sample quality. Since levels of TNFα noted in this study 
are slightly higher than those seen in MONICA-4, they are very much higher than those 
seen in the BRH study (Chapter 6). 
 
7.4.2 Associations of IL-18 and TNFα with Conventional Risk Markers 
 
Despite MONICA-4 (and other studies; Woodward et al, 1997, 2Wannamethee et al, 
2005) confirming that circulating levels of cytokines, including IL-18 and TNFα, are 
increased in smokers, levels of both cytokines increased with age, but were not associated 
with current smoking in the present study. The BRH study found that while TNFα was 
not associated with current smoking (although there was an increasing trend across thirds 
of the population), whereas IL-18 was (p<0.0001). The discrepant results in the FC study 
may be reflective of reduced power of smoking observations in the present study since 
only ~17% of controls smoked, whereas the figure in GLAMIS was 45.6%. This means 
there were only 77 control smokers in the current population; probably not a statistically 
sufficient number to study smoking as a dichotomised (current vs ex/never) variable. 
 
Previous prospective publications generally report that IL-18 shows relatively weak 
associations with HDL cholesterol (inversely) and triglycerides (but not total cholesterol), 
as well as weak but statistically significant associations with CRP and IL-6, but not with 
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age, BMI, or fibrinogen levels (Blankenberg et al, 2002, 2003; Koenig et al, 2006), 
associations which have also been noted in retrospective studies (Hulthe et al, 2006). Our 
findings in this prospective study are broadly similar to these, and we also report no 
association with systolic blood pressure (which has previously been suggested to show 
very weak associations with IL-18: Koenig et al, 2006 & BRH, Chapter 6) or with some 
haemostatic variables (D-dimer and vWF).  
 
Likewise for TNFα, this study generally confirms previous prospective reports (3Ridker 
et al, 2000; 2Cesari et al, 2003; Tuomisto et al, 2006& Chapter 6) that TNFα shows weak 
(but in this study statistically significant) associations with HDL cholesterol (inversely), 
and with other inflammatory markers (IL-6, IL-18 and CRP, although not fibrinogen). 
Also consistent with these reports, TNFα levels showed no strong association with BMI 
or systolic blood pressure, and associations with fibrinolytic variables (D-dimer and t-
PA) were weak. These observations are also broadly similar to those noted in the control 
populations of retrospective studies (Jovinge et al, 1998; Skoog et al, 2002). 
 
IL-6 demonstrated expected associations with HDL cholesterol and inflammatory risk 
markers (including very strongly with CRP and fibrinogen) but, in contrast to IL-18 and 
TNFα, also had strong associations with BMI and fibrinolysis markers (t-PA and D-
dimer). In terms of BMI associations, this result at least demonstrates that the control 
group had sufficient BMI diversity for strong association with some cytokines to be 
possible. 
 
Weak associations of IL-18 and TNFα with BMI and measurements of adiposity will be 
discussed further in Chapter 11. 
 
7.4.3 Associations of Cytokines with Risk of CHD 
 
In this nested case – control study, plasma levels of IL-18 showed a significant 
association with CHD risk. This association was only marginally attenuated after 
adjustment for classical CHD risk factors and CRP to borderline significance. This is in 
agreement with the PRIME study of middle-aged men, where although IL-18 correlated 
with HDL cholesterol and inflammatory markers, adjustment did not result in an 
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attenuation of the association (1Blankenberg et al, 2003). However, this study found that 
univariable risk (OR 1.63), like in the BRH study (OR 1.55), was lower than in the 
PRIME study (OR 1.80). Despite this seeming “regression to the mean” discrepancies in 
the data still exist. The current FC data suggest that adjustment for confounders has little 
effect on risk associations. This is in agreement with PRIME, but not with the BRH 
study, where IL-18 was heavily attenuated on adjustment. Why this discrepancy? It is 
interesting to note that the confounding adjustment models for the three studies are very 
similar, however, the BRH study additionally adjusts for both social class and physical 
activity. Possibly it is the residual association of IL-18 with social class which allows it to 
remain associated with CHD in the FC and PRIME studies (as was seen in the MONICA-
4 chapter). Indeed, social class may be associated with risk of CHD in adjusted models to 
a similar extent to IL-18 (OR 1.28-1.36 in the top two fifths of a population in a recent 
study [Tunstall Pedoe et al, 2006]). Despite this evidence of a moderate association 
between circulating levels of IL-18 and incident CHD, one recent case - control study in 
the MONICA/KORA cohort of healthy men and women (with a similar number of cases 
to PRIME) reported no multivariable association of IL-18 with risk (Koenig et al, 2006). 
It is of note that Koenig et al adjusted for alcohol and physical activity in their model of 
IL-18 risk associations (Koenig et al, 2006) and alcohol consumption is a major correlate 
of social class. 
 
Hence overall, any association between IL-18 and CHD risk in general population studies 
is likely to be moderate overall and confounded by social class and alcohol consumption. 
In addition, the association of IL-18 with atherosclerotic burden has recently been 
debated. Espinola-Klein et al, 2007 found in 720 patients that IL-18 levels were not 
different in patients with no significant CAD, those with CAD, or those with clinically 
relevant multi-vessel disease. Studies in general argue for (Yamashita et al, 2003; 
Yamaoko et al, 2003; Suchanek et al, 2005) or against (Chapman et al, 2006, Espinola-
Klein et al, 2007) significant associations of IL-18 with atherosclerotic burden. Data in 
this study cannot really add to this debate, however Espinola-Klein et al argue that IL-18 
may be a better risk marker in those with prevalent disease. In the current study, 
exclusion of those with baseline CHD did not significantly alter risk associations. 
 
  264
 
Plasma levels of TNFα showed a weak, nonsignificant association with CHD risk in the 
present study (OR 1.33 [0.87, 2.02]), which was attenuated after adjustment for CHD risk 
factors and CRP.  One prospective study with 188 CHD events in people aged 70 -79 
years at entry did find a significant, linear, independent association between circulating 
TNFα levels and CHD (2Cesari et al, 2003). Despite this, overall results are conflicting 
(Table 1.4). A recent population study reported a significant (but non-linear) association 
of TNF with risk, with the top 3 quartiles (combined) of the population at increased risk 
(Tuomisto et al, 2006). In contrast, the BRH Study demonstrated a borderline inverse 
association. Hence overall, the results remain inconsistent. 
 
In the present study, although the top tertile were not at significantly increased risk, it 
remains possible that people with very high circulating levels of TNFα are at increased 
risk of CHD events, and this would be consistent with one previous study of people with 
angina pectoris (3Ridker et al, 2000) and with data in those with active inflammatory 
diseases such as RA who are at increased risk of CHD (Sattar & McInnes, 2005). No 
study to date has been sufficiently powered to test this hypothesis by accurately 
examining risk in the top 10-20% of the population for TNFα expression. It also possible 
that low circulating levels of ΤΝFα may have some atheroprotective effects, since some 
data from mouse models suggests this possibility (Schreyer et al, 1996, 2002). This may 
help explain some non-linear associations with risk found in the literature. Other 
conclusions may be that the ELISA method used is insufficiently sensitive to detect 
levels in normal populations accurately. If this is the case then one would have to 
conclude that epidemiological observations linking TNFα to CHD risk (in various ways) 
were predominantly chance findings, which become more likely when making a large 
number of statistical inferences from one data set (Woodward et al, 2005). However, the 
likelihood of this happening repeatedly over a number of studies for one marker is small. 
Clearly if there is a relationship between ΤΝFα and CHD, it is a complex one that 
requires further studies, and a meta-analysis of these in due course. 
 
IL-6, in contrast to IL-18 and TNFα, demonstrated both strong unadjusted (2.84 [1.73 - 
4.68]) and fully adjusted (2.79 [1.11 - 6.99]) associations with risk of CHD, Cocsistent 
with the Mann et al meta-analysis (1.2.8). 
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7.4.4 General Conclusions 
 
Of the two prospective studies of CHD in this thesis the Fletcher Challenge Cohort is the 
more general population, with relatively young plasma samples (~13 years) that have 
been stored most rigorously (-80oC) and are previously unthawed. Hence despite a 
relatively small size, the study is a good candidate to detect any strong risk associations. 
Indeed, this is re-enforced by the result that IL-6 was a (relatively) strong independent 
predictor of CHD, which is consistent with the literature. Despite this, any associations of 
IL-18 or TNFα with risk of CHD have been shown to be moderate and confounded, such 
that residual associations are probably not clinically significant. This does not preclude a 
causal role of IL-18 or TNFα in the process of atherogenesis, nor as potential therapeutic 
targets.  
 
As a final step in the examination of IL-18 and TNFα with risk of CHD, the next chapter 
will estimate risk associations for cardiovascular disease in the MONICA-4 cross-
sectional population (Chapter 4). 
. 
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CHAPTER 8 
 
RISK ASSOCIATIONS OF IL-18, TNFα, IL-6, FIBRINOGEN AND CRP WITH 
CARDIOVASCULAR DISEASE IN THE MONICA-4 SURVEY: A 
PROSPECTIVE COHORT STUDY 
 
8.1 INTRODUCTION 
 
8.1.1 Risk Associations Within a Cohort 
Prospective nested case-control studies are a powerful means of elucidating risk 
associations of prospective risk markers within a cohort, and the method is relatively 
cheap since the entire cohort is not measured. Although this method is less bias-prone 
than retrospective case-control studies, residual bias is introduced in the process of 
selecting controls from the cohort. Although there are methods available to limit this bias 
(Woodward, 2005) it is difficult to exclude as a confounder entirely.  
 
Estimating the associations of putative risk markers in a cohort is the least bias-prone 
method of establishing a risk association, since the entire “non-case” cohort are controls 
and there is no selection process. Causality still cannot be implied in the absence of 
placebo-controlled trials to specifically alter biological function of the marker (Lowe et 
al, 2005), and there are other trade-offs for limitation of bias confounding. Due to 
controls being unselected there is increased confounding from conventional risk factors 
which could be potentially matched in nested case-control studies (age, sex, geographical 
location, baseline CHD etc), which results in wider confidence intervals after adjustment. 
In addition funding constraints generally limit the cohort size, the rates of CHD events 
are lower than in more selected studies (e.g. BRH study of middle-aged men), and hence 
statistical analysis is powered by fewer cases. 
 
Despite these limitations, cohort studies are the “best” method to estimate risk 
associations, since the control cohort is a more realistic representation than in nested 
case-control studies (because they are unselected).  
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After performing the analysis of the demographic associations of IL-18 and TNFα in the 
MONICA-4 study, data for a 10 year follow-up study of incident CHD became available. 
Due to the cytokines already having been measured, this data was used to estimate 
associations of IL-18 and TNFα (as well as IL-6, fibrinogen and CRP) with CVD risk in 
a general population survey of North Glasgow, as described in Chapter 4. 
 
8.1.2 Previous Cohort Studies of IL-18 and TNFα 
 
There have been no previous reports of full cohort studies of IL-18 and TNFα which 
have examined risk associations. Previously published data in case-control studies is as 
discussed in Chapters 6&7. 
 
All inflammatory markers were measured as described in Chapter 2. As described in 
Chapter 4, MONICA-4 aliquots had not been previously thawed before the measurement 
of IL-18 or TNFα, and were thawed on 1 further occasion to measure IL-6. 
 
8.1.3 Aim 
 
The aim of this study was to elucidate CHD risk associations of IL-18, and TNFα, as 
well as IL-6, fibrinogen and CRP for comparison in the MONICA-4 cohort study, the 
cohort previously described in Chapter 4. This was with the aim of comparing a range of 
novel and established inflammatory risk markers and their relative associations with 
CVD risk, as well as generating additional data on CVD risk associations in IL-18 and 
TNFα to perform a meta-analysis in the concluding stages of this thesis. 
 
8.2 METHODS 
 
8.2.1 Subjects and Methods 
 
The characteristics of the cohort have been described in detail in Chapter 4. In brief, 1836 
men and women aged 25-64 years randomly sampled from GP registers gave blood 
samples and undertook a standard MONICA questionnaire at a health screening clinic in 
1995 (full details see chapter 4). 
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The MONICA-4 cohort was followed for 10 years from baseline for incidence of MI, 
stroke, development of unstable angina or sudden coronary death, which were the 
qualifing events for entry into the case-control study as a case subject. Diagnosis of fatal 
and non-fatal CVD events was based on medical records of general practioner reports and 
hospitalizations according to WHO criteria (Walker et al, 2004) and from death 
certificates using ICD-9 codes 410-414. During follow-up there were 228 qualifying 
CVD events in the cohort (12.4% event rate over 10 years). 
 
8.2.2 Statistical Analysis 
 
Distributions of IL-18, TNFα and IL-6 were log-transformed to approximate normality, 
as were other inflammatory markers where appropriate. Inflammatory markers were 
analysed by pre-specified equal thirds of the control population distribution, as well as 
analysing markers as continuous variables (expressed per 1 quartile increase in the 
distribution for the marker). Odds ratios for CHD were estimated from conditional 
logistic regression models (Woodward, 2005). These were computed both with partial 
adjustment (age and sex) and with full adjustment for potential confounding factors (age, 
sex, serum cholesterol, HDL cholesterol, smoking, diabetes, SBP, family history, and 
socioeconomic status i.e. the ASSIGN risk factors). 
 
8.3 RESULTS 
 
8.3.1 Cardiovascular Disease in the Population 
 
Of the 1836 men and women sampled, 228 experienced a CVD event during the 10 year 
follow-up. The overall event rate for MONICA-4 was therefore 12.4%. Excluding those 
with baseline CVD, there were 131 CVD cases from 1596 participants. 
 
8.3.2 Risk Associations of IL-6, Fibrinogen, and CRP. 
 
Table 8.1 summarises all inflammatory markers for risk associations with risk of all-CVD 
both by tertiles and as continuous variables. 
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IL-6 was significantly associated with risk of CVD as a continuous variable (OR 1.11 
[95% CI 1.03-1.20]). Exclusion of those with prevalent disease did not attenuate these 
associations, and neither did adjustment for conventional risk markers attenuate the 
association (1.12 [1.03-1.22]). The top tertile of IL-6 expression were at a ~2-fold 
increase in risk compared to the bottom tertile, which attenuated to ~1.5-fold after full 
adjustment. A quartile increase in levels of fibrinogen was associated with an increase in 
risk (1.37 [1.19-1.57]), which was marginally attenuated but remained significant after 
full adjustment (1.24 [1.07-1.43]). Excluding those with prevalent disease did not 
markedly improve associations (1.24 [1.03-1.55]). CRP was also associated with risk, a 1 
quartile increase resulting demonstrating an OR of risk of 1.22 (1.15-1.29), which was 
again only marginally attenuated on full adjustment (1.19 [1.12-1.26]) or exclusion of 
those with prevalent disease. 
 
Comparing middle with bottom thirds, no marker was significantly associated with risk 
of CVD in any model. Additional adjustment for alcohol consumption did not further 
attenuate any observed associations (data not shown). 
 
8.3.3 Risk Associations of IL-18 and TNFα 
 
IL-18 showed only borderline significant risk associations with CVD as a continuous 
variable after age and sex adjustment (1.09 [0.97-1.23]). After full adjustment the 
association was abrogated to unity. Excluding those with prevalent disease did not 
materially impact these observations. Comparing extreme thirds of the population in the 
all-CVD group, IL-18 was a significant risk marker on age and sex-adjustment (OR 
1.61), although the result was again attenuated to non-significance (although not 
abrogated) after adjusting (OR 1.25). 
 
In contrast, TNFα was significantly associated with risk of CVD as a continuous marker 
after age and sex adjustment (1.11 [1.03-1.19]) and after full adjustment (1.12 [1.03-
1.21]). Exclusion of those with prevalent disease did not materially impact these results. 
The OR for TNF-α after adjustment for fibrinogen, IL-6 and CRP, as well as all 
conventional risk factors and SES, was 1.12 (1.02-1.24) (data not shown in Table 8.1), 
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indicating that TNFα risk associations were independent of other inflammatory risk 
markers in this study. The only other marker for which this was true was CRP (1.17 
[1.07-1.27] adjusted for conventional risk markers, fibrinogen, IL-6 and TNF-α). In 
tertile analysis, TNFα was a significant risk marker comparing extreme thirds after only 
age and sex adjustment (OR 1.70), but the result was attenuated to borderline significance 
after full adjustment (OR 1.35). 
 
Like the other inflammatory markers, comparing middle with bottom thirds, neither IL-
18 not TNFα was significantly associated with risk of CVD in any model, and adjustment 
for alcohol consumption did not further attenuate any observed associations (data not 
shown) 
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Table 8.1 MONICA-4 follow-up risk associations (ORs) for inflammatory risk markers, 
assessed as continuous variables (per 1 quartile increase of marker in the population) or 
by tertile analysis. Min adjustment model is age and sex-adjusted. Full adjustment model 
adjusts for ASSIGN risk factors (methods). Bold value indicates significance (p<0.05). 
Incident CVD excludes those with baseline CVD (total 131 events from 1596 people 
after exclusions) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Continuous analysis  Tertile analysis 
 All CVD  Incident CVD  All CVD 
Comparison       2 vs 1 3 vs 1 2 vs 1 3 vs 1 
Adjustment Min Full  Min Full  Min Min Full Full 
IL-6 1.11 1.12  1.11 1.12  1.18 2.00 0.94 1.55 
Fib 1.37 1.24  1.43 1.27  1.13 1.81 1.01 1.49 
CRP 1.22 1.19  1.23 1.20  1.63 3.54 1.42 2.82 
IL-18 1.09 1.02  1.08 1.00  1.14 1.61 0.98 1.25 
TNFα 1.11 1.12  1.10 1.12  1.29 1.70 1.12 1.35 
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8.4 DISCUSSION 
 
8.4.1 MONICA-4 Population Event Rate: 
 
An overall event rate of 12.4% in a general population is quite high, especially since the 
eldest subjects in the survey were 64 years. However, the latest estimates from the British 
Heart Foundation (www.heartstats.org; 2007 CVD Report) suggest prevalence rates of 
CHD (which would account for most observed CVD events) in Scotland are 8% in men 
and 6% in women. Given this, and the fact that Glasgow has a poorer public health record 
even than the rest of Scotland (sub-optimal health of the cohort illustrated in Table 4.1), a 
12.4% rate of CVD over ten years is perhaps a proportionate outcome. 
 
8.4.2 CVD Risk Associations in Established Inflammatory Risk Markers 
 
As broadly expected IL-6, fibrinogen, and CRP showed significant and independent CVD 
risk associations in the MONICA-4 study. This is in line with the published literature in 
meta-analyses (Mann et al, submitted; Fibrinogen Studies Collaboration, 2005; Danesh et 
al, 2004). The absence of a significant association of IL-6 with risk in the top tertile of 
the fully adjusted model is suggestive that the study is a little underpowered, since the 
marker is significantly associated with risk on meta-analysis in the literature (Mann et al, 
submitted). Commensurate with a suggestion of lack of power, no marker was associated 
with risk comparing middle with bottom tertiles. Lack of power is generally an issue in 
full cohort studies, which need to be very large to attain large numbers of cases over 
reasonable follow-up periods. 12.4% may be a high event rate for a cohort study over 10 
years, but at this rate the population would require >5000 participants to attain the same 
number of cases, and hence power, as the BRH study. Studies of such size are impractical 
in terms of expense for examining potential novel risk markers. 
 
8.4.3 IL-18 and TNFα Associations with Risk of CVD 
 
To my knowledge, this is the first cohort study examining CVD risk associations of IL-18 
or TNFα. Despite the lack of power discussed above, the design of the study makes it an 
important resource in examining risk associations. 
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Interestingly, the OR of 1.6 comparing extreme thirds of IL-18 in the age and sex 
adjusted model is highly comparable to that seen in the Fletcher challenge study in the 
matched variables model (OR 1.63). Contrasting the studies however, adjustment in the 
full model in this study heavily attenuated the association to a borderline significant 
trend, whereas the association remained uninfluenced (but borderline significant due to 
widening confidence intervals) in the fully adjusted Fletcher Challenge model (Table 
7.3). The main difference in the adjustment models is the additional adjustment for socio-
economic status (by postcode) in the present study. As discussed in Chapter 7, in 7.4.3, 
the attenuation of moderate IL-18 associations with risk after adjusting for socio-
economic status may be commensurate with the published literature (1Blankenberg et al, 
2003; Koenig et al, 2006) and with the data in this body of work (BRH study: Chapter 6). 
This observation is further discussed in Chapter 12. 
 
In this study TNFα demonstrates a positive association with risk of CVD, which is 
independent of conventional risk markers (and other inflammatory markers) in the 
continuous model, but not in the tertiles model, where the association was reduced to 
borderline significance. This positive association is in direct contrast to the BRH study 
(Chapter 6) where the association was inverse, and became stronger on adjustment. The 
association noted here was also stronger than that noted in the Fletcher Challenge study, 
where the OR in the top tertile was non-significant (1.33) and only slightly attenuated on 
adjustment (1.27). Overall, one would conclude that the risk association patterns shown 
by TNFα in this body of data, and in the literature in general (Table 1.4) are inconsistent. 
Reasons for this inconsistency are explored, along with appropriate meta-analysis of both 
IL-18 and TNFα in Chapter 12.  
 
8.4.4 General Conclusions 
 
Despite moderate independent associations of TNFα with risk of CVD in this study, it 
seems unlikely, overall, that either IL-18 or TNFα have strong associations with risk of 
CHD or CVD (Chapters 6-8), although this will be formally tested by meta-analysis in 
Chapter 12. Having extensively examined risk associations with of these cytokines CHD 
and CVD, I moved on to explore the risk associations with stroke. 
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CHAPTER 9 
 
ASSOCIATIONS OF IL-18, TNFα, AND IL-6 WITH PROGRESSING STROKE 
AND WITH OUTCOME FROM ACUTE STROKE: THE STROKE IN 
PROGRESS (SIP) STUDY 
 
9.1 INTRODUCTION 
 
9.1.1 Acute and Progressing Stroke 
 
Acute ischaemic stroke remains clinically problematic to treat, as suggested by the above 
quote. Decades of research have investigated the issues of how to ensure patients 
admitted with such strokes are quickly diagnosed, treated effectively to minimise further 
ischaemia, ensure there is not recurrent thrombosis (without causing haemorrhage), 
prevent subsequent myocardial damage, and prevent further inflammation-driven 
neurological degeneration (Khaja et al, 2007). Despite continued work in these areas and 
many promising therapies being evaluated in animal trials, few pharmacological 
interventions available for acute stroke have not been developed. Indeed, recombinant 
tissue plasminogen activator therapy (rt-PA) is still the only drug recommended for 
thrombolytic therapy in acute stroke, and at that with many contraindictions, such as a 
three hour symptom onset to administration window, and a requirement for systolic blood 
pressure < 2185mmHg and diastolic blood pressure <110mmHg to prevent 
complications.  
 
Progressing stroke is a clinical complication of acute stroke, generally defined as a 
neurological degeneration in the days following admittance. Although it has been 
problematic to agree an international standard of definition there have been recent 
advances in the European Progressive Stroke Study (Birschel et al, 2004). A current 
working definition is a ≥2 Scandinavian Stroke Score (SSS)-point worsening in eithe 
conscious level, arm, leg or eye movement scores, and/or a ≥3 SSS-point worsening in 
speech score comparing the day 3 assessment with the baseline assessment, or death 
occurring within 72 h of onset. Progressing stroke occurs in around 20-25% of patients 
and is prognostic of poor outcome (Hashiniski et al, 1980; Birschel et al, 2004). The 
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pathophysiological mechanism for progressing stroke symptoms is not known, although 
extension of the brain oedema, absence of recanalization and thrombus propagation may 
each play a part (Asplund et al, 1992).  
 
No current anticoagulants, such as heparin are of any benefit to acute stroke patients 
including those with atrial fibrillation or progressing stroke (O’Donnell et al, 2006; 
Rodden-Jullig et al, 2003). There have however been studies showing that individual 
inflammatory or haemostatic biomarkers predict risk of poor outcome or are associated 
with progressing stroke.  
 
9.1.2 Previously Published Data on Acute Stroke and Inflammatory Markers 
 
There is a body of evidence in the literature that elevated levels of fibrinogen and CRP 
predict risk of poor outcome in patients upon admission with acute ischaemic stroke 
(1&2Di Napoli et al, 2001, 2005; Anuk et al, 2002; Turaj et al, 2006). This has led to 
speculation that CRP and/or fibrinogen may be of clinical benefit as prognostic markers 
(Di Napoli et al, 2005, 2006). However, the evidence for the predictive value of 
fibrinogen in the acute stages is weak (1Di Napoli et al, 2001); studies so far have shown 
fibrinogen to be predictive of outcome at 1 year follow-up and levels may not be elevated 
in acute stroke until 1 week after the event (Anuk et al, 2002; Turaj et al, 2006). It is 
likely in these subacute phases that fibrinogen is predicting the risk of recurrent CVD 
events in outcome, and the aetiology of this may be very distinct from outcome in acute 
stroke. Illustrating this, 12% of stroke patients have recurrence within the first year, but 
only 4% in the first month (Hankey et al, 2003). 
 
IL-6 has been shown to be a good predictor of acute ischaemic stroke outcome. IL-6 
predicts neurological deterioration in the first 48 hours independently of clinical risk 
markers (Vila et al, 2000), and peak levels in the first week predict modified Rankin 
score at 3 months and computed tomography (CT) brain infarct volume as well as 12 
month outcome (Smith et al, 2004; Emsley et al, 2003). 
 
One study of 23 ischaemic stroke patients and 15 controls has examined both IL-18 and 
TNFα levels (Zaremba & Losy, 2001; Zaremba and Losy, 2004). This study found that 
both IL-18 and TNFα were elevated in serum and CSF of the patients, and correlated 
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significantly with SSS and Barthel index (BI) scores at baseline, as well as week 1 and 2. 
There was some evidence that IL-18 levels were associated more strongly with outcomes 
in non-lacunar stroke subtypes (Zaremba and Losy, 2004) although numbers are 
obviously very small. In contrast with these findings, a more recent study of TNFα found 
that in 41 patients it did not correlate with lesion size or neurological impairment (Intiso 
et al, 2004). Animal models of IL-18 suggest that IL-18 does not contribute to acute 
ischaemic brain damage (Wheeler et al, 2003) (although this obviously does not preclude 
involvement in pre-thrombotic inflammatory processes). These results in small studies 
require re-examination in larger studies with hard end-points. 
 
The Stroke in Progress (SIP) study in Glasgow Royal Infirmary (Barber et al, 2004) 
showed that D-dimer, but not CRP or other haemostatic variable was independently 
associated with risk of progression in patients with acute ischaemic stroke. The 
availability of stored plasma for this study was a good opportunity to measure pro-
inflammatory cytokines (IL-6, IL-18, and TNFα). Due to a lack of serum samples, MMP-
9 and sCD40L were not measured in the SIP study. 
 
9.1.4 Aims 
 
The aim of this study was to assess whether IL-18, TNFα or IL-6 were associated with 
stroke progression or 30 day outcome in acute ischaemic stroke. This was done 
concurrently with a panel of inflammatory and haemostatic markers since this area is 
relatively unexplored in the literature. Furthermore, the study aimed to ascertain which 
inflammatory or haemostatic markers added greatest prognostic information to current 
clinical markers. 
 
 
9.2 METHODS 
 
9.2.1 Subject Recruitment, Assessment, and Methods 
 
The aim of the SIP study (Barber et al, 2004) was to identify the biomarkers most 
strongly associated with poor outcome and poor prognosis (progressing stroke) 
independently of clinical risk markers. It was hoped that these markers may be able to 
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identify subsets of patients at greatest likelihood to experience clinical benefit from 
interventions such as, anticoagulants, or rt-PA therapy outwith current recommendations, 
or for future drug therapies. Approval to measure novel biomarkers in acute stroke was 
obtained from the local research ethics committee The aim was to assess which from a 
large range of inflammatory and haemostatic biomarkers were the best independent 
prognostic indicators of acute ischaemic stroke outcome (death/dependency/progressing 
stroke; with an initial emphasis on progressing stroke) in a reasonably size cohort. 
 
Patients were recruited from consecutive ischaemic stroke admissions to Glasgow Royal 
Infirmary hospital between April 2002 and October 2003. Patients were excluded on the 
basis of any of the following: > 24 hours from symptom recognition to admission, age < 
18 years, coma (only responding to pain on admission) or suspected epileptic seizures. 
Patients anticoagulated prior to admission were also excluded. No recruited patients were 
prescribed thrombolysis or heparin in the first 72 hours after stroke onset. All patients 
were treated on a standardized protocol for the management of dehydration (2.5 litres of 
0.9% sodium chloride solution intravenously, over the first 24 hours, unless 
contraindicated), hyperglycemia, hypoxia and pyrexia.  
 
A single experienced examiner saw all patients. Assessment included clinical 
classification (Oxfordshire Community Stroke Project (OCSP) classification) and 
measurement of stroke severity using the Scandinavian Stroke Scale (SSS). Follow up 
was at 30 days using the Rankin scale and Barthel Index, which were also administered 
by the same examiner.  
 
Of 474 consecutive admissions assessed, 280 were deemed potentially suitable for 
recruitment. 61 patients were subsequently excluded (blind to blood sample results). Of 
the remaining 219 patients, 54 (25%) met the criteria of progressing stroke. For the 
outcome of death/ dependency (Rankin >2) a further 39 cases were excluded from 
analysis because of a premorbid Rankin of 3-5. This left a group of 180 subjects of whom 
17 (9.4%) died before day 30. In total 94 of the 180 cases were dead or dependent at day 
30. 
 
Progressing stroke was defined using a modification of the European Progressing Stroke 
Study (EPSS) criteria (see 8.1.1; Birschel et al, 2004). Progression is excluded if the 
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conscious level improves significantly between the 2 assessments, even if there has been 
worsening in other criteria. In this study eye movement changes were excluded, because 
there is concern about reliability of this facet of the SSS (Barber et al, 2004) and 
removing the gaze palsy component of the EPSS definition does little to change the 
validity of conclusions made (Birschel et al, 2004). 
 
Investigating an initial emphasis on progressing stroke, the primary results from SIP 
examined the association of haemostatic and inflammatory markers with progressing 
stroke (Barber et al, 2004). These included coagulation factors VII, VIII, XI, prothrombin 
F1+2, thrombin-antithrombin complexes, fibrin D-dimer, APC ratio, t-PA, vWF, PV, 
fibrinogen, CRP and blood leucocyte count, as well as clinical risk markers. CRP, F1+2, 
TAT, VWF and D-dimer levels were univariately associated with progressing stroke (but 
not fibrinogen; p=0.08). In logistic regression analysis, with all significant clinical and 
laboratory variables included, only D-dimer and mean arterial blood pressure remained 
independent predictors of progressing stroke. Associations of D-dimer with progressing 
stroke have subsequently been validated in diagnostic as well as epidemiological 
measurement methodologies (Barber et al, 2006).  
 
IL-6, IL-18, and TNFα were assayed as described in chapter 2 and assays were 
performed on previously unthawed aliquots. 
 
9.2.3 Statistical analysis 
 
Results are expressed as medians throughout the results unless otherwise stated. For non-
normally distributed variables log transformations to normality were made where 
possible. In univariate comparison of categorical variables the chi-squared test was used. 
Univariate analysis of normally distributed and transformed variables was by the 
unpaired t-test, and for remaining non-normally distributed continuous variables the 
Mann Whitney U test was used. Multivariate analysis was by forward stepwise binary 
logistic regression. The probability for stepwise entry was 0.05 and for removal was 0.10. 
Oxfordshire Community Stroke Project (OCSP) classification was included in the model 
as a categorical variable. All analyses were carried out using SPSS for Windows version 
13.0. 
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9.2.4 Power Calculations 
 
In this study, which was specifically designed to assess haemostatic markers in 
progressing stroke, prospective power calculations were performed in aiding study design 
by the principal investigator, Dr Mark Barber. Power calculations assumed a 25% rate of 
progressing stroke among acute stroke patients. For 90% power (p<0.05), to determine 
similar abnormalities in TAT and D-dimer levels (25%), it was estimated that a total 
group size of 189 patients would be required. The 280 patients recruited fulfills this 
criteria even allowing for exclusions. 
 
9.3 RESULTS 
 
9.3.1 Sample Availability 
 
The majority of the 280 stored plasma samples were available for analysis, with a 
minimum of 94% being assayed for TNFα, which required the largest sample volume. 
All blood samples had been stored at -80oC for up to five years, and the aliquots used for 
analysis of IL-18, TNFα and IL-6 were previously unthawed. The sample quality was 
hence excellent. 
 
9.3.2 Clinical and Demographic Differences Between Patients with Alternative Clinical 
Outcomes 
 
Table 9.1 summarises data comparing patients dead or dependent (Modified Rankin 
Score 3-5) at 30 days compared to surviving independent patients. Age was the only 
significant measured demographic predictor of stroke outcome at 30 days (p<0.001). 
Clinically, both OCSP (p=0.007) classification and SSS (p<0.001) were highly 
significant predictors of stroke outcome, as was atrial fibrillation on admission 
electrocardiogram (p=0.02). Comparing only those who died within 30 days to survivors, 
predictors of outcome were similar to death/dependency composite (data not shown), 
with the exceptions that premorbid Rankin score 3-5 increased risk of death (35% versus 
16% p =0.02) as well as presence of a left hemisphere lesion (31% versus 57% p=0.01; 
inverse association) were also associated with outcome.  
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Comparing the progressing stroke patients to the non-progressing group, the clinical and 
demographic differences were again broadly similar to those described in Table 9.1 (data 
not shown; table given in Barber et al, 2004). The only significant differences were that 
progressing stroke was more likely to occur in females (67% vs 51% p=0.04) and in 
those with pyrexia in the first 72 hours (44% vs 28% p=0.02), and hemisphere lesion had 
no bearing on progression. 
 
Known cases of diabetes did not associate with any outcome, but this could be a chance 
finding due to the small numbers of diagnosed cases, or the presence of undiagnosed 
latent disease within the group. 
 
9.3.3 Inflammatory Marker Associations with Progressing Stroke 
 
Univariate comparisons of inflammatory markers in the progressing versus the non-
progressing stroke subgroups are given in Table 9.2. CRP was significantly associated 
with progression (as described previously; Barber et al, 2004), but the association is 
much stronger for IL-6; median levels of circulating IL-6 levels were ~69% higher at 
admission in those who go on to experience stroke progression. In contrast with these 
findings, neither IL-18 nor TNFα were associated with stroke progression.  
 
9.3.4 Inflammatory and Haemostatic Marker Associations with Poor 30 Day Outcome 
 
As seen in Table 9.3, CRP, IL-6, TNFα, fibrinogen, leukocyte count, D-dimer, 
prothrombin fragment F1+2, TAT, vWF, factors VIII and XI, and viscosity all had 
significant associations with 30 day adverse (death or dependency) outcome on 
univariable analysis. The strongest univariate predictors were CRP, IL-6, D-dimer, and 
factor VIIIc (p<0.0001), although the association was also considerable for TNFα 
(p=0.007). Factor VIIc levels had a borderline inverse association with outcome (p=0.07). 
IL-18 and APC ratio were the only variables measured not to have univariate associations 
with 30 day death/dependency outcome.  
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Comparing only those who died versus survivors, all markers remained significantly 
associated with outcome (data not shown) with the exceptions of TNFα (2.6 versus 
2.1pg/ml; p=0.17) and fibrinogen (3.81 versus 3.92 g/L; p=0.53) which became non-
significant, while PV (p=0.07) retained only borderline significance. 
 
In Table 9.4 a logistic regression analysis in 2 separate models is shown for the risk of 
death or dependency in 30 days. Model 1 includes all the variables in Table 9.1 with 
significant univariate associations with death/dependency (p<0.1), as well as selected 
pro-inflammatory markers (CRP, IL-6, IL-18, TNFα). In this analysis after stepwise 
addition/removal of individual markers, age (OR 1.03; 95% CI 1.00-1.07), stroke subtype 
according to OCSP (OR 2.83; 95% CI 1.00-8.05) and SSS (OR 0.94; 95% CI 0.90-0.98) 
were significantly associated with outcome. Of the inflammatory risk markers included in 
the model, only IL-6 retained a significant association with death/dependency (OR 1.07; 
95% CI 1.01-1.13).  
 
 
Model 2 in Table 9.4 includes all the variables in Table 9.1, as well as all markers in 
Table 9.3 with significant univariate associations with death/dependency  (p<0.1).  Here, 
of the demographic and clinical markers, only SSS is significantly associated with 
outcome (OR 0.92; 95% CI 0.88-0.96). The haemostatic marker D-dimer (OR 1.72; 95% 
CI 1.24-2.39) was the only variable required to add prognostic information to SSS in this 
model.  
 
No multivariate analysis of a death only outcome is presented here due to the fairly small 
number of cases, and consequently large confidence intervals. 
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Table 9.1 Demographic and clinical differences between patients dead or dependent 
(Rankin 3-5) at 30 days compared to surviving independent patients. For the purpose of 
this analysis those with a premorbid Rankin of 3-5 were excluded. For continuous 
variables results are expressed as median (interquartile range [IQR]) except for blood 
pressure where results are expressed as mean (standard deviation). 
OCSP; Oxfordshire Community Stroke Project score, TACI; total anterior circulation 
infarct, PACI; partial anterior circulation infarct, LACI; lacunar infarct, POCI; posterior 
circulation infarct, SSS; Scandinavian Stroke Scale, MABP; mean arterial blood pressure, 
ECG; electrocardiogram. 
 
 
 
Variable Dead /Dependent at 30 
days (n=94) 
Alive / independent at 30 
days (n=86) 
p value 
Age (yrs) 72 (65 - 80) 66 (56 - 73) <0.001 
Female gender 53 (56%) 43 (50%) 0.39 
Previous hypertension 49 (52%) 45 (52%) 0.98 
Known diabetic 13 (14%) 11 (13%) 0.84 
Previous stroke 17 (18%) 16 (19%) 0.93 
Antiplatelet therapy 44 (47%) 34 (40%) 0.58 
Current smoker 38 (43%) 32 (39%) 0.63 
Clinical Differences:    
Left hemisphere lesion 52 (55%) 50 (58%) 0.70 
OCSP classification 
TACI 
PACI 
LACI 
POCI 
 
 
40 (43%) 
39 (41%) 
12 (13%) 
3 (3%) 
 
7 (8%) 
44 (51%) 
26 (30%) 
9 (11%) 
<0.001 
Admission SSS score  
(minus gait)(points) 
30 (15 - 40) 41 (36 - 43) <0.001 
Admission MABP (mmHg) 106 (20) 108 (20) 0.64 
Atrial fibrillation on ECG 16 (17%) 5 (6%) 0.02 
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Table 9.2 Circulating inflammatory markers in those who experience either progressing 
or non-progressing acute stroke. For TNFα and IL-6 statistical analysis is by the Mann 
Whitney U test. Values are medians (IQR) 
 
Variable Progressing Stroke 
(n=52-54) 
Stable/ improving stroke 
(n=154-163) 
p value 
    
IL-18 (pg/ml) 
 
278 (216 – 406) 277 (207 - 375) 0.30 
TNFα (pg/ml) 
 
2.36 (1.42 – 3.64) 2.10 (1.48 – 2.86) 0.53 
IL-6 (pg/ml) 
 
11.69 (6.16 – 20.52) 6.90 (3.29 – 13.82) 0.001 
CRP (mg/l) 8.66 (3.69 – 30.45) 5.26 (1.64 – 18.4) 0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  284
 
Table 9.3 Circulating inflammatory, haemostatic and haemorrheological variables in 
patients who died or were dependent at 30 days compared to those who were not. Results 
are expressed as median (interquartile range). For TNFα and IL-6 statistical analysis is 
by the Mann Whitney U test. 
Variable 
Dead /Dependent at 30 
days (n=94) 
Alive / independent at 30 
days (n=86) 
p value 
    
CRP (mg/l) 8.0 (3.5 - 26) 3.3 (1.1 – 8.2) <0.001 
IL-6 (pg/ml) 10.4 (6.0 – 16.7) 4.4 (2.4 – 9.2) <0.001 
TNFα (pg/ml) 2.3 (1.5 - 3.4) 1.8 (1.4 – 2.6) 0.007 
IL-18 (pg/ml) 248 (202 - 358) 284 (196 - 378) 0.26 
Leucocyte count (x109/l) 10.2 (7.9 – 12.6) 9.1 (7.4 – 10.9) 0.002 
Fibrinogen (g/l) 3.98 (3.34 – 4.90) 3.58 (2.95 – 4.30) 0.001 
Fibrin D-dimer (ng/ml) 273 (148 - 788) 128 (59 - 306) <0.001 
Prothrombin F1+2 (nmol/l) 1.1 (0.9 – 1.6) 1.0 (0.7 – 1.4) 0.003 
TAT (µg/l) 4.5 (3.5 – 7.8) 3.7 (2.9 - 5.6) 0.003 
APC ratio (n=133) 2.8 (2.5 – 3.1) 2.8 (2.6 – 3.2) 0.40 
t-PA antigen (ng/ml) 12.4 (8.8 – 17.4) 10.0 (7.8 – 12.8) 0.01 
vWF antigen (iu/dl) 208 (171 - 264) 186 (140 - 216) 0.001 
Factor VIIc (iu/dl) 142 (120 - 165) 149 (129 - 173) 0.07 
Factor VIIIc (iu/dl) 206 (174 - 253) 176 (144 - 218) <0.001 
Factor IXc (iu/dl) 165 (148 - 188) 152 (138 - 171) 0.003 
Plasma viscosity (mPa.s) 1.29 (1.21 – 1.37) 1.23 (1.19 – 1.32) 0.03 
APC; activated protein C, TAT; thrombin-antithrombin complex, t-PA; tissue 
plasminogen activator, vWF, von Willebrand factor 
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Table 9.4 Forward stepwise logistic regression models of predictors of death or 
dependency at 30 days.  
Model 1: All demographic and clinical variables with p value <0.10 in univariate 
analysis, as well CRP, IL-6, IL-18, and TNFα. 
Model 2: All demographic and clinical variables as well as all variables in Table 9.3 with 
p value <0.10 in univariate analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Coefficient B 
(SE) 
Odds Ratio 95% CI p value 
Model 1 
 
    
Constant -0.76 (1.37)    
Age  0.03 (0.02) 1.03 1.00 - 1.07 0.03 
OCSP (TACI or other) 1.04 (0.53) 2.83 1.00 - 8.05 0.05 
SSS score -0.07 (0.02) 0.94 0.90 – 0.98 0.002 
IL6 0.06 (0.03) 1.07 1.01 – 1.13 0.02 
     
Model 2 
 
    
Constant 3.62 (2.19)    
SSS score -0.09 (0.02) 0.92 0.89-0.96 0.00 
D-Dimer 0.48 (0.17) 1.72 1.24-2.39 0.01 
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9.4 DISCUSSION 
 
9.4.1 Patient Population Distribution of Inflammatory Markers 
 
Median circulating levels of TNFα (2.1 pg/ml in all patients) and IL-18 (277pg/ml) were 
not substantially higher than in those in the older age group of MONICA-4 (Chapter 4). 
There was a ~15% increase in median levels for each cytokine; which is minimal 
considering the patients were experiencing acute stroke. In contrast, median IL-6 levels 
were 7.69pg/ml, which is roughly a 3-fold increase from levels seen in a similar 
MONICA-4 age-group. CRP levels were similarly elevated in this population. 
 
9.4.2 IL-18 and TNFα and Associations with Acute and Progressing Stroke and 30 Day 
Outcomes 
 
That IL-18 and TNFα levels were not elevated during acute stroke (compared with 
MONICA-4) suggests that these cytokines are not substantially elevated within the first 
24 hours of stroke onset, and are therefore unlikely to play immediate roles in acute 
stroke pathology, such as early neurological deterioration.  
 
Lack of an association between admission levels of these cytokines and 72 hour stroke 
progression is suggestive of lack of a causal role in the condition, since the 
pathophysiological background required for persistent thrombi-mediated occlusion would 
probably be set in the acute stages of stroke. Consistent with this, one study has shown in 
41 patients that TNFα  levels at admission do not associate with lesion size or 
neurological impairment (Intiso et al, 2004). It should be noted that these results are 
inconsistent with a very small study (Zaremba & Losy, 2001; Zaremba and Losy, 2004), 
showing associations of the IL-18 and TNFα with clinical markers of stroke severity and 
neurological deterioration, but there are too few patients in that study to draw rigorous 
conclusions. 
 
Despite univariable associations with death/dependency composite outcome, levels of 
TNFα no longer predicted outcome in the multivariable model including other 
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inflammatory markers. The possibility that baseline TNFα levels were not maximal 
within the 24 hour inclusion time limit, which might reduce the study’s power to detect 
associations with outcome, cannot be discounted (see 9.4.3). It is interesting to note that 
TNFα was one of the only markers with strong associations with 30 day outcome that did 
not also predict early progression, although there were trends towards increased levels in 
the latter condition. This may be indicative of a differential underlying aetiological role 
for TNFα in acute versus more chronic pathological processes, or alternatively it may be 
a chance finding. 
 
IL-18 was apparently not elevated during the acute stages of stroke, and was not a 
prognostic indictor of progression, 30 day outcome, or death at 30 days. IL-18 has no role 
in knock-out models of stroke induced brain injury in mice (Wheeler et al, 2003), and 
likewise is not a stimulator of the acute phase response (Stuyt et al, 2005). Therefore it 
seems lack of association with both the degree of stroke injury and with the acute phase 
response means IL-18 is not even univariately associated with outcome. 
 
9.4.2 Other Inflammatory and Haemostatic Markers and Associations with 30 Day 
Outcomes 
 
In this study of a cohort of acute ischemic stroke patients, a wide range of inflammatory 
and haemostatic biomarkers predicted poor prognosis as measured by 30 day death or 
dependency in univariate analysis. Such widespread general associations with outcome 
probably reflect the association between these markers and underlying biological 
processes in acute stroke, and hence likelihood of poor outcome. For instance, 
generalised inflammation (such as that measured by CRP and IL-6) probably reflects the 
extent of systemic atherosclerosis, the extent of neurological damage in acute stroke, the 
risk of further atherothrombotic rupture, and the age of the patient (Lowe et al, 2005; 
Hansson et al, 2005) while levels of haemostatic markers may reflect current thrombotic 
potential in the formation of thromboemboli and ongoing fibrinolysis as well as patient 
age (Franchini et al, 2006; Matijevic et al, 2006). Indeed, one study has shown the extent 
of brain injury may largely determine the extent of the acute phase response following 
stroke (Smith et al, 2006). Clinically relevant biological mechanisms that increase the 
risk of poor outcome as well as some confounding associations hence probably explain 
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much of the association between inflammatory and haemostatic risk markers and 
prognosis in acute stroke. 
 
In contrast to TNFα and IL-18, both IL-6 and CRP were elevated on admission, and in 
particular IL-6 was associated strongly with progression. These results for IL-6 were in 
agreement with previous studies showing that it predicts neurological deterioration in the 
first 48 hours independently of clinical risk markers (Vila et al, 2000), and peak levels in 
the first week predict modified Rankin score at 3 months and computed tomography (CT) 
brain infarct volume as well as 12 month outcome (Smith et al, 2004; Emsley et al, 
2003). IL-6 association with 30 day outcome over and above clinical risk markers and 
other inflammatory markers is in line with observations that IL-6 is the pro-inflammatory 
cytokine largely responsible for promotion of the acute phase response, as well as 
perhaps playing roles in endothelial dysfunction, atherogenesis, and the promotion of a 
hypercoagulable state (Yudkin et al, 2000).  
 
Interestingly, fibrinogen shows only borderline association with progressing stroke 
(Barber et al, 2004) and was not associated with 30 day outcome. This suggests that 
although fibrinogen has been considered a good candidate marker of prognosis in stroke 
(Di Napoli et al, 2006), not all the acute phase response is equal in prediction of stroke 
progression. In other studies, fibrinogen appears predictive of longer term outcome and 
risk of recurrent CVD events (Anuk et al, 2002; Di Napoli et al, 2005; Turaj et al, 2006). 
This may be indicative that fibrinogen levels are not elevated to maximal levels within 24 
hours of stroke onset, which is in agreement with one study which has reported 
fibrinogen to be significantly elevated only a week after acute stroke (Lip et al, 2002) 
while another has demonstrated that CRP and IL-6 follow distinct patterns of expression 
following acute stroke, with inter-individual differences also present within these patterns 
(Smith et al, 2004). Hence there may be other markers (such as TNFα and perhaps IL-18) 
which do not show prognostic ability in the acute phase. 
 
When all clinical risk markers significantly associated with prognosis in this study were 
included with all haemostatic and inflammatory markers in the same multivariate model, 
only SSS and D-dimer were required to give the greatest prognostic information. D-dimer 
is perhaps a good prognostic indicator of short-term outcome in ischaemic stroke because 
  289
 
it is both an acute phase reactant and a marker of turnover of cross-linked fibrin, 
generated by activation of coagulation and fibrinolysis, and it hence may represent the 
biological activation of both the inflammatory and haemostatic systems. A previous study 
has suggested that D-dimer levels may be associated specifically with ischaemic stroke 
subtypes (Ageno et al, 2002) and another study found that acute stroke D-dimer levels 
were not associated with long term stroke prognosis after adjustment for stroke subtype 
(Squizzato et al, 2006). Although we have not examined this hypothesis it is possible this 
is a confounding factor for its association with outcome here, but this is also equally 
possible for all markers measured considering the potential differences in aetiology 
(Suwanwela et al, 2006).  
 
9.4.3 Study Strengths and Limitations 
 
The strengths and weaknesses of the present study have been considered previously 
(Barber et al, 2004). A single researcher assessed consecutive admissions to the hospital 
using relatively few exclusion criteria, although those included should be sufficient to 
remove extraneous confounding of acute ischaemic stroke phenotypes seen on hospital 
admittance. Samples were taken within 24 hours of symptom onset and not at a regular 
interval after symptom onset, and this criteria may allow inter-individual confounding 
and, as discussed, may not temporally allow aspects of the inflammatory response to 
peak. Despite this the study time is representative of conditions upon general medical 
ward assessment, and is perhaps more clinically relevant than strict temporally controlled 
exclusion criteria. Detailed functional imaging was not performed as part of the study 
protocol, and hence such data cannot be included. This particular weakness may detract 
from the strength of the multivariable models used, but as such does not influence 
conclusions drawn about IL-18 and TNFα in particular. 
 
9.4.4 General Conclusions 
 
Neither IL-18 nor TNFα were significantly elevated within 24 hours of onset of acute 
stroke, nor were they associated with stroke progression. Therefore hospital admittance 
levels of IL-18 and TNFα are unlikely to be clinically useful in determining stroke 
severity or likihood of progression. Despite a univariate association of admission TNFα 
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with 30 day outcome, the association was not as strong as it was using IL-6 or D-dimer as 
a prognostic biomarker. Negative findings here and elsewhere (Wheeler et al, 2003) 
collectively suggest that IL-18 has minimal involvement in the acute stages of stroke, 
even as a passive bystander.  
 
These results do not preclude a role for either cytokine in predicting recurrent stroke. 
Chapter 11 therefore explores the associations of IL-18 and TNFα with recurrent stroke, 
preceded by a study of incident stroke in Chapter 10. 
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CHAPTER 10 
 
ASSOCIATIONS OF IL-18 AND TNFα WITH INCIDENT STROKE IN AN 
ELDERLY POPULATION WITH PREVALENT VASCULAR DISEASE: 
PROSPECTIVE STUDY OF PRAVASTATIN IN THE ELDERLY AT RISK 
(PROSPER) 
 
INTRODUCTION 
 
10.1.1 Stroke Incidence in the Elderly 
 
In the elderly, chronic vascular disease, and particularly stroke, is by far the major cause 
of morbidity and mortality and is also a major contributor to cognitive decline and 
dementia (Wenger, 1992; Martyn, 1996; Elkind, 2003). Stroke incidence rates double in 
populations for every 10 years after 55 years (Elkind, 2003). The aetiology of stroke, 
particularly in the elderly, therefore requires specific epidemiological consideration. 
10.1.2 Previously Published  Data on Inflammatory Markers and Incident Stroke     
The literature examining the epidemiological relationships of inflammatory markers and 
stroke risk is examined in section 1.7.4/1.7.5. In brief, although they have different 
underlying aetiologies, the association of CRP and fibrinogen with both CHD and stroke 
appears remarkably similar in general populations (Di Napoli et al, 2005; Danesh et al, 
2004; Fibrinogen Studies Collaboration, 2005). The Rotterdam Study recently showed 
prospectively in a study with 498 primary strokes that CRP was very modestly associated 
with risk of all strokes (age- and sex-adjusted OR per SD, 1.14; 95% CI 1.04 - 1.24) and 
risk of ischemic stroke (age- and sex-adjusted OR per SD, 1.17; 95% CI 1.04 - 1.32) (Bos 
et al, 2006). Significant univariable associations of IL-6, CRP and fibrinogen with stroke 
were also recently reported in the Edinburgh Artery Study (Tzoulaki et al, 2007). In the 
whole PROSPER cohort CRP predicts risk of stroke independently of conventional risk 
factors: 1.32 (1.03 - 1.79) comparing extreme tertiles and this, again, is similar to risk 
association seen for CHD in the study 1.33 (1.09 -1.62) (1Sattar et al, 2007) and risk of 
CHD on meta-analysis for CHD (Danesh et al, 2004). 
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The Fibrinogen Studies Collaboration (2005) have published data on the association 
between fibrinogen and incident stroke, and again found broadly similar associations to 
those seen in CHD: for all types of stroke (n=2775) the age and sex-adjusted OR per 1g/L 
increase in fibrinogen was 2.06 (95% CI, 1.83-2.33), for ischemic stroke 2.08 (95% CI, 
1.74-2.48), for hemorrhagic stroke 1.44 (95% CI, 1.05-1.96), and for stroke attributed to 
unclassified causes 2.36 (95% CI, 1.94-2.86). These results are comparable to data for the 
combined OR for all vascular deaths and events: 2.35 (95% CI, 2.21-2.49) and was also 
similar to that for all nonvascular mortality 2.03 (95% CI, 1.90 – 2.08). 
 
For both IL-18 and TNFα there are data that report associations with the composite 
endpoints “MI plus stroke risk” or “all CVD risk,” (e.g. 2Cesari et al, 2003, Wise et al, 
2005, Blankenberg et al, 2006) and although this is reasonable methodology in terms of 
clinical risk assessment, it is not helpful in delineating associations with stroke risk 
specifically. The only published data examining stroke risk specifically and TNFα is 
from the ABC study (2Cesari et al, 2003) and contained only 60 incident strokes in which 
TNFα was not associated with outcome (see Table 1.4). There is no such published data 
for IL-18. Similarly, despite recent interest in positive associations of IL-6 gene 
polymorphisms with stroke (Chamorro et al, 2005; Lalouschek et al, 2006; Yamada et al, 
2006) IL-6 itself has been strongly implicated in stroke risk. For instance, the ABC study 
(which found TNFa to be not associated with risk of stroke in 60 cases [Table 1.4]) found 
that IL-6 predicted stroke risk in healthy elderly people even after adjustment for 
classical risk factors: OR 2.86 (1.71–4.80) (2Cesari et al, 2003). This was significantly 
higher than its association with risk of CHD: OR 1.71 (1.27–2.29). 
 
During this thesis, a PROSPER stroke case/control study was formed from the principal 
cohort, and a full complement of PROSPER plasma case/control samples were available 
in our laboratory. It was a good opportunity to complete the initial assessment of IL-6, 
IL-18 and TNFα in stroke, also examining cytokine associations with incident stroke in a 
population (in addition to acute and recurrent stroke; Chapters 9 and 11). Consent to 
perform the work on new potential cardiovascular risk markers had been obtained at the 
time of the trial recruitment, which was approved by the local research ethics committees. 
Due to the availability of only plasma samples, sCD40L and MMP-9 were not examined 
in this study. 
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10.1.3 Aims 
 
The aim of this study was to assess the associations of IL-18, IL-6 and TNFα with 
incident all-cause and ischaemic stroke in an elderly population with prevalent vascular 
disease and to assess the level of independence of this association from conventional risk 
markers. 
 
10.2 MATERIALS AND METHODS 
 
10.2.1 Establishment of the PROSPER Trial 
 
It is well documented that treatment with statins reduces the burden of CHD in middle-
aged populations both with and without prevalent vascular disease (e.g. Scandinavian 
Simvastatin Survival Study Group (4S), 1994; West of Scotland Coronary Prevention 
Study [WOSCOPS]; Shepherd et al, 2005), and these observations have previously been 
extrapolated to the elderly. However, this assumption may be inaccurate, and the elderly 
may be very different in terms of CHD aetiology and the consequent benefits gained from 
statin use. For instance it is known that the BMI is a poorer index of CHD risk in the 
elderly than in middle-aged populations; this may reflect underlying changes in the 
aetiology of disease as a population ages, for instance loss of skeletal muscle mass as 
well as gain of fat mass being a risk factor, confounding associations of BMI with risk in 
the elderly (Wannamethee et al, 2005).  
 
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) (Shepherd et al, 
1999) was set up to investigate the benefits of statin use to reduce cardiovascular risk in 
the elderly with prevalent vascular disease. The study reported a 34% reduction in serum 
cholesterol after 3 years, and a reduction in risk of CHD events (OR 0.81, 95%CI 0.69-
0.94) in active treatment group versus placebo (Shepherd et al, 2002). Stroke risk was 
unaffected in this study, but this may be due to the 3 year follow-up; some studies 
indicate that it may take in excess of 3 years to see benefit from statin use in terms of 
stroke risk (Byington et al, 2001; Pedersen et al, 1998) and pravastatin is a less potent 
drug for lowering cholesterol than some other statins. In subsequent meta-analysis of 
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randomised controlled tirals of statins (primarily in men), including the prosper trial, the 
Cholesterol Trialists Collaboration reported that statins reduced the risk of all stroke type 
19% (99% CI 11-26%) and ischaemic stroke 22% (99% CI 12–30%) (CTC, Lancet, 
2005). Subsequent clinical issues of whether lipoprotein profiles in the elderly can be 
used to assess those who are best the best targets for statin use have also been examined 
in PROSPER (Packard et al, 2005). Also published from the PROSPER study are data 
(previously discussed in section 1.7.4) demonstrating a weak but significant and 
independent relationship of CRP to CVD event risk in the whole cohort, which was 
shown to add little to the C-statistic of the Framingham risk factors in the elderly, or to 
indicate predictive statin benefit (1Sattar et al, 2007). 
 
10.2.2 Subjects and Methods 
 
The PROSPER study was a randomised placebo-controlled trial of Pravastatin in 5,804 
subjects (2,520 in Scotland, 2,184 Ireland, and 1,100 Netherlands) aged 70-82 years, with 
vascular risk factors or known vascular disease (Shepherd et al, 1999). Half had evidence 
of chronic vascular disease (stable angina or intermittent claudication) and the other half 
having at least one vascular risk factor (hypertension, smoking or diabetes mellitus). 
Blood samples were taken at baseline, prior to study entry. After 3.2 years follow-up a 
nested case-control study was extracted comprising 266 patients with incident stroke who 
were compared with 532 controls from the PROSPER cohort in a 2:1 ratio. Matching 
variables included age (within 5 years), gender and treatment allocated (pravastatin or 
placebo). 
 
Stroke was defined as: (a) rapid onset of focal neurological deficit lasting ≥ 24 hours, (b) 
focal neurological deficit mode of uncertain onset but with no plausible evidence of 
alternative (non-stroke) cause, or (c) rapid onset of global neurological deficit (e.g., 
coma) lasting ≥ 24 hours with no other plausible non-stroke cause. Transient ischaemic 
attacks were defined as rapid onset of focal neurological deficit lasting < 24 hours. 
Strokes were categorised as ischaemic or haemorrhagic on the basis of neuroimaging 
(computed tomography or magnetic resonance imaging) or post mortem. Where no 
neuroimaging or post-mortem was available strokes were categorised as ‘unclassified’. 
Of the 266 strokes in PROSPER 179 (67%) were infarcts, 18 (7%) primary intracerebral 
haemorrhages and 69 (26%) undefined. 
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IL-18 and TNFα were measured on previously unthawed aliquots as described in Chapter 
2. 
 
 
10.2.2 Statistical analysis 
 
Cases and unique controls were compared, for continuous variables, using t-tests after log 
transformations to better approximate normal distributions where necessary. Binary 
variables were compared through chi-square or Fisher’s exact tests. Odds ratios for stroke 
were estimated from univariable logistic regression models (Woodward, 2005) using the 
matched sets as units of observation in both total and ischaemic stroke subgroups. 
Reported odds ratios for continuous variables are those associated with 1 SD change in 
the control population. In addition to unadjusted (except for matching variables) analyses 
for IL-18 and TNFα, multivariable adjustments were made for history of vascular disease 
and for APR-associated inflammation (IL-6 and CRP). 
 
 
10.3 RESULTS 
 
 
10.3.1 Baseline Characteristics 
 
Baseline clinical characteristics of the 266 patients with all incident strokes, compared 
with 532 age and-sex matched controls, are presented in Table 10.1. Prior history of 
stroke (<0.0001) and to a lesser extent history of MI or any vascular disease (p=0.08, 
0.01 respectively) were associated with increased risk of stroke, as was diabetes mellitus 
(p=0.03). Lower cognitive function (Mini-Mental State Examination, p=0.02), reduced 
speed of information processing (STROOP test, p=0.05), lower Instrumental Activities of 
Daily Living score (p=0.02) and reduced Barthel Index (p=0.001) at baseline all were 
associated with increased likelihood of stroke. Alcohol consumption (p=0.006) was more 
likely to be prevalent among the case group, and there was a non-significant trend for 
cases to be current smokers as well. No common cardiovascular medications were 
associated with risk of stroke. SBP showed non-significant trends to be higher among 
cases than in controls, but BMI and DBP did not. Likewise, HDL and LDL cholesterol 
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measurements showed no differences in cases and controls, but non fasting glucose 
measurements were higher in the case group (p=0.009).  
 
Among the inflammatory markers neither fibrinogen, CRP, IL-6, IL-18 nor TNFα 
showed any significant differences between cases and controls, although with the 
exception of TNFα all showed non significant trends to be slightly higher in the case than 
in the control group (overall difference between 1 and 4%). 
 
Similar patterns were seen in the subset of 179 ischaemic stroke patients when compared 
with the control group, and none of the overall results from Table 10.1 differed in this 
analysis (data not shown). 
 
 
10.3.2 Risk Ratios of Stroke                                                                                            
 
As expected from the results in Table 10.1, Table 10.2 demonstrates that neither IL-6, IL-
18, nor TNFα are associated with risk of stroke on univariable analysis. IL-6 
demonstrated only non-significant borderline associations with risk in univariable 
analysis; OR 1.10 (95% CI 0.95-1.28) per SD increase. IL-18 and TNFα show no 
associative trends; 1.06 (0.92-1.22) and 0.91 (0.76-1.10) respectively. Multivariable 
analysis was only performed on IL-18 and TNFα in the ischaemic stroke subgroup 
compared to the control group. Unsurprisingly, after further adjustment for IL-6, CRP 
and history of vascular disease, there was no change in the null-association of the 
cytokines with risk of incident ischaemic stroke (Table 10.2). 
 
 
10.3.3 Correlations 
 
Correlations of cytokines with conventional/clinical risk markers were not explored in 
this study due to the age and prevalence of vascular disease. The correlations are 
therefore unlikely to elicit meaningful results in this population. 
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Table 10.1 Baseline characteristics of all stroke case and control populations: back-
transformed (from log-normalised analysis) means (standard deviations) or percentages. 
Corresponding p-values obtained by two tailed t-test after log-transformations of 
continuous variables where appropriate. Categorical variables compared using chi-
squared test. 
 Cases  
(n=266) 
Controls  
(n=532) 
p-value 
Questionnaire/Clinical exam    
History of vascular disease 143 (53.8%) 236 (44.4%) 0.01 
History of stroke/TIA 53 (19.9%) 49 (9.2%) <0.0001 
History of MI 78 (29.3%) 126 (23.7%) 0.08 
History of diabetes 46 (17.3%) 62 (11.7%) 0.03 
Alcohol intake (any)  161 (60.5%) 271 (50.9%) 0.006 
Current smokers 78 (29.3%) 126 (23.7%) 0.08 
Anti-hypertensive medication 188 (70.7%) 399 (75.0%) 0.19 
Anti-platelet medication 95 (35.7%) 171 (32.1%) 0.31 
Barthel Index 19.6 ( 1.07) 19.8 ( 0.52) 0.001 
MMSE 27.8 ( 1.75) 28.1 ( 1.52) 0.02 
TIDAL score 13.5 ( 1.33) 13.7 (0.91) 0.02 
STROOP 70.9 ( 29.6) 66.9 (25.6) 0.05 
Physical measurements    
Body mass index (kg/m2) 26.5 (4.1) 26.8 (4.0) 0.36 
Systolic blood pressure (mmHg) 157.2 (21.29) 154.9 (23.0) 0.16 
Diastolic blood pressure (mmHg) 84.0 (11.8) 84.3 (11.2) 0.70 
Blood Sample    
LDL cholesterol (mmol/L) 3.76 (0.83) 3.75 (0.82) 0.88 
HDL cholesterol (mmol/L) 1.26 (0.33) 1.27 (0.34) 0.46 
Glucose (mmol/L) 5.81 (2.12) 5.46 (1.44) 0.009 
Fibrinogen (g/L) 3.60 (0.76) 3.56 (0.77) 0.56 
C-reactive protein (mg/L) 1.25 (1.13) 1.13 (1.17) 0.21 
Interleukin-6 (pg/ml) 1.03 (0.70) 0.99 (0.65) 0.45 
Interleukin-18 (pg/ml) 375 (175) 365 (157) 0.39 
TNFα (pg/ml) 1.75 (2.22) 1.96 (2.89) 0.33 
 
MMSE, Mini mental-state exam; TIDAL, Instrumental Activities of Daily Living score; 
STROOP, speed of information processing 
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Table 10.2 Associations of IL-6, IL-18 and TNFα with risk of incident stroke as 
continuous variables (ORs represent risk of 1 standard deviation increase in circulating 
cytokine levels among control population). 
 
 Univariable analysis (age- and 
sex-matched samples) 
Multivariable analysis* 
 Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
All strokes     
IL-6 1.10 (  0.95-1.28) 0.21   
TNFα 0.91 (  0.76-1.10) 0.33   
IL-18 1.06 (  0.92-1.22) 0.39   
Ischaemic Strokes     
TNFα 0.96 (0.79-1.16) 0.65 0.96 (0.79-1.16) 0.66 
IL-18 1.08 (0.92-1.28) 0.34 1.07 (0.90-1.26) 0.45 
* Adjusted for IL-6, CRP and history of vascular disease 
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10.4 DISCUSSION 
 
10.4.1 Population Distributions 
 
The median levels of circulating IL-18 in this population were 330 pg/ml (IQR 255-434) 
for the controls and 336 pg/ml (276-438) for the cases. This is ~30% higher than in the 
eldest age-group (55-64 years) in the MONICA-4 survey (Chapter 4), a result entirely 
consistent with the age (70-82 years) and prevalence of vascular disease within the 
current case-control study. In contrast, circulating levels of TNFα were 1.24 pg/ml (0.89-
2.03) and 1.30 pg/ml (0.93-1.78) for controls and cases respectively. This is ~30% lower 
than the eldest age group in the MONICA-4 study. This unexpected result is unlikely to 
be explicable through sample quality issue. Samples were only ~8 years old, and were 
previously unthawed aliquots. Since TNFα generally increases with age (Chapter 4) the 
simplest logical explanation is a drift in the standards provided by the manufacturer 
between kit lots. 
 
10.4.2 General Null Association of Inflammatory Biomarkers with Risk of All Stroke or 
Ischaemic Stroke 
 
Data from this PROSPER case-control study indicate that not only are IL-18 and TNFα 
not associated with risk of stroke in the elderly, but also that IL-6, fibrinogen and CRP 
demonstrate a similar lack of association. All of the inflammatory markers, with the 
exception of TNFα, showed a non significant trend to be higher in the case than in the 
control group, although on no occasion did the trend reach borderline significance 
(p<0.1).  
 
This result is surprising considering that both the Leiden 85-P (Gussekloo et al, 2000) 
and the Cardiovascular Health (Cao et al, 2003) studies of the elderly found CRP to be a 
significant predictor of risk of stroke in the elderly (median 5.7 vs 2.7 mg/L, P<0.005 for 
Leiden 85-P, and 2.07 vs 1.87 mg/L, p<0.006 respectively) and the current study 
certainly has sufficient power for incident stroke compared with the Leiden 85-P study 
(80 cases). Similarly, the Fibrinogen Studies Collaboration (2005) has shown that a 1g/L 
increase in fibrinogen in the elderly (>70 years) is associated with a RR of 1.90 (95% CI 
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1.54-2.34), which is a less strong association than that seen in the middle aged (OR 2.77 
per 1g/L increase).  
 
A recent cross-sectional study has suggested that IL-6 (but not other inflammatory 
markers) is weakly associated with MMSE (2Wright et al, 2007) so the lack of a 
univariate association of IL-6 with risk was also surprising considering MMSE was 
associated with stroke risk in this cohort. However, this may be explained by the weak 
association of IL-6 with MMSE, and the weak association of MMSE with stroke risk. 
 
10.4.3 Limitations of the Study 
 
Lack of an association of CRP or fibrinogen with risk in this cohort requires careful 
consideration, since IL-18 and TNFα may demonstrate lack of association for potentially 
the same underlying reasons.  
 
This particular cohort were carefully selected elderly patients considered at risk of stroke 
to due the presence of vascular risk factors, or the confirmed presence of vascular 
disease. As in GLAMIS, selection of those with prevalent disease will result in selection 
biases in the data. Indeed the current study found smoking not to be associated with risk 
of stroke, but smoking is a major risk factor for stroke. That the increased smoking/risk 
trend did not reach significance is probably a similar phenomenon to that reported in the 
GLAMIS study, where those with recent health problems may have recently given up 
smoking. However, no “ex-smoker” data is available in this cohort. BMI also was not 
associated with risk in this cohort, and this probably because the population was elderly 
(low muscle as well as fat mass, hence BMI has little to do with vascular risk in this 
population; 3Wannamethee et al, 2005) 
 
As seen for fibrinogen (Fibrinogen Studies Collaboration, 2005) it is likely that 
associations between circulating levels of fibrinogen (and potentially other inflammatory 
markers) are less strongly associated with risk of stroke in the elderly. It is also likely that 
the differences between cases and controls in terms of conventional risk factors is likely 
to be smaller than in an unselected general cohort or a cohort comprising people without 
verified vascular disease. It is possible therefore that associations of inflammatory 
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markers with conventional stroke risk factors seen in other studies are largely lost due to 
the suboptimal health of the case and control populations in this study; a facet of the 
study design. This is reflected by the fact that ~ ¾ of both cases and controls were on 
medication for hypertension and that mean SBP among cases and controls was 
>150mmHg. Even among controls, 44% of the population had a history of vascular 
disease. These disease and risk factor levels were not seen in control populations in 
previous studies of stroke (Gussekloo et al, 2000; Cao et al, 2003; Fibrinogen Studies 
Collaboration, 2005) 
 
A previous report from the PROSPER cohort has shown that within the entire cohort, 
CRP is associated with global vascular risk (1Sattar et al, 2007), and is also associated 
with risk of stroke, although not strongly: OR 1.38 (95% CI 1.08-1.85) in top versus 
bottom thirds of the population after only adjustment for pravastatin. Therefore the null 
association of CRP with risk of stroke in the present study must only be a facet of the 
control population (because the cases are the same ones as in the cohort). This 
observation supports the preceding hypothesis and is further alluded to in the overall 
cohort study, which shows that CRP was more strongly associated with risk of CVD 
events in those with no history of vascular disease (51% higher risk in the fully adjusted 
model) compared with those with a history of vascular disease (30% higher risk) (1Sattar 
et al, 2007). 
 
Hence the present study has some limitations in terms of comparison to more general 
populations. It would be useful to measure TNFα and IL-18 in the whole PROSPER 
cohort. 
 
10.4.3 IL-18 and TNFα and Risk of Stroke in the Elderly 
 
Overall this study suggests that both IL-18 and TNFα are of limited use as biomarkers of 
risk of stroke in elderly patient populations with prevalent vascular disease or vascular 
disease risk. This finding suggests that in other “unselected” studies, potential 
associations of IL-18 and TNFα with risk of stroke may be confounded by both age and 
other vascular risk markers. Previously the PROSPER cohort has demonstrated that CRP 
adds nothing to the Framingham risk score in terms of the C-statistic, and does not add 
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information to indication of who would benefit from pravastatin prescription in the cohort 
(1Sattar et al, 2007). Combined with results from the present study, the conclusion must 
be that inflammatory markers in general may be of little use as risk predicotrs in elderly 
populations with prevalent vascular disease, either as prognostic markers, or as indicators 
of those who benefit from statin administration. More studies in more general elderly 
populations are required to confirm and expand on these findings, as well as further 
studies in middle-aged populations; although attaining large numbers of incident first 
strokes to sufficiently power observations in the latter population is problematic. 
 
As a final step in the examination of associations of IL-18 and TNFα with stroke, I 
examined associations with risk in a case-control study of recurrent stroke. 
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CHAPTER 11 
 
ASSOCIATIONS OF IL-18, TNFα AND THE APR WITH RECURRENT 
STROKE: THE PERINDOPRIL PROTECTION AGAINST RECURRENT 
STROKE (PROGRESS) TRIAL 
 
11.1 INTRODUCTION 
11.1.3 Inflammatory Markers and Recurrent Stroke                                                  
CRP and fibrinogen have been shown to be associated with recurrent stroke (Woodward 
et al, 2005) and with mortality in follow-up after major stroke (Elkind et al, 2006; Turaj 
et al, 2006) although these studies failed to classify initial strokes by major subtypes 
(Elkind et al, 2006) or to report the number of incident recurrent strokes in the 900 
patients during follow-up (Turaj et al, 2006). There were no studies found which assessed 
either IL-18 or TNFα as risk markers for recurrent stroke in the literature. Also, despite 
recent interest in positive associations of IL-6 gene polymorphisms with stroke (Yamada 
et al, 2006; Lalouschek et al, 2006; Chamorro et al, 2005), the biomarker itself is has not 
been studied in either primary or recurrent stroke.  
11.1.4 Aims 
 
The aim of this study was to assess IL-6, IL-18 and TNFα as risk markers for recurrent 
stroke (according to major subtype) and their relative independence in risk prediction 
from conventional risk markers, acute phase reactants, and each other, in multivariate 
models. In addition to univariate associations we thus aimed to elucidate the contribution 
of “generalised” inflammation to risk of recurrent stroke. 
 
 
11.2 MATERIALS AND METHODS 
 
11.2.1 Study Design and Subject Recruitment 
 
Of the estimated 15 million people who experience stroke worldwide each year, 10 
million survive, although over a third of those survivors are classified as disabled (WHO, 
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Global Burden of Stroke, 2004). The survivors of stroke or TIA are at highly increased 
risk of recurrent strokes; around 4% in the first month, 12% in the first year, and 5% for 
every year thereafter (Hankey, 2003). Therefore effective treatment for prevention of 
secondary stroke is a medical priority.  
 
Although it had been known for some time that blood pressure is a key risk factor in 
stroke (Eastern Stroke and Coronary Heart Disease Collaborative Research Group, 1998; 
Prospective Studies Collaboration, 1995), fewer data were available linking it as a risk 
factor to recurrent stroke. One meta-analysis of 2742 patients with history of 
cerebrovascular disease suggested that a SBP 6-8 mm Hg reduction was associated with 
one fifth reduction in stroke, although confidence intervals were wide (Rodgers et al, 
1997). The diuretic inadapamide was reported to be effective in prevention of recurrent 
stroke (PATS Collaborating Group, 1995), but final results of that study were not 
published. The Perindopril Protection Against Recurrent Stroke (PROGRESS) study 
(PROGRESS Management Committee, 1996) was set up as a double blinded placebo 
controlled study of 6105 patients with previous stroke or TIA, who were given the ACE 
inhibitor perindopril, indapamide, combination therapy, or placebo. The aim of the study 
was to estimate the effects of blood pressure lowering on risk of recurrent stroke. 
 
Stroke occurred in 307 patients (10%) in the active treatment group and 420 (14%) in the 
placebo group (relative risk reduction, 28%; 95% CI, 17 to 38%; P<0.0001) (PROGRESS 
Collaborative Group, 2001). Further studies showed active treatment reduced the risk of 
major coronary events by 26% (95% CI: 6-42%; p=0.02) and the risk of congestive heart 
failure by 26% (5-42%; p=0.02). Interestingly, there was no evidence of differences 
between the treatment effects in participants classified as hypertensive or non-
hypertensive, and those with or without a history of coronary heart disease (PROGRESS 
Collaborative Group, 2003). 
 
Since cessation of follow-up (average 3.9 years), the study has provided a valuable case – 
control study of recurrent stroke, with 591 cases matched with 1182 controls.  
 
The PROGRESS case-control study was recently used to assess the hereto relatively 
unknown associations between stroke recurrence and CRP, fibrinogen, plasma viscosity, 
t-PA, and D-dimer (Woodward et al, 2005). Only CRP and fibrinogen were risk 
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predictors of ischaemic stroke (top thirds OR 1.34 [95% CI 1.01 – 1.78], and 1.39 [1.05 – 
1.85] respectively) but not for haemorrhagic stroke. These haemostatic markers showed 
trends to be inversely associated with haemorrhagic stroke, but the association was not 
significant.  
 
Stored plasma samples were available fro  this case-control study, affording the 
oppertunity to measure both IL-18 and TNFα in the study and incorporate them into 
multivariate regression models with CRP and fibrinogen, to see if upstream inflammatory 
markers are responsible for association between acute phase reactants and recurrent 
stroke. The cytokine IL-6 (the major stimulator of the APR) was also measured. As there 
were no serum samples available in the PROGRESS study, MMP-9 and sCD40L were 
not measured here. All markers were measured as described in Chapter 2. Aliquots used 
for the measurement of IL-18 and TNFα had had two previous thaws. 
 
The design of the PROGRESS study has been described in detail elsewhere (PROGRESS 
Management Committee, 1996). Briefly, 6105 patients with a history of stroke or 
transient ischaemic attack (TIA) were recruited and each patient randomly assigned 
active treatment (n=3051) or placebo (n=3054). Entry criteria was based on evidence of 
an acute disturbance of focal neurological or monocular function (with symptoms lasting 
less than 24 h consistent with vascular disease or thrombosis) within the previous 5 years. 
Patients had to have no history of intolerance to angiotensin-converting enzyme (ACE) 
inhibitors, and were required to show tolerance to open label perindopril for two weeks 
before enrolment into the study. For those deemed suitable by the responsible physician, 
mono or - dual therapy was allocated: perindopril and/or indapamide or single/double 
placebo. In the principal study 6105 patients with a history of stroke or transient 
ischaemic attack (TIA) were recruited and each patient randomly assigned active 
treatment (n=3051) or placebo (n=3054). At baseline, venous blood samples collected 
from 97% of patients, were anticoagulated with K2 EDTA, and centrifuged
 at 2000g for 
10 min at 4°C. 1.5ml aliquots of plasma were stored at –80°C. Patients were followed for 
a mean of 3.9 years.  
The base population for the case-control study was all those who had plasma frozen and 
stored within 48 hours of venipuncture and whose most recent qualifying event (stroke or 
TIA) at baseline in the clinical trial occurred >1 month ago. These restrictions give 
  306
 
protection against deterioration of the blood samples and confounding attributable to 
acute-phase reactant increases in blood variables as a result of the incident stroke or its 
acute consequences. 
The final case-control study comprised 591 incident cases matched with 1182 controls, 
which were selected as outlined below. 
11.2.2 Statistical Analysis                                                                                        
During IL-18 measurements, two kits of IL-18 lot 39A were used, whereas the rest of the 
study was measured using lot 42A. There were significant differences between these lots 
(~50% see 12.3.1) and the assays using 39A were adjusted for to combine the different 
lots. This represents ~160 samples proportionately adjusted.  
Stroke cases comprised anyone with an ischaemic or haemorrhagic stroke or transient 
ichaemic attack (TIA) recorded during follow-up. Using standard methodology for nested 
case-control studies (as described in chapter 7, Woodward et al, 2005), each case was 
randomly matched to between 1 and 3 controls selected from all those free of recurrent 
stroke at the time of recurrent stroke for that case. The overall sample size was restricted 
so that the total number of people selected who had no stroke during follow-up 
outnumbered the cases in the ratio of 1 to 2. Matching variables for controls were sex, age 
(within 5 years), principal study treatment arm, region (Australia or New Zealand / China 
/ Japan / France or Belgium/Italy/Sweden/UK or Ireland) and most recent qualifying 
event (ischaemic stroke /TIA/hemorrhagic stroke/stroke of unknown type). Prespecified 
ischaemic and hemorrhagic stroke substudies isolated those cases and their matched 
controls, who had ischaemic or hemorrhagic strokes as their first recorded stroke event.  
Odds ratios were calculated according to equal thirds of the distributions of each of the 
inflammatory markers, and trends across these thirds were tested, using conditional 
logistic regression models. These were computed both with and without adjustment for 
potential confounding factors (systolic blood pressure, smoking, prevalence of peripheral 
artery disease, statin use and antiplatelet use) not controlled for in the matching variables  
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11.3 RESULTS 
 
11.3.1 Sample Availability 
 
The nested case-control study includes 591 cases (83 haemorrhagic strokes, 472 
ischaemic strokes, and 36 of unknown type). Controls satisfying all matching criteria 
were found for 572 of these cases and 19 were incompletely matched (~3%). After the 
addition of cases who acted as matched controls for other cases and taking account of 
controls who acted for >1 case, there were 33 cases with 1, 213 with 2, and 345 with 3 
matched controls. Altogether, 89 cases served as controls for 1 other case. In the 
presentation of this data, “unique” cases and controls are shown, that is, after removing 
duplicates consequent to the unbiased nested design. 1182 “unique” controls who did not 
subsequently become cases (exact ratio 2:1) are hence included in the study. 
 
After performance of assays on all available samples, there were few missing values for 
IL-6, IL-18, fibrinogen or CRP (>95%), but several for TNFα, due to its being the last of 
the assays performed on the limited residual blood supplies, and it requiring 200ul of 
plasma. Sample sizes for TNFα were 433 cases and 859 controls (73% of the total), 
representing equal numbers of missing cases and controls with similar matched 
demographic distributions for missing and assayed samples (p>0.1 for all?). 
 
11.3.2  Population Characteristics 
 
Table 11.1 summarises the baseline demographic data, and shows risk factor data 
according to whether the subject became a case or not during PROGRESS. In the 
ischaemic stroke group, several conventional risk factors for stroke were higher among 
cases than in controls including systolic BP, smoking, presence of diabetes at study entry, 
and presence of PAD at study entry, although not evidence of CHD. Among the 
inflammatory markers IL-6 was significantly (mean level 2.44 vs 2.20 pg/ml; p=0.003) 
higher in cases than in controls, as were fibrinogen and CRP (3.87.vs 3.73 g/L; p=0.005 
and 2.20 mg/L vs 1.91 mg/L; p=0.03 respectively from previously published data; 
Woodward et al 2005). Neither IL-18 nor TNFα was significantly higher in the ischaemic 
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stroke case group, although there was a trend for TNFα to be higher among cases (2.56 
versus 2.45 pg/ml; p=0.15). 
 
For the haemorrhagic stroke case group, blood pressure showed non-significant trends to 
be higher among cases (SBP 2.5% increase p=0.11, DBP 2.8% increase p=0.08), and 
fibrinogen levels showed trends to be lower among cases (5% lower p=0.11). The study 
may be underpowered to detect these potential associations. No other conventional or 
inflammatory markers were significantly different in the haemorrhagic case group. 
 
11.3.3 Risk Associations of Inflammatory Markers: Haemorrhagic Stroke 
 
On analysis by thirds of their distributions, none of the cytokines showed significant 
associations with hemorrhagic stroke (Table 11.2). The highest third of TNFα had a 
moderately elevated risk compared to the lowest third, the adjusted OR being 1.23, 
although the 95% CI were wide (0.55-2.75) due to small numbers. Fibrinogen also 
showed trends towards and association, the highest third of expression having a 
borderline lower risk of haemorrhagic stroke; OR 0.56 (0.29-1.10) in models adjusted 
only for matched variables. 
 
11.3.4 Risk Associations of Inflammatory Markers: Ischaemic Stroke 
 
For ischaemic stroke, IL-6 showed a stepwise increase in OR across thirds, and although 
the trend was reduced to borderline significance after adjustment for conventional risk 
factors, the highest third still had an increased risk compared to the lowest: OR 1.33 
(95%CI 1.00 – 1.78). TNFα showed somewhat similar associations, although the 
significance of its trend was entirely due to the excess risk comparing the highest to 
lowest thirds; OR 1.46 (95%CI 1.02 – 2.10) after adjustment. IL-18 was completely un-
associated with risk of recurrent ischameic stroke even in model adjusted only for 
matched variables where the risk association was unity; OR 0.99 (0.77-1.27). As 
previously discussed, both CRP and fibrinogen were associated with risk of stroke in 
fully adjusted models comparing extreme thirds; OR 1.39 (1.05-1.85) and 1.34 (1.01-
1.78) respectively. 
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11.3.5 Risk Associations of Inflammatory Markers: Total Stroke 
 
For total stroke, both IL-6 and TNFα had a greater significance in trend of risk across 
thirds compared to the major subtypes of stroke. This is because there are slight trends for 
both cytokines to be associated with risk of haemorrhagic stroke in extreme thirds, and 
consequently higher case numbers and smaller confidence intervals when the categories 
are combined. Despite this, the actual estimates of associations were relatively unaffected 
by the addition of hemorrhagic and unknown strokes to ischaemic stroke, probably 
largely due to the predominance of ischaemic stroke as a case in the cohort. The 
significant associated risks were OR 1.47 (1.07-2.03; p=0.01) for TNFα and OR 1.31 
(1.01-1.69; p=0.04) for IL-6 in fully adjusted models comparing extreme thirds (Table 
11.2). Again, both CRP and fibrinogen were borderline risk predictors in the total stroke 
group; OR 1.26 (0.98 –1.61) and 1.24 (0.97-1.59) respectively. 
 
11.3.6 Combinations of Inflammatory Markers as Risk Predictors of Ischaemic Recurrent 
Stroke 
 
Summaries of multivariable models, including either three markers at a time (adjusted for 
one “missing” marker) or all four inflammatory markers at once, in addition to adjusting 
for potential confounders, are shown in Table 11.3. Adjusting TNFα for either IL-6, 
fibrinogen or CRP results in borderline residual associations of TNFα with ischaemic 
stroke. Adjusting either IL-6, CRP or fibrinogen for each other, or for TNFα, resulted in 
non-significant associations of the markers with ischaemic stroke when comparing 
extreme thirds. Inclusion of all four markers in the same model (adjusting each marker 
for the other three) reduced odds ratios for any of the markers to near unity, with the 
exception of the borderline significant residual OR comparing the extreme thirds of 
TNFα, which was 1.43 (95% CI: 0.98-2.10). 
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Table 11.1 Baseline summary data for all subjects in the nested case-control study classified by whether or not they developed either of the 
major subtypes of stroke during PROGRESS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI; confidence intervals, SBP; systolic blood pressure, PAD; peripheral arterial disease, Anti-PT; antiplatelet therapy. 
* Matching variable 
Analysed on logarithmic scale and back-transformed to show estimates 
‡ Previously published: Woodward et al, 2005 
 Haemorrhagic stroke  Ischaemic stroke  
Variable Cases 
(n=83) 
Controls 
(n=199) 
p-value 
Cases 
(n=472) 
Controls 
(n=1011) 
p-value 
Mean (95% CI) 
 
      
Age * (years) 62.5 (60.6–64.5) 62.4 (61.2–63.6) 0.92 66.5 (65.7–67.3) 66.2 (65.7–66.7) 0.48 
SBP (mm Hg) 149.7 (145.4–154.0) 145.9 (143.4–148.4) 0.11 149.9 (148.1–151.6) 147.4 (146.3–148.6) 0.02 
DBP (mm Hg) 88.4 (85.9–91.0) 85.9 (84.5–87.2) 0.08 86.0 (85.1–87.0) 85.0 (84.4–85.7) 0.10 
Fib ‡ (g/L) 3.58 (3.40–3.76) 3.76 (3.63–3.89) 0.11 3.87 (3.79–3.96) 3.73 (3.70–3.78) 0.005 
CRP  ‡ (mg/L) 1.47 (1.10–1.96) 1.62 (1.35–1.94) 0.57 2.20 (1.98–2.45) 1.91 (1.77–2.05) 0.03 
IL-6  (pg/ml) 2.00 (1.70-2.37) 2.00 (1.83-2.18) 0.99 2.44 (2.31-2.59) 2.20 (2.11-2.29) 0.003 
IL-18  (pg/ml) 455 (399-521) 474 (436-517) 0.59 484 (459-511) 481 (463-500) 0.84 
TNFα  (pg/ml) 2.61 (2.24-3.07) 2.48 (2.35-2.62) 0.54 2.56 (2.44-2.69) 2.45 (2.38-2.53) 0.15 
No (%) 
 
      
Males * 63 (76) 154 (77) 0.88 348 (74) 750 (74) 0.85 
Smokers 15 (18) 43 (22) 0.63 110 (23) 173 (17) 0.006 
Diabetes 6 (7) 19 (10) 0.65 85 (18) 113 (11) 0.0004 
Previous CHD 11 (13) 39 (20) 0.23 91 (19) 172 (17) 0.31 
PAD 1 (1) 7 (4) 0.94 32 (7) 39 (4) 0.02 
Statins 5 (6) 13 (7) 1.00 36 (8) 77 (8) 1.00 
Anti-PT 39 (47) 104 (52) 0.44 362 (77) 780 (77) 0.84 
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Table 11.2 Odds Ratios (95% confidence intervals) for haemorrhagic, ischaemic and total stroke by thirds of each variable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
*Adjusted for systolic blood pressure, smoking, prevalence of peripheral artery disease, statin use and antiplatelet use 
 Previously published; Woodward et al, 2005 
 Haemorrhagic Stroke  Ischaemic stroke  Total stroke 
Variable/third Matched Adjusted*  Matched Adjusted*  Matched Adjusted* 
IL-6 (pg/ml)         
1 (<1.70) 1 1  1 1  1 1 
2 (1.70-2.94) 1.10 (0.58-2.06) 1.15 (0.60-2.21)  1.36 (1.03-1.79) 1.33 (1.01-1.77)  1.29 (1.01-1.65) 1.28 (1.00-1.64) 
3 (>2.94) 1.17 (0.61-2.24) 1.18 (0.61-2.27)  1.43 (1.08-1.90) 1.33 (1.00-1.78)  1.37 (1.06-1.76) 1.31 (1.01-1.69) 
p (trend) 0.62 0.60  0.02 0.06  0.02 0.04 
IL-18 (pg/ml)         
1 (<366) 1 1  1 1  1 1 
2 (366-582) 0.70 (0.37-1.33) 0.78 (0.40-1.50)  1.09 (0.83-1.44) 1.07 (0.81-1.41)  1.02 (0.79-1.30) 1.02 (0.79-1.30) 
3 (>582) 0.74 (0.38-1.45) 0.77 (0.39-1.53)  1.04 (0.78-1.39) 0.97 (0.72-1.29)  0.99 (0.77-1.27) 0.94 (0.72-1.21) 
p (trend) 0.36 0.44  0.78 0.84  0.92 0.63 
TNFα (pg/ml)         
1 (<2.17) 1 1  1 1  1 1 
2 (2.17-2.89) 0.88 (0.41-1.88) 0.81 (0.37-1.80)  0.98 (0.68-1.40) 0.96 (0.67-1.39)  1.01 (0.74-1.39) 1.00 (0.73-1.38) 
3 (>2.89) 1.43 (0.66-3.12) 1.23 (0.55-2.75)  1.47 (1.03-2.11) 1.46 (1.02-2.10)  1.49 (1.08-2.05) 1.47 (1.07-2.03) 
p (trend) 0.35 0.58  0.02 0.03  0.01 0.01 
Fib (g/L)          
1 (<3.32) 1 1  1 1  1 1 
2 (3.32–4.04) 1.20 (0.65-2.23) 1.17 (0.61–2.22)  1.22 (0.94–1.60) 1.20 (0.92-1.58)  1.19 (0.93-1.51) 1.17 (0.92-1.49) 
3 (>4.04) 0.56 (0.29-1.10) 0.57 (0.29–1.14)  1.43 (1.08–1.89) 1.34 (1.01-1.78)  1.28 (1.00-1.64) 1.24 (0.97-1.59) 
p (trend) 0.13 0.13  0.009 0.03  0.03 0.06 
CRP (mg/L)          
1 (<1.14) 1 1  1 1  1 1 
2 (1.14–3.34) 0.57 (0.30-1.09) 0.59 (0.31–1.16)  1.37 (1.04–1.80) 1.31 (0.99-1.73)  1.20 (0.94-1.52) 1.16 (0.91-1.49) 
3 (>3.34) 0.77 (0.41-1.46) 0.81 (0.42–1.57)  1.52 (1.15–2.00) 1.39 (1.05-1.85)  1.34 (1.05-1.70) 1.26 (0.98-1.61) 
p (trend) 0.13 0.22  0.03 0.12  0.14 0.32 
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Table 11.3 Odds Ratios (95% confidence intervals) for ischemic Stroke for combinations 
of inflammatory variables in multivariable models, by thirds, adjusted for the “missing” 
variable (1st third not shown; by definition, odds ratio = 1), and then for every other 
marker (final section of rows). All models are adjusted for systolic blood pressure, 
smoking, peripheral artery disease prevalence, statin use and antiplatelet use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Third of the 
population 
TNFα 
 
IL-6 Fibrinogen CRP 
2nd 0.95 (0.65-1.37)  1.22 (0.92-1.62) 1.09 (0.81-1.48) 
3rd  1.44 (0.99-2.10)  1.33 (0.97-1.80) 1.16 (0.84-1.61) 
p (trend) 
 
p=0.05  p=0.08 p=0.31 
2nd 0.97 (0.67-1.39) 1.27 (0.95-1.69)  1.14 (0.85-1.53) 
3rd 1.44 (1.00-2.08) 1.21 (0.89-1.64)  1.18 (0.85-1.62) 
p (trend) 
 
p=0.04 p=0.27  p=0.34 
2nd 0.96 (0.67-1.39) 1.27 (0.94-1.71) 1.20 (0.90-1.59)  
3rd 1.43 (0.99-2.08) 1.24 (0.90-1.72) 1.29 (0.94-1.78)  
p (trend) 
 
p=0.05 p=0.23 p=0.12  
2nd   1.17 (0.83-1.65) 1.07 (0.76-1.50) 0.99 (0.70-1.40) 
3rd  1.08 (0.74-1.57) 1.09 (0.76-1.56) 1.13 (0.79-1.63) 
p (trend) 
 
 p=0.63 p=0.60 p=0.46 
2nd third 0.93 (0.64-1.34) 1.11 (0.76-1.61) 1.07 (0.76-1.53) 0.95 (0.65-1.38) 
3rd third 1.43 (0.98-2.10) 0.99 (0.65-1.50) 1.02 (0.68-1.53) 1.13 (0.73-1.76) 
p (trend) 0.04 0.92 0.89 0.50 
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11.4 DISCUSSION  
 
11.4.1 Comparison of the Population Distributions with MONICA-4 
 
Comparing this population’s distribution of inflammatory markers to that of the 
MONICA-4 study, it is of note that the median IL-18 expression in this cohort (~450 
pg/ml in cases and controls) is much higher than that even of the eldest age groups in the 
MONICA-4 cohort (median male and female in 55-64 years ~250 pg/ml). This could be 
in part be attributed to assay QC drift, due to the lack of an international standard, but use 
of the in-house QC should prevent drift of anything like this magnitude of difference. In a 
similar fashion, TNFα levels were also higher here than medians in the eldest age group 
of MONICA-4 (~2.47 pg/ml in controls and 2.61 pg/ml in cases versus ~1.90 pg/ml in 
MONICA-4). This may suggest that TNFα and particularly IL-18 are elevated in people 
with prevalent cerebrovascular disease after (>1 month in this study) the index event. The 
effect is probably reverse causal-discussion. 
 
11.4.2 Association of Only APR-Associated Inflammatory Markers with Risk or 
Recurrent Stroke 
 
To my knowledge, this is the first reported study of the association between the pro-
inflammatory cytokines IL-6, IL-18 and TNFα and risk of recurrent stroke. We found 
that TNFα and IL-6, but not IL-18, were significant risk predictors of recurrent ischemic 
stroke. In TNFα only the top third of the population was at statistically increased risk. 
This finding is consistent with a previous study of recurrent myocardial infarction, which 
found that only those with very high TNFα expression were at increased risk (Ridker et 
al, 2000). IL-6 appeared to show stepwise increases in risk through thirds of this 
population, although the trend was less notable after adjusting for potential confounders. 
  
A major biological property of IL-6 and TNFα is that these cytokines may actively 
participate in the hepatic stimulation of the APR (Hansson et al, 2005). There is little 
evidence to suggest IL-18, which was not associated with any major stroke subtype in 
this study, directly contributes to the APR (Stuyt et al, 2005). As previously noted in the 
original PROGRESS case-control study (Woodward et al, 2005) and in this thesis, the 
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acute-phase reactant behaviour of fibrinogen, CRP, or any inflammatory marker may be 
viewed as a potential confounder of associations with recurrent stroke. This is because 
the underlying association may be due to “generalised inflammation” (as proximally 
measured by the APR) rather than the causal behaviour of any individual inflammatory 
marker per se (Lowe et al, 2005). However, adjusting acute phase reactants only for each 
other in multivariable models to remove potential acute phase response confounding 
assumes that the APR is an absolute event, with roughly equal effects on circulating CRP 
and fibrinogen levels. This may not be an accurate assumption, particularly when making 
only one baseline observation. A recent publication has shown in acute stroke patients 
that the pattern of expression of CRP is stable in days 1-90 following stroke, while levels 
of fibrinogen increase following the acute phase, and levels of leucocyte counts fall 
(Marquardt et al, 2005). These observations are broadly confirmed by the SIP study. This 
suggests that a “textbook” APR is not seen following an acute stroke, and markers of the 
acute phase response can behave temporally differently. The patients in the current study 
had incident ischaemic stroke up to 5 years ago, and the dynamics of the response may be 
different. Indeed, IL-18 levels (which were not elevated in acute stroke), are substantially 
elevated in the chronic phase as shown in this study. 
 
By adjusting for combinations of CRP, fibrinogen, IL-6 and TNFα, this study shows that 
markers of the APR and stimulators of the APR almost completely explain each other’s 
association with recurrent stroke. This suggests that despite evidence that IL-6, IL-18, 
and TNFα are involved in experimental atherogenesis and atherothrombosis (section 
1.2.8, 1.3.5, and 1.4.5), potential associations with recurrent stroke are almost fully 
explained by conventional risk markers, and proximity to the APR. Equally this suggests 
that CRP and fibrinogen themselves are associated with recurrent stroke due to being 
acute phase reactants rather than necessarily making additional inflammatory 
contributions to atherothrombosis. Clearly an individual inflammatory marker may be a 
“better” risk predictor than others, but this would depend on the time point the 
observation is made in moving from the acute to the chronic response to stroke and 
underlying prevalent CVD. 
 
Just as caution must be employed in drawing conclusions of causality in epidemiological 
studies (Lowe et al, 2005) it is equally important not to exclude causality on the same 
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basis. It is quite possible (perhaps probable) that some inflammatory markers actively 
participate in atherogenesis and atherothrombosis, at least partially through other 
conventional risk factors (e.g. the association of inflammation with smoking or 
cholesterol levels). However, associations of inflammatory markers of the acute phase 
response with recurrent stroke were fully explained by conventional risk markers and 
APR confounding in this model, and this may be consistent with observations that CRP 
adds little to Framingham assessments of primary stroke risk (Bos et al, 2006). This 
suggests that from the inflammatory markers measured in this study, it is only “general 
inflammation” rather than a particular marker that is associated with secondary ischemic 
stroke.  
 
11.4.2 Limitations and Strengths  
 
This was a large nested case-control study from a well-defined cohort of patients, and as 
such was ideal for the measurement of inflammatory cytokines among a novel patient 
group. Despite this there are limitations to this study to consider. Entry into the study was 
only on the basis of a qualifying event in the last 1 month – 5 years. It is possible that 
recurrent events that occurred during the 3.9 year median follow-up would have occurred 
at a greater rate among those with more recent stroke. It is hence possible that those who 
experienced a recurrent event had elevated levels of certain inflammatory markers due to 
the more proximal length of time since their index event, rather than it reflecting risk 
profile per se. Associations between inflammatory markers and risk could hence reflect 
the greater risk those who have had stroke in the last year experience compared with 
subsequent years (12% risk in the first year, and 5% for every year thereafter [Hankey, 
2003]). However, a minimum 1 month since index event should be sufficient to allow any 
residual reverse-caused inflammatory reaction to settle in most patients. More 
specifically, for IL-18 and TNFα, the results from the SIP study argue against profound 
acute phase reaction complications for these cytokines in acute stroke, suggesting 
consequent elevation of these cytokines after the acute event may reflect bona fide 
physiological processes potentially related to recurrent stroke risk. 
 
Entry to the study was based on physician diagnosis of stroke or TIA thought to be 
thrombotic or vascular in origin of ischaemia but was not based on clinical imaging, 
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giving rise to the possibility of inaccurate diagnosis. Despite this the accuracy of a 
clinical examination by an emergency physician is good, with a sensitivity of about 85% 
and a specificity of 99% for ischaemic stroke (von Arbin et al, 1981).  
 
11.4.3 Conclusions 
 
This study finds that TNFα, but not IL-18, is moderately associated with risk of recurrent 
cerebrovascular disease (particularly ischaemic stroke) in those with a history of 
ischaemic stroke or TIA. However, inflammatory markers generally associated with the 
acute phase response (promoters; IL-6 and TNFα, acute phase reactants; CRP and 
fibrinogen) are all associated with risk of recurrent stroke (but not IL-18). These markers 
are dependant on each other in multi-variable models, and once all are included, none are 
independently significant. This suggests that the generalised inflammation of the acute 
phase response predicts recurrent stroke, rather than any particular marker. 
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CHAPTER 12 
 
GENERAL DISCUSSION 
 
12.1 INFLAMMATION AND CARDIOVASCULAR RISK 
 
12.1.1 General Overview 
 
In the mid-1970s, Russell Ross put forth the theory that an injury to the blood vessel wall 
begins the insidious process of inflammation, ulcerated plaque formation and activated 
platelet aggregation at the endothelial layer (Ross, 1976). 30 years on, it is remarkable to 
observe that the implications of this ground breaking theory are still being debated and 
refined. The injury to the blood vessels that Ross proposed is thought to occur as a result 
of anatomical or physiological stress (Lowe, 2003) such as non-laminar flow or DNA 
methylation bringing about genetic aging (Stenvinkle et al, 2007), by exposure to 
oxidised lipids (Cominacini et al, 2001), or perhaps by latent or active infection (Vita and 
Loscalzo, 2002; Liuba and Pesonen, 2005). It seems likely that the combined effects of 
these types of processes are greater than the sum of their parts, and they all converge at 
one central process: the stimulation of inflammation. 
 
As reviewed in Chapter 1, there is increasing awareness of the role of inflammation in the 
promotion of atherosclerosis in the scientific, clinical and lay communities. No longer 
considered a post-script to lipid accumulation and arterial occlusion, inflammation is a 
central component of atherogenesis and its acute complications. Animal models, 
epidemiological evidence, and the non-lipid effects of statins all seem to suggest that 
chronic low-grade systemic inflammation is associated with risk of CVD events, and it is 
easy to illustrate biological mechanisms for these processes (Figs 1.1-1.5). Indeed, 
accumulating evidence suggests that high grade inflammation (such as that seen in RA 
and type 1 diabetes) is also associated with increased cardiovascular risk in a potentially 
causal manner (Solomon et al, 2003; Sattar and McInnes, 2005; Sherer et al, 2006). The 
problem remains however that although the evidence for a role for inflammation in 
general is strong, there are real problems in resolving which are the causally important 
factors, and which are bystanders associated with the inflammatory process. This is an 
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important issue in terms of what markers may be therapeutic targets, and which may add 
clinically useful information to risk prediction algorithms.  
 
Fibrinogen and CRP have both consistently demonstrated moderate associations with risk 
of CHD events in both healthy populations and in populations with prevalent vascular 
disease (Fibrinogen Studies Collaboration, 2005; Danesh et al, 2004), although CRP in 
particular demonstrates evidence of early publication bias (Danesh et al, 2004). 
Furthermore, the causal role of these molecules in atherogenesis have been called into 
question. They are both products of the APR, and are potentially bystanders of low grade 
systemic inflammation. Genetic manipulation of promoters of either molecule in animal 
models suggests that modest overexpression has no significant effect on atherosclerosis 
(Gulledge et al, 2003; Rezaee et al, 2002; Trion et al, 2005). While Pepys et al (Pepys et 
al, 2006) have recently reported a potential inhibitor of CRP in a mouse model, no 
specific therapeutic inhibitors of either molecule exist for field trials in humans to resolve 
this issue. Furthermore there is debate as to the potential clinical utility of these markers, 
since the C-statistic indicates that little may be gained from adding CRP to Framingham 
risk assessments (Folsom et al, 2005; 1Wilson et al, 2005; Tzoulaki et al, 2007). 
Proponents of the clinical measurement of CRP for CVD risk prediction, most notably 
Ridker’s Boston group, have sparked widespread debate as to the clinical utility of the C-
Statistic (Cook et al, 2006; Cook 2007; Ridker, 2007). The C-statistic may be a blunt tool 
for estimating clinical utility of a marker, but it is currently the best statistical means 
available to discriminate additional predictive utility of a marker. 
 
In this thesis I have examined the utility of pro-inflammatory markers which are 
upstream of the APR as potential predictors of CVD events. These markers are 1) directly 
pro-inflammatory in most physiological settings (as opposed to CRP and fibrinogen), 2) 
convincingly pro-atherogenic in animal and tissue models, and 3) upstream of potential 
associations of APR markers. I identified four inflammatory markers (TNFα, IL-18, 
MMP-9, and sCD40L) which have strong putative mechanistic roles in atherogenesis and 
atherothrombosis in experimental studies, which are detectable in the circulation of 
healthy and diseased persons, and for which there was limited literature to suggest that 
they may be associated with CVD risk. 
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12.2 PRE-ANALYTICAL AND PRACTICAL CONSIDERATIONS OF USE OF 
INFLAMMTORY BIOMARKERS  
 
12.2.1 General Considerations 
 
If there is a case for any biomarker (inflammatory or otherwise) to be added to clinical 
risk prediction algorithms, a primary concern is the practical ability to measure the 
markers both in scientific (particularly epidemiological) and clinical settings. Many 
proponents of CRP measurement in risk prediction cite this as one of CRP’s key 
distinguishing properties from other inflammatory markers; a relative biochemical 
stability, indifference to sample source type (plasma/serum), and a well standardised, 
cheap assay (Pearson et al, 2003). Fibrinogen is also a stable, standardised, cost-effective 
biomarker, with an abundance of data linking it to CVD risk (Fibrinogen Studies 
Collaboration, 2005). Other inflammatory markers may also become standardised and 
cheap to measure if demand for the marker from the scientific community (on the basis of 
consistently strong risk associations) grows. 
 
The points considered in this thesis for the four markers are summarised in Table 12.1. 
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Table 12.1 Overview of pre-analytical variables for IL-18, TNFα, MMP-9 and sCD40L, comparing these markers to more established 
inflammatory risk markers of CHD (fibrinogen, CRP and IL-6). + and – ratings are given as a relative comparison. 
*Citrate only for von Clauss detection method 
† Data from Poorhang MSc thesis, 2005, unless otherwise stated 
‡ Data from Emberson et al, 200
 
Assay characteristics 
Marker stability 
 Variability 
 
Sample type  Accuracy Storage  Freeze-thaw 
Short-term Bio     
variation 
4-Year 
regression 
dilution 
 
Use in 
serum? 
Use in 
plasma? 
 
Intra-
assay 
CV 
Inter-
assay 
CV 
Absolute 
values 
stable?  
Correlations 
stable? 
 Absolute 
values 
stable?  
Correlations 
stable?  
Reliability coefficient 
(95% CI) 
Regression 
dilution 
coefficient 
IL-18 + +  ~5% ~10% ++ +/-  +/- +/- 0.66 (0.52-0.93) 0.71 
TNFα + +  ~8% ~12% + (?) + (?)  + ++ 0.58 (0.43-0.89) 0.25 
MMP-9 + -  ~4% ~10% -- ++  -- +/- ? 0.46 
sCD40L + -  ~4% ~15% + ++  --- ++ ? 0.47 
             
Fibrinogen† - +*  ~3% ~4% ++ ++  ++ ++ 0.73 (0.60-0.94) 0.61‡ 
CRP† + +  ~5% ~8% ++ ++  ++ ++ 0.58 (0.43-0.89) 0.52‡ 
IL-6† + +  ~8% ~9% ++ +/-  ++ +/- 0.28 (0.17 – 0.83) ? 
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12.2.2 IL-18 as a Biomarker 
 
Chapter 3 demonstrated that the IL-18 ELISA employed shows IL-18 to be a relatively 
flexible biomarker, suitable for use in serum or in plasma. It has assay CVs generally 
comparable to other inflammatory markers (including CRP and fibrinogen which are 
measured by automated means), which suggests that the assay is sensitive and the data 
reproducible. IL-18 was a relatively biochemically stable marker, despite an initial 
decrease in detectable levels after a second thaw. One would therefore expect there may 
also be a decrease in detectable levels after a thaw for the first time from fresh plasma 
(although this was not investigated here due to the primarily epidemiological rather than 
clinical focus of this thesis). This finding requires further investigation.  
 
IL-18 had a level of short-term biological variation somewhat lower than other 
inflammatory markers, including CRP, although more data is required to narrow 
confidence intervals in order to confirm this result. IL-18 also demonstrated a relatively 
small degree of variation of over 4 years in regression dilution studies. This is in 
agreement with observations that IL-18 levels increase only marginally as middle-aged 
men approach old age (Chapter 4). The conclusion that IL-18 is relatively stable in terms 
of biological expression in the long- and short-term, would make it an attractive clinical 
biomarker. 
 
Based on the evidence presented here, I concluded that IL-18 was suitable for use as an 
epidemiological marker in prospective studies and in cross-sectional studies. 
 
12.2.3 TNFα as a Biomarker 
 
Like IL-18, TNFα is a versatile biomarker and serum or plasma samples are suitable for 
its measurement, although it was noted in Table 3.2 that EDTA levels of TNFα in our 
plasma validation study sample were lower than those reported by the kit manufacturer. 
This difference is further explored in section 12.3.1.  
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The assay error in measurement of TNFα is slightly higher than for the other markers, 
despite the assay being “high-sensitivity.” This is likely to be a reflection of the very low 
circulating levels of the marker. In so far as the available data available allowed 
investigation (due to a kit manufacturing alteration), TNFα was the most robust of the 
four novel inflammatory markers, relatively resistant to both storage and freeze-thaw 
cycles.  
 
Short-term biological variability of TNFα was comparable to most of the other 
inflammatory markers, including CRP. In spite of this, TNFα demonstrated a regression 
dilution coefficient which makes it the most variable marker over 4 years measured to 
date (Emberson et al, 2004). This may mean that associations of TNFα with risk of CHD 
are greatly underestimated in prospective studies. 
 
Based on the evidence presented here, I concluded that TNFα was suitable for use as an 
epidemiological marker in prospective studies and in cross-sectional studies. 
 
12.2.4 MMP-9 as a Biomarker 
 
According to the manufacturers (RandD Systems), MMP-9 can only be measured in 
serum (or heparinised plasma) by ELISA due to chelation by citrate and EDTA. We 
accepted this declaration without further investigation (although some authors recently 
report plasma should be used, but do not investigate the chelation issue [1.5.5]). In this 
work, serum levels were certainly detectable. The assay sensitivity and reproducibility 
was comparable to most other inflammatory markers. MMP-9 levels were biochemically 
labile, and decreased with both time in storage and number of freeze-thaws. Despite this, 
significant rank correlations of the data sets were maintained within the investigative 
limits of the current work.  
 
Short-term biological variation of MMP-9 was not investigated due to non0availability of 
serum. The degree of regression dilution was similar to that observed of CRP, suggesting 
that despite biochemical labiality, variation in circulating concentrations of MMP-9 over 
time is fairly comparable to CRP. Hence the degree of underestimation in prospective 
studies is also likely to be similar. 
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Based on these findings, I concluded that MMP-9 was suitable for use in epidemiological 
studies (in serum) presuming all samples had the same storage and freeze-thaw history 
within the study.  
 
12.2.5 sCD40L as a Biomarker 
 
sCD40L could only be detected with any sensitivity in serum samples. Despite some 
reports that sCD40L should be measured in plasma (1.6.5), we have found plasma levels 
to not be accurately detectable in normal people, and other studies have suggested that, in 
practice, blood sampling procedures will artificially elevate sCD40L levels compared to 
the in vivo setting (1.6.5). The ELISA kit we used showed similar sensitivity and 
reproducibility to other inflammatory markers, although the inter-assay variation may be 
somewhat higher, but this result may be a chance finding and is not in agreement with the 
manufacturer’s report. sCD40L levels were labile when subjected to biochemical stress, 
and decreased with both time in storage and number of freeze-thaws, particularly the 
latter, detectable levels falling almost by half after 4 thaws. Despite this, significant rank 
correlations of the data sets were maintained within the investigative limits of the current 
work.  
 
Short-term biological variation of sCD40L was not investigated due to non-availability of 
serum. The degree of regression dilution was similar to that observed in CRP, suggesting 
that despite biochemical labiality, variation in circulating concentrations of MMP-9 are 
fairly comparable to CRP over time. Hence the degree of underestimation in prospective 
studies is also likely to be similar. 
 
Based on these findings, I concluded that sCD40L was suitable for use in prospective 
case-control studies (in serum) presuming all samples within the study had the same 
storage and freeze-thaw history.  
 
12.2.6 Suggestions for Further Research on the Practical Limitations of the Biomarkers 
 
Fresh blood samples were not used in the present thesis. Similar studies to those reported 
here in fresh samples are required to verify the suitability of these markers for clinical 
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use. Some studies have already investigated this for sCD40L (Ahn et al, 2004; Mason et 
al, 2005; Varo et al, 2006; Weber et al, 2006), although they report on the presumption 
that plasma levels of sCD40L are more suitable for use. I do not believe this to be the 
case (3.2.4). Overall, it is unlikely that sCD40L or MMP-9 could be useful clinical 
markers of risk due to their labile nature and inflexibility in blood letting procedure. IL-
18 and TNFα are more versatile in terms of sample type, and more robust in terms of 
stability, and in that sense are comparable to CRP and fibrinogen. More data subjecting 
both markers to more rigorous tests of stability in the healthy and those with prevalent 
disease are required. 
 
The short-term biological variation data reported is revelant, both from an 
epidemiological and from a clinical aspect. Due to the small number of volunteers 
studied, the confidence intervals from the estimates in the study are wide. More data in 
sick as well as healthy people are required to expand findings and to narrow these 
confidence intervals, although it is problematic practically (in terms of both labour 
intensiveness and finding suitable willing volunteers and patients) to achieve this.  
 
In particular, it may be interesting to study variability over a longer period than 20 weeks. 
This would allow further investigation into the issue of whether some individuals have 
“permanently” elevated variability. If so, are these individuals at elevated CVD risk 
beyond that predicted by their “habitual” inflammatory marker levels? One could 
speculate that they may be; increased variability (aside from transient infection) may be 
indicative of living a “high-risk” lifestyle (e.g. binge drinking). Indeed, one could 
speculate that it may be (at least partially) that those with higher levels of cytokines in 
prospective studies with one baseline measurement are more likely to be “variable” (since 
the variation away from habitual levels is positively skewed). Prospective studies of these 
markers in general cohorts, taking 3-4 baseline blood samples (one week apart) from each 
participant would be interesting, although a formidable undertaking. This would allow 
~90% reliably estimated habitual plasma levels for all the inflammatory markers (perhaps 
with the exception of IL-6) in all participants. This would not only improve “true” risk 
association estimates, but would allow investigation into the hypothesis that variability 
itself may be associated with CVD risk.  
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As discussed in Chapter 4, further study of regression dilution ratios is warranted, both in 
terms of improved estimates (greater n) and investigating regression dilution over other 
timeframes. This is possible to do using the BRH study (Emberson et al, 2004). In 
particular, more data is required to confirm and expand on the relative temporal stability 
of biological expression of IL-18, and the relative instability of TNFα. As noted in 
Chapter 3, the similarity in short-term biological CV of the two cytokines is expected. 
That they should become so divergent in expression stability over time is interesting, and 
may reflect TNFα associations with underlying biological ageing processes (such as 
developing atheroma) while IL-18 is relatively unaffected.  
 
The interaction of short-term variation and long-term regression dilution also requires 
further work. Although regression dilution increases over the years, for most 
inflammatory markers, a large degree of regression dilution is seen within the first week 
(Emberson et al, 2004). It would be an interesting further project to try to develop an 
algorithm to estimate the total overall degree of associative underestimate (both short- 
and long-term) of inflammatory markers 
 
12.3 POPULATION DISTRUBUTIONS OF IL-18 AND TNFα 
 
12.3.1 Comparing Levels of IL-18 and TNFα Across all Thesis Study Populations 
 
Table 12.2 compares median and IQRs of IL-18 and TNFα in all populations in the 
thesis. 
 
IL-18 levels are generally comparable throughout the study. The middle-aged men in 
MONICA-4 have similar levels of IL-18 to those in the prospective CHD studies, BRH 
and Fletcher Challenge. Those with a history of stroke (but not acute stroke) have much 
higher levels of IL-18 (in PROGRESS) which is direct contrast to those with a history of 
CHD (GLAMIS). In agreement with findings of an IL-18 and age correlation in 
MONICA-4 (typical of most inflammatory markers), the elderly (with a history of 
vascular disease; PROSPER) have elevated levels of IL-18.  
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The generally tight agreement of IL-18 levels between studies makes it unlikely that there 
are problems regarding its measurement using the current assay. Despite this, I have 
noted that both the levels of the quality control (QC) sample, and levels in the mean of 
the assay within a population (a secondary QC measurement in large studies) may vary 
between kit lots of IL-18. For example, using IL-18 lot 38A and 39A our QC (777712) 
had a mean value of 197 ± 22 pg/ml (n=32), but using IL-18 lot 42A the mean was 294 ± 
24 pg/ml (n=21). This represent a difference of 49%; hardly negligible, and potentially 
very problematic in terms of directly comparing studies. These differences have not 
affected the majority of this thesis, since it was almost all performed using lot 37, 38A, 
and 39A (highly comparable). Adjustment was used on the few assays where there was 
an issue with lot 42A in the PROGRESS study. Despite this, the issue of cross-lot 
differences and drift is clearly a problem with this particular assay (which is the most 
widespread in use in the literature). IL-18 therefore requires an international standard 
before it can be considered a clinically credible biomarker. Assay standardisation is of 
paramount importance in epidemiological studies. Due to such problems previously with 
other markers, our laboratory has adopted a policy of ordering one kit lot of a marker in 
large epidemiological studies. This at least ensures samples within the same study are 
comparable. 
 
This problem in standardisation of assay lots can also be seen for TNFα. The first TNFα 
studies performed in this thesis were for the pre-analytical study of plasma validation 
(Chapter 3), GLAMIS, and the BRH study. TNFα levels in EDTA plasma in the plasma 
validation study were noted to be lower than the manufacturer’s levels (Table 3.2). Table 
12.2 also shows TNFα levels were also far lower in the GLAMIS and BRH studies than 
elsewhere. These three studies were performed using kit lots 226764 and 227166. 
Analysing the QC data, QC 777710 had mean levels of 0.42 ± 0.18 pg/ml using these 
earlier kit lots (n=42). Subsequently, using kit lot 228849, QC 777710 had a mean of 1.14 
± 0.21 pg/ml. This is an increase by a factor of 2.71. Adjusting the detected levels of 
TNFα in Table 12.2 for GLAMIS and the BRH would clearly help rectify problems in 
cross-comparison with MONICA-4. Other apparent discrepancies to do with other kit lots 
would remain however. For instance, the elderly in PROSPER do not appear to have 
elevated levels of TNFα compared with MONICA-4, which contradicts an age-related 
increase in circulating levels of TNFα suggested by MONICA-4 (Chapter 4). Those with 
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acute (SIP) and with history of stroke (PROGRESS) appear have elevated circulating 
levels of TNFα, again perhaps suggesting one would expect to see elevated levels in 
persons with vascular disease. 
 
In conclusion, although I have shown that these markers are stable enough to be 
examined in cross-study comparisons and using reference ranges, such studies do require 
the assays to be reproducible for the potential of such studies to be realised.  
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Table 12.2 Population distributions of IL-18 and TNFα, in each of the case-control and 
cohort studies. Values are medians and IQRs. 
 
 
 
 
 
 
 
 
 
Study Population IL-18 (pg/ml) TNF (pg/ml) 
MONICA-4 Cohort 222 (169-293) 1.59 (1.28-2.03) 
 Men (55-64 yrs) 251 (191-340) 1.90 (1.50-2.35) 
 Control 219 (166-287) 1.56 (1.26-1.97) 
 Case 249 (188-332) 1.87 (1.49-2.39) 
GLAMIS Control 271 (200-373) 0.77 (0.52-1.22) 
Case 287 (212-404) 0.99 (0.65-1.64) 
BRH Study Control 283 (204-381) 0.92 (0.69-1.36) 
Case 308 (224-406) 0.89 (0.60-1.24) 
Fletcher Challenge Control 271 (203-346) 1.74 (1.39-2.25) 
Case 295 (228-409) 1.89 (228-409) 
SIP Cohort 277 (202-370) 2.10 (1.47-2.84) 
Prosper Control 330 (255-434) 1.24 (0.89-2.03) 
Case 336 (276-438) 1.30 (0.93-1.78) 
PROGRESS Control 450 (335-687) 2.47 (1.94-3.08) 
Case 451 (326-685) 2.61 (2.04-3.28) 
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12.3.2 Future Work on Population Distributions 
 
It is a poor commentary on commercial suppliers when such obvious QC issues are 
spotted by customers, especially when a premium is paid assuming the kits are fully QC-
compliant, and where international standards are available to minimise the risk of these 
mistakes (as for TNFα). It may be the case that development of in house-assays may 
rectify these problems by allowing the researcher to maintain adequate QC themselves. 
As a marker becomes used in a more widespread fashion however (as will happen if the 
marker is epidemiologically interesting) manufacturers will be required to tighten QC 
regulations to ensure that studies in the literature between groups are comparable. 
 
It remains to be seen in future studies if recent changes in the TNFα kit (3.4.1) rectify 
these problems, and the manufacturers have not reported the reason these changes were 
necessary other than “to improve sensitivity”. Eventual development of an IL-18 standard 
should also help this marker. There is nothing inherently wrong with the currently 
reported studies in delineating population distributions (although more studies, larger 
than MONICA-4 are required to confirm and expand on findings), or the presupposed 
reasoning that the populations should be directly comparable. Observations have been 
hampered only by poor manufacturer QC. 
 
12.4 IL-18 AND TNFα ASSOCIATIONS WITH CONVENTIONAL 
CARDIOVASCULAR RISK MARKERS AND MARKERS OF THE METABOLIC 
SYNDROME 
 
12.4.1 Study Heterogeneity in Risk MarkerAssociations 
 
Several studies in the current thesis have delineated associations of IL-18 and TNFα with 
conventional risk markers. The results from these are summarised generally in Table 
12.3. Strengths of associations are summarised in categories (rather than using absolute r-
values) due to differences between studies in term of data analysis methodology. As can 
be seen, there are many similarities in correlations in different studies, but also areas of 
heterogeneity. For instance, IL-18 correlated strongly with age in the Fletcher challenge 
study, not at all in the BRH study or GLAMIS, and moderately in MONICA-4. This 
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highlights the caution that should be employed when examining associations of risk 
markers in highly selected cohorts, as discussed in section 6.4.3. For instance the BRH is 
a highly age-selected, male only study. Although these are actually fairly broad 
qualifying criteria they are likely to impact on observed associations by making age, and 
perhaps other characteristics of the study population (such as BP) more narrow than in a 
general cohort. This limits the ability of the data to powerfully assess associations of 
markers with wide ranges of characteristics (Woodward, 2005). For these reasons, more 
weight must be placed on associations observed in the MONICA-4 cohort. 
 
12.4.2 Associations of IL-18 and TNFα 
 
Both IL-18 and TNFα are generally positively associated with age (Table 12.3), which is 
in agreement with observations in most inflammatory markers (Lowe et al, 1997, 
Woodward et al, 1999, 2003; Fibrinogen Studies Collaboration, 2005; Gimeno et al 2007; 
Miles et al, 2006). It has been known for some time that TNFα increases with age 
(Paolisso et al, 1998), and blood vessels from older mice manufacture increased TNFα, 
which is a potentially contributing factor to circulating concentrations (Belmin et al, 
1995). The specific observation that IL-18 is relatively weakly associated with age has 
also been noted in other recent population studies (Hung et al, 2005; Thorland et al, 
2005). Both cytokines are also higher in men than in women (MONICA-4), which is in 
agreement with other studies (Chapmen et al, 2006; Yamagami et al, 2005). This is in 
contrast to fibrinogen, which is higher in women than in men (Fibrinogen Studies 
Collaboration, 2005). 
 
IL-18 is strongly associated with smoking in both sexes, which is in contrast to TNFα, 
which only shows weak overall associations. Nicotine may inhibit mononuclear cell 
production of TNFα (Madrestma et al, 1996), and clearly this may be a very specific 
inhibitory pathway. General inflammatory marker associations with smoking (CRP, IL-6, 
fibrinogen etc; Woodward et al, 1997 and 2003; 2Wannamethee et al, 2005) are 
suggestive that inflammation may be a key pathophysiological mediator between the 
habit of smoking and the increased risk of CVD, although associations cannot be taken to 
imply causality (Lowe et al, 2005). 
 
  331
 
Blood pressure is a key conventional risk factor, and like smoking, inflammation may 
partially be a cause or consequence of high blood pressure (e.g. due to increased 
endothelial dysfunction in hypertension and increased inflammatory mediator production 
as well as extravasation of monocytes into the tunica intima) (Bautista et al, 2003). For 
instance, CRP may be produced by mouse SMCs in response to angiotensin II (Peng et 
al, 2007) and inhibition of the renin-angiotensin system is thought to suppress general 
inflammation (Sironi et al, 2005) including TNFα production (Schindler et al, 1995). 
Indeed, angiotensin II has also been implicated in promoting IL-18-mediated cross-talk 
between SMCs (Sahar et al, 2005). It may therefore be somewhat surprising that neither 
cytokine was strongly associated with blood pressure in any population in this thesis. A 
recent review discusses the positive relationship between CRP and blood pressure in 
epidemiological studies (Virdis et al, 2007) and points to the particular association 
between CRP and arterial stiffness (and perhaps consequently more with systolic than 
diastolic blood pressure). Whether CRP is produced by stressed vascular endothelium is 
unclear. It seems likely however that a lack of an association of IL-18 and TNFα with 
arterial blood pressure means that hypertension will not directly result in increases of the 
cytokines in circulation. Whether the cytokines are involved in local inflammatory 
vascular cross-talk (such as between SMCs [Sahar et al, 2005]) remains to be verified. 
 
As expected, IL-18 and TNFα were in general both fairly strongly inversely associated 
with the atheroprotective HDL cholesterol. HDL cholesterol, apart from reverse 
cholesterol efflux, is thought to have a wide range of anti-atherogenic properties, 
including potential modulation of the plaque inflammatory response (Barter et al, 2004; 
Vaisar et al, 2007), and is known to show inverse associations with most inflammatory 
markers. The inverse association of HDL with IL-18 and TNFα is hence likely to be a 
consequence of general anti-inflammatory pathways elicited by HDL, which are common 
to most inflammatory markers. Overall, IL-18 and TNFα show little association with 
total cholesterol, suggesting overall positive associations with LDL cholesterol. IL-18 
and TNFα also have moderate associations with triglycerides, which itself has a moderate 
association with CHD risk (Sarwar et al, 2006).  
 
As expected in this thesis, all inflammatory markers generally showed reasonably strong 
inter-correlations. IL-18 and TNFα have strong associations with CRP, but interestingly 
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not fibrinogen. This may underscore potential extra-hepatic sources of CRP production 
(independent of the APR) during chronic low-grade inflammation (such as the vascular 
endothelium). Cytokine associations with BMI are discussed in the next sections 
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Table 12.3 Qualitative overview of associations of IL-18 and TNFα with conventional cardiovascular risk markers (as well as CRP and 
fibrinogen) reported in this thesis. In case-control studies only the results from the control population are shown. IL-18 and TNFα always 
correlated highly significantly (p<0.001) with each other and with IL-6 (where measured). All associations are age- and sex-adjusted 
Spearman or Pearson models. 
 
 
 
 
 
 
 
 
Tc, total cholesterol; HDL, high density lipoprotein cholesterol; Trig, triglycerides; BMI, body mass index; BP, blood pressure; Fib, 
fibrinogen 
 
Blank = not significant 
- = not reported 
= r<0.1 
 =0.2>r>0.1 
 =r>0.2 
 
 
 
 
 
 Age Smoking TC HDL Trig BMI BP CRP Fib 
 IL-18 TNF IL-18 TNF IL-18 TNF IL-18 TNF IL-18 TNF IL-18 TNF IL-18 TNF IL-18 TNF IL-18 TNF 
MONICA-4         - -         
GLAMIS                   
BRH Study                 - - 
Fletcher 
Challenge   
                
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12.4.2 Metabolic Syndrome and Cardiovascular Associations 
 
Due to recent advances in the field it is necessary to comment on insights gained from 
this thesis in terms of novel inflammatory markers and associations with aspects of the 
metabolic syndrome, although it is important to conceding that metabolic syndrome was 
not a primary consideration of the thesis in terms of methodology, and any inferences 
drawn must be with great caution..  
 
Accumulating data in the field indicates that cardiovascular disease and the metabolic 
syndrome may have common underlying causes (1Grundy et al, 2004), to the extent that 
some researchers have taken to employing the phrase “cardiometabolic syndrome” to 
indicate a clinical state indicative of relatively high likelihood to experience type 2 
diabetes or cardiovascular events. Intra-individual clustering of risk factors for 
cardiovascular disease and diabetes have been noted for many years (obesity, 
hyperlipidemia, diabetes, and hypertension; Avogaro, et al, 1967). Indeed, the figure is 
often quoted that those with metabolic syndrome have a 50% increased risk of 
cardiovascular events (although the risk is actually cumulative with increasing numbers 
of “cardiometabolic” risk factors present, and the syndrome is not greater than the sum of 
its parts; Wannamethee et al, 2005). This is logical when considering that metabolic 
syndrome (comprising measurements of adiposity, dyslipidaemia, hypertension, and 
hyperglycemia depending on the definition used) has strikingly overlapping features with 
Framingham/ASSIGN-type cardiovascular risk assessments.  
 
The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel 
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III) presents a simple clinical definition of the metabolic syndrome. The 
simplicity of this definition has led to the suggestion (particularly in the USA) that the 
NCEP definition could replace more complex Framingham assessments (Meigs et al, 
2004). This proposition has been called into question by data indicating collectively that, 
as is logically expected, Framingham assessments are stronger predictors of CHD, and 
NECP metabolic syndrome scores are better predictors of diabetes (Stern et al, 2004; 
2Grundy et al, 2004; McNeill et al, 2005; Wannamethee et al, 2005) suggesting that 
segregation of the scores remains preferable in terms of optimising risk management. 
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This clinical issue is separate however to academic and research interest into the common 
causal pathways in metabolic syndrome and cardiovascular disease. 
 
12.4.3 Metabolic Syndrome and Inflammatory Marker Associations 
 
A common factor that subclinical cardiovascular disease and the pre-diabetic metabolic 
syndrome may have is the presence of low-grade systemic inflammation. Over the last 
few years there has been a shift of interest in the literature reflecting this. As considered 
in a recent review (Hotamisligil, 2006) a common inflammatory root for the conditions is 
perhaps not unrealistic or surprising. Evolutionary data indicate that it is possible that the 
haematopoetic, immune, adipose and hepatic cells compartmentalised into distinct organs 
in mammals may have arisen from related precursors, as seen in the interweaving mesh 
of the homologues of these cells in the fat body of the Drosophila melanogaster 
(Hotamisligil, 2006). 
 
The possibility that low grade inflammation is the key mechanism linking CVD risk to 
metabolic syndrome and risk of type II diabetes is widely considered a realistic 
proposition (Lyon et al, 2003; Rajala and Scherer et al, 2003; Wise, 2004) (Fig 12.1). At 
the heart of this is the theory, for many investigators, is the proposition that excess 
visceral adipose tissue (or resident macrophages therein) acting as an active endocrine 
organ, releases inflammatory markers such as IL-1, IL-18, IL-6 and TNF-α (Hotamiglisi 
et al, 1993 and 2006; Esposito et al, 2002). These inflammatory factors may have the 
ability to mediate, not only features of metabolic syndrome like insulin resistance (Borst 
et al, 2004; Paolisso et al, 1998), but also atherogenesis, hence providing a potential 
common causal pathway for the conditions. However, whether this production of 
inflammatory mediators has true systemic consequences, or is to a greater extent a 
localised autocrine and paracrine cross-talking mechanism for infiltrating macrophages 
within the adipose tissue is not clear. So how important is degree of body fatness in terms 
of defining circulating concentrations of inflammatory markers? 
 
To help answer this question, I aimed to use the limited data in this thesis to assess the 
association of inflammatory markers with a key feature of the metabolic syndrome; 
visceral fat deposits. 
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12.4.4 Association of a Key Component of the Metabolic Syndrome (Visceral Fat) with 
Inflammatory Markers in This Thesis 
 
In MONICA-4, CRP, and to a lesser extent IL-6, were strongly associated with BMI and 
WHR (Table 4.2, section 4.4.4). Both IL-18 and TNFα were weakly associated with 
BMI, but the association improved (particularly for IL-18) when WHR was considered as 
opposed to BMI as a measure of fatness. Unfortunately this “extra” data (waist size or 
WHR) was not available in other studies, although these do show generally poor 
associations of IL-18 and TNFα with BMI. The observation that the relationship of the 
two cytokines with fatness improves when considering WHR (a better marker of 
metabolically active visceral fat and a better marker of cardiometabolic risk than BMI) 
suggests there may be a relationship of IL-18 and TNFα with visceral fat in particular. 
The observation of improved associations of IL-18 when WHR is considered instead of 
BMI is in line with other recent observations for IL-18 (Hung et al, 2005; Thorland et al, 
2005; Villarrasa et al, 2006). Despite this, the improved relationship is marginal, and 
visceral adipose tissue is unlikely to be a major contributor to circulating levels of IL-18, 
a conclusion supported by the MONICA/KORA study (Herder et al, 2006). IL-18 in the 
MONICA-4 study had an association of r = 0.1 for BMI and r = 0.2 for WHR. This 
means variations in BMI explain 1% of circulating IL-18 concentrations while WHR 
explains 4% in a general population - so while visceral fat is responsible for some 
circulating IL-18, it is unlikely to be very biologically significant. Indeed the 
MONICA/KORA study failed to find any association of IL-18 with absolute or 
percentage fat mass. This is in line with observations that levels of IL-18 secreted by 
adipocytes are low (Skurk et al, 2005). Similarly, another study in a generally healthy 
population failed to find strong relationships of TNFα with BMI or WHR (Tuomisto et 
al, 2006). 
 
12.4.5 Conclusions 
Taken together these results suggests that the “central” role that adipose-tissue related 
inflammatory markers (such as IL-18 and TNFα) are purported to play in mediating 
insulin resistance and risk of diabetes as well as cardiovascular disease through 
inflammatory cytokines are debatable. While some inflammatory markers, such as CRP 
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and IL-6, are strongly associated with BMI, their relationship with visceral fat is not 
particularly specific (in that associations with WHR are not particularly better than with 
BMI). Likewise, TNFα may be produced by adipose tissue, but is also produced by many 
other cell types such as muscle cells – the metabolic antithesis of fat (Saghizadeh et al, 
1996). Associations of excess visceral adipose tissue to circulating levels of IL-18 and 
TNFα are far from being clearly biologically significant, thus it is hard to envisage how 
adipose tissue may mediate the systemic development of diabetes through these cytokines 
as a major causal mechanism. 
 
Interestingly, these cytokines themselves may remain associated with risk of diabetes 
(perhaps more strongly than with risk of CHD; Thorland et al, 2005). It remains possible 
that metabolic syndrome and diabetes increase risk of CHD (with or without the presence 
of obesity) through influences on the arterial wall and endothelial dysfunction, which in 
turn may be associated with systemic inflammatory processes. This mechanism does not 
rely on adipose tissue “causing” systemic chronic low grade inflammation, but may 
associate with it as another risk factor. For instance, fatty acids may be causal in bringing 
about diabetes via ectopic-fat induced insulin resistance in muscle cells and key organs 
(Fig12.1) (Seppala et al, 2002; Sinha et al, 2002). Despite this it remains possible that 
these cytokines are related to adipose tissue in individuals who are outside the normal 
range and may be defined as clinically obese (Vilarrasa et al, 2007), although this thesis 
has not examined these associations. Clearly data from this thesis is limited, and more 
work is required both epidemiologically and biologically to help delineate the metabolic 
and inflammatory consequences of large reserves of visceral fat.  
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Fig 12.1 An integrated view of obesity-mediated inflammation acting in the promotion of ectopic fat deposition, insulin resistance (type II 
diabetes), dyslipidaemia, as well as endothelial dysfunction and reduced arterial elasticity via increased atherosclerosis. (adapted from Van 
Gaal et al, 2006) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEFA, non-esterified fatty acids; ROS, Reactive oxygen species; RBP-4, rentional binding protein-4 
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12.4.4 Further research into IL-18, TNFα and Metabolic Syndrome 
 
Clearly this thesis was not designed to contribute significant information to the metabolic 
syndrome debate. More research is required into possible correlates of IL-18 and TNFα 
with other risk factors associated with metabolic syndrome, since body fat appears 
largely unrelated. For instance, insulin resistance is often considered a main mediator of 
risk of type II diabetes, and inflammation may promote this metabolic disorder (Steinberg 
et al, 2007). Alternatively, age is the often forgotten simple risk factor that is also a major 
risk factor for insulin resistance (Kahn, 2006), and the cytokines clearly are age-
associated. Data in large studies are required to elucidate possible associations, and to 
delineate the (possibly strong) associations of IL-18, and TNFα, with risk of diabetes in 
eventual meta-analysis. This should allow further debate as to the inflammatory 
aetiological similarities or differences between CVD and metabolic syndrome. 
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12.5 INFLAMMATORY MARKER ASSOCIATIONS WITH CVD 
 
12.5.1 MMP-9 and sCD40L and Associations with Risk of CHD 
 
Most of the conclusions possible to draw from this thesis regarding these two marker’s 
risk associations are included in Chapter 6, as this is the only opportunity I had to 
measure risk associations for them in serum. 
 
Notwithstanding the aforementioned limitations of MMP-9 as a risk biomarker, the 
results from the BRH study of middle aged men indicate MMP-9 is moderately 
associated with risk of CHD in middle-aged men. MMP-9 was associated with risk of 
incident CHD (OR 1.37, 95% CI 1.04-1.82), although this association was almost 
completely dependant on smoking and on generalised inflammation, since association 
with risk was abrogated after adjustment for smoking and CRP and IL-6. There may have 
been a slight residual association following these adjustments, OR 1.13 (0.82, 1.56), but 
the study was underpowered to detect this, and the association would probably be weak. 
MMP-9 confounding by smoking is in agreement with recent observations that smoking 
increases vascular expression of MMP-9 in a mouse model (2Wright et al, 2007). This 
upregulation was via a TNFR1 dependant mechanism, and hence also alludes to a 
potential inflammatory link for MMP-9, which is consistent with much of the literature 
(1.5.3).  
 
As seen in Table 1.8, much of the data showing the association of MMP-9 with risk is 
inconsistent due to small studies, most of which comprised patients with documented 
CAD. The largest study (2Blankenberg et al, 2003) found a linear increase in risk across 
quartiles, and although risk was attenuated after adjustment for classical and 
inflammatory risk markers, this study still found the top two quartiles for MMP-9 to be at 
significantly increased risk. Despite this, lack of association between MMP-9 and CVD 
risk in some small studies (Wu et al, 2005; Cavusoglu et al, 2006) may be indicative of 
regression to the mean overall when considered concurrently with this BRH study data. 
As discussed previously (6.4.4), it is still possible and interesting to speculate that MMP-
9 may be a “better” risk marker in those with established arterial disease due to its 
putative role in plaque rupture, although the BRH study was underpowered to make a 
robust inference regarding this. Certainly the reduction is risk observed after exclusion of 
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those with baseline disease was not nearly as strong as one would suspect considering the 
associations seen in the Atherogene data (2Blankenberg et al, 2003). 
 
The possibility that serum levels of sCD40L would be inversely related to risk of CHD 
had been previously considered as part of a platelet exhaustion hypothesis (1.6.5). This 
hypothesis has been partially corroborated in other work using serum, where those with 
prevalent disease have lower serum levels of sCD40L (Aukrust et al, 1999; Tanne et al, 
2006) and at least non-significant trends have been observed in other work (Weber et al, 
2007; Kiani et al, 2007). The only other available published prospective work examining 
serum sCD40L associations with CHD showed that in those where serum sCD40L tended 
to be higher (at 90th percentile) there was a non-significant trend for lower risk of CHD: 
OR 0.70 (0.34–1.41), although the study only had 233 cases (Tanne et al, 2006). The 
BRH study, with twice as many cases and twice as long a follow-up, found that 
univariable inverse associations with risk were significant although moderate (OR 0.75 
[0.57, 0.99]), and relatively unconfounded by conventional or inflammatory risk factors, 
although significance was lost due to the loss of power on adjustment. 
 
12.5.2 Further Work to Assess CHD Risk Associations of Serum MMP-9 and sCD40L 
 
More data are obviously needed to confirm and expand on these findings with meta-
analysis in due course.  
 
Further confirmation that MMP-9 was a moderate predictor of CHD, confounded by 
smoking and other inflammatory markers, would essentially preclude it as a useful 
clinical marker (from an epidemiological perspective). Interestingly it may still represent 
a potentially strong therapeutic candidate. It remains to be seen if small therapeutic 
inhibitors can be made specifically enough to inhibit individual MMPs while not 
interacting with others . 
 
It would be particularly interesting to see if the inverse associations of serum sCD40L 
with risk of CHD are reproducible in other large studies. Delineating whether inverse 
associations of sCD40L with risk of CHD were continuous and linear throughout the 
population is also of interest. Assessment would be required of those with very low 
relative levels of serum sCD40L to see if such levels are artefactual or truly reflect 
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exhausted platelets and greater risk. It may also be interesting (if the platelet exhaustion 
hypothesis is verified) to see if those who develop venous thrombosis in prospective 
studies also have exhausted platelets, platelet interactions being a major factor in these 
events (Lowe, submitted review, 2007).  
 
12.5.3 IL-18 and TNFα Power Calculations 
 
Due to the large number of studies conducted on IL-18 and TNFα, the retrospective 
power calculations offer potential for comparison. One must of course bear in mind the 
limitations of these calculations (2.6.2).  
 
Table 12.4 illustrates power calculations across all relevant studies for these two 
cytokines, including IL-6 where appropriate. In the study of prevalent CHD, GLAMIS 
had 70% power to detect risk associations of 1.5 for both IL-18 and TNFα. Among 
prospective CHD studies, the BRH study and MONICA-4 had greater power than 
GLAMIS, demonstrating similar power to each other to detect risk associations of 1.5 
(92% and 83% respectively for IL-18, and 88% and 83% for TNFα respectively). The 
Fletcher Challenge study was somewhat less powerful than this, demonstrating 53% 
power in both markers. Not shown in the figure, sCD40L and MMP-9 had similar power 
in the BRH as did IL-18 and TNFα. 
 
Among the stroke studies, SIP had limited power to detect associations with risk due to 
the small number of “cases” of poor outcome. It is hence possible that the study was 
underpowered to find associations of cytokines with outcome – further studies are 
therefore required. Prospective power calculations however showed the study had 90% 
power to detect 25% differences in D-dimer levels between groups on outcome (9.2.4). 
PROGRESS was the most powerful of the stroke studies, demonstrating 90% power to 
detect associations of 1.5 for IL-18 and 1.6 for TNFα. The null association of IL-18 with 
recurrent stroke is therefore unlikely to be a chance finding. PROSPER showed 59% 
power to detect risk ratios of 1.5 for IL-18 and for TNFα, and therefore there is a 
possibility the study was underpowered. 
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Table 12.4 Power calculations for all relevant studies in the thesis showing both the minimum OR association required at 90% power 
(column “90%”) and the power of the study to detect an OR of 1.5 (column “1.5”). 
Dep, dependant; indep, independant 
 
 
Study Outcome IL-18 90% 1.5  TNF 90% 1.5  IL-6 90% 1.5 
GLAMIS MI 446 cases 
477 controls 
1.69 70  445 cases 
477 control 
1.69 70  n/a   
BRH MI 595 cases 
1238 controls 
1.47 92  535 cases  
1155 controls 
1.52 88  n/a   
FC MI 229 cases 
442 controls 
1.93 53  229 cases 
442 controls 
1.93 53  229 cases 
442 controls 
1.93 53 
MONICA-4 MI 1484 1.56 83  1484 1.56 83  1437 1.57 82 
SIP Death/dep 
(acute stroke) 
94 dead/dep 
86 indep 
3.39 19  94 dead/dep 
86 indep 
3.39 19  94 dead/dep 
86 indep 
3.39 19 
PROGRESS Recurrent 
Stroke 
591 cases 
1182 controls 
1.50 90  433 cases 
859 controls 
1.60 80  591 cases 
1182 controls 
1.50 90 
PROSPER Incident 
stroke 
266 cases 
532 controls 
1.83 59  266 cases 
532 controls 
1.83 59  n/a   
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12.5.4 IL-18 Risk Associations with CHD and Stroke and Meta-Analysis 
 
IL-18 demonstrated consistently significant, but moderate, univariable associations with 
CHD in all studies in this thesis. In GLAMIS, IL-18 levels were elevated in those who 
were retrospective CHD cases relative to controls, although the difference was not large 
(9.6%). In the BRH prospective study, the difference between cases and controls was 
again moderate (9.8%), as it was in Fletcher challenge (10.8%), and MONICA-4 
(13.7%). The difference of ~10% between cases and controls is hence a consistent 
observation, both in populations with prevalent disease and in normal populations. This 
data is broadly similar to other publications comparing cases and controls for levels of 
IL-18 retrospectively (4.2%: Hulthe et al, 2006) and prospectively both in patients with 
prevalent disease (16%: Blankenberg et al, 2002; 10.6%: Blankenberg et al, 2006) and in 
healthy patients (10.4%: Blankenberg et al, 2003; 6.9%: Koenig et al, 2006). This 
suggests that IL-18 may have minimal confounding associations with prevalent disease, 
since associations with hard end points are similar regardless of the patient population 
studied.  
 
In all studies of CHD (BRH study, FC study and MONICA-4) IL-18 was associated with 
risk after adjustment for matching variables (age and sex) (ORs 1.55, 1.63, and 1.61 
respectively comparing extreme tertiles, all p<0.05). After adjustment for only short-term 
biological variability (R=0.66; Chapter 3; not adjusted for regression dilution due to a 
lack of data), an OR of ~1.60 would become ~2.04. 
 
Commensurate with the observation that IL-18 may be relatively free of confounding by 
some conventional vascular risk factors, I observed that IL-18 risk associations on 
multivariable analysis were not markedly attenuated by adjustment for classical risk 
markers in the FC study, but were attenuated in the BRH study and MONICA-4 studies 
where social class was adjusted for. This is again consistent with other studies 
(Blankenberg et al, 2001; 1Blankenberg et al, 2003; Tiret et al, 2005; Koenig et al, 2006; 
Table 1.6). Despite this, the univariable association of IL-18 was moderate enough that in 
full adjustment models (with or without social class) observations were generally 
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rendered borderline significant by increasing the confidence intervals. Therefore more 
power is needed to confirm these adjusted observations. This can be achieved by meta-
analysis of the data.  
 
For stroke, IL-18 levels were not substantially elevated in the SIP acute stroke cohort 
compared to the MONICA-4 population or other case-control studies, although the 
possibility that this is due to drifts in kit calibration or differences in sample quality is 
hard to exclude. The latter is unlikely since reduced sample quality would be expected to 
lead to drops in detectable IL-18 levels, and the SIP samples are relatively recent (~4 
years), and the aliquots used were previously unthawed. IL-18 also demonstrated no 
associations with 72 hour stroke progression or with 30 day death dependency outcome. 
Absence of an association with stroke in the acute stages is commensurate with animal 
data since elevated IL-18 is not required for or associated with acute ischaemic brain 
injury in mice (Wheeler et al, 2003). All inflammatory markers measured apart from IL-
18 were univariably associated with the 30 day death/dependency outcome. Hence the 
inflammatory marker prediction of 30 death/dependency outcome seems likely to be a 
general APR-associated phenomenon (Stuyt et al, 2005). Indeed, in the multivariable SIP 
model, D-dimer was one of the only independent indictors of outcome; and as well as 
being a marker of fibrinlysis it is also APR-associated. This speculation requires some 
degree of caution because the study was small and poorly powered (Table 12.4). IL-18 
was not associated with recurrent stroke (haemorrhagic, ischaemic, or total recurrent 
stroke [PROGRESS]), despite IL-18 levels being elevated in the cohort. The latter 
observation may be directly due to changes in kit lot however (lot 42A; 12.3.1) and 
requires verification. The PROSPER study also failed to implicate IL-18 as a risk 
predictor of incident stroke in a population of elderly people with vascular disease. This 
may have been due to limitations of the study, since the case-control PROSPER study 
found CRP and fibrinogen to not be associated with risk of stroke, although these 
inflammatory markers are established risk predictors of stroke (1.7.4). IL-18 associations 
with incident stroke require further study in general populations. Overall however, this 
thesis fails to find any evidence of an association of IL-18 with stroke. 
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As previously discussed, pooling of the data on risk associations is required to better 
estimate the associations of IL-18 with risk of CVD. Firstly, this requires studies 
appropriate for this meta-analysis to be identified. GLAMIS and SIP were excluded on 
the basis of their retrospective and acute investigative natures (consistent with 
methodologies in other published meta-analyses e.g. Fibrinogen Studies Collaboration, 
2004). PROSPER was excluded on the basis of the limitations of its study design 
(10.4.3).  
 
Meta-analysis of the remaining studies was performed by pooling and weighting of ORs 
(comparing adjusted extreme population thirds) in a fixed model (Woodward, 2005). 
Analysis of heterogeneity was performed using the I2 statistic (as opposed to Cochrane’s 
Q) due to the small number of studies (Higgins and Thompson, 2002). 
 
Analysis of heterogeneity between the studies suggests that there were no significant 
differences between the studies of IL-18 (p=0.36), and hence pooling of the data is a 
valid methodology, since pooling of the data will theoretically only improve power and 
not bias the data by inclusion of widely differing studies. 
 
Data from the IL-18 meta-analysis from fully adjusted models in each of the studies is 
shown in Fig 12.2. In the fully adjusted models IL-18 shows a weak, borderline 
significant association with risk of CVD, such that comparing extreme thirds the 
additional risk is OR 1.18 (95% CI 0.95-1.48). Looking at the data given in the figure, it 
is obvious that the PROGRESS study of recurrent stroke is an outlier compared to the 
studies of CHD. Hence, further sub-analysis of CHD-only associations should be 
performed. There are plans for such analysis to be performed in the near future, 
increasing the amount of data by including data from the published literature (in 
collaboration with Prof P Whincup). Therefore this sub-analysis is not included here. 
Adjustment for short-term or biological variability in the present meta-analysis is not 
possible due to absence of such data for conventional risk markers (which would also be 
required to be adjusted for in a further model). 
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The possibility that IL-18 may be (albeit moderately) associated with CHD but not stroke 
is intriguing. Markers of the acute phase response (e.g. fibrinogen and CRP [Fibrinogen 
Studies Collaboration, 2005, Danesh et al, 2004]) predict CHD and stroke to a similar 
degree. If IL-18 associates with only CHD, it may reflect the different underlying causes 
of stroke and CHD. While nearly all CHD is linked to coronary atheroma, only half of 
ischaemic stroke cases are due to large vessel atheroma such as in the middle cerebral 
artery (Di Napoli et al, 2002) cardiac disorders (e.g atrial fibrillation, heart valve disease) 
or small vessel disease causing lacunar strokes. These different aetiologies may have 
potentially different inflammatory associations.  
 
Overall, with or without stroke data, IL-18 appears a moderate predictor of CHD, and 
risk associations generally weaken to borderline significance on adjustment for 
conventional risk markers.  
 
There are speculations current in the literature that IL-18 may act in both a pro-
inflammatory manner (as in Chapter 1) as well as an anti-inflammatory manner (due to 
stronger associations with TGF-β than most other inflammatory risk markers), as 
considered in the WISE study (Kip et al, 2005). This study also considers TNFα a 
potential candidate for these opposing mechanistic effects on risk (Kip et al, 2005). 
Whether opposing pro- and anti-inflammatory actions of these cytokines have any impact 
on risk associations requires more study. It is possible however, that these cytokines are 
important in atherogenesis at a local level, but that circulating concentrations of the 
cytokines may not reflect this, and hence display limited risk associations. 
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Fig 12.2 Meta-analysis of IL-18 in the four pooled studies (full adjustment models from 
this thesis) comparing risk in the top versus bottom tertiles of the population distribution. 
Filled box size indicates relative weighting (by study power), and lines indicate 95% CI. 
Unfilled box indicates overall combined OR 1.18 (95% CI 0.95-1.48). 
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12.5.5 TNFα and Risk Associations with CHD and Stroke and Meta-Analysis 
 
TNFα demonstrated inconsistent associations with CHD in this thesis. Levels of TNFα 
were more elevated than IL-18 in the GLAMIS study of patients with prevalent MI 
compared to matched controls (28.6%). This is in agreement with published literature 
(Jovinge et al, 1998; Bennett et al, 2006, Hulthe et al, 2006), although the two cytokines 
had not been directly compared in the same study previously. In prospective studies 
TNFα was lower among cases in the BRH study (8.8%), and higher in the FC study as 
well as the MONICA-4 study (10.0% and 19.9% respectively). Hence TNFα appears, in 
comparison to IL-18, to show stronger association with prevalent CHD (previous MI) 
than with incident CHD in general populations. More data is required to confirm these 
observations. 
 
Although some reports have shown that elevated levels of TNFα are associated with 
prospective risk of CHD risk in people with recent MI (3Ridker et al, 2000), in a general 
elderly population (2Cesari et al, 2003), and in a general population (Tuomisto et al, 
2006), the data are not entirely clear. A small recent study suggests that TNFα does not 
predict events in people with prevalent MI (Sukhija et al, 2007), although the study is 
small (n cases = 55). The FINRISK study, which is the most general population in the 
published literature, shows that the association of TNFα with risk of CHD is strong 
(OR>2.0 above first quartile) but non-linear, with particularly notable non-significant 
inverse association with risk in the second quartile of women for cardiovascular (OR 0.74 
[0.18-30.5]) and coronary (OR 0.25 [0.01-5.27]) risk (Tuomisto et al, 2006). Clearly this 
observation may be a chance finding, since confidence intervals are very wide and 
numbers per quartile small. The BRH study result may be a symptom of “regression to 
the mean” (i.e. a more or less null association overall, including the published literature), 
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or alternatively it may be a reflection of poor sample quality (although the results of 
Chapter 3 and the positive associations of IL-18 suggest otherwise). 
 
In other studies in this thesis, TNFα results were no more conclusive. In the FC study, 
TNFα showed a non-significant positive trend to be associated with CHD risk in the top 
third of the population; OR 1.33 (0.87, 2.02), and the result was only marginally 
attenuated by adjustment for classical risk markers (OR 1.23). Interestingly however, 
there was an inverse trend in the middle third, which became stronger after adjustment 
for classical risk factors; OR 0.68 (0.41-1.12). In MONICA-4 the top third of the 
population were at increased risk of CHD: OR 1.70 (1.11-2.59), a result marginally 
attenuated by adjustment (OR 1.40). Also, in MONICA-4, in contrast with FC, risk 
associations were linear through the middle third of the population. Due to these 
inconsistencies no attempt was made to adjust univariable associations for short-term 
biological variation, as was done for IL-18. 
 
Overall then, these results are inconclusive in terms of delineating an association of 
TNFα with risk of CHD. It is possible there is an association of high levels of TNFα with 
risk in general populations, although this is likely to be weak. It is also possible that the 
association is non-linear, such that those with moderate expression levels have some 
protection. This may be in line with observations from previous authors suggesting that 
TNFα and IL-18 have both pro- and anti-inflammatory properties in the WISE study (Kip 
et al, 2005).  
 
Performing meta-analysis of the TNFα data may help to observe overall trends from data 
in this thesis. Meta-analysis was therefore performed on TNFα in the same manner as IL-
18. Data from this analysis is shown in Fig 12.3. Analysis from pooling of the data 
showed significant heterogeneity of the data (p<0.02), hence meta-analysis should be 
performed with caution. Clearly the BRH study is a major outlier in this data set. Yet it 
should not be excluded from analysis on the basis of its difference for risk of obtaining a 
biased false positive result, and cross-study heterogeneity in associations is perhaps 
consistent with the published data (Table 1.4). Differences between studies may due to 
differing study populations such as their age ranges, genders and the prevalence of 
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disease. This thesis has shown TNFα increases with age, suggests that levels are higher 
in males than females, and perhaps that it is associated more strongly with prevalent 
disease (compared to IL-18). How these differences impact on prospective risk 
associations is not clear, and requires more research, but perhaps generally explains study 
heterogeneity. As seen in Fig 12.3, fully adjusted models show that TNFα has an 
association with risk very close to unity comparing extreme tertiles: OR 1.05 (0.67-1.64). 
It is hence possible that all the speculation of differing risk associations in different 
populations is misplaced, and overall regression to the mean in the data show that TNFα 
does not predict risk at all beyond associations with conventional risk markers. More data 
would be required to establish this one way or the other. 
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Fig 12.3 Meta-analysis of TNFα in the four pooled studies (full adjustment models from 
this thesis) comparing risk in the top versus bottom tertiles of the population distribution. 
Filled box size indicates relative weighting (by study power), and lines indicate 95% CI. 
Unfilled box indicates overall combined OR 1.05 (0.67-1.64). Studies are heterogeneous 
(p<0.02).  
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12.5.6 High grade Inflammatory Risk and IL-18 and TNFα in the Literature 
 
IL-18 and TNFα may be poorly associated with CVD in these populations, which are 
typical of research into low-grade inflammation-associated CVD. Data is currently 
accumulating which suggests that those with high-grade inflammatory disease (such as 
rheumatoid arthritis [RA] and type-1 diabetes) are at increased risk of CHD. This 
increased risk is not fully explained by cardiovascular risk factors in studies of 
rheumatoid patients: the excess risk after adjustment for these factors in RA populations 
is thought to be ~3-fold (del Rincon et al, 2001). There is hence the possibility that high-
grade inflammation may contribute to systemic cardiovascular risk in a causal manner. 
IL-18 (Gracie et al, 2003) as well as TNFα (Sattar and McInnes et al, 2005) are likely to 
be major contributors to such systemic Th1 type inflammation. There is good evidence 
that treatment with statins reduces levels of inflammatory markers, including in those 
with RA (McCarey et al, 2004). Recent studies have however indicated that simavastatin 
offers little additional anti-inflammatory or endothelial function/aortic stiffness 
improvement above ezetimebe (the latter being a non-statin cholesterol lowering agent 
restricted to the small intestine) (Maki-Petaja et al, 2007). This would suggest that the 
systemic anti-inflammatory effects of statins are largely linked to cholesterol-altering 
mechanisms. The potentially causal role of inflammation in high grade inflammatory 
CVD requires clarification. 
 
In this respect, TNFα is in a unique research position, in that it is one of the only 
cytokines that have specific monoclonal antibodies liscensed for treatment of human 
disease. As previously discussed, the current generation of TNFα-inhibitors are 
unsuitable for use in those with subclinical disease, and may also be pathological in those 
with advanced CHF (1.3.8). Despite this, the drugs are fairly commonly used in those 
with RA unresponsive to methotrexate treatment. A recent double-blinded placebo 
controlled trial in 127 patients with psoriatic arthritis used onercept (a mAb TNFα 
inhibitor) to show that short-term treatment resulted in lowered Lp(a) and homocysteine 
levels and elevated Apo A-I,  changes suggestive of cardiovascular protection (2Sattar et 
al, 2007). In addition however, levels of triglycerides and Apo B were raised (adverse 
phenotype), and the authors recommend that further studies using measures of extent of 
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atherosclerotic disease (such as IMT) or hard end-points are required. It is possible that 
general dampening of an inflammatory state would show greater efficacy than targeting 
an individual pro-inflammatory molecule. This remains to be investigated.  
 
12.5.7 Further Work for IL-18 and TNFα 
 
In general, more data are required to delineate associations of both IL-18 and TNFα with 
risk of CVD in a range of populations. This is particularly true of TNFα; in particular, 
research into those with very high circulating levels of TNFα is required (3Ridker et al, 
2000) as well as data in general populations in order to evaluate risk associations in large 
populations with valid sub-analysis by gender and by age, and prevalence of disease. This 
data may help to elucidate possible mechanistic risk associations.  
 
Overall, one would conclude from all current data that any independent risk associations 
of either cytokine in general populations are likely to be very small, and unlikely to be 
clinically significant. Even if associations are stronger in sub-populations, these are 
unlikely to be of clinical benefit in terms of risk prediction. The molecules may 
nonetheless be therapeutic targets. Research into TNFα blockade in RA patients and 
assessment of risk reduction in hard end-points is required. This may be problematic for a 
number of reasons relating to recruitment of sufficient numbers and study design. 
Primarily, RA patients receiving TNFα blockade medication are generally highly 
selected, having non-methotrexate responsive and clinically severe disease, and hence 
may be at increased risk of CVD. Ethical recruitment of controls (of similar disease 
severity to not bias the data) is therefore problematic. 
 
Furthermore, research is needed into the experimental and epidemiological implications 
of the potential “anti-inflammatory” properties of IL-18 and TNFα, and the implications 
of this for atherogenesis. It seems likely that these properties are likely to act in the 
promotion of the Th2 response (and hence suppression of Th1) rather than Th1 
suppression directly. Population-wide patterns of low grade Th1 versus Th2 circulating 
inflammatory expression may be required to compare the elevated Th1 responses seen in 
those with prevalent vascular disease (Szodoray et al, 2006). The role of the systemic 
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Th1/Th2 balance in atherogenesis is speculative however, and it is important to remain 
conservative as to its importance in atherogenesis. Mast cells have recently been shown 
to be involved in atherogenesis (Bot et al, 2007), and mast cells are conventionally 
activated by Th2 stimuli such as IgE. It is hence possible that localised inflammation 
within the intima and adventitia of the vascular lesion will advance atherosclerosis in the 
presence of endothelial dysfunction (irrespective of the type of inflammation). 
 
12.6 CONCLUDING REMARKS 
 
This thesis has shown that circulating levels of IL-18, TNFα, and MMP-9 generally have 
limited positive associations with risk of CVD in population studies, which are likely to 
be both moderate and confounded. Univariable associations with prospective risk of CVD 
suggest the markers may have some role in arterial disease progression, although this 
requires more study. After adjustment for conventional risk markers the associations with 
risk are likely to be small, although further studies are required to delineate risk 
associations accurately in sub-populations. Serum sCD40L was shown to be inversely 
associated with risk, perhaps due to platelet exhaustion in those at increased risk. More 
studies are required to confirm this observation, although the marker is unlikely to be of 
any clinical utility due to pre-analytical issues. 
 
IL-18 and TNFα were the most extensively studied markers. At the outset of this thesis 
there was published data estimating risk associations from 450 CVD cases for IL-18. 
Since then there have been an extra 1236 cases added in published literature, and the 
current thesis adds 2239 cases to that. Similarly for TNFα there were 542 cases in 
prospective data, 260 cases have been added in the last 3 years, and the current body of 
work adds a further 2179 cases. This work therefore adds significant data to currently 
published work, potentially making risk observations much more accurate. 
 
In this thesis, both cytokines were associated with aspects of the metabolic syndrome (in 
line with cardiometabolic risk factor clustering), although their association with 
population markers of adiposity was limited, despite literature linking them to obesity 
and visceral adipose tissue. The demographic associations of IL-18 and TNFα were 
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similar to those seen for other risk associated inflammatory markers (CRP, fibrinogen 
and IL-6), both increasing with age and showing some gender associations, as well as 
associations with smoking, alcohol intake and social class. Animal and tissue models 
indicate IL-18 and TNFα are important in the development of atheromatous lesions. The 
limited association of these cytokines with CVD risk, while markers associated with 
acute phase response (CRP, fibrinogen and IL-6) are more strongly associated with risk 
(although arguably still moderate) suggests that the APR may be a “better” indicator of 
CVD risk than circulating levels of inflammatory markers associated with Th1 
inflammatory responses.  
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